metformin has been researched along with Weight Loss in 419 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In overweight or obese patients with T2DM, a once-weekly subcutaneous administration of PEG-Loxe for 16 weeks, in addition to lifestyle interventions or oral antidiabetic drug therapy, resulted in significantly greater weight loss compared to metformin." | 9.69 | Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. ( Cai, H; Chen, Q; Duan, Y; Zhang, X; Zhao, Y, 2023) |
| "Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events." | 9.69 | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. ( Chen, Q; Chen, Y; Fang, S; Liang, Y; Tian, Y; Wen, Q; Yuan, J, 2023) |
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 9.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 9.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "We investigated effects of weight loss, an intensive lifestyle intervention (ILS), and metformin on the relationship between insulin secretion and sensitivity using repository data from 2931 participants in the Diabetes Prevention Program clinical trial in adults at high risk of developing type 2 diabetes." | 9.51 | Weight Loss, Lifestyle Intervention, and Metformin Affect Longitudinal Relationship of Insulin Secretion and Sensitivity. ( Hanson, RL; Knowler, WC; Vazquez Arreola, E, 2022) |
| "Cancer survivors with overweight or obesity were randomized to (1) self-directed weight loss (comparison), (2) coach-directed weight loss, or (3) metformin treatment." | 9.41 | Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. ( Appel, LJ; Carducci, MA; Charleston, J; Dalcin, AT; Durkin, N; Hassoon, A; Jerome, GJ; Juraschek, SP; Kanarek, NF; Lansey, DG; Maruthur, NM; Miller, ER; Mueller, NT; Tseng, E; Wang, NY; White, K; Yeh, HC, 2021) |
| "Forty metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes mellitus, received liraglutide (1." | 9.34 | Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. ( Boccatonda, A; Cipollone, F; Consoli, A; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tripaldi, R; Vadini, F, 2020) |
| " We evaluated whether liraglutide in combination with metformin (MET-LIRA) is more effective than metformin monotherapy (MET-P) in improving insulin action and reducing body weight in overweight prior GDM (pGDM) women." | 9.34 | Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled ( Elkind-Hirsch, KE; Harris, R; Shaler, D, 2020) |
| " The use of dapagliflozin in this population could improve weight loss and other cardiovascular factors." | 9.34 | Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial. ( Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C, 2020) |
| " To study the combined efficacy of exercise and metformin on above parameters in women with polycystic ovary syndrome." | 9.30 | Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. ( Jain, S; Pasrija, S; Tiwari, N, 2019) |
| "The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo." | 9.30 | Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. ( Apolzan, JW; Boyko, EJ; Dabelea, D; Edelstein, SL; Franks, PW; Gadde, KM; Kalyani, RR; Knowler, WC; Pi-Sunyer, X; Srikanthan, P; Venditti, EM, 2019) |
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 9.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| "This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD)." | 9.27 | Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. ( Fushimi, N; Hachiya, H; Ito, S; Kawai, H; Kawai, M; Mori, A; Ohashi, N; Shibuya, T; Yoshida, Y, 2018) |
| " PCOS is associated with obesity, dyslipidaemia and insulin resistance, and metformin treatment may improve such metabolic features." | 9.27 | The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. ( Andersen, M; Christensen, MMH; Glintborg, D; Pedersen, AJT; Stage, TB, 2018) |
| " Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation." | 9.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "Proof-of-concept study to investigate the amplifying effects of diazoxide (DZX)-mediated insulin suppression on lifestyle-induced weight loss in nondiabetic, hyperinsulinemic, obese men." | 9.27 | High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention. ( Brandon, T; de Boer, H; Filius, M; Hermus, A; Loves, S; Mekking, M; Tack, CJ; van Groningen, L, 2018) |
| "001) and the average weight loss was 2 kg after 16 weeks' treatment of metformin." | 9.24 | The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from data of a phase IV open-labeled trial. ( Cai, X; Han, X; Ji, L; Yang, W; Zhou, L, 2017) |
| "Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1." | 9.24 | Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. ( Angelucci, E; Bonadonna, RC; Cianfarani, S; Consoli, A; Davì, G; Di Castelnuovo, A; Federico, V; Guagnano, MT; Leo, M; Maccarone, MT; Manzoli, L; Santilli, F; Sborgia, C; Simeone, PG; Tartaro, A, 2017) |
| "Steady-state population pharmacokinetics of a noncommercial immediate-release metformin (hydrochloride) drug product were characterized in 28 severely obese children with insulin resistance." | 9.24 | Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ( Alfaro, RM; Calis, KA; Hon, YY; Reynolds, JC; Roza, O; Sam, WJ; Yanovski, JA, 2017) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 9.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| "Our results show that Metformin and acupuncture combined therapy significantly improves body weight, body mass index (BMI), fasting blood sugar (FBS), fasting insulin (FINS), homeostasis model assessment (HOMA) index, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), leptin, adiponectin, glucagon-like peptide-1 (GLP-1), resistin, serotonin, free fatty acids (FFAs), triglyceride (TG), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and ceramides." | 9.22 | Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. ( Firouzjaei, A; Li, GC; Liu, WX; Wang, N; Zhu, BM, 2016) |
| "To evaluate the proportion of patients with type 2 diabetes mellitus (T2DM) achieving reductions in both glycated hemoglobin (HbA1c) and body weight with canagliflozin, a sodium glucose co-transporter 2 inhibitor, versus sitagliptin over 52 weeks." | 9.22 | Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. ( Canovatchel, W; Davidson, JA; Jodon, H; Lavalle-González, FJ; Qiu, R; Schernthaner, G; Vijapurkar, U, 2016) |
| "We sought to compare weight loss in the first 6 weeks postpartum among women with gestational diabetes mellitus (GDM) treated with metformin or placebo, a promising therapy to reduce later risk of progression to diabetes mellitus." | 9.20 | The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial. ( Blackwell, SC; Hutchinson, M; Pedroza, C; Ramin, SM; Refuerzo, JS; Tyson, JE; Viteri, OA, 2015) |
| " The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH." | 9.20 | Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. ( Baig, F; Lang, CC; McSwiggan, S; Mohan, M; Rutherford, L, 2015) |
| "Short-term monotherapy with liraglutide or roflumilast was associated with significant weight loss in obese PCOS." | 9.20 | Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. ( Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E, 2015) |
| "The effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory." | 9.19 | Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. ( Janez, A; Jensterle Sever, M; Kocjan, T; Kravos, NA; Pfeifer, M, 2014) |
| "This study evaluated change in health-related quality of life (HRQOL) associated with ongoing weight change among patients with type 2 diabetes mellitus (T2DM) treated with dapagliflozin, a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion and is associated with body weight reductions." | 9.19 | Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. ( Grandy, S; Hashemi, M; Langkilde, AM; Parikh, S; Sjöström, CD, 2014) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 9.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "In obese, difficult-to-treat patients with T2DM inadequately controlled on high MDI insulin doses, empagliflozin improved glycemic control and reduced weight without increasing the risk of hypoglycemia and with lower insulin requirements." | 9.19 | Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. ( Broedl, UC; Frappin, G; Jelaska, A; Kim, G; Rosenstock, J; Salsali, A; Woerle, HJ, 2014) |
| " The primary aim is to determine the efficacy of: levonorgestrel intrauterine device (LNG-IUD); with or without metformin (an antidiabetic drug); and with or without a weight loss intervention to achieve a pathological complete response (pCR) in EC at six months from study treatment initiation." | 9.19 | Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. ( Armes, J; Brennan, D; Gebski, V; Hawkes, AL; Janda, M; Obermair, A; Quinn, M, 2014) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 9.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| "We tested genetic associations with weight loss and weight regain in the Diabetes Prevention Program, a randomized controlled trial of weight loss-inducing interventions (lifestyle and metformin) versus placebo." | 9.16 | Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. ( Delahanty, LM; Florez, JC; Franks, PW; Jablonski, KA; Kahn, SE; Knowler, WC; McCaffery, JM; Pan, Q; Shuldiner, A; Watson, KE, 2012) |
| "Exenatide is an analogue of GLP1 designed to improve the glycemic control in patients with obesity and type 2 diabetes." | 9.16 | [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide]. ( Ferrer Gómez, M; García Zafra, MV; Hellín Gil, MD; Pujante Alarcón, P; Román, LM; Tébar Massó, J, 2012) |
| "The objective was to determine the effect of metformin on the concentrations of resistin and other markers of insulin resistance or inflammation (C-reactive protein, cytokines, body weight, HbA1c, among others) in minors with glucose intolerance." | 9.16 | Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. ( Aguilar-Salinas, CA; Cruz, M; Gómez-Díaz, RA; Mondragón-González, R; Ortiz-Navarrete, FV; Pool, EC; Solórzano-Santos, F; Talavera, JO; Valladares-Salgado, A; Wacher, NH, 2012) |
| "Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP)." | 9.16 | Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. ( , 2012) |
| "To determine if metformin improves markers of inflammation, thrombosis, and intrahepatic fat contents in children with uncomplicated obesity." | 9.16 | Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. ( Balagopal, P; Bird, K; Damaso, L; DelGiorno, C; Hossain, J; Killen, K; Mauras, N; Merinbaum, D; Weltman, A, 2012) |
| " Liraglutide provides greater sustained glycaemic control and body weight reduction over 52 weeks." | 9.15 | One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. ( Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB, 2011) |
| "Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with polycystic ovary syndrome (PCOS) compared to metformin." | 9.14 | Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2009) |
| "To test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain and abnormalities in insulin sensitivity." | 9.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 9.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "To compare the effects of insulin sensitization with metformin to weight reduction by rimonabant on biochemical hyperandrogenaemia and insulin resistance in patients with PCOS." | 9.13 | A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2008) |
| "The beneficial effects of metformin in patients with type 2 diabetes mellitus (T2DM) and polycystic ovarian syndrome (PCOS) are thought to be in part due to weight reduction." | 9.13 | Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS). ( Batterham, RL; Conway, GS; Tsilchorozidou, T, 2008) |
| "In a randomized double-blind placebo controlled trial, 85 adolescents with insulin resistance were randomized to receive metformin (70%) or placebo (30%), along with monthly goal setting for diet and exercise modification." | 9.13 | Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. ( Love-Osborne, K; Sheeder, J; Zeitler, P, 2008) |
| " Metformin is known to decrease insulin resistance and is also associated with weight loss." | 9.12 | Postpartum Use of Weight Loss and Metformin for the Prevention of Type 2 Diabetes Mellitus: a Review of the Evidence. ( Ayala, NK; Werner, EF; Whelan, AR, 2021) |
| " Therefore, this study assessed the effect of sitagliptin as monotherapy and add-on therapy to metformin on weight reduction in overweight or obese cases with type 2 diabetes." | 9.12 | Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. ( Bamehr, H; Janani, L; Mirzabeigi, P; Montazeri, H; Tanha, K; Tarighi, P, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 9.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "8 kg/m2, we assessed effeicacy of metformin-diet for 1 year for reduction of weight, insulin, HOMA insulin resistance (IR), cholesterol, triglycerides, and resumption of regular menses." | 9.12 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Luo, G; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo." | 9.12 | An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007) |
| "to compare the clinical, hormonal and biochemical changes after the application of the two ways of influence upon insulin resistance in women with PCOS - reduction of weight and application of metformin." | 9.12 | [Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome]. ( Kavŭrdzhikova, S; Mitkov, M; Pekhlivanov, B, 2006) |
| "Our aim was to investigate the effect of pre-treatment with metformin in women with polycystic ovary syndrome (PCOS) scheduled for IVF stimulation." | 9.11 | Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. ( Carlsen, SM; Kjøtrød, SB; von Düring, V, 2004) |
| "The effect of metformin (1000 mg twice a day) on markers of endothelial activation, inflammation, and coagulation was investigated in subjects with impaired glucose tolerance (IGT) in a 16-wk, randomized, placebo-controlled, double-blind study." | 9.11 | The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. ( Aguilar-Salinas, CA; Caballero, AE; Cabrera, T; Castillo, JL; Delgado, A; Gomez-Perez, FJ; Herrera, AN; Rull, JA, 2004) |
| " Modest weight reduction was found in all treatment groups, with the most significant reduction occurring with the combination of metformin and lifestyle intervention." | 9.11 | A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. ( Craig, K; Guzick, DS; Hoeger, KM; Kochman, L; Miller, RK; Wixom, N, 2004) |
| " metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS)." | 9.11 | Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. ( Atkin, SL; Holding, S; Jayagopal, V; Jennings, PE; Kilpatrick, ES, 2005) |
| "Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses." | 9.11 | Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. ( Fleming, R; Harborne, LR; Norman, JE; Sattar, N, 2005) |
| "Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity." | 9.11 | Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. ( Allen, HF; Heptulla, RA; Koenigs, L; Mazzoni, C; Miller, N; Murray, MA; Reiter, EO, 2005) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 9.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "To assess the effect of metformin on insulin sensitivity, glucose tolerance and components of the metabolic syndrome in patients with impaired glucose tolerance (IGT)." | 9.09 | Metabolic effects of metformin in patients with impaired glucose tolerance. ( Eriksson, JG; Forsén, B; Groop, L; Gullström, M; Häggblom, M; Lehtovirta, M; Taskinen, MR, 2001) |
| "Metformin often promotes weight loss in patients with obesity with non-insulin-dependent diabetes mellitus (NIDDM)." | 9.08 | Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. ( Lee, A; Morley, JE, 1998) |
| "Metformin effects on insulin resistance and insulin/glucose relationships during an oral glucose tolerance test (OGTT) were investigated in 60 non-diabetic male patients previously treated with coronary artery bypass surgery or angioplasty in an open, 12 week prospective study." | 9.08 | Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. ( Carlsen, SM; Følling, I; Grill, V, 1998) |
| " Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus." | 9.05 | Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. ( Constantinidou, KG; Filippou, PK; Papaetis, GS; Stylianou, CS, 2020) |
| " conclude that metformin, a drug used for treatment of type 2 diabetes mellitus, can be used effectively for weight loss, and that this effect is even more pronounced in individuals who weigh more at baseline." | 9.01 | Neglecting regression to the mean continues to lead to unwarranted conclusions: Letter regarding "The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from ( Allison, DB; Hannon, BA; Siu, CO; Thomas, DM, 2019) |
| "In September 2018, we searched PubMed, Embase, and the Cochrane Library for studies published in English using the keywords metformin, obesity/overweight, and weight loss." | 8.98 | Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. ( Knibbe, CAJ; Lentferink, YE; van der Vorst, MMJ, 2018) |
| "Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment." | 8.93 | Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity. ( Apovian, CM; Aronne, LJ; Igel, LI; Saunders, KH; Sinha, A; Vojta, D, 2016) |
| "Despite the known glucose-lowering effects of metformin, more recent clinical interest lies in its potential as a weight loss drug." | 8.90 | Effects of metformin on weight loss: potential mechanisms. ( Kashyap, SR; Malin, SK, 2014) |
| "A review of the existing literature on weight loss through lifestyle modification and/or metformin treatment in overweight women with PCOS." | 8.89 | Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. ( Glintborg, D; Haugen, AG; Ravn, P, 2013) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 8.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "Metformin, the most widely prescribed medication for obesity-associated type 2 diabetes (T2D), lowers plasma glucose levels, food intake, and body weight in rodents and humans, but the mechanistic site(s) of action remain elusive." | 8.31 | Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight. ( Barros, DR; Bruce, K; Cherney, DZ; Chiu, JFM; Danaei, Z; Kuah, R; Lam, TKT; Li, RJW; Lim, YM; Mariani, LH; Reich, HN; Zhang, SY, 2023) |
| "We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic." | 8.12 | Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. ( Bi, Y; Feng, W; Fu, Y; Gao, L; Huang, H; Zhang, L; Zhang, N; Zhu, D, 2022) |
| "Metformin has been associated with modest weight reduction in the non-pregnant population." | 8.12 | Weight gain in pregnancy: can metformin steady the scales? ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Poehlmann, J; Racine, JL; Rhoades, J; Stewart, K, 2022) |
| "T2DM patients that performed regular exercise, had normal renal function and were receiving metformin were more likely to have clinically meaningful body weight reduction after one year treatment with dapagliflozin." | 8.12 | Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care. ( Huh, Y; Kim, YS, 2022) |
| " The aim of this study is the comparison of 3 mg liraglutide and metformin combination, metformin monotherapy on the blood glucose regulation, weight loss and lipid panel in the patients with Type 2 diabetes mellitus whose BMI is ≥ 30 kg/m2." | 8.12 | Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus. ( Keskin, L; Yaprak, B, 2022) |
| " Metformin increases insulin sensitivity, but it is associated with unsatisfied benefits of weight loss." | 8.02 | The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. ( Deng, Y; Ding, X; Ma, R; Sun, A; Wang, Y, 2021) |
| "This study investigated the effects of metformin and weight loss on biomarkers associated with breast cancer prognosis." | 7.88 | The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Laughlin, GA; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, BA; Patterson, RE; Sears, DD; Villaseñor, A, 2018) |
| "The present post hoc analysis investigated whether changes in endogenous glucagon-like peptide-1 (∆GLP-1) levels are associated with weight loss in newly diagnosed diabetes patients." | 7.85 | Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment. ( Wang, N; Wang, X; Xing, XY; Yang, WY; Yang, ZJ; Zhang, B; Zhang, JP, 2017) |
| "Canagliflozin 100 and 300 mg provided sustained reductions in body weight, BMI, and waist circumference in a greater proportion of patients with T2DM versus glimepiride or placebo over 104 weeks." | 7.83 | Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. ( Blonde, L; Canovatchel, W; Fung, A; Meininger, G; Stenlöf, K; Xie, J, 2016) |
| "The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS)." | 7.81 | The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. ( Atiomo, W; Chapman, C; Ghani, NA; Hatta, AZ; Malik, DA; Mokhtar, NM; Omar, MH; Seedhouse, C; Shafiee, MN; Yunos, RI, 2015) |
| " Metformin is a first-line treatment of type 2 diabetes, with minimal weight loss in humans." | 7.81 | Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice. ( Al-Barazanji, K; Benson, W; Binz, J; Chen, L; Generaux, C; McNulty, J; Young, A, 2015) |
| "The aim of this retrospective observational study was to evaluate whether adding liraglutide to lifestyle changes, metformin (Met) and testosterone replacement therapy (TRT), by means of improving weight and glycaemic control, could boost erectile function in type 2 diabetic obese men with overt hypogonadism and erectile dysfunction (ED) in a 'real-life setting'." | 7.81 | Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. ( Carbone, MD; De Pergola, G; Giagulli, VA; Guastamacchia, E; Licchelli, B; Ramunni, MI; Sabbà, C; Triggiani, V, 2015) |
| "Using ApoE−/− C57BL/6J mice, we found that metformin attenuates atherosclerosis and vascular senescence in mice fed a high‐fat diet and prevents the upregulation of angiotensin II type 1 receptor by a high‐fat diet in the aortas of mice." | 7.80 | Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. ( Alexander, RW; Fei, B; Forouzandeh, F; Hilenski, L; Patrushev, N; Salazar, G; Xiong, S, 2014) |
| "The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials with inconclusive results." | 7.79 | Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. ( Schehler, B; Schneider, HJ; Seifarth, C, 2013) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "Hyperuricemia may underlie obesity and related disorders, but the impact of weight reduction and metformin on serum uric acid (sUA) in Caucasian children/adolescents is unknown." | 7.77 | The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents. ( Chrzanowska, J; Gamian, A; Krzystek-Korpacka, M; Kustrzeba-Wojcicka, I; Noczynska, A; Patryn, E, 2011) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 7.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 7.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| "In 74 women with polycystic ovary syndrome, treated for 4 years with metformin (MET) and diet, we prospectively assessed whether, and to what degree, weight loss, reduction of insulin resistance, and amelioration of coronary heart disease risk factors could be sustained." | 7.73 | Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "In an observational study of 13 women with polycystic ovary syndrome (PCOS) not optimally responsive to metformin diet, we assessed the efficacy and safety of addition of pioglitazone." | 7.72 | Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. ( Glueck, CJ; Goldenberg, N; Moreira, A; Sieve, L; Wang, P, 2003) |
| "Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD)." | 6.94 | Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. ( Guo, W; Lin, L; Tian, W; Xu, X, 2020) |
| "Treatment with cetilistat 80 or 120 mg t." | 6.75 | Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). ( Bryson, A; Groot, Gde H; Hallam, R; Hickling, RI; Kopelman, P; Palmer, R; Rissanen, A; Rossner, S; Toubro, S, 2010) |
| "Metformin has been shown to improve insulin sensitivity and fibrinolysis." | 6.69 | Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. ( André, P; Charles, MA; Eschwège, E; Juhan-Vague, I; Morange, P; Vague, P, 1998) |
| "Metformin is a first-line therapy for type 2 diabetes." | 6.61 | Metformin: Mechanisms in Human Obesity and Weight Loss. ( Soukas, AA; Yerevanian, A, 2019) |
| "Weight gain is a clinically important side effect of antipsychotic drug therapy." | 6.47 | Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. ( Asplund, AB; Björkhem-Bergman, L; Lindh, JD, 2011) |
| " After adjustment for HbA1c, use of metformin and weight loss >5% were independently associated with slower increases in frailty." | 5.69 | An Examination of Whether Diabetes Control and Treatments Are Associated With Change in Frailty Index Across 8 Years: An Ancillary Exploratory Study From the Action for Health in Diabetes (Look AHEAD) Trial. ( Boyko, EJ; Espeland, MA; Ferris, CK; Justice, JN; Kritchevsky, SB; Munshi, MN; Pilla, SJ; Simpson, FR, 2023) |
| "In overweight or obese patients with T2DM, a once-weekly subcutaneous administration of PEG-Loxe for 16 weeks, in addition to lifestyle interventions or oral antidiabetic drug therapy, resulted in significantly greater weight loss compared to metformin." | 5.69 | Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. ( Cai, H; Chen, Q; Duan, Y; Zhang, X; Zhao, Y, 2023) |
| "Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events." | 5.69 | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. ( Chen, Q; Chen, Y; Fang, S; Liang, Y; Tian, Y; Wen, Q; Yuan, J, 2023) |
| " Behavioral weight loss and metformin have distinct effects on the gut microbiome, but their impact on gut permeability to lipopolysaccharides is unknown." | 5.51 | A behavioral weight-loss intervention, but not metformin, decreases a marker of gut barrier permeability: results from the SPIRIT randomized trial. ( Appel, LJ; Juraschek, SP; Maruthur, N; Miller, ER; Mueller, NT; Tilves, C; Yeh, HC, 2022) |
| " We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D." | 5.51 | Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects. ( Arguelles-Tello, FA; Barranco-Garduño, LM; Huerta-Cruz, JC; Kammar-García, A; Reyes-García, JG; Rocha-González, HI; Trejo-Jasso, CA, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 5.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "We investigated effects of weight loss, an intensive lifestyle intervention (ILS), and metformin on the relationship between insulin secretion and sensitivity using repository data from 2931 participants in the Diabetes Prevention Program clinical trial in adults at high risk of developing type 2 diabetes." | 5.51 | Weight Loss, Lifestyle Intervention, and Metformin Affect Longitudinal Relationship of Insulin Secretion and Sensitivity. ( Hanson, RL; Knowler, WC; Vazquez Arreola, E, 2022) |
| " The study determined the extent to which LNG-IUD with or without metformin (M) or weight loss (WL) achieves a pathological complete response (pCR) in patients with EAC or EHA." | 5.41 | Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. ( Alizart, M; Armes, JE; Chen, C; Chetty, N; Cummings, M; Eva, L; Garrett, A; Gebski, V; Hoet, G; Janda, M; Land, R; Leung, Y; McNally, O; Nicklin, JL; Obermair, A; Oehler, MK; Perrin, LC; Robledo, KP; Sowden, K; Sykes, P; Tang, A; Tristram, A; Walker, G, 2021) |
| "Cancer survivors with overweight or obesity were randomized to (1) self-directed weight loss (comparison), (2) coach-directed weight loss, or (3) metformin treatment." | 5.41 | Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial. ( Appel, LJ; Carducci, MA; Charleston, J; Dalcin, AT; Durkin, N; Hassoon, A; Jerome, GJ; Juraschek, SP; Kanarek, NF; Lansey, DG; Maruthur, NM; Miller, ER; Mueller, NT; Tseng, E; Wang, NY; White, K; Yeh, HC, 2021) |
| "To determine the longer-term effects of metformin treatment and behavioral weight loss on gut microbiota and short-chain fatty acids (SCFAs)." | 5.41 | Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial. ( Appel, LJ; Differding, MK; Juraschek, SP; Maruthur, NM; Miller, ER; Mueller, NT; Yeh, HC; Zhang, M, 2021) |
| "Metformin has beneficial effects on insulin resistance and endothelial functions." | 5.38 | The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. ( Akpek, M; Calapkorur, B; Celik, A; Karaca, Z; Kaya, MG; Kelestimur, F; Unluhizarci, K; Yildirim, S, 2012) |
| "Forty metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes mellitus, received liraglutide (1." | 5.34 | Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. ( Boccatonda, A; Cipollone, F; Consoli, A; Di Castelnuovo, A; Guagnano, MT; Liani, R; Santilli, F; Simeone, PG; Tripaldi, R; Vadini, F, 2020) |
| " We evaluated whether liraglutide in combination with metformin (MET-LIRA) is more effective than metformin monotherapy (MET-P) in improving insulin action and reducing body weight in overweight prior GDM (pGDM) women." | 5.34 | Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled ( Elkind-Hirsch, KE; Harris, R; Shaler, D, 2020) |
| " The use of dapagliflozin in this population could improve weight loss and other cardiovascular factors." | 5.34 | Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial. ( Espinosa, E; Ferreira-Hermosillo, A; Garrido-Mendoza, AP; Mendoza-Zubieta, V; Mercado, M; Molina-Ayala, MA; Molina-Guerrero, D; Ramírez-Rentería, C, 2020) |
| "Metformin was assessed as a treatment for weight gain in children taking olanzapine, risperidone, quetiapine, or valproate." | 5.31 | Metformin for weight loss in pediatric patients taking psychotropic drugs. ( Barton, BA; Cottingham, EM; Morrison, JA, 2002) |
| ", the Diabetes Prevention Program) and metformin reduce type 2 diabetes risk among patients with prediabetes." | 5.30 | Effectiveness of Shared Decision-making for Diabetes Prevention: 12-Month Results from the Prediabetes Informed Decision and Education (PRIDE) Trial. ( Castellon-Lopez, Y; Chon, JS; Duru, OK; Frosch, DL; Jeffers, KS; Mangione, CM; Martin, JM; Moin, T; Norris, K; Tseng, CH; Turk, N, 2019) |
| " To study the combined efficacy of exercise and metformin on above parameters in women with polycystic ovary syndrome." | 5.30 | Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. ( Jain, S; Pasrija, S; Tiwari, N, 2019) |
| "The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo." | 5.30 | Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study. ( Apolzan, JW; Boyko, EJ; Dabelea, D; Edelstein, SL; Franks, PW; Gadde, KM; Kalyani, RR; Knowler, WC; Pi-Sunyer, X; Srikanthan, P; Venditti, EM, 2019) |
| "Overweight/obese postmenopausal breast cancer survivors (n = 333) were randomized to a weight loss intervention versus control and metformin versus placebo in a 2 × 2 factorial design." | 5.30 | The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study. ( Hartman, SJ; Marinac, CR; Natarajan, L; Nelson, SH; Parker, BA; Patterson, RE, 2019) |
| "This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD)." | 5.27 | Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. ( Fushimi, N; Hachiya, H; Ito, S; Kawai, H; Kawai, M; Mori, A; Ohashi, N; Shibuya, T; Yoshida, Y, 2018) |
| " PCOS is associated with obesity, dyslipidaemia and insulin resistance, and metformin treatment may improve such metabolic features." | 5.27 | The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. ( Andersen, M; Christensen, MMH; Glintborg, D; Pedersen, AJT; Stage, TB, 2018) |
| " Although there is evidence for weight loss with metformin for people with obesity who are already taking clozapine, there have been no published trials that have investigated the effect of metformin in attenuating weight gain at the time of clozapine initiation." | 5.27 | CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. ( Baker, A; Flaws, D; Friend, N; Kisely, S; Lim, C; McGrath, JJ; Moudgil, V; Patterson, S; Russell, A; Sardinha, S; Siskind, D; Stedman, T; Suetani, S; Winckel, K, 2018) |
| "Proof-of-concept study to investigate the amplifying effects of diazoxide (DZX)-mediated insulin suppression on lifestyle-induced weight loss in nondiabetic, hyperinsulinemic, obese men." | 5.27 | High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention. ( Brandon, T; de Boer, H; Filius, M; Hermus, A; Loves, S; Mekking, M; Tack, CJ; van Groningen, L, 2018) |
| "001) and the average weight loss was 2 kg after 16 weeks' treatment of metformin." | 5.24 | The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from data of a phase IV open-labeled trial. ( Cai, X; Han, X; Ji, L; Yang, W; Zhou, L, 2017) |
| "Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1." | 5.24 | Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. ( Angelucci, E; Bonadonna, RC; Cianfarani, S; Consoli, A; Davì, G; Di Castelnuovo, A; Federico, V; Guagnano, MT; Leo, M; Maccarone, MT; Manzoli, L; Santilli, F; Sborgia, C; Simeone, PG; Tartaro, A, 2017) |
| "Steady-state population pharmacokinetics of a noncommercial immediate-release metformin (hydrochloride) drug product were characterized in 28 severely obese children with insulin resistance." | 5.24 | Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ( Alfaro, RM; Calis, KA; Hon, YY; Reynolds, JC; Roza, O; Sam, WJ; Yanovski, JA, 2017) |
| "Liraglutide 3 mg was recently approved as an anti-obesity drug." | 5.24 | Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. ( Goričar, K; Janez, A; Jensterle, M; Kravos, NA, 2017) |
| "In the first comparative effectiveness trial of diabetes prevention treatments, a 12-month ILI produced significantly greater weight loss than metformin and standard care among Latinas with prediabetes." | 5.24 | PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin. ( Ackermann, RT; Alos, VA; Ciolino, JD; Foster, GD; Homko, C; O'Brien, MJ; Perez, A; Scanlan, AB; Whitaker, RC, 2017) |
| "This meta-analysis focused on the slimming effect, safety, and correlation of metformin, orlistat, exenatide, liraglutide, and topiramate in children with obesity." | 5.22 | Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis. ( Liu, H; Wu, F; Xie, Y; Yin, S; Zhang, Q; Zhao, G, 2022) |
| "In combination with a novel carbohydrate modified diet, metformin enhanced 12-month weight loss and improved body composition in ethnically diverse normoglycemic, hyperinsulinemic women with midlife weight gain." | 5.22 | METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN. ( Freeman, R; Mogul, H; Nguyen, K, 2016) |
| "Changes in weight, waist circumference, estimated total body fat, index of central obesity and visceral adiposity index were assessed using analysis of covariance and testing of treatment by strata for age, sex and baseline waist circumference in patients with type 2 diabetes mellitus randomized to blinded treatment with empagliflozin versus placebo in clinical trials of 12 weeks (cohort 1) or 24 weeks (cohort 2) duration." | 5.22 | Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. ( Broedl, UC; Chilton, R; Crowe, S; Johansen, OE; Lund, SS; McGuire, DK; Neeland, IJ; Woerle, HJ, 2016) |
| "These results suggest that the effect of exenatide on weight loss may be related with the suppression of serum ghrelin levels, which is an orexigenic peptide." | 5.22 | Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women. ( Cavun, S; Guclu, M; Gul, Z; Kisakol, G; Kiyici, S; Sigirli, D; Topyildiz, F, 2016) |
| "The effects of a 1year period of intensive lifestyle change aimed at achieving 7% weight loss or metformin 850mg twice daily versus placebo on HDL-C were assessed in 3070 participants with impaired glucose tolerance, and on HDL particle concentration (HDL-P) and size in a subgroup of 1645 individuals." | 5.22 | Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. ( Bray, G; Goldberg, RB; Horton, E; Kitabchi, A; Krakoff, J; Marcovina, S; Mather, K; Mele, L; Orchard, T; Perreault, L; Temprosa, M; White, N, 2016) |
| "Our results show that Metformin and acupuncture combined therapy significantly improves body weight, body mass index (BMI), fasting blood sugar (FBS), fasting insulin (FINS), homeostasis model assessment (HOMA) index, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), leptin, adiponectin, glucagon-like peptide-1 (GLP-1), resistin, serotonin, free fatty acids (FFAs), triglyceride (TG), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and ceramides." | 5.22 | Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients. ( Firouzjaei, A; Li, GC; Liu, WX; Wang, N; Zhu, BM, 2016) |
| "To evaluate the proportion of patients with type 2 diabetes mellitus (T2DM) achieving reductions in both glycated hemoglobin (HbA1c) and body weight with canagliflozin, a sodium glucose co-transporter 2 inhibitor, versus sitagliptin over 52 weeks." | 5.22 | Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes. ( Canovatchel, W; Davidson, JA; Jodon, H; Lavalle-González, FJ; Qiu, R; Schernthaner, G; Vijapurkar, U, 2016) |
| "Beneficial effects were observed on serum leptin concentration, weight loss, and body composition for all interventions and in all examined groups, with the greatest advantage being associated with the orlistat treatment." | 5.22 | Improvement of serum adiponectin and leptin concentrations: effects of a low-calorie or isocaloric diet combined with metformin or orlistat - a prospective randomized open-label trial. ( Bogdański, P; Grzymisławska, M; Kargulewicz, A; Kręgielska-Narożna, M; Kujawska-Łuczak, M; Musialik, K; Swora-Cwynar, E; Szulińska, M, 2016) |
| " This study aimed to explore the association between the estimated insulin demand of the diet, as measured by glycemic and insulin load, weight loss, percentage body fat and insulin sensitivity index (ISI) in obese adolescents with clinical features of insulin resistance and/or prediabetes after a 3 month lifestyle and metformin intervention." | 5.20 | Dietary glycemic load, insulin load, and weight loss in obese, insulin resistant adolescents: RESIST study. ( Buyken, AE; Cowell, CT; Garnett, SP; Goletzke, J; Gow, M; Halim, J; Ho, M; Joslowski, G; Louie, JC, 2015) |
| " Women were randomized to intensive lifestyle change (ILS) with the goals of weight reduction of at least 7% of initial weight and 150 min per week of moderate-intensity exercise, metformin 850 mg twice a day, or placebo administered twice a day." | 5.20 | Weight loss increases follicle stimulating hormone in overweight postmenopausal women [corrected]. ( Barrett-Connor, E; Golden, SH; Kim, C; Kong, S; Labrie, F; Nan, B; Randolph, JF, 2015) |
| "This study was undertaken to determine whether metformin would ameliorate insulin resistance, reduce weight and waist circumference and improve lipids in obese, but not morbidly obese, euglycemic women." | 5.20 | Metformin for overweight women at midlife: a double-blind, randomized, controlled trial. ( Bell, RJ; Davis, SR; Jane, F; Robinson, PJ; Worsley, R, 2015) |
| "We sought to compare weight loss in the first 6 weeks postpartum among women with gestational diabetes mellitus (GDM) treated with metformin or placebo, a promising therapy to reduce later risk of progression to diabetes mellitus." | 5.20 | The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial. ( Blackwell, SC; Hutchinson, M; Pedroza, C; Ramin, SM; Refuerzo, JS; Tyson, JE; Viteri, OA, 2015) |
| " The diabetic medication, Metformin, reduces IR and aids weight loss and may therefore regress LVH." | 5.20 | Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study. ( Baig, F; Lang, CC; McSwiggan, S; Mohan, M; Rutherford, L, 2015) |
| "Short-term monotherapy with liraglutide or roflumilast was associated with significant weight loss in obese PCOS." | 5.20 | Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. ( Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E, 2015) |
| "5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia." | 5.20 | Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). ( Benroubi, M; Giorgino, F; Pechtner, V; Sun, JH; Zimmermann, AG, 2015) |
| "The Diabetes Prevention Program randomized overweight or obese dysglycemic participants to lifestyle change with the goals of weight reduction of >7% of initial weight and 150 minutes per week of exercise, metformin, or placebo." | 5.19 | Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program. ( Barrett-Connor, E; Golden, SH; Kim, C; Kong, S; Mather, KJ; Nan, B; Randolph, JF, 2014) |
| "The effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory." | 5.19 | Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. ( Janez, A; Jensterle Sever, M; Kocjan, T; Kravos, NA; Pfeifer, M, 2014) |
| "IDeg+Lira improved long-term glycaemic control, with weight loss and less hypoglycaemia versus adding a single daily dose of IAsp in patients with T2DM inadequately controlled with IDeg + metformin." | 5.19 | A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). ( Cariou, B; Handelsman, Y; Mathieu, C; Ocampo Francisco, AM; Philis-Tsimikas, A; Rana, A; Rodbard, HW; Zinman, B, 2014) |
| "This study evaluated change in health-related quality of life (HRQOL) associated with ongoing weight change among patients with type 2 diabetes mellitus (T2DM) treated with dapagliflozin, a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by increasing urinary glucose excretion and is associated with body weight reductions." | 5.19 | Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. ( Grandy, S; Hashemi, M; Langkilde, AM; Parikh, S; Sjöström, CD, 2014) |
| "To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia." | 5.19 | Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. ( Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D, 2014) |
| "In obese, difficult-to-treat patients with T2DM inadequately controlled on high MDI insulin doses, empagliflozin improved glycemic control and reduced weight without increasing the risk of hypoglycemia and with lower insulin requirements." | 5.19 | Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. ( Broedl, UC; Frappin, G; Jelaska, A; Kim, G; Rosenstock, J; Salsali, A; Woerle, HJ, 2014) |
| " The primary aim is to determine the efficacy of: levonorgestrel intrauterine device (LNG-IUD); with or without metformin (an antidiabetic drug); and with or without a weight loss intervention to achieve a pathological complete response (pCR) in EC at six months from study treatment initiation." | 5.19 | Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial. ( Armes, J; Brennan, D; Gebski, V; Hawkes, AL; Janda, M; Obermair, A; Quinn, M, 2014) |
| "5% (48 mmol/mol) from 8 to 33%, a rapid reduction in alanine aminotransferase (∼10 units/L), and weight loss (2%) in metformin-cotreated patients." | 5.19 | Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study. ( Chambers, J; Krippner, G; MacGinley, R; Nicholson, GC; Orford, N; Phillips, G; Proietto, J; Sanders, KM; Sarah, A; Simpson, RW; Skoff, K; Wacher, VJ; Walder, K, 2014) |
| "Diabetes prevention program (DPP) participants (N = 3,819, of whom 3,356 were genotyped for baseline and 3,234 for longitudinal analyses) were randomized into intensive lifestyle modification (diet, exercise, weight loss), metformin or placebo control." | 5.17 | Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the diabetes prevention program. ( Delahanty, LM; Florez, JC; Franks, PW; Jablonski, KA; Kahn, SE; Knowler, WC; Pan, Q, 2013) |
| "The aim of this study was to evaluate the effectiveness of sitagliptin, alone or in combination with metformin, in kidney transplant patients with newly diagnosed new-onset diabetes mellitus after transplant who had inadequate glycemic control, compared with a group of patients receiving insulin glargine with special emphasis on weight gain." | 5.17 | Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant. ( Fathy, A; Khashab, S; Shaheen, N; Soliman, AR; Soliman, MA, 2013) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 5.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| "In patients with type 2 diabetes, empagliflozin resulted in dose-dependent, clinically meaningful reductions in HbA1c and FPG, and reductions in body weight compared with placebo." | 5.17 | A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. ( Ferrannini, E; Hantel, S; Pinnetti, S; Seewaldt-Becker, E; Seman, L; Woerle, HJ, 2013) |
| " We assessed serum lipocalin-2 levels in polycystic ovary syndrome (PCOS) and the effects of weight loss or metformin on these levels." | 5.16 | Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. ( Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C, 2012) |
| "We tested genetic associations with weight loss and weight regain in the Diabetes Prevention Program, a randomized controlled trial of weight loss-inducing interventions (lifestyle and metformin) versus placebo." | 5.16 | Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program. ( Delahanty, LM; Florez, JC; Franks, PW; Jablonski, KA; Kahn, SE; Knowler, WC; McCaffery, JM; Pan, Q; Shuldiner, A; Watson, KE, 2012) |
| "Exenatide is an analogue of GLP1 designed to improve the glycemic control in patients with obesity and type 2 diabetes." | 5.16 | [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide]. ( Ferrer Gómez, M; García Zafra, MV; Hellín Gil, MD; Pujante Alarcón, P; Román, LM; Tébar Massó, J, 2012) |
| "The objective was to determine the effect of metformin on the concentrations of resistin and other markers of insulin resistance or inflammation (C-reactive protein, cytokines, body weight, HbA1c, among others) in minors with glucose intolerance." | 5.16 | Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial. ( Aguilar-Salinas, CA; Cruz, M; Gómez-Díaz, RA; Mondragón-González, R; Ortiz-Navarrete, FV; Pool, EC; Solórzano-Santos, F; Talavera, JO; Valladares-Salgado, A; Wacher, NH, 2012) |
| "Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP)." | 5.16 | Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. ( , 2012) |
| "Canagliflozin added onto metformin significantly improved glycemic control in type 2 diabetes and was associated with low incidence of hypoglycemia and significant weight loss." | 5.16 | Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. ( Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y, 2012) |
| "The addition of vildagliptin to metformin gave a better improvement of glycemic control, insulin resistance, and β-cell function compared with metformin alone." | 5.16 | Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. ( Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D, 2012) |
| "Eligible patients 10 to 17 years of age were treated with metformin (at a dose of 1000 mg twice daily) to attain a glycated hemoglobin level of less than 8% and were randomly assigned to continued treatment with metformin alone or to metformin combined with rosiglitazone (4 mg twice a day) or a lifestyle-intervention program focusing on weight loss through eating and activity behaviors." | 5.16 | A clinical trial to maintain glycemic control in youth with type 2 diabetes. ( Arslanian, S; Copeland, K; Cuttler, L; Hirst, K; Kaufman, F; Linder, B; Nathan, DM; Pyle, L; Tollefsen, S; Wilfley, D; Zeitler, P, 2012) |
| "To determine if metformin improves markers of inflammation, thrombosis, and intrahepatic fat contents in children with uncomplicated obesity." | 5.16 | Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat. ( Balagopal, P; Bird, K; Damaso, L; DelGiorno, C; Hossain, J; Killen, K; Mauras, N; Merinbaum, D; Weltman, A, 2012) |
| "Exenatide demonstrated more beneficial effects on HbA(1C), weight reduction and insulin resistance during 26 weeks of treatment, but there were more hypoglycemic events and mild-to-moderate nausea compared with metformin." | 5.16 | Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. ( Gao, Y; Guo, XH; Huang, YY; Song, WL; Yuan, GH, 2012) |
| " Weight, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) index as well as serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), insulin, total and direct bilirubin, fasting blood sugar (FBS), glycated hemoglobin (HbA1c), uric acid, albumin and lipid profile were evaluated at baseline and at the end of trial." | 5.16 | Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. ( Beiraghdar, F; Ghamarchehreh, ME; Jalalian, HR; Panahi, Y; Sahebkar, A; Zare, R, 2012) |
| " Liraglutide provides greater sustained glycaemic control and body weight reduction over 52 weeks." | 5.15 | One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. ( Bailey, T; Cuddihy, R; Davies, M; Filetti, S; Garber, A; Hartvig, H; Montanya, E; Nauck, M; Pratley, R; Thomsen, AB, 2011) |
| "Both metformin and orlistat show a similar effect on weight loss, ovulation rates and androgen concentrations." | 5.14 | An RCT of metformin versus orlistat for the management of obese anovulatory women. ( Amer, S; Ledger, WL; Li, TC; Metwally, M, 2009) |
| "Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia." | 5.14 | Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. ( Fiedorek, FT; List, JF; Morales, E; Tang, W; Woo, V, 2009) |
| "Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with polycystic ovary syndrome (PCOS) compared to metformin." | 5.14 | Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2009) |
| " Among the treatment groups, EE/CA-metformin may be a more effective therapeutic option than the other protocols and this may be due to the beneficial effect of EE/CA-metformin on insulin resistance." | 5.14 | Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. ( Alacacioglu, A; Kebapcilar, AG; Kebapcilar, L; Sari, I; Taner, CE, 2010) |
| " We evaluated whether changes in body weight were associated with changes in health utilities in the Diabetes Prevention Program (DPP) and whether associations differed by treatment assignment (lifestyle intervention, metformin, placebo) or baseline obesity severity." | 5.14 | Changes in health state utilities with changes in body mass in the Diabetes Prevention Program. ( Ackermann, RT; Edelstein, SL; Engelgau, MM; Herman, WH; Marrero, DG; Narayan, KM; Zhang, P, 2009) |
| "Metformin was assessed as an interventional medication for weight gain in children and adolescents taking atypical antipsychotic agents." | 5.14 | Metformin for weight control in pediatric patients on atypical antipsychotic medication. ( Breeze, JL; Bregman, H; Frazier, JA; Noyes, N; Shin, L, 2009) |
| " The modest weight loss with metformin was maintained." | 5.14 | 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. ( Brenneman, AT; Brown-Friday, JO; Christophi, CA; Fowler, SE; Goldberg, R; Hamman, RF; Hoffman, HJ; Knowler, WC; Nathan, DM; Venditti, E, 2009) |
| "Sibutramine and metformin are drugs commonly used to obtain weight loss." | 5.14 | Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. ( Akbas, H; Coban, E; Eray, E; Ozdem, S; Sari, R, 2010) |
| "Our study shows that in severely obese, non-diabetic, hyperinsulinaemic patients undergoing a nutritional programme, rosiglitazone is more effective than metformin in producing favourable changes in fasting-based indexes of glucose metabolism, with a reduction of both insulin resistance and hyperinsulinaemia." | 5.13 | Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients. ( Brunani, A; Castagna, G; Caumo, A; Graci, S; Liuzzi, A; Viberti, G, 2008) |
| "7), 439 patients (40%) who received treatment with diet alone, diet followed by metformin or metformin alone demonstrated a maintained weight reduction in addition to improved glycaemic control." | 5.13 | Weight changes in type 2 diabetes and the impact of gender. ( McKenna, MJ; McKenna, TJ; O'Shea, D; Tuthill, A, 2008) |
| "To test the efficacy of lifestyle intervention and metformin alone and in combination for antipsychotic-induced weight gain and abnormalities in insulin sensitivity." | 5.13 | Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. ( Chen, JD; Fang, MS; Guo, XF; He, YQ; Jin, H; Li, LH; Liu, YJ; Shao, P; Wu, RR; Zhao, JP, 2008) |
| "While exenatide treatment provided similarly effective glycemic control compared with insulin analogue therapy, it was also associated with weight reduction in the majority of subjects (73." | 5.13 | Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. ( Bergenstal, RM; Brodows, R; Gates, JR; Glass, LC; Kim, D; Lenox, S; Qu, Y; Trautmann, M, 2008) |
| "Metformin (850-1700 mg) plus sibutramine (10-20 mg, n=13) or placebo (n=15) was administered for 12 weeks in olanzapine-treated chronic schizophrenia patients." | 5.13 | Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. ( Baptista, T; Beaulieu, S; de Baptista, EA; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E, 2008) |
| "To compare the effects of insulin sensitization with metformin to weight reduction by rimonabant on biochemical hyperandrogenaemia and insulin resistance in patients with PCOS." | 5.13 | A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2008) |
| "To provide the specific weight loss outcomes for African-American, Hispanic, and white men and women in the lifestyle and metformin treatment arms of the Diabetes Prevention Program (DPP) by race-gender group to facilitate researchers translating similar interventions to minority populations, as well as provide realistic weight loss expectations for clinicians." | 5.13 | Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program. ( Bursac, Z; Elaine Prewitt, T; Felix, HC; West, DS, 2008) |
| "The beneficial effects of metformin in patients with type 2 diabetes mellitus (T2DM) and polycystic ovarian syndrome (PCOS) are thought to be in part due to weight reduction." | 5.13 | Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS). ( Batterham, RL; Conway, GS; Tsilchorozidou, T, 2008) |
| "In a randomized double-blind placebo controlled trial, 85 adolescents with insulin resistance were randomized to receive metformin (70%) or placebo (30%), along with monthly goal setting for diet and exercise modification." | 5.13 | Addition of metformin to a lifestyle modification program in adolescents with insulin resistance. ( Love-Osborne, K; Sheeder, J; Zeitler, P, 2008) |
| " Metformin is known to decrease insulin resistance and is also associated with weight loss." | 5.12 | Postpartum Use of Weight Loss and Metformin for the Prevention of Type 2 Diabetes Mellitus: a Review of the Evidence. ( Ayala, NK; Werner, EF; Whelan, AR, 2021) |
| " Therefore, this study assessed the effect of sitagliptin as monotherapy and add-on therapy to metformin on weight reduction in overweight or obese cases with type 2 diabetes." | 5.12 | Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. ( Bamehr, H; Janani, L; Mirzabeigi, P; Montazeri, H; Tanha, K; Tarighi, P, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 5.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "Topiramate was effective for weight reduction and improvement in glycemic control in obese subjects with type 2 diabetes treated with metformin monotherapy." | 5.12 | Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. ( Fitchet, M; Gorska, M; Hamann, A; Masson, E; Moore, R; Sun, X; Toplak, H; Vercruysse, F, 2007) |
| "8 kg/m2, we assessed effeicacy of metformin-diet for 1 year for reduction of weight, insulin, HOMA insulin resistance (IR), cholesterol, triglycerides, and resumption of regular menses." | 5.12 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Luo, G; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "In comparison with placebo (n = 17), metformin recipients (n = 16) showed significant reductions in weight and in homeostatic model assessment for insulin resistance (p < 0." | 5.12 | Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study. ( Cobbe, SM; Ferrell, W; Greer, IA; Jadhav, S; Petrie, JR; Sattar, N, 2006) |
| "This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo." | 5.12 | An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007) |
| "to compare the clinical, hormonal and biochemical changes after the application of the two ways of influence upon insulin resistance in women with PCOS - reduction of weight and application of metformin." | 5.12 | [Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome]. ( Kavŭrdzhikova, S; Mitkov, M; Pekhlivanov, B, 2006) |
| " The Diabetes Prevention Program (DPP) recruited and randomized individuals with impaired glucose tolerance to treatment with placebo, metformin, or lifestyle modification." | 5.12 | Body size and shape changes and the risk of diabetes in the diabetes prevention program. ( Barrett-Connor, E; Bray, GA; Fujimoto, WY; Haffner, S; Hanson, R; Hill, JO; Hubbard, V; Jablonski, KA; Kriska, A; Pi-Sunyer, FX; Stamm, E, 2007) |
| "Our aim was to investigate the effect of pre-treatment with metformin in women with polycystic ovary syndrome (PCOS) scheduled for IVF stimulation." | 5.11 | Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. ( Carlsen, SM; Kjøtrød, SB; von Düring, V, 2004) |
| "The effect of metformin (1000 mg twice a day) on markers of endothelial activation, inflammation, and coagulation was investigated in subjects with impaired glucose tolerance (IGT) in a 16-wk, randomized, placebo-controlled, double-blind study." | 5.11 | The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. ( Aguilar-Salinas, CA; Caballero, AE; Cabrera, T; Castillo, JL; Delgado, A; Gomez-Perez, FJ; Herrera, AN; Rull, JA, 2004) |
| " Modest weight reduction was found in all treatment groups, with the most significant reduction occurring with the combination of metformin and lifestyle intervention." | 5.11 | A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. ( Craig, K; Guzick, DS; Hoeger, KM; Kochman, L; Miller, RK; Wixom, N, 2004) |
| "Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility." | 5.11 | Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004) |
| " metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS)." | 5.11 | Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. ( Atkin, SL; Holding, S; Jayagopal, V; Jennings, PE; Kilpatrick, ES, 2005) |
| "Orlistat, in combination with a reduced calorie diet and a weight management programme, promotes weight loss and clinically relevant improvements in glycaemic control and other cardiovascular risk factors in obese patients with Type 2 diabetes." | 5.11 | A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. ( Berne, C, 2005) |
| "Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses." | 5.11 | Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. ( Fleming, R; Harborne, LR; Norman, JE; Sattar, N, 2005) |
| "Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity." | 5.11 | Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. ( Allen, HF; Heptulla, RA; Koenigs, L; Mazzoni, C; Miller, N; Murray, MA; Reiter, EO, 2005) |
| "We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week." | 5.10 | Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. ( Barrett-Connor, E; Fowler, SE; Hamman, RF; Knowler, WC; Lachin, JM; Nathan, DM; Walker, EA, 2002) |
| "The results of this study confirm that sibutramine, orlistat and metformin are all effective and safe medications that reduce cardiovascular risk and can decrease the risk of type 2 diabetes mellitus in obese females." | 5.10 | Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. ( BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N, 2002) |
| "To assess the effect of metformin on insulin sensitivity, glucose tolerance and components of the metabolic syndrome in patients with impaired glucose tolerance (IGT)." | 5.09 | Metabolic effects of metformin in patients with impaired glucose tolerance. ( Eriksson, JG; Forsén, B; Groop, L; Gullström, M; Häggblom, M; Lehtovirta, M; Taskinen, MR, 2001) |
| "The addition of sibutramine to oral hypoglycemic therapy resulted in significant weight loss and improvement in metabolic parameters in this patient group." | 5.09 | Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. ( Ertorer, EM; Gokcel, A; Guvener, N; Karakose, H; Tanaci, N; Tutuncu, NB, 2001) |
| "Metformin often promotes weight loss in patients with obesity with non-insulin-dependent diabetes mellitus (NIDDM)." | 5.08 | Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. ( Lee, A; Morley, JE, 1998) |
| "Metformin effects on insulin resistance and insulin/glucose relationships during an oral glucose tolerance test (OGTT) were investigated in 60 non-diabetic male patients previously treated with coronary artery bypass surgery or angioplasty in an open, 12 week prospective study." | 5.08 | Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease. ( Carlsen, SM; Følling, I; Grill, V, 1998) |
| " Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus." | 5.05 | Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. ( Constantinidou, KG; Filippou, PK; Papaetis, GS; Stylianou, CS, 2020) |
| " conclude that metformin, a drug used for treatment of type 2 diabetes mellitus, can be used effectively for weight loss, and that this effect is even more pronounced in individuals who weigh more at baseline." | 5.01 | Neglecting regression to the mean continues to lead to unwarranted conclusions: Letter regarding "The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from ( Allison, DB; Hannon, BA; Siu, CO; Thomas, DM, 2019) |
| "In September 2018, we searched PubMed, Embase, and the Cochrane Library for studies published in English using the keywords metformin, obesity/overweight, and weight loss." | 4.98 | Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. ( Knibbe, CAJ; Lentferink, YE; van der Vorst, MMJ, 2018) |
| " The vast majority of published data on insulin sensitizing PCOS treatments are reported in adult women; these have included weight loss, metformin, thiazolidinediones, and the inositols." | 4.95 | Insulin sensitizers in adolescents with polycystic ovary syndrome. ( LE, TN; Nestler, JE; Wickham, EP, 2017) |
| "English-language trials of benefits or harms of screening or treatment (behavior-based, orlistat, metformin) for overweight or obesity in children aged 2 through 18 years, conducted in or recruited from health care settings." | 4.95 | Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Burda, BU; Eder, M; Evans, CV; Lozano, P; O'Connor, EA; Walsh, ES, 2017) |
| " If the patient does not respond with a weight loss of at least 5% and if the HbA1C values are not normalized, pharmacological management should be initiated with a metformin dose of 500 mg / day, increasing up to 1,500 - 1,700 mg / day, according to tolerance." | 4.95 | Prediabetes in Colombia: Expert Consensus. ( Calderón, C; Castillo, J; Escobar, ID; López-Jaramillo, P; Melgarejo, E; Parra, GA, 2017) |
| "Metformin is not currently used for weight loss or diabetes prevention because it lacks an FDA indication for obesity and/or pre-diabetes treatment." | 4.93 | Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity. ( Apovian, CM; Aronne, LJ; Igel, LI; Saunders, KH; Sinha, A; Vojta, D, 2016) |
| "Orlistat should be considered as an addition to lifestyle interventions in the treatment of obesity." | 4.90 | The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. ( Carter, P; Chilton, M; Davies, MJ; Dunkley, A; Gray, LJ; Khunti, K, 2014) |
| "A MEDLINE, Pubmed and Cochrane Review database search using a combination of keywords, which included non-alcoholic fatty liver disease, non-alcoholic hepatic steatosis, NAFLD, NASH, treatment, therapeutics, vitamin E, orlistat and bariatric surgery." | 4.90 | Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. ( Henry, L; Mehta, R; Mishra, A; Reyes, MJ; Younossi, ZM, 2014) |
| "The effect of acarbose on weight loss seems to be more pronounced in Eastern than in Western populations with hyperglycaemia, and is superior to that of placebo, nateglinide and metformin across both ethnicities." | 4.90 | Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-analysis. ( Huang, L; Li, Y; Tong, N; Tong, Y; Wu, T; Zhang, Y, 2014) |
| "Despite the known glucose-lowering effects of metformin, more recent clinical interest lies in its potential as a weight loss drug." | 4.90 | Effects of metformin on weight loss: potential mechanisms. ( Kashyap, SR; Malin, SK, 2014) |
| "A review of the existing literature on weight loss through lifestyle modification and/or metformin treatment in overweight women with PCOS." | 4.89 | Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. ( Glintborg, D; Haugen, AG; Ravn, P, 2013) |
| "7% as monotherapy or in combination with metformin (MET), sulfonylureas (SFU), and/or thiazolidinediones (TZD); with mean weight losses of -1." | 4.89 | Evolution of exenatide as a diabetes therapeutic. ( Bhavsar, S; Cherrington, A; Mudaliar, S, 2013) |
| "Substantial evidence confirms the weight benefits of metformin and shows that, of the newer available agents, glucagon-like peptide-1 (GLP-1) agonists and amylin analogs promote weight loss." | 4.87 | Weight beneficial treatments for type 2 diabetes. ( Caputo, S; Damçi, T; Khunti, K; Liebl, A; Meneghini, LF; Orozco-Beltran, D; Ross, SA, 2011) |
| " Agents that decrease intestinal carbohydrate digestion (alpha-glucosidase inhibitors) or decrease insulin resistance (metformin) might be alternative adjunctive therapies in T1DM, though its benefits are marginally supported by clinical data." | 4.86 | Adjunct therapy for type 1 diabetes mellitus. ( Lebovitz, HE, 2010) |
| " Results showed that (i) polycystic ovary syndrome is a risk factor forT2DM but the magnitude of risk is uncertain, (ii) fasting plasma glucose is an inadequate screening test forT2DM in this population and the oral glucose tolerance test is superior, (iii) the identification of women with PCOS for diabetes screening is constrained by current diagnostic criteria for PCOS; however, women with oligomenorrhoea and those with diagnosed PCOS and obesity or a family history of T2DM are at highest risk, (iv) risk factors for T2DM are improved by weight loss interventions and by metformin." | 4.86 | Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? ( Millward, A; Pinkney, J; Stenhouse, E; Tomlinson, J, 2010) |
| " Metformin has attracted attention as a potential treatment option because it is thought to result in weight reduction and improved glycemic control in obese patients with and without type 2 diabetes mellitus." | 4.86 | The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review. ( Ali, F; Dahmen, MM; Girrens, K; Khan, AY; Macaluso, M; McHale, RJ, 2010) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: finasteride, flutamide, metformin, spironolactone, cyproterone acetate-ethinylestradiol (co-cyprindiol), interventions to achieve weight loss, ketoconazole, and mechanical hair removal." | 4.85 | PCOS. ( Cahill, D, 2009) |
| " Metformin is currently the preferred insulin-sensitizing drug for chronic treatment of PCOS and has been shown to improve the metabolic profile, menstrual cyclicity and fertility in women with PCOS, and is associated with weight loss." | 4.85 | Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Palermo, V; Petraglia, F, 2009) |
| "To evaluate the efficacy and safety of metformin for weight management in overweight and obese patients without type 2 diabetes." | 4.84 | Role of metformin for weight management in patients without type 2 diabetes. ( Desilets, AR; Dhakal-Karki, S; Dunican, KC, 2008) |
| " This review provides information regarding diagnosis of type 2 diabetes in children, as well as prevention strategies, such as lifestyle modification and pharmacologic options for weight loss, including metformin, orlistat, and sibutramine." | 4.83 | The treatment of type 2 diabetes mellitus in youth : which therapies? ( Miller, JL; Silverstein, JH, 2006) |
| " Both of them clearly demonstrate the possibility to delay and/or prevent the onset of type 2 diabetes in at high-risk subjects with impaired glucose tolerance, through changes in lifestyle (dietary intervention, weight reduction, increased physical activity) or drug treatment (metformin, acarbose, orlistat)." | 4.82 | [Is it possible to prevent type 2 diabetes?]. ( Laville, M, 2003) |
| " In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome." | 4.82 | Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003) |
| "Metformin, the most widely prescribed medication for obesity-associated type 2 diabetes (T2D), lowers plasma glucose levels, food intake, and body weight in rodents and humans, but the mechanistic site(s) of action remain elusive." | 4.31 | Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight. ( Barros, DR; Bruce, K; Cherney, DZ; Chiu, JFM; Danaei, Z; Kuah, R; Lam, TKT; Li, RJW; Lim, YM; Mariani, LH; Reich, HN; Zhang, SY, 2023) |
| "Our findings showed that Dapagliflozin and Metformin may inhibit bulimia induced obesity with different mechanisms." | 4.31 | Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity. ( Gu, R; Hao, H; Jia, J; Kang, L; Li, Z; Qi, Y; Qiao, S; Sun, X; Wang, K; Xu, B; Zhang, Q; Zhang, X, 2023) |
| " When the patients were compared to whether they had diabetes or used metformin, there was a statistically significant difference between the groups according to weight loss." | 4.31 | Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups. ( Coskun, H; Demır, AS; Ersöz, HÖ; Gunay, YE; Karakullukçu, S; Kişioğlu, SV; Kocak, M; Nuhoglu, I; Tufekcı, D, 2023) |
| "We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic." | 4.12 | Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients. ( Bi, Y; Feng, W; Fu, Y; Gao, L; Huang, H; Zhang, L; Zhang, N; Zhu, D, 2022) |
| "Metformin has been associated with modest weight reduction in the non-pregnant population." | 4.12 | Weight gain in pregnancy: can metformin steady the scales? ( Adams, JH; Antony, KM; Eddy, A; Hoppe, KK; Iruretagoyena, JI; Poehlmann, J; Racine, JL; Rhoades, J; Stewart, K, 2022) |
| "T2DM patients that performed regular exercise, had normal renal function and were receiving metformin were more likely to have clinically meaningful body weight reduction after one year treatment with dapagliflozin." | 4.12 | Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care. ( Huh, Y; Kim, YS, 2022) |
| " The aim of this study is the comparison of 3 mg liraglutide and metformin combination, metformin monotherapy on the blood glucose regulation, weight loss and lipid panel in the patients with Type 2 diabetes mellitus whose BMI is ≥ 30 kg/m2." | 4.12 | Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus. ( Keskin, L; Yaprak, B, 2022) |
| " Metformin is regarded the first-line diabetes therapy for all ages; still it is associated with weight loss and frailty in older adults." | 4.12 | Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin. ( Bahat, G; Catikkas, NM; Karan, MA; Petrovic, M, 2022) |
| " Its circulating levels are acutely increased by the type 2 diabetes medication metformin, resulting in reduced appetite and weight loss." | 4.02 | Genetically proxied growth-differentiation factor 15 levels and body mass index. ( Gill, D; Karhunen, V; Larsson, SC, 2021) |
| " Metformin increases insulin sensitivity, but it is associated with unsatisfied benefits of weight loss." | 4.02 | The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. ( Deng, Y; Ding, X; Ma, R; Sun, A; Wang, Y, 2021) |
| " Weight loss, lifestyle modification and combined hormonal pill and metformin are considered first-line treatment." | 3.96 | Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome. ( Dahiya, R; Kimble, R; O'Brien, B, 2020) |
| " His HbA1c-concentration is 71 mmol/mol, despite an initial 8% weight loss and treatment with metformin and glimepiride." | 3.96 | [Starting insulin or not? And if so, which basal insulin?] ( Tack, CJ; van de Laar, FA, 2020) |
| "The antidiabetic drug metformin causes weight loss, but the underlying mechanisms are unclear." | 3.91 | Metformin Triggers PYY Secretion in Human Gut Mucosa. ( de Fontgalland, D; Hollington, P; Keating, DJ; Martin, AM; Rabbitt, P; Sun, EW; Wattchow, DA; Young, RL, 2019) |
| "This study investigated the effects of metformin and weight loss on biomarkers associated with breast cancer prognosis." | 3.88 | The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes. ( Cadmus-Bertram, L; Flatt, SW; Godbole, S; Hartman, SJ; Kerr, J; Laughlin, GA; Li, H; Marinac, CR; Natarajan, L; Oratowski-Coleman, J; Parker, BA; Patterson, RE; Sears, DD; Villaseñor, A, 2018) |
| "Use of metformin for weight loss for children in a clinical setting has not been well described; therefore, we aimed to identify characteristics of obese patients prescribed metformin in a clinical setting and evaluate changes in anthropometric measures." | 3.88 | Use of Metformin for Weight Management in Children and Adolescents With Obesity in the Clinical Setting. ( Ariza, AJ; Binns, HJ; Kadakia, RB; Kwon, S; Kyler, KE; Palac, HL, 2018) |
| "The present post hoc analysis investigated whether changes in endogenous glucagon-like peptide-1 (∆GLP-1) levels are associated with weight loss in newly diagnosed diabetes patients." | 3.85 | Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment. ( Wang, N; Wang, X; Xing, XY; Yang, WY; Yang, ZJ; Zhang, B; Zhang, JP, 2017) |
| "Linagliptin added to basal insulin and metformin improved glycaemic control, without increasing the risk of hypoglycaemia or body weight gain." | 3.83 | Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes. ( Durán-Garcia, S; Hehnke, U; Lee, J; Patel, S; Rosenstock, J; Thiemann, S; Woerle, HJ; Yki-Järvinen, H, 2016) |
| "Canagliflozin 100 and 300 mg provided sustained reductions in body weight, BMI, and waist circumference in a greater proportion of patients with T2DM versus glimepiride or placebo over 104 weeks." | 3.83 | Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. ( Blonde, L; Canovatchel, W; Fung, A; Meininger, G; Stenlöf, K; Xie, J, 2016) |
| "The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS)." | 3.81 | The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. ( Atiomo, W; Chapman, C; Ghani, NA; Hatta, AZ; Malik, DA; Mokhtar, NM; Omar, MH; Seedhouse, C; Shafiee, MN; Yunos, RI, 2015) |
| " Metformin is a first-line treatment of type 2 diabetes, with minimal weight loss in humans." | 3.81 | Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice. ( Al-Barazanji, K; Benson, W; Binz, J; Chen, L; Generaux, C; McNulty, J; Young, A, 2015) |
| "The aim of this retrospective observational study was to evaluate whether adding liraglutide to lifestyle changes, metformin (Met) and testosterone replacement therapy (TRT), by means of improving weight and glycaemic control, could boost erectile function in type 2 diabetic obese men with overt hypogonadism and erectile dysfunction (ED) in a 'real-life setting'." | 3.81 | Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. ( Carbone, MD; De Pergola, G; Giagulli, VA; Guastamacchia, E; Licchelli, B; Ramunni, MI; Sabbà, C; Triggiani, V, 2015) |
| "One year of diet control with lifestyle modifications and pharmacological treatment with glucagon-like peptide-1 receptor agonists and metformin markedly decreased hemoglobin A1c levels and resulted in effective and substantial weight loss in a morbidly obese patient with dysregulated diabetes during the preoperative period." | 3.80 | Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report. ( Chen, JH; Lee, CH; Tang, WH, 2014) |
| "Using ApoE−/− C57BL/6J mice, we found that metformin attenuates atherosclerosis and vascular senescence in mice fed a high‐fat diet and prevents the upregulation of angiotensin II type 1 receptor by a high‐fat diet in the aortas of mice." | 3.80 | Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. ( Alexander, RW; Fei, B; Forouzandeh, F; Hilenski, L; Patrushev, N; Salazar, G; Xiong, S, 2014) |
| " Peripheral insulin resistance was also enhanced and the GP in charge decided to discontinue the dosing of metformin as a result." | 3.80 | [Improvement of clinical parameters in a patient with metabolic syndrome through intervention in nutrition education and improvement of lifestyle]. ( Alegre, A; Ferri, A; Martinez, MI; Mateos, AM, 2014) |
| "The antidiabetic drug Metformin causes weight loss in both diabetic and non-diabetic individuals." | 3.79 | Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. ( Anini, Y; Gagnon, J; Sheppard, E, 2013) |
| "The efficacy of metformin for the treatment of obesity has been evaluated in few clinical trials with inconclusive results." | 3.79 | Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. ( Schehler, B; Schneider, HJ; Seifarth, C, 2013) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "Hyperuricemia may underlie obesity and related disorders, but the impact of weight reduction and metformin on serum uric acid (sUA) in Caucasian children/adolescents is unknown." | 3.77 | The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents. ( Chrzanowska, J; Gamian, A; Krzystek-Korpacka, M; Kustrzeba-Wojcicka, I; Noczynska, A; Patryn, E, 2011) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 3.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| " During the first year of treatment, exenatide, in combination with metformin and repaglinide, led to a weight loss of 14 kg and fat mass and waist circumference were respectively reduced from 31 to 25." | 3.77 | Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. ( Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P, 2011) |
| " The variables evaluated were first-line methods of weight reduction used, proportion of women with PCOS seen that were obese, whether the patients had tried other weight reduction methods before seeking help, the optimal dietary advice and optimal composition, the optimal duration and frequency of exercise suggested, BMI used for suggesting weight loss, percentage of women in whom weight loss worked, length of time allowed prior to suggesting another method, methods considered most effective by patients, use of metformin for weight loss, criteria used for prescribing metformin, first-line anti-obesity drugs preferred if any, second- and third-line methods used, referral to other specialists and criteria for referral for bariatric surgery." | 3.76 | National survey on management of weight reduction in PCOS women in the United Kingdom. ( Atiomo, W; Sharma, A; Walker, DM, 2010) |
| "Prominent weight gain (mostly subcutaneous fat area) was observed in the pioglitazone-treated OLETF (O-P) rats versus significant weight loss was observed in the metformin-treated OLETF (O-M) rats." | 3.74 | The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. ( Ahn, CW; Cha, BS; Choi, SH; Kim, DJ; Kim, SK; Lee, HC; Lee, YJ; Lim, SK; Zhao, ZS, 2007) |
| "In 74 women with polycystic ovary syndrome, treated for 4 years with metformin (MET) and diet, we prospectively assessed whether, and to what degree, weight loss, reduction of insulin resistance, and amelioration of coronary heart disease risk factors could be sustained." | 3.73 | Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "In an observational study of 13 women with polycystic ovary syndrome (PCOS) not optimally responsive to metformin diet, we assessed the efficacy and safety of addition of pioglitazone." | 3.72 | Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. ( Glueck, CJ; Goldenberg, N; Moreira, A; Sieve, L; Wang, P, 2003) |
| " Since the clinical utility of metformin in diabetes is probably traceable to inhibition of gluconeogenesis, its use as an adjunct to HCA/carnitine treatment of obesity in diabetics deserves evaluation, particularly as metformin therapy itself tends to reduce body weight." | 3.70 | Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics. ( McCarty, MF, 1998) |
| "Among patients with type 2 diabetes and inadequate glycemic control despite treatment with insulin glargine, the addition of subcutaneous tirzepatide, compared with placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 weeks." | 3.11 | Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. ( Bray, R; Dahl, D; Huh, R; Norwood, P; Onishi, Y; Patel, H; Rodríguez, Á, 2022) |
| "In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks." | 3.01 | Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. ( Bergman, BK; Brown, K; Cui, X; Davies, MJ; Fernández Landó, L; Frías, JP; Liu, B; Pérez Manghi, FC; Rosenstock, J, 2021) |
| "Men and women with type 2 diabetes treated with lifestyle modification ± metformin were included." | 2.94 | Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus. ( Andrew, R; Olsson, T; Otten, J; Ryberg, M; Stomby, A; Walker, BR, 2020) |
| "Metformin treatment was analyzed as a potential modulator of the response." | 2.94 | Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial. ( Amadieu, C; Azzi, AS; Bindelle, J; Bindels, LB; Cani, PD; Cnop, M; Delzenne, NM; Gianfrancesco, MA; Gomes da Silveira Cauduro, C; Hiel, S; Kalala, G; Klein, O; Lanthier, N; Leyrolle, Q; Loumaye, A; Luminet, O; Mulders, MDGH; Neyrinck, AM; Pachikian, BD; Paquot, N; Portheault, D; Rodriguez, J; Thissen, JP; Trefois, P; Zamariola, G, 2020) |
| "Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD)." | 2.94 | Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. ( Guo, W; Lin, L; Tian, W; Xu, X, 2020) |
| " The metformin group will begin dosing at 250 mg/day, increasing to a maximum of 1,000 mg/day." | 2.90 | Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study. ( Ahn, KJ; Chon, S; Rhee, SY; Woo, JT, 2019) |
| "Metformin therapy was associated with smaller weight loss (-4." | 2.90 | Does metformin therapy influence the effects of intensive lifestyle intervention? Exploring the interaction between first line therapies in the Look AHEAD trial. ( Boulé, NG; Terada, T, 2019) |
| "Obesity increases risk of endometrial cancer through dysregulation of estrogen and insulin signaling." | 2.87 | Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. ( Basen-Engquist, K; Broaddus, RR; Coletta, AM; Fellman, B; Levy, E; Lu, K; Medepalli, M; Milbourne, A; Nebgen, D; Schmandt, RE; Soletsky, B; Urbauer, D; Yates, MS; Yuan, Y; Zhang, Q, 2018) |
| "Among patients with uncontrolled type 2 diabetes taking glargine and metformin, treatment with degludec/liraglutide compared with up-titration of glargine resulted in noninferior HbA1c levels, with secondary analyses indicating greater HbA1c level reduction after 26 weeks of treatment." | 2.82 | Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. ( Buse, JB; García-Hernández, P; Lehmann, L; Lingvay, I; Norwood, P; Pérez Manghi, F; Tarp-Johansen, MJ, 2016) |
| "The dapagliflozin treatment arm was associated with a mean incremental benefit of 0." | 2.80 | The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. ( Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R, 2015) |
| " Gastrointestinal adverse events were more common with dulaglutide 1." | 2.80 | Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study. ( Guerci, B; Milicevic, Z; Nauck, MA; Skrivanek, Z; Umpierrez, G; Weinstock, RS, 2015) |
| " Overall, all treatments were well tolerated and no new adverse events or tolerability issues were observed for IDegLira." | 2.80 | One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. ( Bode, BW; Buse, JB; Gough, SC; Linjawi, S; Reiter, PD; Rodbard, HW; Woo, VC; Zacho, M, 2015) |
| " Adverse events (AEs) were evaluated throughout 104 weeks." | 2.79 | Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. ( Parikh, S; Rohwedder, K; Sugg, J; Wilding, JP; Woo, V, 2014) |
| " Overall adverse event (AE) incidence over 52 weeks was 69." | 2.79 | Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. ( Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J, 2014) |
| "Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China." | 2.79 | Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China. ( Liao, Y; Liu, LY; Liu, W; Ma, J; Tao, T; Wu, PH, 2014) |
| " Pharmacodynamic parameters were assessed at baseline and at weeks 1 and 12." | 2.79 | Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. ( Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS, 2014) |
| " Overall, lixisenatide once daily was well tolerated, with a similar proportion of treatment-emergent adverse events (TEAEs) and serious TEAEs between groups (lixisenatide: 72." | 2.78 | Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). ( Aronson, R; Goldenberg, R; Guo, H; Muehlen-Bartmer, I; Niemoeller, E; Pinget, M, 2013) |
| "Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM)." | 2.78 | Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. ( Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP, 2013) |
| "Although weight loss is frequently initiated successfully, most patients regain substantial amounts of weight within the first year after completing a weight loss programme." | 2.77 | Weight loss/maintenance as an effective tool for controlling type 2 diabetes: novel methodology to sustain weight reduction. ( Gage, D, 2012) |
| "TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) is a federally funded multicenter randomized clinical trial comparing three treatments of youth onset type 2 diabetes." | 2.77 | Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. ( Chang, N; Grey, M; Hale, D; Higgins, L; Hirst, K; Izquierdo, R; Laffel, L; Larkin, M; Macha, C; Pham, T; Wauters, A; Weinstock, RS, 2012) |
| "Vitamin D deficiency was recompensed in 74% of the PCOS patients who had taken calcium & vitamin D supplementation." | 2.77 | Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. ( Aflatoonian, A; Firouzabadi, Rd; Modarresi, S; MohammadTaheri, S; Sekhavat, L, 2012) |
| "A total of 174 patients with Type 2 diabetes with poor glycaemic control were instructed to take metformin for 8 ± 2 months, then they were randomly assigned to exenatide (5 μg twice a day for the first 4 weeks and forced titration to 10 μg twice a day thereafter) or placebo for 12 months." | 2.77 | Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes. ( Carbone, A; Ciccarelli, L; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F, 2012) |
| "Treatment with liraglutide 1." | 2.76 | Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl ( Bech, OM; Bhattacharyya, A; Chen, L; Ji, Q; Kim, KW; Kumar, A; Liu, X; Ma, J; Tandon, N; Yang, W; Yoon, KH; Zychma, M, 2011) |
| " Safety endpoints included adverse events (AEs) and hypoglycaemia." | 2.76 | Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. ( Hollander, P; Liutkus, JF; Raslova, K; Råstam, J; Skjøth, TV, 2011) |
| "We genotyped 34 type 2 diabetes-associated variants in 2,843 DPP participants at high risk of type 2 diabetes from five ethnic groups representative of the U." | 2.76 | Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. ( Altshuler, D; Florez, JC; Franks, PW; Haffner, S; Hamman, RF; Hivert, MF; Jablonski, KA; Kahn, SE; Knowler, WC; McAteer, JB; Meigs, JB; Perreault, L; Saxena, R, 2011) |
| "Treatment with cetilistat 80 or 120 mg t." | 2.75 | Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). ( Bryson, A; Groot, Gde H; Hallam, R; Hickling, RI; Kopelman, P; Palmer, R; Rissanen, A; Rossner, S; Toubro, S, 2010) |
| "Two hundred seventy-one type 2 diabetes mellitus patients with poor glycemic control and who were overweight were enrolled in this study." | 2.74 | Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA, 2009) |
| " It is proposed that these effects are in part related to improved kidney function resulting in increased Hct and blood viscosity which increases vascular wall shear stress and NO bioavailability leading to a vasodilator effect." | 2.73 | Increased hematocrit and reduced blood pressure following control of glycemia in diabetes. ( Cabrales, P; Díaz, JS; Intaglietta, M; Negrete, AC; Salazar Vázquez, BY; Salazar Vázquez, MA; Venzor, VC, 2008) |
| "Obesity is the most significant risk factor for the development of diabetes." | 2.72 | Obesity and Diabetes. ( Aras, M; Pape, J; Tchang, BG, 2021) |
| "Obesity has health consequences going beyond glucose elevation." | 2.72 | Pharmacotherapeutic options for prediabetes. ( Rendell, M, 2021) |
| "Metformin treatment had no significant impact on GSK-3 protein expression in either adipocytes or skeletal muscle." | 2.72 | Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. ( Baxi, S; Christiansen, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, S; Nikoulina, SE; Oh, DK, 2006) |
| "Mean body weight was unchanged in the rosiglitazone group, while it decreased by 2." | 2.71 | Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. ( Hällsten, K; Huupponen, R; Janatuinen, T; Knuuti, J; Lönnqvist, F; Lönnroth, P; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, T; Virtanen, KA, 2003) |
| "After GB, weight loss was 21 +/- 14." | 2.71 | Metabolic and psychosocial effects of minimal invasive gastric banding for morbid obesity. ( Dittmar, M; Egle, UT; Hardt, J; Heintz, A; Kahaly, GJ, 2003) |
| "Metformin has been shown to improve insulin sensitivity and fibrinolysis." | 2.69 | Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. ( André, P; Charles, MA; Eschwège, E; Juhan-Vague, I; Morange, P; Vague, P, 1998) |
| "Subjects with NIDDM in four treatment strata: 77 on diet alone, 83 also treated with metformin, 103 also treated with sulfonylurea and 91 also treated with insulin." | 2.68 | Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. ( Chiasson, JL; Hunt, JA; Josse, RG; Palmason, C; Rodger, NW; Ross, SA; Ryan, EA; Tan, MH; Wolever, TM, 1997) |
| "Obesity is responsible for an increased risk of sub-fecundity and infertility." | 2.66 | Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. ( Cena, H; Chiovato, L; Nappi, RE, 2020) |
| "It is thought that it exerts its anti-cancer effect through the inhibition of the mammalian target of rapamycin (mTOR) signalling pathway." | 2.61 | The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. ( Amin, S; Lux, A; O'Callaghan, F, 2019) |
| "Obesity is one of the main risk factors for type 2 diabetes (T2D), representing a major worldwide health crisis." | 2.61 | Body Weight Considerations in the Management of Type 2 Diabetes. ( Apovian, CM; O'Neil, PM; Okemah, J, 2019) |
| "Metformin is a first-line therapy for type 2 diabetes." | 2.61 | Metformin: Mechanisms in Human Obesity and Weight Loss. ( Soukas, AA; Yerevanian, A, 2019) |
| " Two studies indicated dose-response relationship for sUA, achieving sUA target and gout attacks." | 2.55 | Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. ( Astrup, A; Bartels, EM; Bliddal, H; Carmona, L; Christensen, R; Gudbergsen, H; Henriksen, M; Knop, FK; Kristensen, LE; Nielsen, SM; Perez-Ruiz, F; Singh, JA; Taylor, WJ; Wæhrens, EE, 2017) |
| "The link between NAFLD/NASH and PCOS is not just a coincidence." | 2.53 | Hepatic manifestations of women with polycystic ovary syndrome. ( Chen, MJ; Ho, HN, 2016) |
| "Obesity is now a major international health concern." | 2.52 | Obesity and polycystic ovary syndrome. ( Boyle, J; De Courten, B; Joham, A; Naderpoor, N; Shorakae, S; Teede, HJ, 2015) |
| "Obesity is associated with a range of health outcomes that are of clinical and public health significance, including cancer." | 2.52 | Obesity and cancer: mechanistic insights from transdisciplinary studies. ( Allott, EH; Hursting, SD, 2015) |
| "As the incidence of obesity is increasing worldwide, there is an urgent need for adequate preclinical models and preclinical and clinical studies designed to investigate how to inhibit the tumor-promoting activity of the adipose tissue." | 2.52 | Mechanisms of obesity in the development of breast cancer. ( Bertolini, F; Orecchioni, S; Reggiani, F; Talarico, G, 2015) |
| "In particular, when obesity is present, lifestyle intervention should be always considered, and if necessary combined with pharmacotherapy." | 2.50 | Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. ( Gambineri, A; Pasquali, R, 2014) |
| "Childhood obesity is an important public health problem with increasing prevalence." | 2.50 | Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. ( Foley, C; McDonagh, MS; Ozpinar, A; Selph, S, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world comprising a spectrum of liver damage from fatty liver infiltration to end-stage liver disease, in patients without significant alcohol consumption." | 2.50 | Nonalcoholic fatty liver disease and polycystic ovary syndrome. ( Vassilatou, E, 2014) |
| "The incidence of type 2 diabetes mellitus (T2DM) has risen to epidemic proportions, and this is associated with enormous cost." | 2.50 | What are the pharmacotherapy options for treating prediabetes? ( Abdul-Ghani, M; Daniele, G; DeFronzo, RA, 2014) |
| " The glucose-dependency of their glucagon-inhibiting and insulin-enhancing effects, together with their weight-sparing properties, make the incretin therapies a logical proposition for use in combination with exogenous basal insulin therapy." | 2.49 | Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. ( Bain, SC; Damci, T; Dzida, G; Hollander, P; Meneghini, LF; Ross, SA; Vora, J, 2013) |
| "Obesity is also a feature of this syndrome and contributes to associated metabolic abnormalities." | 2.48 | Polycystic ovarian syndrome management options. ( Bates, GW; Propst, AM, 2012) |
| "Polycystic ovarian syndrome is the major cause of anovulation and is generally associated with obesity." | 2.48 | Evaluation and treatment of anovulatory and unexplained infertility. ( Bates, GW; Propst, AM, 2012) |
| "Weight gain is a clinically important side effect of antipsychotic drug therapy." | 2.47 | Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. ( Asplund, AB; Björkhem-Bergman, L; Lindh, JD, 2011) |
| "Non-alcoholic fatty liver disease (NAFLD) is closely linked with obesity and the prevalence of NAFLD is about 17% to 33% in the Western world." | 2.47 | Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review. ( Clar, C; Fraser, A; Ghouri, N; Gurung, T; Henderson, R; Preiss, D; Sattar, N; Shyangdan, D; Waugh, N, 2011) |
| "Weight loss is the best treatment option, which can be a challenging task for patients to achieve and maintain." | 2.46 | Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management. ( Brown, A; Desai, M; Taneja, D; Tannock, LR, 2010) |
| "Nonalcoholic steatohepatitis (NASH) is one of the most common liver disorders in North America." | 2.44 | Treatment of fibrosis in nonalcoholic fatty liver disease. ( Anania, FA; Hoteit, MA, 2007) |
| "Metformin has little effect on any of the adipose tissue derived factors but appears to reduce diabetes related mortality according to limited evidence." | 2.44 | Adipose tissue and diabetes therapy: do we hit the target? ( Pfeiffer, AF, 2007) |
| "Weight loss has been shown to improve sensitivity to insulin as a result of either altered diet or exercise." | 2.44 | Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications. ( Cokkinos, D; Stefanadis, C; Tousoulis, D; Tsarpalis, K, 2008) |
| "The recommended first step for treatment of metabolic syndrome is lifestyle modifications such as weight loss, aerobic exercise, smoking cessation, and improved diet which independently improve insulin resistance and slow progression to type 2 diabetes mellitus." | 2.44 | Metabolic syndrome: are we at risk? ( Paudel, B, 2007) |
| "Type 2 diabetes and obesity are common metabolic disorders characterized by resistance to the actions of insulin to stimulate skeletal muscle glucose disposal." | 2.43 | Insulin resistance and improvements in signal transduction. ( Goodyear, LJ; Musi, N, 2006) |
| "With the prevalence of type 2 diabetes mellitus having increased to approximately 8% during recent years and a further rise likely, type 2 diabetes will develop into a major health care problem in Europe." | 2.42 | [Optimized diabetes therapy in type 2 diabetics]. ( Clemens, A; Riemann, JF; Siegel, EG, 2003) |
| "Insulin resistance is a common feature of PCOS and is more marked in obese women, suggesting that PCOS and obesity have a synergistic effect on the magnitude of the insulin disorder." | 2.42 | Insulin-lowering agents in the management of polycystic ovary syndrome. ( De Leo, V; la Marca, A; Petraglia, F, 2003) |
| "Treatment with metformin was less effective than lifestyle modifications, resulting in an average reduction of risk for development of type 2 diabetes by 31% compared with placebo." | 2.42 | [Progress in the prevention of type 2 diabetes]. ( Schernthaner, G, 2003) |
| "Treatment with metformin was less effective than lifestyle modifications, resulting in an average reduction of risk of T2D of 31% compared with placebo." | 2.41 | Can reducing peaks prevent type 2 diabetes: implication from recent diabetes prevention trials. ( Haffner, SM, 2002) |
| "For now, the goals and methods of treating hypertension and dyslipidemia are the same in people with the metabolic syndrome as in the general population." | 2.41 | A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. ( Hoogwerf, BJ; Nambi, V; Sprecher, DL, 2002) |
| "Obesity is a chronic disease and requires ongoing treatment." | 2.40 | Obesity medications and the treatment of type 2 diabetes. ( Greenway, F, 1999) |
| "Recent research has demonstrated that Type 2 Diabetes (T2D) risk is influenced by a number of common polymorphisms, including MC4R rs17782313, PPARG rs1801282, and TCF7L2 rs7903146." | 1.72 | Association of gene polymorphisms with body weight changes in prediabetic patients. ( Ahmetov, II; Egorova, ES; Khasanova, KB; Kiseleva, TA; Medvedeva, MS; Pickering, C; Valeeva, EV; Valeeva, FV, 2022) |
| "Metformin is a blood-glucose-lowering medication with physiological effects that extend beyond its anti-diabetic indication." | 1.72 | The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance. ( Blond, MB; Clemmensen, C; Fritzen, AM; Færch, K; Gil, C; Johann, K; Karstoft, K; Klein, AB; Kleinert, M; Lund, J; Mathiesen, CV; Nicolaisen, TS; Pilmark, NS; Quist, JS; Seeley, RJ, 2022) |
| "Weight loss was 0." | 1.72 | A Health Care Professional Delivered Low Carbohydrate Diet Program Reduces Body Weight, Haemoglobin A1c, Diabetes Medication Use and Cardiovascular Risk Markers-A Single-Arm Intervention Analysis. ( Brinkworth, GD; Taylor, PJ; Thompson, CH; Wycherley, TP, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are serious health concerns for which lifestyle interventions are the only effective first-line treatment." | 1.72 | Combining Dietary Intervention with Metformin Treatment Enhances Non-Alcoholic Steatohepatitis Remission in Mice Fed a High-Fat High-Sucrose Diet. ( Amigó, N; Baiges-Gaya, G; Camps, J; Castañé, H; Jiménez-Franco, A; Joven, J; Rodríguez-Tomàs, E, 2022) |
| "Bariatric surgery leads to type 2 diabetes mellitus (T2DM) remission, but recurrence can ensue afterwards." | 1.51 | Long-term diabetes outcomes after bariatric surgery-managing medication withdrawl. ( Belo, S; Carvalho, D; Freitas, P; Magalhães, D; Neves, JS; Oliveira, SC; Pedro, J; Souteiro, P; Varela, A, 2019) |
| "Although the overall rate of child and adolescent obesity has stabilized over the last decade after increasing steadily for 3 decades, obesity rates continue to increase in certain populations, such as African American girls and Hispanic boys." | 1.46 | Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Bibbins-Domingo, K; Curry, SJ; Davidson, KW; Doubeni, CA; Epling, JW; Grossman, DC; Kemper, AR; Krist, AH; Kurth, AE; Landefeld, CS; Mangione, CM; Phipps, MG; Silverstein, M; Simon, MA; Tseng, CW, 2017) |
| "Polycystic ovary syndrome is the most common endocrinopathy among reproductive-aged women in the United States, affecting approximately 7% of female patients." | 1.43 | Diagnosis and Treatment of Polycystic Ovary Syndrome. ( Mortada, R; Porter, S; Williams, T, 2016) |
| "The number of patients with type 2 diabetes (T2DM) is increasing." | 1.43 | A Prospective Analysis of the Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors: Real World Evidence from Clinical Practice in India. ( Joshi, SR; Kumar, PM; Sosale, AR; Sosale, B, 2016) |
| "Bariatric surgery rapidly improves Type 2 diabetes mellitus (T2DM)." | 1.42 | Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats. ( Abegg, K; Boza, C; Corteville, C; Docherty, NG; le Roux, CW; Lutz, TA; Muñoz, R, 2015) |
| "For patients with type 2 diabetes mellitus (T2DM), there is a growing interest in sodium glucose co-transporter 2 (SGLT2) inhibitors, a class of glucose-lowering agents that act independently of insulin secretion and insulin action and also have a weight-lowering effect." | 1.42 | Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin. ( Blevins, T, 2015) |
| "Weight gain was associated with a significant increase in all-cause costs of $3400 per year compared with the weight-neutral cohort; however, differences in T2DM-specific costs and discontinuation rates did not reach significance levels." | 1.40 | Economic implications of weight change in patients with type 2 diabetes mellitus. ( Bell, K; D'Souza, A; Graham, J; Lamerato, L; Parasuraman, S; Raju, A; Shah, M, 2014) |
| "Metformin has beneficial effects on insulin resistance and endothelial functions." | 1.38 | The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. ( Akpek, M; Calapkorur, B; Celik, A; Karaca, Z; Kaya, MG; Kelestimur, F; Unluhizarci, K; Yildirim, S, 2012) |
| "Type 2 diabetes mellitus is one of the significant comorbidities of obesity." | 1.37 | Obesity and type 2 diabetes mellitus in South Dakota: focused insight into prevalence, physiology and treatment. ( Eid, WE, 2011) |
| "Hypertension is a common comorbidity (34%), whereas early nephropathy appears to be rare (4%)." | 1.35 | Management and 1 year outcome for UK children with type 2 diabetes. ( Barrett, TG; Haines, L; Lynn, R; Shield, JP; Wan, KC, 2009) |
| "For women in whom weight loss is not possible, or for lean women with PCOS, clomiphene citrate is an effective first-line method of ovulation induction." | 1.34 | Ovulation induction management of PCOS. ( Guzick, DS, 2007) |
| "(1) When type 2 diabetes is inadequately controlled with oral antidiabetic therapy, one option is to add subcutaneous insulin injections (or to accept less stringent glycaemic control)." | 1.34 | Exenatide: new drug. Type 2 diabetes for some overweight patients. ( , 2007) |
| "A 57-year-old Caucasian woman with Type 2 diabetes treated for seven years with diet and oral combination hypoglycaemic therapy was referred because of the progressive deterioration of glycaemic control." | 1.33 | Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change. ( Atkin, SL; González, S; Kilpatrick, ES, 2005) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| "Weight reduction was observed in all the treatment groups." | 1.32 | [Therapy objectives and daily practice--to which extent are blood sugar target values accessible in daily practice?]. ( Stalder, Dde M, 2004) |
| "Metformin was assessed as a treatment for weight gain in children taking olanzapine, risperidone, quetiapine, or valproate." | 1.31 | Metformin for weight loss in pediatric patients taking psychotropic drugs. ( Barton, BA; Cottingham, EM; Morrison, JA, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.24) | 18.7374 |
| 1990's | 10 (2.39) | 18.2507 |
| 2000's | 126 (30.07) | 29.6817 |
| 2010's | 221 (52.74) | 24.3611 |
| 2020's | 61 (14.56) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, A | 2 |
| Sharma, S | 1 |
| Gupta, LP | 1 |
| Ahmad, P | 1 |
| Srivastava, SP | 1 |
| Rahuja, N | 1 |
| Tamrakar, AK | 1 |
| Srivastava, AK | 1 |
| Whelan, AR | 1 |
| Ayala, NK | 1 |
| Werner, EF | 1 |
| Aras, M | 1 |
| Tchang, BG | 1 |
| Pape, J | 1 |
| Gao, L | 1 |
| Huang, H | 1 |
| Zhang, L | 1 |
| Zhang, N | 1 |
| Fu, Y | 1 |
| Zhu, D | 2 |
| Bi, Y | 2 |
| Feng, W | 1 |
| Tulipano, G | 1 |
| Tilves, C | 1 |
| Yeh, HC | 3 |
| Maruthur, N | 1 |
| Juraschek, SP | 3 |
| Miller, ER | 3 |
| Appel, LJ | 3 |
| Mueller, NT | 3 |
| Dahl, D | 1 |
| Onishi, Y | 1 |
| Norwood, P | 2 |
| Huh, R | 1 |
| Bray, R | 1 |
| Patel, H | 1 |
| Rodríguez, Á | 2 |
| Adams, JH | 1 |
| Poehlmann, J | 1 |
| Racine, JL | 1 |
| Iruretagoyena, JI | 1 |
| Eddy, A | 1 |
| Hoppe, KK | 1 |
| Stewart, K | 1 |
| Rhoades, J | 1 |
| Antony, KM | 1 |
| Valeeva, FV | 1 |
| Medvedeva, MS | 1 |
| Khasanova, KB | 1 |
| Valeeva, EV | 1 |
| Kiseleva, TA | 1 |
| Egorova, ES | 1 |
| Pickering, C | 1 |
| Ahmetov, II | 1 |
| Hu, L | 2 |
| Ma, L | 1 |
| Xia, X | 1 |
| Ying, T | 1 |
| Zhou, M | 1 |
| Zou, S | 1 |
| Yu, H | 1 |
| Yin, J | 1 |
| O'Brien, H | 1 |
| Travis, C | 1 |
| Huh, Y | 1 |
| Kim, YS | 1 |
| Arguelles-Tello, FA | 1 |
| Kammar-García, A | 1 |
| Trejo-Jasso, CA | 1 |
| Huerta-Cruz, JC | 1 |
| Barranco-Garduño, LM | 1 |
| Rocha-González, HI | 1 |
| Reyes-García, JG | 1 |
| Li, R | 1 |
| Mai, T | 1 |
| Zheng, S | 1 |
| Zhang, Y | 2 |
| Utzschneider, KM | 1 |
| Ehrmann, DA | 1 |
| Arslanian, SA | 1 |
| Barengolts, E | 1 |
| Buchanan, TA | 1 |
| Caprio, S | 1 |
| Edelstein, SL | 5 |
| Hannon, TS | 1 |
| Kahn, SE | 5 |
| Kozedub, A | 1 |
| Mather, KJ | 2 |
| Nadeau, KJ | 1 |
| Sam, S | 1 |
| Tripputi, M | 1 |
| Xiang, AH | 1 |
| El Ghormli, L | 1 |
| Klein, AB | 1 |
| Nicolaisen, TS | 1 |
| Johann, K | 1 |
| Fritzen, AM | 1 |
| Mathiesen, CV | 1 |
| Gil, C | 1 |
| Pilmark, NS | 1 |
| Karstoft, K | 1 |
| Blond, MB | 1 |
| Quist, JS | 1 |
| Seeley, RJ | 1 |
| Færch, K | 1 |
| Lund, J | 1 |
| Kleinert, M | 1 |
| Clemmensen, C | 1 |
| Zhao, G | 1 |
| Zhang, Q | 3 |
| Wu, F | 1 |
| Yin, S | 1 |
| Xie, Y | 1 |
| Liu, H | 1 |
| Vazquez Arreola, E | 1 |
| Knowler, WC | 11 |
| Hanson, RL | 1 |
| Popp, CJ | 1 |
| Kharmats, AY | 1 |
| Curran, M | 1 |
| Berube, L | 1 |
| Wang, C | 1 |
| Pompeii, ML | 1 |
| Illiano, P | 1 |
| St-Jules, DE | 1 |
| Mottern, M | 1 |
| Li, H | 2 |
| Williams, N | 1 |
| Schoenthaler, A | 1 |
| Segal, E | 1 |
| Godneva, A | 1 |
| Thomas, D | 1 |
| Bergman, M | 1 |
| Schmidt, AM | 1 |
| Sevick, MA | 1 |
| Keskin, L | 1 |
| Yaprak, B | 1 |
| Brinkworth, GD | 1 |
| Wycherley, TP | 1 |
| Taylor, PJ | 1 |
| Thompson, CH | 1 |
| Simpson, FR | 1 |
| Justice, JN | 1 |
| Pilla, SJ | 1 |
| Kritchevsky, SB | 1 |
| Boyko, EJ | 2 |
| Munshi, MN | 1 |
| Ferris, CK | 1 |
| Espeland, MA | 1 |
| Baiges-Gaya, G | 1 |
| Rodríguez-Tomàs, E | 1 |
| Castañé, H | 1 |
| Jiménez-Franco, A | 1 |
| Amigó, N | 1 |
| Camps, J | 1 |
| Joven, J | 1 |
| Cai, H | 1 |
| Chen, Q | 2 |
| Duan, Y | 1 |
| Zhao, Y | 2 |
| Zhang, X | 2 |
| Zhang, SY | 1 |
| Bruce, K | 1 |
| Danaei, Z | 1 |
| Li, RJW | 1 |
| Barros, DR | 1 |
| Kuah, R | 1 |
| Lim, YM | 1 |
| Mariani, LH | 1 |
| Cherney, DZ | 1 |
| Chiu, JFM | 1 |
| Reich, HN | 1 |
| Lam, TKT | 1 |
| Li, Z | 1 |
| Jia, J | 1 |
| Hao, H | 1 |
| Qiao, S | 1 |
| Qi, Y | 1 |
| Sun, X | 2 |
| Wang, K | 1 |
| Gu, R | 1 |
| Kang, L | 1 |
| Xu, B | 1 |
| Wen, Q | 1 |
| Fang, S | 1 |
| Liang, Y | 1 |
| Tian, Y | 1 |
| Chen, Y | 2 |
| Yuan, J | 1 |
| Bahat, G | 2 |
| Ozkok, S | 1 |
| Petrovic, M | 2 |
| Gunay, YE | 1 |
| Kişioğlu, SV | 1 |
| Karakullukçu, S | 1 |
| Tufekcı, D | 1 |
| Demır, AS | 1 |
| Coskun, H | 1 |
| Nuhoglu, I | 1 |
| Kocak, M | 1 |
| Ersöz, HÖ | 1 |
| Duru, OK | 2 |
| Mangione, CM | 3 |
| Turk, N | 2 |
| Chon, J | 1 |
| Fu, J | 1 |
| Cheng, G | 1 |
| Cheng, F | 1 |
| Moss, A | 1 |
| Frosch, D | 1 |
| Jeffers, KS | 2 |
| Castellon-Lopez, Y | 2 |
| Tseng, CH | 2 |
| Maranon, R | 1 |
| Norris, KC | 1 |
| Moin, T | 2 |
| Małecki, MT | 1 |
| Batterham, RL | 2 |
| Sattar, N | 5 |
| Levine, JA | 1 |
| Bergman, BK | 2 |
| Wang, H | 1 |
| Ghimpeteanu, G | 1 |
| Lee, CJ | 1 |
| Chon, JS | 1 |
| Frosch, DL | 1 |
| Martin, JM | 1 |
| Norris, K | 1 |
| Zinman, B | 3 |
| Aroda, VR | 1 |
| Buse, JB | 5 |
| Cariou, B | 2 |
| Harris, SB | 1 |
| Hoff, ST | 1 |
| Pedersen, KB | 1 |
| Tarp-Johansen, MJ | 2 |
| Araki, E | 1 |
| Hannon, BA | 1 |
| Thomas, DM | 1 |
| Siu, CO | 1 |
| Allison, DB | 1 |
| Coll, AP | 1 |
| Chen, M | 1 |
| Taskar, P | 1 |
| Rimmington, D | 1 |
| Patel, S | 3 |
| Tadross, JA | 1 |
| Cimino, I | 1 |
| Yang, M | 1 |
| Welsh, P | 1 |
| Virtue, S | 1 |
| Goldspink, DA | 1 |
| Miedzybrodzka, EL | 1 |
| Konopka, AR | 1 |
| Esponda, RR | 1 |
| Huang, JT | 1 |
| Tung, YCL | 1 |
| Rodriguez-Cuenca, S | 1 |
| Tomaz, RA | 1 |
| Harding, HP | 1 |
| Melvin, A | 1 |
| Yeo, GSH | 1 |
| Preiss, D | 2 |
| Vidal-Puig, A | 1 |
| Vallier, L | 1 |
| Nair, KS | 1 |
| Wareham, NJ | 1 |
| Ron, D | 1 |
| Gribble, FM | 1 |
| Reimann, F | 1 |
| Savage, DB | 1 |
| Allan, BB | 1 |
| O'Rahilly, S | 1 |
| Vatopoulou, A | 1 |
| Tziomalos, K | 4 |
| Vadini, F | 1 |
| Simeone, PG | 2 |
| Boccatonda, A | 1 |
| Guagnano, MT | 2 |
| Liani, R | 1 |
| Tripaldi, R | 1 |
| Di Castelnuovo, A | 2 |
| Cipollone, F | 1 |
| Consoli, A | 2 |
| Santilli, F | 2 |
| Elkind-Hirsch, KE | 2 |
| Shaler, D | 1 |
| Harris, R | 1 |
| Ferreira-Hermosillo, A | 1 |
| Molina-Ayala, MA | 1 |
| Molina-Guerrero, D | 1 |
| Garrido-Mendoza, AP | 1 |
| Ramírez-Rentería, C | 1 |
| Mendoza-Zubieta, V | 1 |
| Espinosa, E | 1 |
| Mercado, M | 1 |
| Stomby, A | 1 |
| Otten, J | 1 |
| Ryberg, M | 1 |
| Andrew, R | 1 |
| Walker, BR | 1 |
| Olsson, T | 1 |
| O'Brien, B | 1 |
| Dahiya, R | 1 |
| Kimble, R | 1 |
| Hiel, S | 1 |
| Gianfrancesco, MA | 1 |
| Rodriguez, J | 1 |
| Portheault, D | 1 |
| Leyrolle, Q | 1 |
| Bindels, LB | 1 |
| Gomes da Silveira Cauduro, C | 1 |
| Mulders, MDGH | 1 |
| Zamariola, G | 1 |
| Azzi, AS | 1 |
| Kalala, G | 1 |
| Pachikian, BD | 1 |
| Amadieu, C | 1 |
| Neyrinck, AM | 1 |
| Loumaye, A | 1 |
| Cani, PD | 1 |
| Lanthier, N | 1 |
| Trefois, P | 1 |
| Klein, O | 1 |
| Luminet, O | 1 |
| Bindelle, J | 1 |
| Paquot, N | 1 |
| Cnop, M | 1 |
| Thissen, JP | 1 |
| Delzenne, NM | 1 |
| Parween, S | 1 |
| Rihs, S | 1 |
| Flück, CE | 1 |
| Koretz, RL | 1 |
| Cena, H | 1 |
| Chiovato, L | 1 |
| Nappi, RE | 1 |
| Papaetis, GS | 1 |
| Filippou, PK | 1 |
| Constantinidou, KG | 1 |
| Stylianou, CS | 1 |
| Day, EA | 1 |
| Ford, RJ | 1 |
| Smith, BK | 1 |
| Mohammadi-Shemirani, P | 1 |
| Morrow, MR | 1 |
| Gutgesell, RM | 1 |
| Lu, R | 1 |
| Raphenya, AR | 1 |
| Kabiri, M | 1 |
| McArthur, AG | 1 |
| McInnes, N | 1 |
| Hess, S | 1 |
| Paré, G | 1 |
| Gerstein, HC | 1 |
| Steinberg, GR | 1 |
| Rendell, M | 1 |
| Guo, W | 1 |
| Tian, W | 1 |
| Lin, L | 1 |
| Xu, X | 1 |
| Chang, N | 2 |
| Yeh, MY | 1 |
| Raymond, JK | 1 |
| Geffner, ME | 1 |
| Ryoo, JH | 1 |
| Chao, LC | 1 |
| Tack, CJ | 2 |
| van de Laar, FA | 1 |
| Ouyang, J | 1 |
| Isnard, S | 1 |
| Lin, J | 1 |
| Fombuena, B | 1 |
| Peng, X | 1 |
| Routy, JP | 1 |
| Fu, X | 1 |
| Zhou, X | 1 |
| Liu, Y | 1 |
| Lei, Y | 1 |
| Xie, H | 1 |
| Leng, Y | 1 |
| Gao, H | 1 |
| Xie, C | 1 |
| Karhunen, V | 1 |
| Larsson, SC | 1 |
| Gill, D | 1 |
| Sari, C | 1 |
| Seip, RL | 1 |
| Umashanker, D | 1 |
| Janda, M | 2 |
| Robledo, KP | 1 |
| Gebski, V | 2 |
| Armes, JE | 1 |
| Alizart, M | 1 |
| Cummings, M | 1 |
| Chen, C | 1 |
| Leung, Y | 1 |
| Sykes, P | 1 |
| McNally, O | 1 |
| Oehler, MK | 1 |
| Walker, G | 1 |
| Garrett, A | 1 |
| Tang, A | 1 |
| Land, R | 1 |
| Nicklin, JL | 1 |
| Chetty, N | 1 |
| Perrin, LC | 1 |
| Hoet, G | 1 |
| Sowden, K | 1 |
| Eva, L | 1 |
| Tristram, A | 1 |
| Obermair, A | 2 |
| Taghavi, SA | 1 |
| van Wely, M | 1 |
| Jahanfar, S | 1 |
| Bazarganipour, F | 1 |
| Maruthur, NM | 2 |
| Wang, NY | 1 |
| Jerome, GJ | 1 |
| Dalcin, AT | 1 |
| Tseng, E | 1 |
| White, K | 1 |
| Charleston, J | 1 |
| Durkin, N | 1 |
| Hassoon, A | 1 |
| Lansey, DG | 1 |
| Kanarek, NF | 1 |
| Carducci, MA | 1 |
| Differding, MK | 1 |
| Zhang, M | 1 |
| Siamashvili, M | 1 |
| Davis, SN | 1 |
| Chappell, N | 1 |
| Seidemann, E | 1 |
| Storment, J | 1 |
| Bellanger, D | 1 |
| Ma, R | 1 |
| Ding, X | 1 |
| Wang, Y | 1 |
| Deng, Y | 1 |
| Sun, A | 1 |
| Frías, JP | 2 |
| Davies, MJ | 2 |
| Rosenstock, J | 6 |
| Pérez Manghi, FC | 1 |
| Fernández Landó, L | 1 |
| Liu, B | 1 |
| Cui, X | 1 |
| Brown, K | 1 |
| Catikkas, NM | 1 |
| Karan, MA | 1 |
| Janani, L | 1 |
| Bamehr, H | 1 |
| Tanha, K | 1 |
| Mirzabeigi, P | 1 |
| Montazeri, H | 1 |
| Tarighi, P | 1 |
| Grøndahl, MFG | 1 |
| Johannesen, J | 1 |
| Kristensen, K | 1 |
| Knop, FK | 2 |
| LE, TN | 1 |
| Wickham, EP | 1 |
| Nestler, JE | 1 |
| O'Connor, EA | 1 |
| Evans, CV | 1 |
| Burda, BU | 1 |
| Walsh, ES | 1 |
| Eder, M | 1 |
| Lozano, P | 1 |
| Grossman, DC | 1 |
| Bibbins-Domingo, K | 1 |
| Curry, SJ | 1 |
| Barry, MJ | 2 |
| Davidson, KW | 1 |
| Doubeni, CA | 1 |
| Epling, JW | 1 |
| Kemper, AR | 1 |
| Krist, AH | 1 |
| Kurth, AE | 1 |
| Landefeld, CS | 1 |
| Phipps, MG | 1 |
| Silverstein, M | 1 |
| Simon, MA | 1 |
| Tseng, CW | 1 |
| Lingvay, I | 2 |
| Harris, S | 1 |
| Jaeckel, E | 1 |
| Chandarana, K | 1 |
| Ranthe, MF | 1 |
| Jódar, E | 1 |
| Wang, Z | 2 |
| Sun, J | 1 |
| Han, R | 1 |
| Fan, D | 1 |
| Dong, X | 1 |
| Luan, Z | 1 |
| Xiang, R | 1 |
| Zhao, M | 1 |
| Yang, J | 1 |
| Zhou, L | 1 |
| Cai, X | 1 |
| Yang, W | 2 |
| Han, X | 1 |
| Ji, L | 1 |
| Dawson, AJ | 2 |
| Kilpatrick, ES | 7 |
| Coady, AM | 4 |
| Elshewehy, AMM | 1 |
| Dakroury, Y | 1 |
| Ahmed, L | 1 |
| Atkin, SL | 8 |
| Sathyapalan, T | 5 |
| Esquivel, MA | 1 |
| Lansang, MC | 1 |
| Shibuya, T | 1 |
| Fushimi, N | 1 |
| Kawai, M | 1 |
| Yoshida, Y | 1 |
| Hachiya, H | 1 |
| Ito, S | 1 |
| Kawai, H | 1 |
| Ohashi, N | 1 |
| Mori, A | 1 |
| Pedersen, AJT | 1 |
| Stage, TB | 1 |
| Glintborg, D | 2 |
| Andersen, M | 1 |
| Christensen, MMH | 1 |
| Morgante, G | 2 |
| Massaro, MG | 1 |
| Di Sabatino, A | 2 |
| Cappelli, V | 1 |
| De Leo, V | 3 |
| Frias, J | 1 |
| Páll, D | 1 |
| Charbonnel, B | 1 |
| Pascu, R | 1 |
| Saur, D | 1 |
| Darekar, A | 1 |
| Huyck, S | 1 |
| Shi, H | 1 |
| Lauring, B | 1 |
| Terra, SG | 1 |
| Nielsen, SM | 1 |
| Bartels, EM | 1 |
| Henriksen, M | 1 |
| Wæhrens, EE | 1 |
| Gudbergsen, H | 1 |
| Bliddal, H | 1 |
| Astrup, A | 1 |
| Carmona, L | 1 |
| Taylor, WJ | 1 |
| Singh, JA | 1 |
| Perez-Ruiz, F | 1 |
| Kristensen, LE | 1 |
| Christensen, R | 1 |
| Leo, M | 1 |
| Maccarone, MT | 1 |
| Sborgia, C | 1 |
| Bonadonna, RC | 1 |
| Angelucci, E | 1 |
| Federico, V | 1 |
| Cianfarani, S | 1 |
| Manzoli, L | 1 |
| Davì, G | 1 |
| Tartaro, A | 1 |
| Sharma, M | 1 |
| Beckley, N | 1 |
| Nazareth, I | 1 |
| Petersen, I | 1 |
| Pace, E | 1 |
| Tingen, J | 1 |
| Siskind, D | 1 |
| Friend, N | 1 |
| Russell, A | 1 |
| McGrath, JJ | 1 |
| Lim, C | 1 |
| Patterson, S | 1 |
| Flaws, D | 1 |
| Stedman, T | 1 |
| Moudgil, V | 1 |
| Sardinha, S | 1 |
| Suetani, S | 1 |
| Kisely, S | 1 |
| Winckel, K | 1 |
| Baker, A | 1 |
| El-Arabey, AA | 1 |
| López-Jaramillo, P | 1 |
| Calderón, C | 1 |
| Castillo, J | 1 |
| Escobar, ID | 1 |
| Melgarejo, E | 1 |
| Parra, GA | 1 |
| Yates, MS | 1 |
| Coletta, AM | 1 |
| Schmandt, RE | 1 |
| Medepalli, M | 1 |
| Nebgen, D | 1 |
| Soletsky, B | 1 |
| Milbourne, A | 1 |
| Levy, E | 1 |
| Fellman, B | 1 |
| Urbauer, D | 1 |
| Yuan, Y | 1 |
| Broaddus, RR | 1 |
| Basen-Engquist, K | 1 |
| Lu, K | 1 |
| Lohmann, AE | 1 |
| Pimentel, I | 1 |
| Goodwin, PJ | 1 |
| Patterson, RE | 2 |
| Marinac, CR | 2 |
| Sears, DD | 1 |
| Kerr, J | 1 |
| Hartman, SJ | 2 |
| Cadmus-Bertram, L | 1 |
| Villaseñor, A | 1 |
| Flatt, SW | 1 |
| Godbole, S | 1 |
| Laughlin, GA | 1 |
| Oratowski-Coleman, J | 1 |
| Parker, BA | 2 |
| Natarajan, L | 2 |
| Wang, J | 1 |
| Wang, L | 1 |
| Zhou, J | 1 |
| Qin, A | 1 |
| Chen, Z | 1 |
| Qian, D | 1 |
| Zhang, T | 1 |
| Tan, X | 1 |
| Zheng, P | 1 |
| Liang, Z | 1 |
| Xie, J | 3 |
| Jiang, J | 1 |
| Situ, B | 1 |
| Loves, S | 1 |
| van Groningen, L | 1 |
| Filius, M | 1 |
| Mekking, M | 1 |
| Brandon, T | 1 |
| Hermus, A | 1 |
| de Boer, H | 1 |
| Kyler, KE | 1 |
| Kadakia, RB | 1 |
| Palac, HL | 1 |
| Kwon, S | 1 |
| Ariza, AJ | 1 |
| Binns, HJ | 1 |
| Amin, S | 1 |
| Lux, A | 1 |
| O'Callaghan, F | 1 |
| Rhee, SY | 1 |
| Chon, S | 1 |
| Ahn, KJ | 1 |
| Woo, JT | 1 |
| Apovian, CM | 2 |
| Okemah, J | 1 |
| O'Neil, PM | 1 |
| Lentferink, YE | 1 |
| Knibbe, CAJ | 1 |
| van der Vorst, MMJ | 1 |
| Carvalho, V | 1 |
| Martins, J | 1 |
| Bassez, G | 1 |
| Audureau, E | 1 |
| Peschanski, M | 1 |
| Terada, T | 1 |
| Boulé, NG | 1 |
| Tiwari, N | 1 |
| Pasrija, S | 1 |
| Jain, S | 1 |
| Souteiro, P | 1 |
| Belo, S | 1 |
| Magalhães, D | 1 |
| Pedro, J | 1 |
| Neves, JS | 1 |
| Oliveira, SC | 1 |
| Freitas, P | 1 |
| Varela, A | 1 |
| Carvalho, D | 1 |
| Sun, EW | 1 |
| Martin, AM | 1 |
| Wattchow, DA | 1 |
| de Fontgalland, D | 1 |
| Rabbitt, P | 1 |
| Hollington, P | 1 |
| Young, RL | 1 |
| Keating, DJ | 1 |
| Yerevanian, A | 1 |
| Soukas, AA | 1 |
| Katzel, LI | 1 |
| Sorkin, JD | 1 |
| Apolzan, JW | 1 |
| Venditti, EM | 2 |
| Dabelea, D | 1 |
| Pi-Sunyer, X | 1 |
| Kalyani, RR | 1 |
| Franks, PW | 6 |
| Srikanthan, P | 1 |
| Gadde, KM | 1 |
| Wynne, AG | 1 |
| Matyjaszek-Matuszek, B | 1 |
| Bartaskova, D | 1 |
| Cox, DA | 1 |
| Woodward, B | 1 |
| Li, YG | 1 |
| Tham, LS | 1 |
| Milicevic, Z | 2 |
| Nelson, SH | 1 |
| Pratte, KA | 1 |
| Johnson, A | 1 |
| Beals, J | 1 |
| Bullock, A | 1 |
| Manson, SM | 1 |
| Jiang, L | 1 |
| Hollander, P | 5 |
| Lasko, B | 1 |
| Barnett, AH | 1 |
| Bengus, M | 1 |
| Kanitra, L | 1 |
| Pi-Sunyer, FX | 2 |
| Balena, R | 1 |
| Wysham, C | 1 |
| Grimm, M | 1 |
| Chen, S | 1 |
| Ravn, P | 1 |
| Haugen, AG | 1 |
| Malin, SK | 2 |
| Nightingale, J | 1 |
| Choi, SE | 1 |
| Chipkin, SR | 1 |
| Braun, B | 1 |
| Pan, Q | 3 |
| Delahanty, LM | 5 |
| Jablonski, KA | 6 |
| Florez, JC | 5 |
| Garnett, SP | 2 |
| Gow, M | 2 |
| Ho, M | 2 |
| Baur, LA | 1 |
| Noakes, M | 1 |
| Woodhead, HJ | 1 |
| Broderick, CR | 1 |
| Burrell, S | 1 |
| Chisholm, K | 1 |
| Halim, J | 2 |
| De, S | 1 |
| Steinbeck, K | 1 |
| Srinivasan, S | 1 |
| Ambler, GR | 1 |
| Kohn, MR | 1 |
| Cowell, CT | 2 |
| Schumm-Draeger, PM | 1 |
| Pinget, M | 1 |
| Goldenberg, R | 2 |
| Niemoeller, E | 1 |
| Muehlen-Bartmer, I | 1 |
| Guo, H | 1 |
| Aronson, R | 1 |
| Helseth, R | 1 |
| Vanky, E | 1 |
| Salvesen, O | 1 |
| Carlsen, SM | 3 |
| Kim, C | 2 |
| Barrett-Connor, E | 6 |
| Randolph, JF | 2 |
| Kong, S | 2 |
| Nan, B | 2 |
| Golden, SH | 2 |
| Kovacs, CS | 1 |
| Seshiah, V | 1 |
| Swallow, R | 1 |
| Jones, R | 1 |
| Rattunde, H | 1 |
| Woerle, HJ | 6 |
| Broedl, UC | 4 |
| Bolinder, J | 1 |
| Ljunggren, Ö | 1 |
| Johansson, L | 1 |
| Wilding, J | 2 |
| Langkilde, AM | 2 |
| Sjöström, CD | 2 |
| Sugg, J | 3 |
| Parikh, S | 4 |
| Wilding, JP | 2 |
| Woo, V | 2 |
| Rohwedder, K | 1 |
| Chilton, M | 1 |
| Dunkley, A | 1 |
| Carter, P | 1 |
| Khunti, K | 2 |
| Gray, LJ | 1 |
| Panidis, D | 3 |
| Papadakis, E | 1 |
| Katsikis, I | 3 |
| Scheinfeld, N | 1 |
| Gadéa, É | 1 |
| Thivat, É | 1 |
| Wang-Lopez, Q | 1 |
| Viala, M | 1 |
| Paulon, R | 1 |
| Planchat, É | 1 |
| Chadeyras, JB | 1 |
| Merlin, C | 1 |
| Coudert, B | 1 |
| Bignon, YJ | 1 |
| Morio, B | 1 |
| Durando, X | 1 |
| Kleefstra, N | 1 |
| Drion, I | 1 |
| van Hateren, KJ | 1 |
| Holleman, F | 1 |
| Goudswaard, AN | 1 |
| Bilo, HJ | 1 |
| Charpentier, G | 1 |
| González-Gálvez, G | 1 |
| Mathieu, C | 2 |
| Vercruysse, F | 3 |
| Usiskin, K | 2 |
| Law, G | 1 |
| Black, S | 1 |
| Canovatchel, W | 5 |
| Meininger, G | 4 |
| Jabbour, SA | 1 |
| Hardy, E | 1 |
| Younossi, ZM | 1 |
| Reyes, MJ | 1 |
| Mishra, A | 1 |
| Mehta, R | 1 |
| Henry, L | 1 |
| Pasquali, R | 1 |
| Gambineri, A | 1 |
| Christophi, CA | 3 |
| Billings, LK | 1 |
| Horton, ES | 2 |
| McDonagh, MS | 1 |
| Selph, S | 1 |
| Ozpinar, A | 1 |
| Foley, C | 1 |
| Soliman, AR | 1 |
| Fathy, A | 1 |
| Khashab, S | 1 |
| Shaheen, N | 1 |
| Soliman, MA | 1 |
| Jensterle Sever, M | 1 |
| Kocjan, T | 2 |
| Pfeifer, M | 1 |
| Kravos, NA | 2 |
| Janez, A | 3 |
| Schulte, JM | 1 |
| Rothaus, CS | 1 |
| Adler, JN | 1 |
| Rodbard, HW | 3 |
| Handelsman, Y | 1 |
| Philis-Tsimikas, A | 1 |
| Ocampo Francisco, AM | 1 |
| Rana, A | 1 |
| Grandy, S | 1 |
| Hashemi, M | 1 |
| Gómez-Pérez, AM | 1 |
| Fernández-García, JC | 1 |
| Mancha Doblas, I | 1 |
| Tinahones, FJ | 1 |
| Hollenrieder, V | 1 |
| Ke, RW | 1 |
| Forst, T | 1 |
| Guthrie, R | 1 |
| Yee, J | 1 |
| Vijapurkar, U | 2 |
| Stein, P | 1 |
| Joslowski, G | 1 |
| Goletzke, J | 1 |
| Louie, JC | 1 |
| Buyken, AE | 1 |
| Ma, J | 2 |
| Liu, LY | 1 |
| Wu, PH | 1 |
| Liao, Y | 1 |
| Tao, T | 1 |
| Liu, W | 1 |
| Li, Y | 1 |
| Tong, Y | 1 |
| Huang, L | 1 |
| Wu, T | 1 |
| Tong, N | 1 |
| Derosa, G | 4 |
| Bonaventura, A | 2 |
| Bianchi, L | 2 |
| Romano, D | 2 |
| Fogari, E | 3 |
| D'Angelo, A | 2 |
| Maffioli, P | 4 |
| Jelaska, A | 1 |
| Frappin, G | 1 |
| Salsali, A | 1 |
| Kim, G | 1 |
| Sha, S | 1 |
| Polidori, D | 2 |
| Heise, T | 1 |
| Natarajan, J | 1 |
| Farrell, K | 1 |
| Wang, SS | 1 |
| Sica, D | 1 |
| Rothenberg, P | 1 |
| Plum-Mörschel, L | 1 |
| Hawkes, AL | 1 |
| Quinn, M | 1 |
| Armes, J | 1 |
| Brennan, D | 1 |
| Vassilatou, E | 1 |
| Kashyap, SR | 1 |
| Vilsbøll, T | 1 |
| Thurman, J | 1 |
| Blevins, TC | 1 |
| Langbakke, IH | 1 |
| Bøttcher, SG | 1 |
| Simpson, RW | 1 |
| Nicholson, GC | 1 |
| Proietto, J | 1 |
| Sarah, A | 1 |
| Sanders, KM | 1 |
| Phillips, G | 1 |
| Chambers, J | 1 |
| MacGinley, R | 1 |
| Orford, N | 1 |
| Walder, K | 1 |
| Krippner, G | 1 |
| Skoff, K | 1 |
| Wacher, VJ | 1 |
| Daniele, G | 1 |
| Abdul-Ghani, M | 1 |
| DeFronzo, RA | 3 |
| Leiter, LA | 1 |
| Yoon, KH | 2 |
| Arias, P | 1 |
| Langslet, G | 1 |
| Balis, DA | 1 |
| Millington, D | 1 |
| Chen, JH | 1 |
| Tang, WH | 1 |
| Lee, CH | 1 |
| Cefalu, WT | 2 |
| Lapuerta, P | 1 |
| Zambrowicz, B | 1 |
| Ogbaa, I | 1 |
| Banks, P | 1 |
| Sands, A | 1 |
| Labrie, F | 1 |
| Bell, K | 1 |
| Parasuraman, S | 1 |
| Shah, M | 1 |
| Raju, A | 1 |
| Graham, J | 2 |
| Lamerato, L | 1 |
| D'Souza, A | 1 |
| Worsley, R | 1 |
| Jane, F | 1 |
| Robinson, PJ | 1 |
| Bell, RJ | 1 |
| Davis, SR | 1 |
| Linneke, JL | 1 |
| Jørgensen, GK | 1 |
| Csillag, C | 1 |
| Naderpoor, N | 1 |
| Shorakae, S | 1 |
| Joham, A | 1 |
| Boyle, J | 1 |
| De Courten, B | 1 |
| Teede, HJ | 1 |
| Abdul-Ghani, MA | 1 |
| Puckett, C | 1 |
| Triplitt, C | 1 |
| Maggs, D | 2 |
| Adams, J | 1 |
| Cersosimo, E | 1 |
| Lecube, A | 1 |
| Bueno, M | 1 |
| Suárez, X | 1 |
| Glechner, A | 1 |
| Harreiter, J | 1 |
| Gartlehner, G | 1 |
| Rohleder, S | 1 |
| Kautzky, A | 1 |
| Tuomilehto, J | 1 |
| Van Noord, M | 1 |
| Kaminski-Hartenthaler, A | 1 |
| Kautzky-Willer, A | 1 |
| Adeyemo, MA | 1 |
| McDuffie, JR | 1 |
| Kozlosky, M | 1 |
| Krakoff, J | 3 |
| Calis, KA | 2 |
| Brady, SM | 1 |
| Yanovski, JA | 2 |
| Shafiee, MN | 1 |
| Malik, DA | 1 |
| Yunos, RI | 1 |
| Atiomo, W | 2 |
| Omar, MH | 1 |
| Ghani, NA | 1 |
| Hatta, AZ | 1 |
| Seedhouse, C | 1 |
| Chapman, C | 1 |
| Mokhtar, NM | 1 |
| Refuerzo, JS | 1 |
| Viteri, OA | 1 |
| Hutchinson, M | 1 |
| Pedroza, C | 1 |
| Blackwell, SC | 1 |
| Tyson, JE | 1 |
| Ramin, SM | 1 |
| Forouzandeh, F | 1 |
| Salazar, G | 1 |
| Patrushev, N | 1 |
| Xiong, S | 1 |
| Hilenski, L | 1 |
| Fei, B | 1 |
| Alexander, RW | 1 |
| Alušík, Š | 1 |
| Paluch, Z | 1 |
| Abegg, K | 1 |
| Corteville, C | 1 |
| Docherty, NG | 1 |
| Boza, C | 1 |
| Lutz, TA | 1 |
| Muñoz, R | 1 |
| le Roux, CW | 1 |
| Mohan, M | 1 |
| McSwiggan, S | 1 |
| Baig, F | 1 |
| Rutherford, L | 1 |
| Lang, CC | 1 |
| Lewin, A | 1 |
| Liu, D | 1 |
| Kaste, R | 1 |
| Martinez, MI | 1 |
| Ferri, A | 1 |
| Mateos, AM | 1 |
| Alegre, A | 1 |
| Al-Barazanji, K | 1 |
| McNulty, J | 1 |
| Binz, J | 1 |
| Generaux, C | 1 |
| Benson, W | 1 |
| Young, A | 1 |
| Chen, L | 2 |
| Spritzer, PM | 1 |
| Motta, AB | 1 |
| Sir-Petermann, T | 1 |
| Diamanti-Kandarakis, E | 1 |
| Blevins, T | 1 |
| Charokopou, M | 1 |
| McEwan, P | 1 |
| Lister, S | 1 |
| Callan, L | 1 |
| Bergenheim, K | 1 |
| Tolley, K | 1 |
| Postema, R | 1 |
| Townsend, R | 1 |
| Roudaut, M | 1 |
| Ge, Z | 1 |
| Zhang, P | 2 |
| Li, C | 1 |
| Yang, H | 1 |
| Weinstock, RS | 2 |
| Guerci, B | 1 |
| Umpierrez, G | 1 |
| Nauck, MA | 1 |
| Skrivanek, Z | 1 |
| Gough, SC | 1 |
| Bode, BW | 1 |
| Woo, VC | 1 |
| Linjawi, S | 1 |
| Zacho, M | 1 |
| Reiter, PD | 1 |
| O'Brien, MJ | 2 |
| Whitaker, RC | 2 |
| Yu, D | 1 |
| Ackermann, RT | 3 |
| Jensterle, M | 2 |
| Salamun, V | 1 |
| Vrtacnik Bokal, E | 1 |
| Giorgino, F | 1 |
| Benroubi, M | 1 |
| Sun, JH | 1 |
| Zimmermann, AG | 1 |
| Pechtner, V | 1 |
| Tokmak, M | 1 |
| Altiok, IB | 1 |
| Guven, M | 1 |
| Aras, AB | 1 |
| Cosar, M | 1 |
| Shaefer, CF | 1 |
| Kushner, P | 1 |
| Aguilar, R | 1 |
| Allott, EH | 1 |
| Hursting, SD | 1 |
| Giagulli, VA | 1 |
| Carbone, MD | 1 |
| Ramunni, MI | 1 |
| Licchelli, B | 1 |
| De Pergola, G | 1 |
| Sabbà, C | 1 |
| Guastamacchia, E | 1 |
| Triggiani, V | 1 |
| Orecchioni, S | 1 |
| Reggiani, F | 1 |
| Talarico, G | 1 |
| Bertolini, F | 1 |
| Durán-Garcia, S | 1 |
| Lee, J | 1 |
| Yki-Järvinen, H | 1 |
| Hehnke, U | 1 |
| Thiemann, S | 1 |
| Mogul, H | 1 |
| Freeman, R | 1 |
| Nguyen, K | 1 |
| Neeland, IJ | 1 |
| McGuire, DK | 1 |
| Chilton, R | 1 |
| Crowe, S | 1 |
| Lund, SS | 1 |
| Johansen, OE | 1 |
| Igel, LI | 1 |
| Sinha, A | 1 |
| Saunders, KH | 1 |
| Vojta, D | 1 |
| Aronne, LJ | 1 |
| Shyangdan, DS | 1 |
| Uthman, OA | 1 |
| Waugh, N | 3 |
| Pérez Manghi, F | 1 |
| García-Hernández, P | 1 |
| Lehmann, L | 1 |
| Topyildiz, F | 1 |
| Kiyici, S | 1 |
| Gul, Z | 1 |
| Sigirli, D | 1 |
| Guclu, M | 1 |
| Kisakol, G | 1 |
| Cavun, S | 1 |
| Blonde, L | 2 |
| Stenlöf, K | 1 |
| Fung, A | 1 |
| Goldberg, RB | 2 |
| Temprosa, M | 1 |
| Mele, L | 1 |
| Orchard, T | 1 |
| Mather, K | 1 |
| Bray, G | 1 |
| Horton, E | 2 |
| Kitabchi, A | 1 |
| Marcovina, S | 1 |
| Perreault, L | 4 |
| White, N | 1 |
| Hodge, RJ | 1 |
| Paulik, MA | 1 |
| Walker, A | 1 |
| Boucheron, JA | 1 |
| McMullen, SL | 1 |
| Gillmor, DS | 1 |
| Nunez, DJ | 1 |
| Pérez-Hernández, O | 1 |
| González-Pérez, JM | 1 |
| Martínez-Riera, A | 1 |
| Durán-Castellón, Mdel C | 1 |
| Monereo-Muñoz, MB | 1 |
| Martín-González, C | 1 |
| Santolaria-Fernández, F | 1 |
| Chen, MJ | 1 |
| Ho, HN | 1 |
| Kelly, AS | 1 |
| Fox, CK | 1 |
| Rudser, KD | 1 |
| Gross, AC | 1 |
| Ryder, JR | 1 |
| Firouzjaei, A | 1 |
| Li, GC | 1 |
| Wang, N | 2 |
| Liu, WX | 1 |
| Zhu, BM | 1 |
| Schernthaner, G | 2 |
| Lavalle-González, FJ | 1 |
| Davidson, JA | 1 |
| Jodon, H | 1 |
| Qiu, R | 1 |
| Sam, WJ | 1 |
| Roza, O | 1 |
| Hon, YY | 1 |
| Alfaro, RM | 1 |
| Reynolds, JC | 1 |
| Williams, T | 1 |
| Mortada, R | 1 |
| Porter, S | 1 |
| Javed, Z | 1 |
| Zhang, JP | 1 |
| Xing, XY | 1 |
| Yang, ZJ | 1 |
| Zhang, B | 3 |
| Wang, X | 1 |
| Yang, WY | 1 |
| Kargulewicz, A | 1 |
| Szulińska, M | 1 |
| Kujawska-Łuczak, M | 1 |
| Swora-Cwynar, E | 1 |
| Musialik, K | 1 |
| Grzymisławska, M | 1 |
| Kręgielska-Narożna, M | 1 |
| Bogdański, P | 1 |
| Sosale, B | 1 |
| Sosale, AR | 1 |
| Kumar, PM | 1 |
| Joshi, SR | 1 |
| Rohde, U | 1 |
| Demir, S | 1 |
| Temizkan, S | 1 |
| Sargin, M | 1 |
| Kim, T | 1 |
| Holleman, CL | 1 |
| Ptacek, T | 1 |
| Morrow, CD | 1 |
| Habegger, KM | 1 |
| Qaseem, A | 2 |
| Humphrey, LL | 2 |
| Forciea, MA | 1 |
| Fitterman, N | 1 |
| Horwitch, C | 1 |
| Kansagara, D | 1 |
| McLean, RM | 1 |
| Wilt, TJ | 1 |
| Goričar, K | 1 |
| Hussain, M | 1 |
| Atif, MA | 1 |
| Ghafoor, MB | 1 |
| Perez, A | 1 |
| Scanlan, AB | 1 |
| Alos, VA | 1 |
| Foster, GD | 1 |
| Ciolino, JD | 1 |
| Homko, C | 1 |
| Bray, GA | 2 |
| Carrion-Petersen, ML | 1 |
| Hamman, RF | 5 |
| Hoskin, MA | 1 |
| Ma, Y | 3 |
| Alamiri, B | 1 |
| Shield, JP | 1 |
| Lynn, R | 1 |
| Wan, KC | 1 |
| Haines, L | 1 |
| Barrett, TG | 1 |
| Kashi, MR | 1 |
| Torres, DM | 1 |
| Harrison, SA | 1 |
| Vuppalanchi, R | 1 |
| Chalasani, N | 1 |
| Hart, R | 1 |
| Metwally, M | 1 |
| Amer, S | 1 |
| Li, TC | 1 |
| Ledger, WL | 1 |
| List, JF | 1 |
| Morales, E | 1 |
| Tang, W | 1 |
| Fiedorek, FT | 1 |
| Cho, LW | 3 |
| Kebapcilar, L | 1 |
| Taner, CE | 1 |
| Kebapcilar, AG | 1 |
| Alacacioglu, A | 1 |
| Sari, I | 1 |
| Narayan, KM | 1 |
| Engelgau, MM | 1 |
| Herman, WH | 1 |
| Marrero, DG | 1 |
| Salvadeo, SA | 1 |
| Ferrari, I | 1 |
| Gravina, A | 1 |
| Mereu, R | 1 |
| Palumbo, I | 1 |
| Cicero, AF | 2 |
| Cahill, D | 1 |
| Kopelman, P | 1 |
| Groot, Gde H | 1 |
| Rissanen, A | 1 |
| Rossner, S | 1 |
| Toubro, S | 1 |
| Palmer, R | 1 |
| Hallam, R | 1 |
| Bryson, A | 1 |
| Hickling, RI | 1 |
| Shin, L | 1 |
| Bregman, H | 1 |
| Breeze, JL | 1 |
| Noyes, N | 1 |
| Frazier, JA | 1 |
| Mitri, J | 1 |
| Hamdy, O | 1 |
| Jiang, S | 1 |
| Riethoven, JJ | 1 |
| Xia, Y | 1 |
| Miner, J | 1 |
| Fromm, M | 1 |
| Fowler, SE | 2 |
| Hoffman, HJ | 1 |
| Brenneman, AT | 1 |
| Brown-Friday, JO | 1 |
| Goldberg, R | 1 |
| Venditti, E | 1 |
| Nathan, DM | 3 |
| Sari, R | 1 |
| Eray, E | 1 |
| Ozdem, S | 1 |
| Akbas, H | 1 |
| Coban, E | 1 |
| Arnold, KC | 1 |
| Musacchio, MC | 1 |
| Palermo, V | 1 |
| Petraglia, F | 2 |
| Björkhem-Bergman, L | 1 |
| Asplund, AB | 1 |
| Lindh, JD | 1 |
| Brown, A | 1 |
| Desai, M | 1 |
| Taneja, D | 1 |
| Tannock, LR | 1 |
| Clark, JM | 1 |
| Crandall, JP | 1 |
| Wilson, C | 1 |
| Molitch, ME | 1 |
| Brancati, FL | 1 |
| Menge, BA | 1 |
| Meier, JJ | 1 |
| Schmidt, WE | 1 |
| Lebovitz, HE | 1 |
| Winsberg, B | 2 |
| Yeager, C | 1 |
| Hobbs, B | 2 |
| Wei, R | 1 |
| Elangovan, N | 1 |
| Marsh, KA | 1 |
| Steinbeck, KS | 1 |
| Atkinson, FS | 1 |
| Petocz, P | 1 |
| Brand-Miller, JC | 1 |
| Tomlinson, J | 1 |
| Millward, A | 1 |
| Stenhouse, E | 1 |
| Pinkney, J | 1 |
| Bestermann, WH | 1 |
| Sharma, A | 1 |
| Walker, DM | 1 |
| Campbell, RK | 1 |
| Cobble, ME | 1 |
| Reid, TS | 1 |
| Shomali, ME | 1 |
| Vause, TD | 1 |
| Cheung, AP | 1 |
| Sierra, S | 1 |
| Claman, P | 1 |
| Guillemin, JA | 1 |
| Lapensée, L | 1 |
| Steward, S | 1 |
| Wong, BC | 1 |
| Khan, AY | 1 |
| Macaluso, M | 1 |
| McHale, RJ | 1 |
| Dahmen, MM | 1 |
| Girrens, K | 1 |
| Ali, F | 1 |
| Al-Jebawi, AF | 1 |
| Ji, Q | 1 |
| Liu, X | 1 |
| Tandon, N | 1 |
| Bhattacharyya, A | 1 |
| Kim, KW | 1 |
| Bech, OM | 1 |
| Zychma, M | 1 |
| Mellor, DD | 1 |
| Raslova, K | 1 |
| Skjøth, TV | 1 |
| Råstam, J | 1 |
| Liutkus, JF | 1 |
| Krzystek-Korpacka, M | 1 |
| Patryn, E | 1 |
| Kustrzeba-Wojcicka, I | 1 |
| Chrzanowska, J | 1 |
| Gamian, A | 1 |
| Noczynska, A | 1 |
| Koiou, E | 2 |
| Dinas, K | 1 |
| Kalaitzakis, E | 2 |
| Delkos, D | 2 |
| Kandaraki, EA | 2 |
| Pratley, R | 1 |
| Nauck, M | 2 |
| Bailey, T | 1 |
| Montanya, E | 1 |
| Cuddihy, R | 1 |
| Filetti, S | 1 |
| Garber, A | 1 |
| Thomsen, AB | 2 |
| Hartvig, H | 1 |
| Davies, M | 1 |
| Hivert, MF | 1 |
| Saxena, R | 1 |
| McAteer, JB | 1 |
| Haffner, S | 2 |
| Meigs, JB | 1 |
| Altshuler, D | 2 |
| Shyangdan, D | 2 |
| Cummins, E | 1 |
| Royle, P | 1 |
| Oriot, P | 1 |
| Hermans, MP | 1 |
| Selvais, P | 1 |
| Buysschaert, M | 1 |
| de la Tribonnière, X | 1 |
| Yeager, CA | 1 |
| Eid, WE | 1 |
| Vosnakis, C | 1 |
| Meneghini, LF | 2 |
| Orozco-Beltran, D | 1 |
| Caputo, S | 1 |
| Damçi, T | 2 |
| Liebl, A | 1 |
| Ross, SA | 3 |
| Rynders, C | 1 |
| Weltman, A | 2 |
| Delgiorno, C | 2 |
| Balagopal, P | 2 |
| Damaso, L | 2 |
| Killen, K | 2 |
| Mauras, N | 2 |
| Clar, C | 1 |
| Ghouri, N | 1 |
| Henderson, R | 1 |
| Gurung, T | 1 |
| Fraser, A | 1 |
| Watson, KE | 1 |
| McCaffery, JM | 1 |
| Shuldiner, A | 1 |
| Pujante Alarcón, P | 1 |
| Hellín Gil, MD | 1 |
| Román, LM | 1 |
| Ferrer Gómez, M | 1 |
| García Zafra, MV | 1 |
| Tébar Massó, J | 1 |
| Gage, D | 1 |
| Sweet, DE | 1 |
| Starkey, M | 1 |
| Shekelle, P | 1 |
| Laffel, L | 1 |
| Grey, M | 1 |
| Hale, D | 1 |
| Higgins, L | 1 |
| Hirst, K | 2 |
| Izquierdo, R | 1 |
| Larkin, M | 1 |
| Macha, C | 1 |
| Pham, T | 1 |
| Wauters, A | 1 |
| Gómez-Díaz, RA | 1 |
| Talavera, JO | 1 |
| Pool, EC | 1 |
| Ortiz-Navarrete, FV | 1 |
| Solórzano-Santos, F | 1 |
| Mondragón-González, R | 1 |
| Valladares-Salgado, A | 1 |
| Cruz, M | 1 |
| Aguilar-Salinas, CA | 2 |
| Wacher, NH | 1 |
| Kulshreshtha, B | 1 |
| Gupta, N | 1 |
| Ganie, MA | 1 |
| Ammini, AC | 1 |
| Aggarwal, N | 1 |
| Arbit, D | 1 |
| Capuano, G | 1 |
| Firouzabadi, Rd | 1 |
| Aflatoonian, A | 1 |
| Modarresi, S | 1 |
| Sekhavat, L | 1 |
| MohammadTaheri, S | 1 |
| Ragonesi, PD | 1 |
| Carbone, A | 2 |
| Janczyk, W | 1 |
| Socha, P | 1 |
| Franzetti, IG | 1 |
| Querci, F | 1 |
| Ciccarelli, L | 1 |
| Piccinni, MN | 1 |
| Zeitler, P | 3 |
| Pyle, L | 1 |
| Linder, B | 1 |
| Copeland, K | 1 |
| Arslanian, S | 1 |
| Cuttler, L | 1 |
| Tollefsen, S | 1 |
| Wilfley, D | 1 |
| Kaufman, F | 1 |
| Kaya, MG | 1 |
| Calapkorur, B | 1 |
| Karaca, Z | 1 |
| Yildirim, S | 1 |
| Celik, A | 1 |
| Akpek, M | 1 |
| Unluhizarci, K | 1 |
| Kelestimur, F | 1 |
| Hossain, J | 1 |
| Bird, K | 1 |
| Merinbaum, D | 1 |
| Lansdown, A | 1 |
| Rees, DA | 1 |
| Yuan, GH | 1 |
| Song, WL | 1 |
| Huang, YY | 1 |
| Guo, XH | 1 |
| Gao, Y | 1 |
| Pollin, TI | 1 |
| Isakova, T | 1 |
| de Bakker, PI | 1 |
| Taylor, A | 1 |
| McAteer, J | 1 |
| Shuldiner, AR | 1 |
| Frid, A | 1 |
| Hermansen, K | 1 |
| During, M | 1 |
| Shah, N | 1 |
| Tankova, T | 1 |
| Mitha, I | 1 |
| Matthews, DR | 1 |
| Vora, J | 1 |
| Bain, SC | 1 |
| Dzida, G | 1 |
| Singh-Franco, D | 1 |
| Elrod, S | 1 |
| Harrington, C | 1 |
| McLaughlin-Middlekauff, J | 1 |
| Gagnon, J | 1 |
| Sheppard, E | 1 |
| Anini, Y | 1 |
| Geier, LM | 1 |
| Bekx, MT | 1 |
| Connor, EL | 1 |
| Seifarth, C | 1 |
| Schehler, B | 1 |
| Schneider, HJ | 1 |
| Bates, GW | 2 |
| Propst, AM | 2 |
| Panahi, Y | 1 |
| Ghamarchehreh, ME | 1 |
| Beiraghdar, F | 1 |
| Zare, R | 1 |
| Jalalian, HR | 1 |
| Sahebkar, A | 1 |
| Bhavsar, S | 1 |
| Mudaliar, S | 2 |
| Cherrington, A | 1 |
| Esfahanian, F | 1 |
| Zamani, MM | 1 |
| Heshmat, R | 1 |
| Moini nia, F | 1 |
| Ferrannini, E | 1 |
| Seman, L | 1 |
| Seewaldt-Becker, E | 1 |
| Hantel, S | 1 |
| Pinnetti, S | 1 |
| Haffner, SM | 2 |
| Martikainen, H | 1 |
| Virtanen, KA | 1 |
| Hällsten, K | 1 |
| Parkkola, R | 1 |
| Janatuinen, T | 1 |
| Lönnqvist, F | 1 |
| Viljanen, T | 1 |
| Rönnemaa, T | 1 |
| Knuuti, J | 1 |
| Huupponen, R | 1 |
| Lönnroth, P | 1 |
| Nuutila, P | 1 |
| Nambi, V | 1 |
| Hoogwerf, BJ | 2 |
| Sprecher, DL | 1 |
| Pugeat, M | 1 |
| Wong, LL | 1 |
| Wong, TC | 1 |
| Glueck, CJ | 3 |
| Moreira, A | 1 |
| Goldenberg, N | 1 |
| Sieve, L | 3 |
| Wang, P | 3 |
| Laville, M | 1 |
| Siraj, ES | 1 |
| PEDERSEN, J | 1 |
| Després, JP | 1 |
| Clemens, A | 1 |
| Riemann, JF | 1 |
| Siegel, EG | 1 |
| la Marca, A | 1 |
| Dittmar, M | 1 |
| Heintz, A | 1 |
| Hardt, J | 1 |
| Egle, UT | 1 |
| Kahaly, GJ | 1 |
| Magill, SB | 1 |
| Weiss, D | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Barbieri, RL | 1 |
| Gargiulo, AR | 1 |
| Maggs, DG | 2 |
| Ruggles, JA | 1 |
| Fineman, M | 1 |
| Shen, L | 1 |
| Kolterman, OG | 1 |
| Weyer, C | 1 |
| Kjøtrød, SB | 1 |
| von Düring, V | 1 |
| Saleh, AM | 1 |
| Khalil, HS | 1 |
| Iglesias, P | 1 |
| Alvarez Fidalgo, P | 1 |
| Codoceo, R | 1 |
| Díez, JJ | 1 |
| Caballero, AE | 1 |
| Delgado, A | 1 |
| Herrera, AN | 1 |
| Castillo, JL | 1 |
| Cabrera, T | 1 |
| Gomez-Perez, FJ | 1 |
| Rull, JA | 1 |
| Hoeger, KM | 1 |
| Kochman, L | 1 |
| Wixom, N | 1 |
| Craig, K | 1 |
| Miller, RK | 1 |
| Guzick, DS | 2 |
| Lavine, JE | 1 |
| Schwimmer, JB | 1 |
| Stalder, Dde M | 1 |
| Lazurova, I | 1 |
| Dravecka, I | 1 |
| Kraus, V | 1 |
| Petrovicova, J | 1 |
| Jayagopal, V | 1 |
| Holding, S | 1 |
| Jennings, PE | 1 |
| González, S | 1 |
| Asakura, T | 1 |
| Ito, Y | 1 |
| Berne, C | 1 |
| Harborne, LR | 1 |
| Norman, JE | 1 |
| Fleming, R | 1 |
| Lombard, L | 1 |
| Hoo, P | 1 |
| Shaw, R | 1 |
| Qublan, HS | 1 |
| Malkawi, HY | 1 |
| Tang, T | 1 |
| Glanville, J | 1 |
| Hayden, CJ | 1 |
| White, D | 1 |
| Barth, JH | 1 |
| Balen, AH | 1 |
| Allen, HF | 1 |
| Mazzoni, C | 1 |
| Heptulla, RA | 1 |
| Murray, MA | 1 |
| Miller, N | 1 |
| Koenigs, L | 1 |
| Reiter, EO | 1 |
| Marchesini, G | 1 |
| Natale, S | 1 |
| Manini, R | 1 |
| Agostini, F | 1 |
| Brown, JS | 1 |
| Wing, R | 1 |
| Nyberg, LM | 1 |
| Kusek, JW | 1 |
| Orchard, TJ | 1 |
| Vittinghoff, E | 1 |
| Kanaya, AM | 1 |
| Palomba, S | 1 |
| Zullo, F | 1 |
| Siebler, J | 1 |
| Galle, PR | 1 |
| Musi, N | 1 |
| Goodyear, LJ | 1 |
| Toplak, H | 1 |
| Hamann, A | 1 |
| Moore, R | 1 |
| Masson, E | 1 |
| Gorska, M | 1 |
| Fitchet, M | 1 |
| Ciaraldi, TP | 1 |
| Oh, DK | 1 |
| Christiansen, L | 1 |
| Nikoulina, SE | 1 |
| Kong, AP | 1 |
| Baxi, S | 1 |
| Henry, RR | 1 |
| Ratner, RE | 1 |
| Nielsen, LL | 2 |
| Stonehouse, AH | 1 |
| Poon, T | 1 |
| Bicsak, TA | 1 |
| Brodows, RG | 2 |
| Kim, DD | 3 |
| Klein, EJ | 1 |
| Han, J | 1 |
| Mac, SM | 1 |
| Poon, TH | 1 |
| Taylor, KL | 1 |
| Trautmann, ME | 2 |
| Kendall, DM | 1 |
| de Fine Olivarius, N | 1 |
| Andreasen, AH | 1 |
| Siersma, V | 1 |
| Richelsen, B | 1 |
| Beck-Nielsen, H | 1 |
| Miller, JL | 1 |
| Silverstein, JH | 1 |
| Aregawi, D | 2 |
| Winiarska, M | 2 |
| Agloria, M | 2 |
| Luo, G | 1 |
| Jadhav, S | 1 |
| Ferrell, W | 1 |
| Greer, IA | 1 |
| Petrie, JR | 1 |
| Cobbe, SM | 1 |
| Dastjerdi, MS | 1 |
| Kazemi, F | 1 |
| Najafian, A | 1 |
| Mohammady, M | 1 |
| Aminorroaya, A | 1 |
| Amini, M | 1 |
| Göke, B | 1 |
| Schmidt-Trucksäss, A | 1 |
| Dimo, T | 1 |
| Rakotonirina, SV | 1 |
| Tan, PV | 1 |
| Azay, J | 1 |
| Dongo, E | 1 |
| Kamtchouing, P | 1 |
| Cros, G | 1 |
| Pekhlivanov, B | 1 |
| Mitkov, M | 1 |
| Kavŭrdzhikova, S | 1 |
| Hoteit, MA | 1 |
| Anania, FA | 1 |
| Fujimoto, WY | 1 |
| Kriska, A | 1 |
| Hanson, R | 1 |
| Hill, JO | 1 |
| Hubbard, V | 1 |
| Stamm, E | 1 |
| Klonoff, DC | 1 |
| Guan, X | 1 |
| Bowlus, CL | 1 |
| Holcombe, JH | 1 |
| Wintle, ME | 1 |
| Brunani, A | 1 |
| Caumo, A | 1 |
| Graci, S | 1 |
| Castagna, G | 1 |
| Viberti, G | 1 |
| Liuzzi, A | 1 |
| Durán García, S | 1 |
| Milton, DR | 1 |
| Giaconia, JM | 1 |
| Choi, SH | 1 |
| Zhao, ZS | 1 |
| Lee, YJ | 1 |
| Kim, SK | 1 |
| Kim, DJ | 1 |
| Ahn, CW | 1 |
| Lim, SK | 1 |
| Lee, HC | 1 |
| Cha, BS | 1 |
| Homburg, R | 1 |
| Tuthill, A | 1 |
| McKenna, MJ | 1 |
| O'Shea, D | 1 |
| McKenna, TJ | 1 |
| Pfeiffer, AF | 1 |
| Tousoulis, D | 1 |
| Tsarpalis, K | 1 |
| Cokkinos, D | 1 |
| Stefanadis, C | 1 |
| Cubeddu, LX | 1 |
| Alfieri, AB | 1 |
| Hoffmann, IS | 1 |
| Paudel, B | 1 |
| Salazar Vázquez, BY | 1 |
| Salazar Vázquez, MA | 1 |
| Venzor, VC | 1 |
| Negrete, AC | 1 |
| Cabrales, P | 1 |
| Díaz, JS | 1 |
| Intaglietta, M | 1 |
| Wu, RR | 1 |
| Zhao, JP | 1 |
| Jin, H | 1 |
| Shao, P | 1 |
| Fang, MS | 1 |
| Guo, XF | 1 |
| He, YQ | 1 |
| Liu, YJ | 1 |
| Chen, JD | 1 |
| Li, LH | 1 |
| Glass, LC | 1 |
| Qu, Y | 1 |
| Lenox, S | 1 |
| Kim, D | 1 |
| Gates, JR | 1 |
| Brodows, R | 1 |
| Trautmann, M | 1 |
| Bergenstal, RM | 1 |
| Stumvoll, M | 1 |
| Häring, HU | 1 |
| Matthaei, S | 1 |
| Hexeberg, S | 1 |
| Lindberg, FA | 1 |
| Dagogo-Jack, S | 1 |
| Marrero, D | 1 |
| Crandall, J | 1 |
| Baptista, T | 2 |
| Uzcátegui, E | 1 |
| Rangel, N | 1 |
| El Fakih, Y | 1 |
| Galeazzi, T | 1 |
| Beaulieu, S | 1 |
| de Baptista, EA | 1 |
| West, DS | 1 |
| Elaine Prewitt, T | 1 |
| Bursac, Z | 1 |
| Felix, HC | 1 |
| Tsilchorozidou, T | 1 |
| Conway, GS | 1 |
| Desilets, AR | 1 |
| Dhakal-Karki, S | 1 |
| Dunican, KC | 1 |
| Love-Osborne, K | 1 |
| Sheeder, J | 1 |
| Wolever, TM | 1 |
| Chiasson, JL | 1 |
| Josse, RG | 1 |
| Hunt, JA | 1 |
| Palmason, C | 1 |
| Rodger, NW | 1 |
| Ryan, EA | 1 |
| Tan, MH | 1 |
| Lee, A | 1 |
| Morley, JE | 1 |
| Grill, V | 1 |
| Følling, I | 1 |
| Charles, MA | 1 |
| Morange, P | 1 |
| Eschwège, E | 1 |
| André, P | 1 |
| Vague, P | 1 |
| Juhan-Vague, I | 1 |
| McCarty, MF | 1 |
| Pinhas-Hamiel, O | 1 |
| Chan, NN | 1 |
| Feher, MD | 1 |
| Bridges, NA | 1 |
| Hirsch, IB | 1 |
| Willms, B | 1 |
| Ruge, D | 1 |
| Genuth, S | 1 |
| Gougeon, R | 1 |
| Styhler, K | 1 |
| Morais, JA | 1 |
| Jones, PJ | 1 |
| Marliss, EB | 1 |
| Greenway, F | 1 |
| Lehtovirta, M | 1 |
| Forsén, B | 1 |
| Gullström, M | 1 |
| Häggblom, M | 1 |
| Eriksson, JG | 1 |
| Taskinen, MR | 1 |
| Groop, L | 1 |
| Hernàndez, L | 1 |
| Prieto, LA | 1 |
| Boyero, EC | 1 |
| de Mendoza, S | 1 |
| Gokcel, A | 2 |
| Karakose, H | 2 |
| Ertorer, EM | 1 |
| Tanaci, N | 2 |
| Tutuncu, NB | 1 |
| Guvener, N | 2 |
| Kay, JP | 1 |
| Alemzadeh, R | 1 |
| Langley, G | 1 |
| D'Angelo, L | 1 |
| Smith, P | 1 |
| Holshouser, S | 1 |
| Lachin, JM | 1 |
| Walker, EA | 1 |
| Gumurdulu, Y | 1 |
| Melek Ertorer, E | 1 |
| BascilTutuncu, N | 1 |
| Morrison, JA | 1 |
| Cottingham, EM | 1 |
| Barton, BA | 1 |
| Brousseau, VJ | 1 |
| Mulchahey, KM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Implementation of a Pragmatic Approach to Lower Diabetes Mellitus Risk After a Diagnosis of Gestational Diabetes Mellitus[NCT05280496] | Phase 3 | 36 participants (Anticipated) | Interventional | 2022-06-01 | Recruiting | ||
| Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors[NCT02431676] | Phase 2 | 121 participants (Actual) | Interventional | 2015-05-31 | Completed | ||
| Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin[NCT04039503] | Phase 3 | 475 participants (Actual) | Interventional | 2019-08-30 | Completed | ||
| Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome: a Prospective, Randomized, Open, Controlled Study[NCT05702905] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-04-30 | Not yet recruiting | ||
| Beta Cell Restoration Through Fat Mitigation[NCT01763346] | 88 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Restoring Insulin Secretion Adult Medication Study[NCT01779362] | Phase 3 | 267 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Personalized Technology-Supported Counseling to Reduce Glycemic Response in Dietary Weight Loss: The Personal Diet Study[NCT03336411] | 269 participants (Actual) | Interventional | 2017-12-12 | Completed | |||
| A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program[NCT02384109] | 521 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin. A 52-week, Randomised, Double-blind, Placebo-controlled Trial (PIONEER 8 - Insulin add-on)[NCT03021187] | Phase 3 | 731 participants (Actual) | Interventional | 2017-02-02 | Completed | ||
| Effects of Intervention With the Glucagon-like Peptide 1 (GLP-1) Analog Liraglutide Plus Metformin Versus Metformin Monotherapy in Overweight/Obese Women With Metabolic Defects and Recent History of Gestational Diabetes Mellitus (GDM)[NCT01234649] | Phase 3 | 153 participants (Actual) | Interventional | 2011-08-11 | Completed | ||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| Impact of a Diet Rich in Inulin-type Fructans Combined With Inulin Supplementation on Gut Microbiota Composition and Metabolic Parameters in Obese Patients[NCT03852069] | 106 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium[NCT01686126] | Phase 2 | 165 participants (Actual) | Interventional | 2012-12-31 | Active, not recruiting | ||
| Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women[NCT02635386] | Phase 3 | 119 participants (Actual) | Interventional | 2016-03-22 | Completed | ||
| A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes[NCT03987919] | Phase 3 | 1,879 participants (Actual) | Interventional | 2019-07-30 | Completed | ||
| Family Inclusive Childhood Obesity Treatment Designed for Low Income and Hispanic Families[NCT05041855] | 658 participants (Anticipated) | Interventional | 2021-11-15 | Recruiting | |||
| Type 2 Diabetes Prevention in Community Health Care Settings for at Risk Children and Mothers[NCT03781102] | 120 participants (Anticipated) | Interventional | 2019-07-01 | Suspended (stopped due to COVID19) | |||
| Mediterranean Enriched Diet for Tackling Youth Obesity[NCT04719052] | 240 participants (Anticipated) | Interventional | 2021-05-25 | Active, not recruiting | |||
| Eating Better Together: A Pilot Study[NCT05028205] | 30 participants (Anticipated) | Interventional | 2021-08-16 | Recruiting | |||
| A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)[NCT01952145] | Phase 3 | 557 participants (Actual) | Interventional | 2013-09-20 | Completed | ||
| Effects of Metformin on Metabolic and Reproductive Outcomes in Chinese PCOS Patients[NCT05463627] | 1,440 participants (Anticipated) | Observational | 2016-01-01 | Recruiting | |||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monothe[NCT02033889] | Phase 3 | 621 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Diazoxide-mediated Insulin Suppression in Hyperinsulinemic Obese Men, Part III[NCT00631033] | Phase 2 | 51 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Hospital-based Diabetes Prevention Study in Korea: A Prospective, Multi-center, Randomized, Open-label Controlled Study[NCT02981121] | Phase 4 | 744 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome[NCT03355469] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2017-08-07 | Recruiting | ||
| A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequate[NCT00763815] | Phase 3 | 484 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Effects of Lixisenatide on Gastric Emptying, Glycaemia and 'Postprandial' Blood Pressure in Type 2 Diabetes and Healthy Subjects.[NCT02308254] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2013-11-30 | Recruiting | ||
| SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)[NCT02798744] | Phase 4 | 68 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-Controlled,Phase III Study With a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type2 Diabetes Mellitus Who Have I[NCT00855166] | Phase 3 | 182 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion[NCT02113241] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin[NCT03076112] | Phase 3 | 170 participants (Actual) | Interventional | 2017-04-25 | Completed | ||
| A 24-week International, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Patients With Type 2 Diabetes W[NCT00673231] | Phase 3 | 1,240 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559] | Phase 4 | 135 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk[NCT03878706] | 240 participants (Anticipated) | Observational [Patient Registry] | 2017-11-03 | Recruiting | |||
| A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, International Phase III Study With 24 Week Extension to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg/Day in Patients With Type 2 Diabetes Who Have Inadequate [NCT00984867] | Phase 3 | 833 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Omics-based Predictors of NAFLD/Potential NASH: A New Era Towards Valid and Reliable Non-invasive Diagnosis and Personalized Therapy[NCT05301231] | 450 participants (Anticipated) | Observational [Patient Registry] | 2022-08-01 | Not yet recruiting | |||
| Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial[NCT06098625] | 200 participants (Anticipated) | Interventional | 2023-11-10 | Not yet recruiting | |||
| Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial (EmLina Renal Trial)[NCT06095492] | 200 participants (Anticipated) | Interventional | 2023-10-30 | Recruiting | |||
| Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation[NCT03352869] | Phase 4 | 183 participants (Actual) | Interventional | 2017-11-28 | Completed | ||
| Short Term Weight Loss With Liraglutide and Metformin Before IVF in Infertile Obese PCOS Patients[NCT03034941] | Phase 4 | 35 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| The Effect of Liraglutide on Pregnancy Rates in Obese Women With PCOS Undergoing in Vitro Fertilization: a Pilot Randomized Study[NCT03353948] | Phase 4 | 30 participants (Actual) | Interventional | 2014-09-01 | Completed | ||
| A Trial Comparing the Efficacy and Safety of Adding Liraglutide Versus Addition of Insulin Aspart With the Largest Meal to Insulin Degludec, Both in Combination With Metformin, in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification (BEG[NCT01388361] | Phase 3 | 413 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetes[NCT04183868] | Phase 4 | 26 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on[NCT01306214] | Phase 3 | 566 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation (DAPA-AF) Prospective, Randomized, Multicenter, Placebo-Controlled Trial[NCT04792190] | Phase 4 | 25 participants (Actual) | Interventional | 2021-07-27 | Completed | ||
| Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes[NCT03132181] | Phase 2 | 40 participants (Actual) | Interventional | 2017-04-24 | Completed | ||
| Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2019-01-09 | Completed | ||
| A 26-week Randomised, Parallel Two-arm, Double-blind, Multi-centre, Multinational, Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide With Insulin Degludec in Subjects With Type 2 Diabetes[NCT01392573] | Phase 3 | 413 participants (Actual) | Interventional | 2011-11-28 | Completed | ||
| A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Co[NCT00968812] | Phase 3 | 1,452 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of LX4211 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metfor[NCT01376557] | Phase 2 | 299 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632] | Phase 3 | 104 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
| A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy[NCT02613897] | 56 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction[NCT03658031] | Phase 3 | 576 participants (Anticipated) | Interventional | 2019-03-01 | Not yet recruiting | ||
| Effects of Metformin on Energy Intake, Energy Expenditure, and Body Weight in Overweight Children With Insulin Resistance[NCT00005669] | Phase 2 | 100 participants (Actual) | Interventional | 2000-05-31 | Completed | ||
| MetfoRmin and Its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease[NCT02226510] | Phase 4 | 68 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| A Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Oral Administration of BI 10773 25 mg/Linagliptin 5 mg and BI 10773 10 mg/Linagliptin 5 mg Fixed Dose Combination Tablets Compared With the Indivi[NCT01422876] | Phase 3 | 1,405 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus on Metformin[NCT00734474] | Phase 2/Phase 3 | 1,202 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Tr[NCT01336023] | Phase 3 | 1,663 participants (Actual) | Interventional | 2011-05-23 | Completed | ||
| Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome[NCT02187250] | Phase 4 | 45 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial[NCT03590626] | 60 participants (Actual) | Interventional | 2019-01-01 | Completed | |||
| A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Glimepiride[NCT01075282] | Phase 3 | 810 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| EMPOWIR: Enhance the Metabolic Profile of Women With Insulin Resistance: Carbohydrate Modified Diet Alone and in Combination With Metformin or Metformin Plus Avandia in Non-diabetic Women With Midlife Weight Gain and Documented Insulin Elevations (Syndrom[NCT00618072] | Phase 2 | 46 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Contr[NCT01106651] | Phase 3 | 716 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Double-blind [Sponsor Unblinded], Randomized, Placebo-controlled, Staggered-parallel Study to Investigate the Safety, Tolerability, and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes[NCT01725126] | Phase 2 | 53 participants (Actual) | Interventional | 2013-02-10 | Completed | ||
| A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Versus Sitagliptin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformi[NCT01137812] | Phase 3 | 756 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Randomized, Double-Blind, Placebo and Active-Controlled, 4-Arm, Parallel Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Con[NCT01106677] | Phase 3 | 1,284 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment[NCT05298657] | 200 participants (Anticipated) | Observational [Patient Registry] | 2022-09-01 | Not yet recruiting | |||
| Role of Synchronized Lifestyle Modification Program on Diabetic Peripheral Neuropathy Patients Taking Oral Hypoglycemics and GLP-1 Analogues[NCT04813146] | 216 participants (Anticipated) | Interventional | 2021-02-05 | Recruiting | |||
| [NCT02909933] | Phase 4 | 30 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian Multicenter National Study[NCT04081571] | 1,080 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
| A Randomised Controlled Clinical Trial of Metformin Versus Orlistat for the Management of Obese Anovulatory Women.[NCT00292799] | 36 participants (Actual) | Interventional | 2006-02-28 | Completed | |||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-512148 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Treatment Naive And Have Inadequate Glycemic Cont[NCT00263276] | Phase 2 | 389 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Previous Metformin Treatment[NCT02304081] | Phase 4 | 64 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat[NCT00156897] | Phase 2 | 600 participants | Interventional | 2004-12-31 | Completed | ||
| Comprehensive Treatment of Angina in Women With Microvascular Dysfunction - a Proof of Concept Study of the iPower Cohort[NCT02910154] | 62 participants (Actual) | Interventional | 2016-12-31 | Completed | |||
| The Impact of Consumption of Eggs in the Context of Plant-Based Diets on[NCT04316429] | 35 participants (Actual) | Interventional | 2020-06-09 | Completed | |||
| WellStart Type 2 Diabetes Study[NCT03731533] | 0 participants (Actual) | Interventional | 2018-12-01 | Withdrawn (stopped due to Grantor withdrew from study) | |||
| Metabolic Syndrome and Severe Obesity: Randomized Nutritional Trial to Study Long Term Effect of Very-low-calories Ketogenic Diet (VLCKD) on Weight Control and Cardiovascular Risk Factors[NCT05781269] | 100 participants (Anticipated) | Interventional | 2022-02-20 | Recruiting | |||
| Benefits of Adding Continuous Glucose Monitoring to Glycemic Load, Exercise, and Monitoring of Blood Glucose (GEM) for Adults With Type 2 Diabetes - Phase 2[NCT03207893] | 24 participants (Actual) | Interventional | 2018-07-19 | Completed | |||
| Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification[NCT03196895] | 192 participants (Actual) | Interventional | 2017-06-28 | Completed | |||
| Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes[NCT03398902] | 150 participants (Anticipated) | Interventional | 2020-09-01 | Recruiting | |||
| Assessment of Designer Functional Foods on Parameters of Metabolic and Vascular Status in Individuals With Prediabetes.[NCT02400450] | 0 participants (Actual) | Interventional | 2016-09-30 | Withdrawn | |||
| Liraglutide in the Treatment of Type 1 Diabetes Mellitus[NCT01722266] | Phase 3 | 72 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet on Reproductive and Metabolic Parameters in Women With Polycystic Ovary Syndrome[NCT05428566] | 110 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) - Pilot Study[NCT00816907] | Phase 4 | 146 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Effect of Liraglutide or Glimepiride Added to Metformin on Glycaemic Control in Subjects With Type 2 Diabetes[NCT00614120] | Phase 3 | 929 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Effect of Detemir and Sitagliptin on Blood Glucose Control in Subjects With Type 2 Diabetes Mellitus[NCT00789191] | Phase 3 | 222 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Multi-centre, Open-labeled, Randomized, Parallel Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After 26 Weeks Treatment With Insulin Detemir Once Daily Versus Insulin NPH Once Daily[NCT01310452] | 50 participants (Anticipated) | Interventional | 2011-01-31 | Active, not recruiting | |||
| The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Ext[NCT00700817] | Phase 3 | 665 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Understanding the Effects of Therapeutic Intervention on Cardiovascular Risk Markers, Insulin Resistance, and Intra-Hepatic Fat Contents in Obese Children at High Risk for the Metabolic Syndrome.[NCT00139477] | 66 participants (Actual) | Interventional | 2003-11-30 | Completed | |||
| The Effect of a Checklist on the Education of Simulated Patients During Insulin Initiation: a Randomized Controlled Trial[NCT02266303] | 100 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | |||
| The Effect of a Checklist on the Quality of Education During Insulin Initiation by Trained Medical Students: a Randomized Controlled Trial[NCT02313805] | 100 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | |||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Metformin Decreases Plasma Resistin Concentrations in Pediatric Patients With Impaired Glucose Tolerance: A Placebo-controlled Randomized Clinical Trial[NCT01394887] | Phase 2/Phase 3 | 52 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection[NCT04267809] | Phase 2 | 44 participants (Anticipated) | Interventional | 2021-10-22 | Recruiting | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study[NCT02694263] | Phase 4 | 25 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 [NCT00642278] | Phase 2 | 451 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Glucose Homeostasis, Incretin Effect and Cardiovascular Risk Burden in T2DM in the Youth- a Study of the Malaysian Population[NCT02845557] | 48 participants (Actual) | Observational | 2013-02-28 | Completed | |||
| Feasibility of the FreeStyle Libre Continuous Glucose Monitoring System in Youth With Type 2 Diabetes (FREE_CGM)[NCT06089070] | 30 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Sleep and Stigma: Novel Moderators in the Relationship Between Weight Status and Cognitive Function[NCT04346433] | 61 participants (Actual) | Interventional | 2020-09-01 | Completed | |||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Prospective, Parallel Goups Study, Aimed to Evaluating Possible Benefits of the Treatment of New Generation Hypoglycaemic Drugs Compared to Sulphonylureas for the Tratment of Type 2 Diabetes Mellitus[NCT04272359] | 138 participants (Anticipated) | Observational [Patient Registry] | 2019-05-06 | Recruiting | |||
| Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With[NCT00318461] | Phase 3 | 1,091 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study[NCT02686476] | 100 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation: a Randomized Controlled Trial[NCT05042505] | 100 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| Metformin Treatment Before IVF in Women With Ultrasound Evidence of Polycystic Ovaries; a Prospective, Randomised, Double Blind, Placebo Study[NCT01046032] | 134 participants (Actual) | Interventional | 2005-12-31 | Completed | |||
| Vigorous Exercise Versus Moderate Exercise to Improve Glucose Metabolism and Metabolic Parameters in Women With Polycystic Ovary Syndrome and Insulin Resistance: A Prospective Randomized Pilot Study[NCT02303470] | 47 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Topiramate and Severe Obesity in Children and Adolescents[NCT02273804] | Phase 3 | 18 participants (Actual) | Interventional | 2016-06-01 | Completed | ||
| A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Alone[NCT00039013] | Phase 3 | 336 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| An Open Label Study to Examine the Long Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes Mellitus[NCT00111540] | Phase 3 | 456 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318] | Phase 4 | 50 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects[NCT00856609] | Phase 3 | 150 participants (Actual) | Interventional | 2009-03-03 | Completed | ||
| Effects Of Exenatide (Byetta®) On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Non-Alcoholic Fatty Liver Disease[NCT00529204] | Phase 2 | 1 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to Lack of recruitment) | ||
| Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin[NCT00099320] | Phase 3 | 182 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain: a Randomized Double-Blind Placebo- Controlled Comparison[NCT00451399] | Phase 4 | 128 participants | Interventional | 2004-10-31 | Completed | ||
| Efficacy and Safety of Metformin in Preventing Patients With Risperidone From Weight Gain and Amenorrhea:a 24-week, Randomized, Placebo-controlled, Double-blind, Fixed-dose Study[NCT01423487] | 0 participants (Actual) | Interventional | 2011-08-31 | Withdrawn (stopped due to Difficult to obtain informed consent) | |||
| The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).[NCT05646199] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| The STRENGTH Study: Shapely Sisters Targeting Realistic Exercise and Nutrition Goals Through Healthy Habits[NCT02253641] | 40 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| Inflammatory Mediators in Obese Adolescents With Insulin Resistance Following Metformin Treatment: Controlled Randomized Clinical Trial[NCT01410604] | Phase 4 | 31 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Randomized Clinical Trial, Effect of Metformin and Rosiglitazone Over Glucose Homeoastasis in no Diabetic With Metabolic Syndrome Patients.[NCT04148183] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2004-01-01 | Completed | ||
| Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial[NCT04377451] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| The Impact of Novel Strategies to Improve Cardiometabolic Status and Adherence to Exercise Regimens in Patients at High Risk for Cardiovascular Disease[NCT03103854] | 500 participants (Anticipated) | Interventional | 2014-01-01 | Recruiting | |||
| Group Medical Visits (GMVs) in Primary Care: An RCT of Group-Based Versus Individual Appointments to Reduce HbA1c in Older People[NCT02002143] | 128 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Effects of a Smartphone-based Weight Loss Programme Targeting Chinese Overweight Adults With Pre-diabetes: A Randomized Controlled Trial[NCT04875780] | 282 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | |||
| Testing the Effectiveness of Different Messaging Approaches to Increase Doctor Visits to Confirm or Exclude a Diagnosis of Prediabetes or Diabetes Amongst Individuals With Risk Factors for Diabetes: A Randomised, Controlled Trial[NCT05755555] | 5,000 participants (Actual) | Interventional | 2022-08-04 | Active, not recruiting | |||
| Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal[NCT02660905] | Phase 3 | 25 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| GluCoach - Technology-enabled Lifestyle Intervention Study[NCT04905680] | 260 participants (Anticipated) | Interventional | 2021-05-04 | Recruiting | |||
| Culturally Adapted Community-based Translational Diabetes Prevention Program for Obese and Pre-diabetic Hispanic/Latino Females[NCT04052815] | 30 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | |||
| Evaluation of Rosiglitazone in Reversing Metabolic Defects of Pre-Diabetes and Type 2 Diabetes Mellitus[NCT00094796] | Phase 2 | 70 participants | Interventional | 2004-10-20 | Completed | ||
| Diet, Exercise and Breastfeeding Intervention (DEBI) Program for Women With Gestational Diabetes[NCT00460018] | Phase 2 | 180 participants (Anticipated) | Interventional | 2005-09-30 | Completed | ||
| Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus[NCT02744300] | 180 participants (Anticipated) | Interventional | 2016-09-30 | Completed | |||
| Physical Activity and Sedentary Behavior Change; Impact on Lifestyle Intervention Effects for Diabetes Translation[NCT02467881] | 308 participants (Actual) | Interventional | 2015-09-30 | Active, not recruiting | |||
| Use of MCT Oil for Enhancement of Weight Loss and Glycemic Control in Obese Diabetic Patients 2002-292G[NCT00207233] | Phase 1/Phase 2 | 42 participants (Anticipated) | Interventional | 2004-07-31 | Completed | ||
| Weight Management in Nonalcoholic Steatohepatitis (NASH)[NCT00266019] | Phase 2 | 30 participants (Anticipated) | Interventional | 2005-01-31 | Completed | ||
| Extreme Exercise and Energy Expenditure (4E) Study[NCT05895916] | 13 participants (Actual) | Interventional | 2018-06-07 | Completed | |||
| A Comprehensive Intervention Study on Klotho Gene Methylation and Cardiovascular Risk Factors[NCT02773823] | 190 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| Characterization of a Portable Solid-State Breath Acetone Testing Device for Real-Time Ketosis Status and Comparison to Blood Ketone Testing[NCT04130724] | 21 participants (Actual) | Observational | 2019-10-16 | Completed | |||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| Collaborations for Health Improvement in East Harlem-Project HEED[NCT01004848] | 402 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| A Prospective, Randomized, Parallel-group, Adaptive Design Phase IIb/III, Multicenter Study, to Assess the Efficacy of Polychemotherapy for Inducing Remission of Newly Diagnosed Type 2 Diabetes.[NCT04271189] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial[NCT06064669] | 988 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| Diabetes and Osteopathic Manipulative Medicine: A Randomized Controlled Trial[NCT03663322] | 100 participants (Anticipated) | Interventional | 2018-11-15 | Recruiting | |||
| Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men Initiating Androgen Deprivation Therapy For Prostate Cancer[NCT00932672] | Phase 2 | 45 participants (Actual) | Interventional | 2009-06-30 | Terminated (stopped due to slow recruitment, lack of funding and PI transferred) | ||
| Age, Lifestyle, Muscle Mechanisms in Insulin Resistance[NCT00971594] | 15 participants (Actual) | Interventional | 2004-06-30 | Completed | |||
| Virtual Lifestyle Management: Prevention Through the UPMC Patient Portal[NCT00409786] | 50 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Iron Reduction by Phlebotomy for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease[NCT03696797] | 240 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | |||
| A Community-based Lifestyle Intervention to Reduce the Risk of Diabetes in Qingdao, China----Qingdao Diabetes Prevention Project (2005-2012)[NCT01053195] | 276,793 participants (Actual) | Interventional | 2005-12-31 | Completed | |||
| Screening, Training, Education and Prevention Service of the University of Pittsburgh, Phase 2[NCT00480779] | 48 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Sleep for Health: A Randomized Clinical Trial Examining the Effects of Cognitive Behavioral Therapy for Insomnia on Diabetes Risk[NCT06067139] | 300 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | |||
| The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)[NCT00105066] | Phase 2 | 77 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Modulation of Insulin and Exercise Responses by Vitamin E and Vitamin C[NCT01369043] | 1 participants (Actual) | Interventional | 2011-05-31 | Terminated (stopped due to Lack of successful recruiting, budget cuts, and potential study flaws.) | |||
| Exercise, Prediabetes and Diabetes After Renal Transplantation.[NCT04489043] | 60 participants (Anticipated) | Interventional | 2019-09-05 | Recruiting | |||
| Effects of Exercise Behavior Modification on Plasma Adiponectin and Insulin Resistance in High Risk Subjects of Diabetes[NCT01136096] | 216 participants (Actual) | Interventional | 2004-01-31 | Completed | |||
| Pragmatic Randomized Trial of Polygenic Risk Scoring for Common Diseases in Primary Care[NCT04331535] | 1,076 participants (Anticipated) | Interventional | 2020-07-17 | Recruiting | |||
| Determinants of Progression From Impaired Fasting Glucose to Diabetes Mellitus Among Chinese - a 3-year Follow up Study[NCT03617757] | 386 participants (Actual) | Interventional | 2017-10-01 | Completed | |||
| Improving Cognitive-Behavioral and Cardio-Metabolic Health Through Continuous Glucose Monitoring (CGM)[NCT04920058] | 66 participants (Actual) | Interventional | 2021-05-10 | Completed | |||
| Medicaid Incentives for the Prevention of Chronic Diseases: Diabetes Prevention[NCT03139019] | 596 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Obesity Group Visits. A Novel Way to Approach the Obesity Epidemic in an Inner-City Setting[NCT04725058] | 1,000 participants (Anticipated) | Interventional | 2020-02-03 | Recruiting | |||
| Abdominal Obesity as a Therapeutic Target: Long-term Benefits of Abdominal Fat Loss and Weight Stabilization in High-risk Abdominally Obese Dyslipidemic Patients With the Features of the Metabolic Syndrome (SYNERGIE Study)[NCT06158191] | 186 participants (Actual) | Interventional | 2004-03-26 | Completed | |||
| Insulin Superheroes Club: Diabetes Prevention Program in Youth (12-month Supplement to the CDC DPP for Adults)[NCT03042936] | 33 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| Early Diagnosis and Management of Patients at Risk for Diabetes[NCT03949504] | 1,500 participants (Actual) | Observational | 2019-01-09 | Completed | |||
| Effects of a Web/Smartphone-based Lifestyle Coaching Program on Gestational Weight Gain in Pregnant Women With Gestational Diabetes[NCT03249896] | 340 participants (Actual) | Interventional | 2017-09-05 | Active, not recruiting | |||
| Effects of a Community-based Weight Loss Programme Targetting Chinese Overweight Adults With Pre-diabetes: A Randomized Controlled Trial[NCT03609697] | 180 participants (Anticipated) | Interventional | 2018-08-10 | Active, not recruiting | |||
| Dietary Oxysterols and β-Cell Function Among African Americans[NCT05072587] | 24 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| Canadian Health Advanced By Nutrition and Graded Exercise: CHANGE Health Paradigm[NCT01616563] | 305 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial[NCT03004612] | Phase 4 | 144 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Prospective Consortium Evaluating the Long-term Follow-up of Patients With Type 2 Diabetes Enrolled In a Randomized Controlled Trial Comparing Bariatric Surgery Versus Medical Management[NCT02328599] | 302 participants (Anticipated) | Observational | 2018-04-10 | Enrolling by invitation | |||
| The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes[NCT01741467] | 110 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
IGF-1 at 12 months (NCT02431676)
Timeframe: 12 months
| Intervention | ng/ml (Mean) |
|---|---|
| Self-Directed | 73.4 |
| Coach Directed Behavioral Weight Loss | 76.6 |
| Metformin | 76.2 |
Insulin-like growth factor (IGF)-1 levels (ng/ml) at 6 months. (NCT02431676)
Timeframe: 6 months
| Intervention | ng/ml (Mean) |
|---|---|
| Self-Directed | 73.2 |
| Coach Directed Behavioral Weight Loss | 73.6 |
| Metformin | 71.2 |
IGF-1 level to IGFBP3 level ratio (molar ratio) at 6 months. (NCT02431676)
Timeframe: 6 months
| Intervention | ratio (Mean) |
|---|---|
| Self-Directed | 0.18 |
| Coach Directed Behavioral Weight Loss | 0.18 |
| Metformin | 0.17 |
Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (<= 8.0%, >8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares). (NCT04039503)
Timeframe: Baseline, Week 40
| Intervention | Kilograms (kg) (Least Squares Mean) |
|---|---|
| 5 mg Tirzepatide | -6.2 |
| 10 mg Tirzepatide | -8.2 |
| 15 mg Tirzepatide | -10.9 |
| Placebo | 1.7 |
Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. LS Mean was determined by MMRM model with Baseline + Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (<= 8.0%, >8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. (NCT04039503)
Timeframe: Baseline, Week 40
| Intervention | milligram per Deciliter (mg/dL) (Least Squares Mean) |
|---|---|
| 5 mg Tirzepatide | -61.4 |
| 10 mg Tirzepatide | -67.9 |
| 15 mg Tirzepatide | -67.7 |
| Placebo | -38.9 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares). (NCT04039503)
Timeframe: Baseline, Week 40
| Intervention | Percentage of HbA1c (Least Squares Mean) |
|---|---|
| 5 mg Tirzepatide | -2.23 |
| Placebo | -0.93 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares). (NCT04039503)
Timeframe: Baseline, Week 40
| Intervention | Percentage of HbA1c (Least Squares Mean) |
|---|---|
| 10 mg Tirzepatide | -2.59 |
| 15 mg Tirzepatide | -2.59 |
| Placebo | -0.93 |
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Baseline HbA1c Group (<= 8.0%, >8.0%) + Baseline Metformin Use (Yes, No) + Pooled Country + Treatment (Type III sum of squares). (NCT04039503)
Timeframe: Baseline, Week 40
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| 5 mg Tirzepatide | -67.1 |
| 10 mg Tirzepatide | -71.7 |
| 15 mg Tirzepatide | -73.7 |
| Placebo | -39.4 |
LS mean was calculated using MMRM model with log (Baseline) + Baseline Metformin Use (Yes, No) + Pooled Country + Baseline HbA1c Group (<= 8.0%, >8.0%) + Treatment + Time + Treatment*Time (Type III sum of squares) as variables. (NCT04039503)
Timeframe: Baseline, Week 40
| Intervention | International Units (IU) (Least Squares Mean) |
|---|---|
| 5 mg Tirzepatide | 13.0 |
| 10 mg Tirzepatide | 8.1 |
| 15 mg Tirzepatide | -11.4 |
| Placebo | 75.0 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. (NCT04039503)
Timeframe: Week 40
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Tirzepatide | 26.09 |
| 10 mg Tirzepatide | 47.79 |
| 15 mg Tirzepatide | 62.39 |
| Placebo | 2.54 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A.HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. (NCT04039503)
Timeframe: Week 40
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Tirzepatide | 93.04 |
| 10 mg Tirzepatide | 97.35 |
| 15 mg Tirzepatide | 94.02 |
| Placebo | 33.90 |
Percentage of Participants who Achieved Weight Loss ≥5%. (NCT04039503)
Timeframe: Week 40
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Tirzepatide | 53.91 |
| 10 mg Tirzepatide | 64.60 |
| 15 mg Tirzepatide | 84.62 |
| Placebo | 5.93 |
AUC is a combined measure obtained from Week 7, 15, 23 and 39 and a single averaged measure of AUC was reported. (NCT04039503)
Timeframe: Week 7, 15, 23 and 39 post dose
| Intervention | nanogram*hour per milliliter (ng*h/mL) (Geometric Mean) |
|---|---|
| 5 mg Tirzepatide | 79700 |
| 10 mg Tirzepatide | 164000 |
| 15 mg Tirzepatide | 246000 |
The hypoglycemia events were defined by participant reported events with blood glucose <54mg/dL) (<3.0 mmol/L] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline Metformin Use (Yes, No) + Baseline HbA1c Group (<= 8.0%, >8.0%) + Treatment, with log (exposure in days/365.25) as an offset variable. (NCT04039503)
Timeframe: Baseline through Safety Follow-Up (Up to Week 44)
| Intervention | Episodes/participant/365.25 days (Mean) |
|---|---|
| 5 mg Tirzepatide | 0.49 |
| 10 mg Tirzepatide | 0.66 |
| 15 mg Tirzepatide | 0.38 |
| Placebo | 0.51 |
HbA1C (NCT01763346)
Timeframe: 24 months
| Intervention | percent of hemoglobin (Mean) |
|---|---|
| Metformin | 5.84 |
| Gastric Banding | 5.73 |
mean plasma C-peptide concentration during clamp steady state, adjusted for mean clamp insulin sensitivity (NCT01763346)
Timeframe: 24 months
| Intervention | (nmol/L) adjusted for M/I (Geometric Mean) |
|---|---|
| Metformin | 3.01 |
| Gastric Banding | 3.19 |
fasting and 2-hour OGTT glucose levels (NCT01763346)
Timeframe: 24 months
| Intervention | mmol/l (Mean) | |
|---|---|---|
| fasting glucose | 2-hour glucose | |
| Gastric Banding | 5.85 | 9.92 |
| Metformin | 5.95 | 10.87 |
First phase response from the hyperglycemic clamp (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | nmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 1.68 |
| Glargine Followed by Metformin | 1.68 |
| Placebo | 1.68 |
| Liraglutide + Metformin | 1.68 |
Clamp measure of insulin sensitivity (NCT01779362)
Timeframe: 3-months after a medication washout
| Intervention | x 10-5 mmol/kg/min per pmol/L (Geometric Mean) |
|---|---|
| Metformin Alone | 3.53 |
| Glargine Followed by Metformin | 3.38 |
| Placebo | 3.63 |
| Liraglutide + Metformin | 3.49 |
Participants had 12-months of active therapy. Secondary results at the end of active intervention. (NCT01779362)
Timeframe: Secondary analysis was on all participants with a Month 12 visit.
| Intervention | nmol/L (Geometric Mean) | ||
|---|---|---|---|
| ACRPg | Steady State C-peptide | ACRPmax | |
| Glargine Followed by Metformin | 1.88 | 11.6 | 14.1 |
| Liraglutide + Metformin | 2.68 | 21.2 | 10.1 |
| Metformin Alone | 1.93 | 11.7 | 13.4 |
| Placebo | 1.69 | 10.8 | 13.6 |
Clamp measures of ß-cell response, co-primary outcomes (NCT01779362)
Timeframe: 3-months after medication washout (Month 15)
| Intervention | nmol/L (Geometric Mean) | |
|---|---|---|
| Steady State C-peptide | ACPRmax | |
| Glargine Followed by Metformin | 3.58 | 4.32 |
| Liraglutide + Metformin | 3.73 | 4.58 |
| Metformin Alone | 3.65 | 4.61 |
| Placebo | 3.60 | 4.45 |
Change from baseline (week 0) in body weight to week 52. The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 52
| Intervention | Kg (Mean) |
|---|---|
| Oral Semaglutide 3 mg | -0.9 |
| Oral Semaglutide 7 mg | -2.2 |
| Oral Semaglutide 14 mg | -3.8 |
| Placebo | 0.5 |
Change from baseline (week 0) in HbA1c to week 52. The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 52
| Intervention | Percentage of HbA1c (Mean) |
|---|---|
| Oral Semaglutide 3 mg | -0.6 |
| Oral Semaglutide 7 mg | -0.9 |
| Oral Semaglutide 14 mg | -1.2 |
| Placebo | -0.2 |
Treatment emergent adverse events (TEAEs) were recorded from week 0 to week 57 (52-week treatment period plus the 5-week follow-up period). Adverse events (AEs) with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period was defined as the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication. (NCT03021187)
Timeframe: Weeks 0-57
| Intervention | Events (Number) |
|---|---|
| Oral Semaglutide 3 mg | 626 |
| Oral Semaglutide 7 mg | 555 |
| Oral Semaglutide 14 mg | 586 |
| Placebo | 464 |
Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were recorded during week 0 to week 57 (52-week treatment period plus the 5-week follow-up period). Hypoglycaemic episodes with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period was defined as the time period when a subject was on treatment with trial product, including any period after initiation of rescue medication. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia: Confirmed by a glucose value <3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. (NCT03021187)
Timeframe: Weeks 0-57
| Intervention | Episodes (Number) |
|---|---|
| Oral Semaglutide 3 mg | 196 |
| Oral Semaglutide 7 mg | 180 |
| Oral Semaglutide 14 mg | 147 |
| Placebo | 156 |
Treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes were recorded during week 0 to week 57 (52-week treatment period plus the 5-week follow-up period). Hypoglycaemic episodes with onset during the on-treatment observation period were considered treatment-emergent. On-treatment observation period was defined as the time period when a subject was on treatment with trial product, including any period after initiation of rescue medication. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia: Confirmed by a glucose value <3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. (NCT03021187)
Timeframe: Weeks 0-57
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Semaglutide 3 mg | 52 |
| Oral Semaglutide 7 mg | 47 |
| Oral Semaglutide 14 mg | 48 |
| Placebo | 54 |
Change from baseline (week 0) in amylase (units/litre (U/L)) at weeks 26 and 52 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Ratio of amylase (Geometric Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | 1.14 | 1.17 |
| Oral Semaglutide 3 mg | 1.08 | 1.07 |
| Oral Semaglutide 7 mg | 1.12 | 1.11 |
| Placebo | 1.01 | 0.99 |
Change from baseline (week 0) in body mass index (BMI) was evaluated at weeks 26 and 52. BMI was calculated based on body weight and height based on the formula: BMI kg/m^2 = body weight (kg)/(Height (m) x Height (m)). Data based on in-trial observation period is presented. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | kg/m^2 (Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | -1.4 | -1.4 |
| Oral Semaglutide 3 mg | -0.5 | -0.3 |
| Oral Semaglutide 7 mg | -1.0 | -0.8 |
| Placebo | -0.2 | 0.2 |
Relative change from baseline (week 0) in body weight (%) was evaluated at weeks 26 and 52.The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Percentage change (Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | -4.30 | -4.42 |
| Oral Semaglutide 3 mg | -1.73 | -1.18 |
| Oral Semaglutide 7 mg | -3.11 | -2.54 |
| Placebo | -0.47 | 0.65 |
Change from baseline (week 0) in body weight was evaluated at week 26. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. The endpoint was also evaluated based on data from the on-treatment without rescue medication observation period. It started at the date of first dose of trial product and excluded the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26
| Intervention | Kg (Mean) | |
|---|---|---|
| In trial | On-treatment without rescue medication | |
| Oral Semaglutide 14 mg | -3.7 | -3.9 |
| Oral Semaglutide 3 mg | -1.4 | -1.5 |
| Oral Semaglutide 7 mg | -2.6 | -3.0 |
| Placebo | -0.5 | -0.5 |
"Change from baseline (week 0) in Diabetes Treatment Satisfaction Questionnaire - status version (DTSQs) was evaluated at week 26 and week 52. The DTSQs items are scored on a 7-point graded response scale ranging from 6 to 0. Higher scores indicate higher levels of treatment satisfaction for DTSQs items 1, 4 -8. For items 2 and 3 a higher score indicates a higher patient perceived experience of hyperglycaemia and hypoglycaemia, respectively. Thus, lower scores indicate a perception of blood glucose levels being none of the time unacceptably high (item 2) or low (item 3). The domain score of total treatment satisfaction (total treatment satisfaction score) was computed by adding the six items scores 1, 4-8. The score has a minimum of 0 and a maximum of 36. A higher treatment satisfaction score indicates a higher level of treatment satisfaction." (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Score on a scale (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Satisfaction with treatment: wk 26 | Satisfaction with treatment: wk 52 | Feeling of unacceptably high blood sugars: wk 26 | Feeling of unacceptably high blood sugars: wk 52 | Feeling of unacceptably low blood sugars: wk 26 | Feeling of unacceptably low blood sugars: wk 52 | Convenience of treatment: wk 26 | Convenience of treatment: wk 52 | Flexibility of treatment: wk 26 | Flexibility of treatment: wk 52 | Satisfaction with understading of diabetes: wk 26 | Satisfaction with understading of diabetes: wk 52 | Recommending treatment to others: wk 26 | Recommending treatment to others: wk 52 | Satisfaction to continue present treatment: wk 26 | Satisfaction to continue present treatment: wk 52 | Total treatment satisfaction: wk 26 | Total treatmemt satisfaction: wk 52 | |
| Oral Semaglutide 14 mg | 0.63 | 0.78 | -1.29 | -1.34 | 0.13 | -0.06 | 0.50 | 0.44 | 0.40 | 0.46 | 0.27 | 0.34 | 0.53 | 0.65 | 0.58 | 0.65 | 2.90 | 3.32 |
| Oral Semaglutide 3 mg | 0.47 | 0.53 | -0.62 | -0.70 | 0.07 | 0.04 | 0.51 | 0.38 | 0.31 | 0.25 | 0.24 | 0.25 | 0.20 | 0.32 | 0.40 | 0.41 | 2.12 | 2.14 |
| Oral Semaglutide 7 mg | 0.59 | 0.51 | -1.23 | -1.15 | -0.06 | -0.10 | 0.50 | 0.52 | 0.37 | 0.42 | 0.31 | 0.35 | 0.66 | 0.63 | 0.57 | 0.56 | 3.00 | 2.99 |
| Placebo | 0.18 | 0.20 | -0.28 | -0.41 | -0.15 | -0.02 | 0.20 | 0.19 | 0.23 | 0.23 | 0.04 | 0.03 | 0.02 | -0.01 | 0.09 | 0.03 | 0.76 | 0.67 |
Change from baseline (week 0) in electrocardiogram (ECG) was evaluated at weeks 26 and 52. Change from baseline results are presented as shift in findings (normal; abnormal and not clinically significant (NCS); abnormal and clinically significant (CS)) from week 0 to week 26 and 52. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal (week 0) to Normal (week 26) | Normal (week 0) to Abnormal NCS (week 26) | Normal (week 0) to Abnormal CS (week 26) | Abnormal NCS (week 0) to Normal (week 26) | Abnormal NCS (week 0) to Abnormal NCS (week 26) | Abnormal NCS (week 0) to Abnormal CS (week 26) | Abnormal CS (week 0) to Normal (week 26) | Abnormal CS (week 0) to Abnormal NCS (week 26) | Abnormal CS (week 0) to Abnormal CS (week 26) | Normal (week 0) to Normal (week 52) | Normal (week 0) to Abnormal NCS (week 52) | Normal (week 0) to Abnormal CS (week 52) | Abnormal NCS to Normal (Week 52) | Abnormal NCS to Abnormal NCS (Week 52) | Abnormal NCS to Abnormal CS (Week 52) | Abnormal CS to Normal (Week 52) | Abnormal CS to Abnormal NCS (Week 52) | Abnormal CS to Abnormal CS (Week 52) | |
| Oral Semaglutide 14 mg | 90 | 17 | 0 | 16 | 47 | 0 | 1 | 1 | 1 | 85 | 20 | 1 | 19 | 42 | 0 | 0 | 2 | 1 |
| Oral Semaglutide 3 mg | 101 | 10 | 0 | 22 | 44 | 0 | 0 | 0 | 0 | 95 | 14 | 2 | 13 | 50 | 0 | 0 | 0 | 0 |
| Oral Semaglutide 7 mg | 98 | 12 | 0 | 17 | 42 | 0 | 0 | 0 | 4 | 91 | 15 | 2 | 17 | 40 | 1 | 0 | 0 | 4 |
| Placebo | 93 | 12 | 0 | 19 | 51 | 0 | 1 | 0 | 1 | 84 | 17 | 1 | 21 | 47 | 1 | 0 | 1 | 1 |
Change from baseline (week 0) in FPG to week 26 and week 52. The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | -1.36 | -1.60 |
| Oral Semaglutide 3 mg | -0.45 | -0.81 |
| Oral Semaglutide 7 mg | -1.14 | -1.12 |
| Placebo | 0.51 | -0.09 |
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 26. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. The endpoint was also analysed based on data from the on-treatment without rescue medication observation period. On-treatment without rescue medication observation period started at the date of the first dose of trial product and includes the period after initiation of rescue medication, if any, and excludes the period after premature trial discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26
| Intervention | Percentage of HbA1c (Mean) | |
|---|---|---|
| In-trial | On-treatment without rescue medication | |
| Oral Semaglutide 14 mg | -1.3 | -1.4 |
| Oral Semaglutide 3 mg | -0.5 | -0.6 |
| Oral Semaglutide 7 mg | -1.0 | -1.1 |
| Placebo | -0.1 | -0.1 |
Change from baseline (week 0) in HDL cholesterol (mmol/L) at weeks 26 and 52 is presented as ratio to baseline. Results are based on the data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Ratio of HDL cholesterol (Geometric Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | 0.98 | 1.01 |
| Oral Semaglutide 3 mg | 1.00 | 1.01 |
| Oral Semaglutide 7 mg | 0.98 | 0.98 |
| Placebo | 1.01 | 1.00 |
The Impact of Weight on Quality of Life Clinical Trials Version (IWQOL-Lite-CT) is designed to assess the impact of changes in weight on patients' quality of life within the context of clinical trials. The items of the IWQOL-Lite-CT pertain to physical functioning (physical, physical function and pain/discomfort) and psychosocial domains and all items employ a 5-point graded response scale (never, rarely, sometimes, usually, always; or not at all true, a little true, moderately true, mostly true, completely true). All IWQOL-Lite-CT composite scores range from 0 to 100, with higher scores reflecting better levels of functioning. Results are based on the data from the in-trial observation period, which started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1) Psychosocial (Week 26) | 1) Psychosocial (Week 52) | 2) Physical (Week 26) | 2) Physical (Week 52) | 3) Physical function(Week 26) | 3) Physical function(Week 52) | 4) Pain/discomfort (Week 26) | 4) Pain/discomfort (Week 52) | 5) IWQOL-Lite-CT Total (Week 26) | 5) IWQOL-Lite-CT Total (Week 52) | |
| Oral Semaglutide 14 mg | 4.10 | 5.35 | 2.15 | 2.50 | 2.51 | 2.59 | 1.23 | 2.28 | 3.41 | 4.35 |
| Oral Semaglutide 3 mg | 1.45 | 1.96 | 2.29 | 3.10 | 1.88 | 3.45 | 3.30 | 2.23 | 1.74 | 2.35 |
| Oral Semaglutide 7 mg | -0.32 | -0.92 | -0.66 | -0.53 | -0.35 | -0.59 | -1.45 | -0.37 | -0.45 | -0.79 |
| Placebo | -0.49 | -0.46 | -1.75 | -1.24 | -1.70 | -0.98 | -1.85 | -1.88 | -0.94 | -0.73 |
Change from baseline in LDL cholesterol (mmol/L) is presented as ratio to baseline at week 26 and week 52. Results are based on the data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Ratio of LDL cholesterol (Geometric Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | 0.93 | 0.95 |
| Oral Semaglutide 3 mg | 0.98 | 0.97 |
| Oral Semaglutide 7 mg | 0.93 | 0.96 |
| Placebo | 1.03 | 1.00 |
Change from baseline (week 0) in lipase (units/litre (U/L)) at weeks 26 and 52 is presented as ratio to baseline. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Ratio of lipase (Geometric Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | 1.35 | 1.35 |
| Oral Semaglutide 3 mg | 1.14 | 1.09 |
| Oral Semaglutide 7 mg | 1.34 | 1.25 |
| Placebo | 0.99 | 0.99 |
Change from baseline (week 0) in pulse rate was evaluated at weeks 26 and 52 Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Beats/minute (Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | 3 | 2 |
| Oral Semaglutide 3 mg | 1 | -0 |
| Oral Semaglutide 7 mg | 2 | 1 |
| Placebo | -0 | 0 |
Change from baseline (week 0) in systolic blood pressure (SBP) and diastolic blood pressure (DBP) was evaluated at weeks 26 and 52 Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| SBP: Week 26 | SBP: Week 52 | DBP: Week 26 | DBP: Week 52 | |
| Oral Semaglutide 14 mg | -5 | -6 | -1 | -2 |
| Oral Semaglutide 3 mg | -1 | -1 | -0 | -1 |
| Oral Semaglutide 7 mg | -3 | -3 | -1 | -2 |
| Placebo | 1 | 0 | 0 | -0 |
Change from baseline (week 0) in self-measured plasma glucose (SMPG) mean 7-point profile to week 26 and week 52. SMPG was recorded at the following 7 time points: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after dinner and at bedtime. Mean 7-point profile was defined as the area under the profile, calculated using the trapezoidal method, divided by the measurement time. The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | -2.0 | -2.0 |
| Oral Semaglutide 3 mg | -1.2 | -1.6 |
| Oral Semaglutide 7 mg | -1.8 | -1.7 |
| Placebo | -0.3 | -0.9 |
SF-36 is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The 0-100 scale scores (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively of the 2009 U.S. general population. Change from baseline (week 0) in the domain scores and component summary (PCS and MCS) scores were evaluated at weeks 26 and 52. A positive change score indicates an improvement since baseline. Results are based on the data from the in-trial observation period. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Score on a scale (Mean) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1) Physical functioning (Week 26) | 1) Physical functioning (Week 52) | 2) Role Physical (Week 26) | 2) Role Physical (Week 52) | 3) Bodily Pain (Week 26) | 3) Bodily Pain (Week 52) | 4) General Health (Week 26) | 4) General Health (Week 52) | 5) Vitality (Week 26) | 5) Vitality (Week 52) | 6) Social functioning (Week 26) | 6) Social functioning (Week 52) | 7) Role emotional (Week 26) | 7) Role emotional (Week 52) | 8) Mental health (Week 26) | 8) Mental health (Week 52) | 9) Physical component summary (Week 26) | 9) Physical component summary (Week 52) | 10) Mental component summary (Week 26) | 10) Mental component summary (Week 52) | |
| Oral Semaglutide 14 mg | -0.07 | -0.32 | 0.04 | -0.87 | -0.18 | -0.21 | 1.26 | 1.38 | 0.14 | 0.70 | -0.51 | 0.03 | 0.24 | 0.09 | 0.99 | 0.89 | -0.02 | -0.36 | 0.49 | 0.82 |
| Oral Semaglutide 3 mg | 0.53 | 0.51 | -0.32 | 0.00 | -0.02 | -0.40 | 1.43 | 0.92 | -0.56 | -0.53 | -0.31 | 0.11 | -0.94 | 0.77 | -1.41 | -0.48 | 0.94 | 0.26 | -1.41 | -0.09 |
| Oral Semaglutide 7 mg | 0.52 | -0.40 | -0.43 | -0.76 | 1.47 | 0.56 | 0.70 | 0.75 | -1.27 | -1.43 | 0.34 | -0.61 | 0.62 | -0.34 | -0.82 | -0.74 | 0.75 | 0.12 | -0.55 | -0.89 |
| Placebo | -0.82 | -0.77 | -0.39 | -0.93 | -0.72 | -0.64 | -0.36 | -1.43 | -1.69 | -1.09 | -1.10 | -1.74 | -1.50 | -2.78 | -2.32 | -1.30 | -0.05 | -0.41 | -2.16 | -2.19 |
Change from baseline (week 0) in SMPG mean postprandial increment over all meals to week 26 and week 52. The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | mmol/L (Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | -1.2 | -0.7 |
| Oral Semaglutide 3 mg | -0.3 | -0.3 |
| Oral Semaglutide 7 mg | -0.8 | -0.7 |
| Placebo | -0.1 | -0.3 |
Change from baseline in total cholesterol (mmol/L) is presented as ratio to baseline at week 26 and week 52. Results are based on the data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Ratio of total cholesterol (Geometric Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | 0.95 | 0.95 |
| Oral Semaglutide 3 mg | 0.99 | 0.98 |
| Oral Semaglutide 7 mg | 0.95 | 0.97 |
| Placebo | 1.03 | 1.00 |
Change from baseline in total daily insulin dose to week 26 and week 52 is presented. Results are based on the data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Units/day (Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | -8 | -5 |
| Oral Semaglutide 3 mg | -5 | 1 |
| Oral Semaglutide 7 mg | -9 | -8 |
| Placebo | -2 | 8 |
Change from baseline (week 0) in triglycerides (mmol/L) at weeks 26 and 52 is presented as ratio to baseline. Results are based on the data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | Ratio of triglycerides (Geometric Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | 0.91 | 0.86 |
| Oral Semaglutide 3 mg | 0.97 | 0.93 |
| Oral Semaglutide 7 mg | 0.92 | 0.94 |
| Placebo | 0.99 | 0.97 |
Change from baseline (week 0) in waist circumference was evaluated at weeks 26 and 52.The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 0, week 26, week 52
| Intervention | cm (Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Oral Semaglutide 14 mg | -3.6 | -4.0 |
| Oral Semaglutide 3 mg | -0.9 | -0.8 |
| Oral Semaglutide 7 mg | -2.3 | -2.3 |
| Placebo | -0.6 | 0.3 |
This outcome measure is only applicable for the oral semaglutide treatment arms (3 mg, 7 mg and 14 mg). Semaglutide plasma concentrations were measured at week 4, 14, 26, 38 and 52. Results are based on the data from the on-treatment observation period which was the time period when a participant was on treatment with trial product, including any period after initiation of rescue medication. (NCT03021187)
Timeframe: Weeks 0-52
| Intervention | nmol/L (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 14 | Week 26 | Week 38 | Week 52 | |
| Oral Semaglutide 14 mg | 2.9 | 14.5 | 12.6 | 10.8 | 11.9 |
| Oral Semaglutide 3 mg | 2.9 | 2.9 | 2.7 | 2.5 | 2.4 |
| Oral Semaglutide 7 mg | 2.9 | 7.5 | 7.2 | 6.9 | 5.8 |
Presented results are the number of participants who had taken additional anti-diabetic medication anytime during the periods, from week 0 to week 26 and week 0 to week 52. Additional anti-diabetic medication was defined as use of new anti-diabetic medication for more than 21 days with the initiation at or after randomisation (week 0) and before (planned) end-of-treatment (week 52), and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before (planned) end-of-treatment. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. (NCT03021187)
Timeframe: Weeks 0-52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 0-26 | Week 0-52 | |
| Oral Semaglutide 14 mg | 8 | 44 |
| Oral Semaglutide 3 mg | 9 | 61 |
| Oral Semaglutide 7 mg | 8 | 45 |
| Placebo | 11 | 75 |
Presented results are the number of participants who had taken rescue medication anytime during the periods, from week 0 to week 26 and week 0 to week 52. Rescue medication was defined as use of new anti-diabetic medication as add-on to trial product and used for more than 21 days with the initiation at or after randomisation (week 1) and before last day on trial product, and/or intensification of anti-diabetic medication (a more than 20% increase in dose relative to baseline) for more than 21 days with the intensification at or after randomisation and before last day on trial product. Results are based on the data from the on-treatment without rescue medication observation period, which was the time period when a participant was on treatment with trial product, excluding any period after initiation of rescue medication and/or premature trial product discontinuation. (NCT03021187)
Timeframe: Weeks 0-52
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Week 0-26 | Week 0-52 | |
| Oral Semaglutide 14 mg | 4 | 31 |
| Oral Semaglutide 3 mg | 5 | 54 |
| Oral Semaglutide 7 mg | 2 | 33 |
| Placebo | 9 | 67 |
Participants with eye examination (fundoscopy) findings, normal, abnormal NCS and abnormal CS at baseline (week -2) and week 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. (NCT03021187)
Timeframe: Week -2, week 52
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Left eye (week -2)72577392 | Left eye (week -2)72577393 | Left eye (week -2)72577394 | Left eye (week -2)72577395 | Left eye (week 52)72577392 | Left eye (week 52)72577393 | Left eye (week 52)72577394 | Left eye (week 52)72577395 | Right eye (week -2)72577392 | Right eye (week -2)72577393 | Right eye (week -2)72577394 | Right eye (week -2)72577395 | Right eye (week 52)72577392 | Right eye (week 52)72577393 | Right eye (week 52)72577394 | Right eye (week 52)72577395 | |||||||||||||||||||||||||||||||||
| Normal | Abnormal NCS | Abnormal CS | ||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 89 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 108 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 64 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 55 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 19 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 21 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 83 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 102 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 92 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 88 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 65 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 51 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 52 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 53 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 22 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 25 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 85 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 104 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 99 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 106 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 76 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 63 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 64 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 58 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 13 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 18 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 20 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 79 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 99 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 97 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 90 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 67 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 54 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 51 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 50 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 23 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 14 | |||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 15 | |||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 26 | |||||||||||||||||||||||||||||||||||||||||||||||
Participants with physical examination findings, normal, abnormal NCS and abnormal CS at baseline (weeks -2) and weeks 52 presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system; 2) Central and peripheral nervous system; 3) Gastrointestinal system, incl. mouth; 4) General appearance; 5) Head, ears, eyes, nose, throat, neck; 6) Lymph node palpation; 7) Musculoskeletal system; 8) Respiratory system; 9) Skin; 10) Thyroid gland. (NCT03021187)
Timeframe: Week -2, week 52
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1) Cardiovascular system (week -2)72577392 | 1) Cardiovascular system (week -2)72577393 | 1) Cardiovascular system (week -2)72577394 | 1) Cardiovascular system (week -2)72577395 | 1) Cardiovascular system (week 52)72577392 | 1) Cardiovascular system (week 52)72577393 | 1) Cardiovascular system (week 52)72577394 | 1) Cardiovascular system (week 52)72577395 | 2) Central and peripheral nervous system (week -2)72577392 | 2) Central and peripheral nervous system (week -2)72577395 | 2) Central and peripheral nervous system (week -2)72577393 | 2) Central and peripheral nervous system (week -2)72577394 | 2) Central and peripheral nervous system (week 52)72577392 | 2) Central and peripheral nervous system (week 52)72577393 | 2) Central and peripheral nervous system (week 52)72577394 | 2) Central and peripheral nervous system (week 52)72577395 | 3) Gastrointestinal system, incl. mouth (week -2)72577393 | 3) Gastrointestinal system, incl. mouth (week -2)72577395 | 3) Gastrointestinal system, incl. mouth (week -2)72577392 | 3) Gastrointestinal system, incl. mouth (week -2)72577394 | 3) Gastrointestinal system, incl. mouth (week 52)72577392 | 3) Gastrointestinal system, incl. mouth (week 52)72577393 | 3) Gastrointestinal system, incl. mouth (week 52)72577395 | 3) Gastrointestinal system, incl. mouth (week 52)72577394 | 4) General appearance (week -2)72577392 | 4) General appearance (week -2)72577393 | 4) General appearance (week -2)72577394 | 4) General appearance (week -2)72577395 | 4) General appearance (week 52)72577392 | 4) General appearance (week 52)72577393 | 4) General appearance (week 52)72577394 | 4) General appearance (week 52)72577395 | 5) Head, ears, eyes, nose, throat, neck (week -2)72577392 | 5) Head, ears, eyes, nose, throat, neck (week -2)72577393 | 5) Head, ears, eyes, nose, throat, neck (week -2)72577394 | 5) Head, ears, eyes, nose, throat, neck (week -2)72577395 | 5) Head, ears, eyes, nose, throat, neck (week 52)72577392 | 5) Head, ears, eyes, nose, throat, neck (week 52)72577393 | 5) Head, ears, eyes, nose, throat, neck (week 52)72577394 | 5) Head, ears, eyes, nose, throat, neck (week 52)72577395 | 6) Lymph node palpation (week -2)72577392 | 6) Lymph node palpation (week -2)72577393 | 6) Lymph node palpation (week -2)72577394 | 6) Lymph node palpation (week -2)72577395 | 6) Lymph node palpation (week 52)72577392 | 6) Lymph node palpation (week 52)72577393 | 6) Lymph node palpation (week 52)72577394 | 6) Lymph node palpation (week 52)72577395 | 7) Musculoskeletal system (week -2)72577392 | 7) Musculoskeletal system (week -2)72577393 | 7) Musculoskeletal system (week -2)72577395 | 7) Musculoskeletal system (week -2)72577394 | 7) Musculoskeletal system (week 52)72577392 | 7) Musculoskeletal system (week 52)72577393 | 7) Musculoskeletal system (week 52)72577394 | 7) Musculoskeletal system (week 52)72577395 | 8) Respiratory system (week -2)72577392 | 8) Respiratory system (week -2)72577393 | 8) Respiratory system (week -2)72577394 | 8) Respiratory system (week -2)72577395 | 8) Respiratory system (week 52)72577392 | 8) Respiratory system (week 52)72577393 | 8) Respiratory system (week 52)72577394 | 8) Respiratory system (week 52)72577395 | 9) Skin (week -2)72577392 | 9) Skin (week -2)72577393 | 9) Skin (week -2)72577394 | 9) Skin (week -2)72577395 | 9) Skin (week 52)72577392 | 9) Skin (week 52)72577393 | 9) Skin (week 52)72577394 | 9) Skin (week 52)72577395 | 10) Thyroid gland (week -2)72577393 | 10) Thyroid gland (week -2)72577392 | 10) Thyroid gland (week -2)72577394 | 10) Thyroid gland (week -2)72577395 | 10) Thyroid gland (week 52)72577393 | 10) Thyroid gland (week 52)72577392 | 10) Thyroid gland (week 52)72577394 | 10) Thyroid gland (week 52)72577395 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abnormal NCS | Normal | Abnormal CS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 166 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 166 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 157 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 170 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 157 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 158 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 145 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 160 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 158 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 157 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 158 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 163 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 24 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 149 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 150 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 147 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 25 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 175 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 177 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 180 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 163 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 166 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 171 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 159 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 162 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 160 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 22 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 151 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 148 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 153 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 152 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 17 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 168 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 173 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 172 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 178 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 161 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 165 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 166 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 184 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 181 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 181 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 172 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 172 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 171 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 170 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 169 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 175 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 160 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 160 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 164 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 182 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 177 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 180 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 184 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 173 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 164 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 170 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 173 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 156 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 153 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 159 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 162 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 27 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 28 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 21 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 152 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 144 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 151 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 155 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 20 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 26 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 18 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 177 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 176 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 176 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 177 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 7 mg | 165 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 14 mg | 168 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Oral Semaglutide 3 mg | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Placebo | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Participants who achieved weight loss more than or equal to 10% of their baseline body weight (yes/no) at weeks 26 and 52 are presented. The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. Results are based on the data from the in-trial observation period, which started at the date of randomisation and included the period after initiatiion of of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 26, week 52
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2672577393 | Week 2672577394 | Week 2672577395 | Week 2672577392 | Week 5272577392 | Week 5272577393 | Week 5272577395 | Week 5272577394 | |||||||||
| Yes | No | |||||||||||||||
| Oral Semaglutide 3 mg | 2 | |||||||||||||||
| Oral Semaglutide 7 mg | 12 | |||||||||||||||
| Oral Semaglutide 14 mg | 19 | |||||||||||||||
| Placebo | 1 | |||||||||||||||
| Oral Semaglutide 3 mg | 175 | |||||||||||||||
| Oral Semaglutide 7 mg | 162 | |||||||||||||||
| Oral Semaglutide 14 mg | 154 | |||||||||||||||
| Placebo | 176 | |||||||||||||||
| Oral Semaglutide 3 mg | 4 | |||||||||||||||
| Oral Semaglutide 7 mg | 17 | |||||||||||||||
| Oral Semaglutide 14 mg | 21 | |||||||||||||||
| Oral Semaglutide 3 mg | 170 | |||||||||||||||
| Oral Semaglutide 7 mg | 154 | |||||||||||||||
| Oral Semaglutide 14 mg | 149 | |||||||||||||||
| Placebo | 172 | |||||||||||||||
Participants who achieved weight loss more than or equal to 5% of their baseline body weight (yes/no) at weeks 26 and 52 are presented. The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 26, week 52
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2672577392 | Week 2672577393 | Week 2672577394 | Week 2672577395 | Week 5272577395 | Week 5272577392 | Week 5272577393 | Week 5272577394 | |||||||||
| Yes | No | |||||||||||||||
| Oral Semaglutide 3 mg | 23 | |||||||||||||||
| Oral Semaglutide 7 mg | 53 | |||||||||||||||
| Placebo | 5 | |||||||||||||||
| Oral Semaglutide 3 mg | 154 | |||||||||||||||
| Oral Semaglutide 7 mg | 121 | |||||||||||||||
| Oral Semaglutide 14 mg | 106 | |||||||||||||||
| Placebo | 172 | |||||||||||||||
| Oral Semaglutide 3 mg | 30 | |||||||||||||||
| Oral Semaglutide 7 mg | 48 | |||||||||||||||
| Oral Semaglutide 14 mg | 67 | |||||||||||||||
| Placebo | 9 | |||||||||||||||
| Oral Semaglutide 3 mg | 144 | |||||||||||||||
| Oral Semaglutide 7 mg | 123 | |||||||||||||||
| Oral Semaglutide 14 mg | 103 | |||||||||||||||
| Placebo | 164 | |||||||||||||||
Participants who achieved HbA1c less than 7.0 % without severe or blood glucose (BG) confirmed symptomatic hypoglycaemia and without weight gain (yes/no) at weeks 26 and 52 are presented. Severe hypoglycaemia was defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or take other corrective actions. BG-confirmed symptomatic hypoglycaemia was defined as an episode with plasma glucose value <3.1 mmol/L with symptoms consistent with hypoglycaemia. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. (NCT03021187)
Timeframe: Week 26, week 52
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2672577392 | Week 2672577394 | Week 2672577393 | Week 2672577395 | Week 5272577392 | Week 5272577393 | Week 5272577394 | Week 5272577395 | |||||||||
| Yes | No | |||||||||||||||
| Oral Semaglutide 3 mg | 32 | |||||||||||||||
| Oral Semaglutide 7 mg | 47 | |||||||||||||||
| Oral Semaglutide 14 mg | 76 | |||||||||||||||
| Placebo | 4 | |||||||||||||||
| Oral Semaglutide 3 mg | 144 | |||||||||||||||
| Oral Semaglutide 7 mg | 127 | |||||||||||||||
| Oral Semaglutide 14 mg | 97 | |||||||||||||||
| Placebo | 172 | |||||||||||||||
| Oral Semaglutide 3 mg | 27 | |||||||||||||||
| Oral Semaglutide 7 mg | 43 | |||||||||||||||
| Oral Semaglutide 14 mg | 61 | |||||||||||||||
| Placebo | 8 | |||||||||||||||
| Oral Semaglutide 3 mg | 146 | |||||||||||||||
| Oral Semaglutide 7 mg | 126 | |||||||||||||||
| Oral Semaglutide 14 mg | 107 | |||||||||||||||
| Placebo | 164 | |||||||||||||||
Participants who achieved HbA1c reduction more than or equal to 1% of their baseline HbA1c and weight loss of more than or equal to 3% of their baseline body weight (yes/no) at weeks 26 and 52 are presented. Results are based on the data from the in-trial observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. (NCT03021187)
Timeframe: Week 26, week 52
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2672577392 | Week 2672577395 | Week 2672577393 | Week 2672577394 | Week 5272577395 | Week 5272577392 | Week 5272577393 | Week 5272577394 | |||||||||
| Yes | No | |||||||||||||||
| Oral Semaglutide 3 mg | 28 | |||||||||||||||
| Oral Semaglutide 7 mg | 51 | |||||||||||||||
| Oral Semaglutide 14 mg | 76 | |||||||||||||||
| Placebo | 7 | |||||||||||||||
| Oral Semaglutide 3 mg | 148 | |||||||||||||||
| Oral Semaglutide 7 mg | 123 | |||||||||||||||
| Oral Semaglutide 14 mg | 97 | |||||||||||||||
| Placebo | 169 | |||||||||||||||
| Oral Semaglutide 3 mg | 20 | |||||||||||||||
| Oral Semaglutide 7 mg | 37 | |||||||||||||||
| Oral Semaglutide 14 mg | 64 | |||||||||||||||
| Placebo | 5 | |||||||||||||||
| Oral Semaglutide 3 mg | 153 | |||||||||||||||
| Oral Semaglutide 7 mg | 132 | |||||||||||||||
| Oral Semaglutide 14 mg | 104 | |||||||||||||||
| Placebo | 167 | |||||||||||||||
Number of particpants achieving HbA1c < 7.0 % (53 mmol/mol) according to American Diabetes Association (ADA) target, at week 26 and week 52. The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 26, week 52
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2672577394 | Week 2672577395 | Week 2672577392 | Week 2672577393 | Week 5272577392 | Week 5272577393 | Week 5272577394 | Week 5272577395 | |||||||||
| No | Yes | |||||||||||||||
| Oral Semaglutide 7 mg | 74 | |||||||||||||||
| Oral Semaglutide 14 mg | 101 | |||||||||||||||
| Placebo | 12 | |||||||||||||||
| Oral Semaglutide 3 mg | 126 | |||||||||||||||
| Oral Semaglutide 7 mg | 100 | |||||||||||||||
| Oral Semaglutide 14 mg | 72 | |||||||||||||||
| Placebo | 164 | |||||||||||||||
| Oral Semaglutide 3 mg | 50 | |||||||||||||||
| Oral Semaglutide 7 mg | 67 | |||||||||||||||
| Oral Semaglutide 14 mg | 91 | |||||||||||||||
| Placebo | 16 | |||||||||||||||
| Oral Semaglutide 3 mg | 123 | |||||||||||||||
| Oral Semaglutide 7 mg | 102 | |||||||||||||||
| Oral Semaglutide 14 mg | 77 | |||||||||||||||
| Placebo | 156 | |||||||||||||||
Number of participants achieving HbA1c ≤ 6.5% (48 mmol/mol) according to American Association of Clinical Endocrinologists (AACE) target, at week 26 and week 52. The endpoint was evaluated based on data from the in-trial observation period. In trial observation period started at the date of randomisation and included the period after initiation of rescue medication and/or premature trial product discontinuation, if any. (NCT03021187)
Timeframe: Week 26, week 52
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 2672577393 | Week 2672577394 | Week 2672577395 | Week 2672577392 | Week 5272577392 | Week 5272577394 | Week 5272577395 | Week 5272577393 | |||||||||
| Yes | No | |||||||||||||||
| Oral Semaglutide 3 mg | 24 | |||||||||||||||
| Oral Semaglutide 7 mg | 45 | |||||||||||||||
| Oral Semaglutide 14 mg | 74 | |||||||||||||||
| Placebo | 6 | |||||||||||||||
| Oral Semaglutide 3 mg | 152 | |||||||||||||||
| Oral Semaglutide 7 mg | 129 | |||||||||||||||
| Oral Semaglutide 14 mg | 99 | |||||||||||||||
| Placebo | 170 | |||||||||||||||
| Oral Semaglutide 3 mg | 20 | |||||||||||||||
| Oral Semaglutide 7 mg | 33 | |||||||||||||||
| Oral Semaglutide 14 mg | 65 | |||||||||||||||
| Placebo | 4 | |||||||||||||||
| Oral Semaglutide 3 mg | 153 | |||||||||||||||
| Oral Semaglutide 7 mg | 136 | |||||||||||||||
| Oral Semaglutide 14 mg | 103 | |||||||||||||||
| Placebo | 168 | |||||||||||||||
Body weight in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | kilograms (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 94.2 |
| Metformin XR Plus Placebo | 91.3 |
Hepatic enzyme, ALT, associated with insulin resistance, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | U/L (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 32.3 |
| Metformin XR Plus Placebo | 31 |
ALT/AST ratio, used to assess liver function in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of ALT (U/L)/ AST (U/L) (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 1.2 |
| Metformin XR Plus Placebo | 1.18 |
The hepatic marker, AST, associated with insulin resistance in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | U/L (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 27 |
| Metformin XR Plus Placebo | 28 |
BMI, a measure of total body adiposity, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | weight (kg) /height (m) squared (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 33.8 |
| Metformin XR Plus Placebo | 32.8 |
Change in body weight from baseline to end o f study in LIRA-MET group compared with PL-MET group. The number was derived from final weight minus baseline and normalized to a percent. (NCT01234649)
Timeframe: Change from baseline (time 0) to study end (84 weeks)
| Intervention | percent change in weight from baseline (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | -7.2 |
| Metformin XR Plus Placebo | -3.1 |
DBP in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 77.6 |
| Metformin XR Plus Placebo | 77 |
Fasting glucose levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 90 |
| Metformin XR Plus Placebo | 91.7 |
HDL-C levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 51 |
| Metformin XR Plus Placebo | 48.7 |
HOMA-IR, a measure of insulin resistance derived from fasting values, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 2.2 |
| Metformin XR Plus Placebo | 2.45 |
IS-SI in liraglutide-metformin (LIRA-MET) therapy compared to metformin alone (PLacebo-MET) (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 418.4 |
| Metformin XR Plus Placebo | 333 |
IGI/HOMA-IR, a measure of early insulin response corrected by fasting insulin resistance, in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 0.8 |
| Metformin XR Plus Placebo | 0.62 |
LDL-Cholesterol levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 110 |
| Metformin XR Plus Placebo | 107 |
OGTT- derived insulin sensitivity index in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | index (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 5.9 |
| Metformin XR Plus Placebo | 5.4 |
MBG derived from average glucose measured during OGTT in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 121.6 |
| Metformin XR Plus Placebo | 118.8 |
SBP in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 122 |
| Metformin XR Plus Placebo | 123 |
CHOL levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 183.7 |
| Metformin XR Plus Placebo | 183.8 |
TRG concentrations in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 120 |
| Metformin XR Plus Placebo | 125 |
TRG/HDL-Cholesterol levels in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of TRG (mg/dL)/HDL-C (mg/dl) (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 2.56 |
| Metformin XR Plus Placebo | 2.95 |
Waist size (measure of truncal adiposity) with LIRA-MET compared to PL-MET (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | 94.3 |
| Metformin XR Plus Placebo | 95.3 |
Waist circumference divided by height (measure of body fat distribution) in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of waist /height (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | .56 |
| Metformin XR Plus Placebo | .57 |
Waist circumference divided by hip circumference (a measure of central adiposity) in LIRA-MET group compared with PL-MET group (NCT01234649)
Timeframe: 84 weeks of treatment
| Intervention | ratio of waist/hip circumference (Mean) |
|---|---|
| Metformin XR Plus Liraglutide | .81 |
| Metformin XR Plus Placebo | .81 |
Treatment effect on body weight at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 100.4 |
| Dapagliflozin (DAPA) | 102.6 |
| EQW Plus DAPA | 99 |
| Dapagliflozin Plus Glucophage (MET ER) | 101.2 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 97 |
treatment impact on measure of central adiposity as determined by android/gynoid ratio (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.07 |
| Dapagliflozin (DAPA) | 1.02 |
| EQW Plus DAPA | 1.04 |
| Dapagliflozin Plus Glucophage (MET ER) | 1.04 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 1.03 |
Treatment efficacy in reducing body mass at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram/meter squared (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 37.3 |
| Dapagliflozin (DAPA) | 37.4 |
| EQW Plus DAPA | 36.7 |
| Dapagliflozin Plus Glucophage (MET ER) | 37 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 35.3 |
Treatment effect on loss of central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 104 |
| Dapagliflozin (DAPA) | 101 |
| EQW Plus DAPA | 106 |
| Dapagliflozin Plus Glucophage (MET ER) | 101.3 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 97 |
Treatment effect on change in percent body weight from baseline (NCT02635386)
Timeframe: Change from baseline (time 0) to study end (24 weeks)
| Intervention | percentage change in body weight (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.8 |
| Dapagliflozin (DAPA) | 1.5 |
| EQW Plus DAPA | 6.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 1.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 8.1 |
Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.03 |
| Dapagliflozin (DAPA) | 0.6 |
| EQW Plus DAPA | 0.91 |
| Dapagliflozin Plus Glucophage (MET ER) | 0.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 1.1 |
Treatment effect on blood concentrations of DHEA-S (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mcg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 165 |
| Dapagliflozin (DAPA) | 187 |
| EQW Plus DAPA | 169 |
| Dapagliflozin Plus Glucophage (MET ER) | 189 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 201 |
Treatment effect on DBP after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 81 |
| Dapagliflozin (DAPA) | 79.8 |
| EQW Plus DAPA | 76 |
| Dapagliflozin Plus Glucophage (MET ER) | 82 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 83.6 |
Treatment impact on fasting concentration of glucose in the blood (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 91 |
| Dapagliflozin (DAPA) | 93 |
| EQW Plus DAPA | 86.5 |
| Dapagliflozin Plus Glucophage (MET ER) | 89 |
| Phentermine /Topiramate (PHEN/ TPM ER | 91.4 |
Treatment effect on the ratio HOMA-IR which is insulin resistance measure derived from fasting blood glucose and insulin and is calculated by insulin (mU/ml)*glucose (mmol/L)/22,5. The higher thenumber the more insulin resistant. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.7 |
| Dapagliflozin (DAPA) | 3.6 |
| EQW Plus DAPA | 2.6 |
| Dapagliflozin Plus Glucophage (MET ER) | 3.3 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 3.4 |
Treatment effect on FAI calculated from total testosterone divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 5.3 |
| Dapagliflozin (DAPA) | 4.7 |
| EQW Plus DAPA | 5.2 |
| Dapagliflozin Plus Glucophage (MET ER) | 5.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 5 |
The SI IOGTT is a measure of peripheral insulin sensitivity derived from the values of Insulin (microunits per milliliter) and Glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values. SI (OGTT) = 10,000/ [(G fasting x I fasting) x (G OGTTmean x I OGTTmean)], where fasting glucose and insulin data are taken from time 0 of the OGTT and mean data represent the average glucose and insulin values obtained during the entire OGTT. The square root is used to correct for nonlinear distribution of insulin, and 10,000 is a scaling factor in the equation. The higher value, the more sensitive to insulin. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.1 |
| Dapagliflozin (DAPA) | 3.6 |
| EQW Plus DAPA | 3.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 4.8 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 4.7 |
Treatment effect on MBG measured during the oral glucose tolerance test (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 118 |
| Dapagliflozin (DAPA) | 126.4 |
| EQW Plus DAPA | 112 |
| Dapagliflozin Plus Glucophage (MET ER) | 119 |
| Phentermine /Topiramate (PHEN/ TPM ER | 113 |
An estimation of β-cell compensatory function, the insulin secretion-sensitivity index (IS-SI) will be derived by applying the concept of the oral disposition index to measurements obtained during the 2-h OGTT and calculated as the index of insulin secretion factored by insulin sensitivity (ΔINS/ΔPG 30 x Matsuda SIOGTT) from the OGTT. A higher score shows improved pancreatic insulin responsiveness relative to resistance. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 471 |
| Dapagliflozin (DAPA) | 311 |
| EQW Plus DAPA | 503 |
| Dapagliflozin Plus Glucophage (MET ER) | 395 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 545 |
Treatment effect on SBP after 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks treatment
| Intervention | mmHg (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 123.6 |
| Dapagliflozin (DAPA) | 123 |
| EQW Plus DAPA | 122 |
| Dapagliflozin Plus Glucophage (MET ER) | 128 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 124 |
Treatment impact on percent total body fat by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | percent fat mass (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 46.1 |
| Dapagliflozin (DAPA) | 46.4 |
| EQW Plus DAPA | 45.8 |
| Dapagliflozin Plus Glucophage (MET ER) | 46.1 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 45.2 |
Treatment effect on blood concentrations of total cholesterol (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 189 |
| Dapagliflozin (DAPA) | 186 |
| EQW Plus DAPA | 185 |
| Dapagliflozin Plus Glucophage (MET ER) | 192 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 178 |
Treatment impact on total fat mass by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 47.6 |
| Dapagliflozin (DAPA) | 47.8 |
| EQW Plus DAPA | 45.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 48 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 44.5 |
Treatment effect on blood concentrations of total testosterone (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ng/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 38.8 |
| Dapagliflozin (DAPA) | 35 |
| EQW Plus DAPA | 42.6 |
| Dapagliflozin Plus Glucophage (MET ER) | 39.5 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 45.5 |
Treatment effect on blood concentrations of triglycerides (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 130 |
| Dapagliflozin (DAPA) | 132 |
| EQW Plus DAPA | 112 |
| Dapagliflozin Plus Glucophage (MET ER) | 105 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 110 |
Treatment impact on trunk/limb ratio (measure of central adiposity) by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.03 |
| Dapagliflozin (DAPA) | .95 |
| EQW Plus DAPA | .93 |
| Dapagliflozin Plus Glucophage (MET ER) | .98 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .99 |
Treatment impact on WHtR which is a measure of central adiposity (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | .64 |
| Dapagliflozin (DAPA) | .61 |
| EQW Plus DAPA | .65 |
| Dapagliflozin Plus Glucophage (MET ER) | .61 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .59 |
Treatment impact on central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | .83 |
| Dapagliflozin (DAPA) | .79 |
| EQW Plus DAPA | .86 |
| Dapagliflozin Plus Glucophage (MET ER) | .83 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .81 |
Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (<=8.5%, >8.5%) + Treatment + Time + Treatment*Time (Type III sum of squares). (NCT03987919)
Timeframe: Baseline, Week 40
| Intervention | Kilograms (kg) (Least Squares Mean) |
|---|---|
| 5 mg Tirzepatide | -7.8 |
| 10 mg Tirzepatide | -10.3 |
| 15 mg Tirzepatide | -12.4 |
| 1 mg Semaglutide | -6.2 |
Fasting serum glucose (FSG) is a test to determine sugar levels in serum sample after an overnight fast. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (<=8.5%, >8.5%) + Treatment + Time + Treatment*Time (Type III sum of squares). (NCT03987919)
Timeframe: Baseline, Week 40
| Intervention | milligram per Deciliter (mg/dL) (Least Squares Mean) |
|---|---|
| 5 mg Tirzepatide | -56.0 |
| 10 mg Tirzepatide | -61.6 |
| 15 mg Tirzepatide | -63.4 |
| 1 mg Semaglutide | -48.6 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares). (NCT03987919)
Timeframe: Baseline, Week 40
| Intervention | Percentage of HbA1c (Least Squares Mean) |
|---|---|
| 5 mg Tirzepatide | -2.09 |
| 1 mg Semaglutide | -1.86 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Treatment + Time + Treatment*Time (Type III sum of squares). (NCT03987919)
Timeframe: Baseline, Week 40
| Intervention | Percentage of HbA1c (Least Squares Mean) |
|---|---|
| 10 mg Tirzepatide | -2.37 |
| 15 mg Tirzepatide | -2.46 |
| 1 mg Semaglutide | -1.86 |
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Postmeal, Midday Premeal, Midday 2-hour Postmeal, Evening Premeal, Evening 2-hour Postmeal and Bedtime. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with Baseline + Pooled Country + Baseline HbA1c Group (<=8.5%, >8.5%) + Treatment + Time + Treatment*Time (Type III sum of squares). (NCT03987919)
Timeframe: Baseline, Week 40
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| 5 mg Tirzepatide | -65.4 |
| 10 mg Tirzepatide | -70.6 |
| 15 mg Tirzepatide | -74.3 |
| 1 mg Semaglutide | -61.4 |
Percentage of Participants Achieving an HbA1c Target Value of <5.7%. (NCT03987919)
Timeframe: Week 40
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Tirzepatide | 29.28 |
| 10 mg Tirzepatide | 44.66 |
| 15 mg Tirzepatide | 50.86 |
| 1 mg Semaglutide | 19.74 |
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. (NCT03987919)
Timeframe: Week 40
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Tirzepatide | 85.47 |
| 10 mg Tirzepatide | 88.89 |
| 15 mg Tirzepatide | 92.24 |
| 1 mg Semaglutide | 81.13 |
Percentage of Participants who Achieved Weight Loss ≥5%. (NCT03987919)
Timeframe: Week 40
| Intervention | Percentage of Participants (Number) |
|---|---|
| 5 mg Tirzepatide | 68.55 |
| 10 mg Tirzepatide | 82.35 |
| 15 mg Tirzepatide | 86.21 |
| 1 mg Semaglutide | 58.44 |
The hypoglycemia events were defined by participant reported events with blood glucose <54mg/dL) (<3.0 mmol/L] or severe hypoglycemia. Severe hypoglycemia is defined as an episode with severe cognitive impairment requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be associated with sufficient neuroglycopenia to induce seizure or coma. The rate of postbaseline hypoglycemia was estimated by negative binomial model: number of episodes = Pooled Country + Baseline HbA1c Group (<=8.5%, >8.5%) + Treatment. (NCT03987919)
Timeframe: Baseline through Safety Follow-Up (Up to Week 44)
| Intervention | Episodes/participant/365.25 days (Mean) |
|---|---|
| 5 mg Tirzepatide | 0.0102 |
| 10 mg Tirzepatide | 0.0046 |
| 15 mg Tirzepatide | 0.0202 |
| 1 mg Semaglutide | 0.0046 |
DTSQc, an 8-item questionnaire, assesses relative change in treatment satisfaction perceived frequency of hyperglycemia, and perceived frequency of hypoglycemia from baseline to week 40 or early termination. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale. The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 to 18 where the higher the score the greater the improvement in satisfaction with treatment. The lower the score the greater the deterioration in satisfaction with treatment. The hyperglycemia and hypoglycemia scores range from -3 to 3 where negative scores indicate fewer problems with blood glucose levels and positive scores indicate more problems than before. LS Mean was determined by ANCOVA with Baseline DTSQs + Pooled Country + Baseline HbA1c Group (<=8.5%, >8.5%) + Treatment (Type III sum of squares). (NCT03987919)
Timeframe: Baseline, Week 40
| Intervention | Units on a Scale (Least Squares Mean) | ||
|---|---|---|---|
| Hyperglycemia | Hypoglycemia | Total Score | |
| 1 mg Semaglutide | -1.1 | -0.7 | 15.8 |
| 10 mg Tirzepatide | -1.4 | -0.7 | 15.6 |
| 15 mg Tirzepatide | -1.5 | -0.8 | 16.1 |
| 5 mg Tirzepatide | -1.3 | -0.7 | 15.7 |
Change from baseline in body weight after 26 weeks of treatment (NCT01952145)
Timeframe: Week 0, week 26
| Intervention | Kg (Mean) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | -1.4 |
| Insulin Glargine (IGlar) | 1.8 |
Change from baseline in HbA1c after 26 weeks of treatment (NCT01952145)
Timeframe: Week 0, week 26
| Intervention | Percentage (%) (Mean) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | -1.81 |
| Insulin Glargine (IGlar) | -1.13 |
Confirmed hypoglycaemic episodes were defined as either: Severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or an episode biochemically confirmed by a plasma glucose value of <3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia. (NCT01952145)
Timeframe: During 26 weeks of treatment
| Intervention | Number of episodes (Number) |
|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | 289 |
| Insulin Glargine (IGlar) | 683 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | Percent A1C (Mean) |
|---|---|
| Placebo/Glimepiride | -0.58 |
| Ertugliflozin 5 mg | -0.60 |
| Ertugliflozin 15 mg | -0.89 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | Percent A1C (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.03 |
| Ertugliflozin 5 mg | -0.73 |
| Ertugliflozin 15 mg | -0.91 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | Percent A1C (Mean) |
|---|---|
| Placebo/Glimepiride | -0.68 |
| Ertugliflozin 5 mg | -0.72 |
| Ertugliflozin 15 mg | -0.96 |
The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | Kilograms (Mean) |
|---|---|
| Placebo/Glimepiride | -0.18 |
| Ertugliflozin 5 mg | -3.77 |
| Ertugliflozin 15 mg | -3.63 |
The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | Kilograms (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -1.33 |
| Ertugliflozin 5 mg | -3.01 |
| Ertugliflozin 15 mg | -2.93 |
The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | Kilograms (Mean) |
|---|---|
| Placebo/Glimepiride | 0.07 |
| Ertugliflozin 5 mg | -3.23 |
| Ertugliflozin 15 mg | -3.35 |
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo/Glimepiride | -10.9 |
| Ertugliflozin 5 mg | -18.2 |
| Ertugliflozin 15 mg | -28.2 |
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.85 |
| Ertugliflozin 5 mg | -27.54 |
| Ertugliflozin 15 mg | -39.10 |
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo/Glimepiride | -12.0 |
| Ertugliflozin 5 mg | -22.4 |
| Ertugliflozin 15 mg | -35.2 |
This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | mmHg (Mean) |
|---|---|
| Placebo/Glimepiride | -0.46 |
| Ertugliflozin 5 mg | -2.36 |
| Ertugliflozin 15 mg | -1.52 |
This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | 0.23 |
| Ertugliflozin 5 mg | -1.59 |
| Ertugliflozin 15 mg | -2.19 |
This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | mmHg (Mean) |
|---|---|
| Placebo/Glimepiride | 0.38 |
| Ertugliflozin 5 mg | -1.40 |
| Ertugliflozin 15 mg | -1.19 |
This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | mmHg (Mean) |
|---|---|
| Placebo/Glimepiride | 0.05 |
| Ertugliflozin 5 mg | -3.61 |
| Ertugliflozin 15 mg | -3.13 |
This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.70 |
| Ertugliflozin 5 mg | -4.38 |
| Ertugliflozin 15 mg | -5.20 |
This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | mmHg (Mean) |
|---|---|
| Placebo/Glimepiride | 0.65 |
| Ertugliflozin 5 mg | -2.63 |
| Ertugliflozin 15 mg | -4.28 |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -1.23 |
| Ertugliflozin 5 mg | -1.11 |
| Ertugliflozin 15 mg | -0.96 |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | 0.09 |
| Ertugliflozin 5 mg | -0.19 |
| Ertugliflozin 15 mg | -0.13 |
BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -1.18 |
| Ertugliflozin 5 mg | -1.72 |
| Ertugliflozin 15 mg | -2.02 |
BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | 0.06 |
| Ertugliflozin 5 mg | -0.15 |
| Ertugliflozin 15 mg | -0.13 |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.40 |
| Ertugliflozin 5 mg | -0.10 |
| Ertugliflozin 15 mg | 0.30 |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | Percentage change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | 0.22 |
| Ertugliflozin 5 mg | -0.01 |
| Ertugliflozin 15 mg | 0.12 |
BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.63 |
| Ertugliflozin 5 mg | -0.55 |
| Ertugliflozin 15 mg | -0.36 |
BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.44 |
| Ertugliflozin 5 mg | -0.59 |
| Ertugliflozin 15 mg | -0.39 |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.69 |
| Ertugliflozin 5 mg | -0.49 |
| Ertugliflozin 15 mg | -0.44 |
BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.10 |
| Ertugliflozin 5 mg | -0.28 |
| Ertugliflozin 15 mg | 0.07 |
BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.82 |
| Ertugliflozin 5 mg | -1.04 |
| Ertugliflozin 15 mg | -1.32 |
CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | Percent change (Mean) |
|---|---|
| Placebo/Glimepiride | 10.8 |
| Ertugliflozin 5 mg | 51.9 |
| Ertugliflozin 15 mg | 80.2 |
CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | Percent change (Mean) |
|---|---|
| Placebo/Glimepiride | 19.29 |
| Ertugliflozin 5 mg | 26.94 |
| Ertugliflozin 15 mg | 32.53 |
CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | Percent change (Mean) |
|---|---|
| Placebo/Glimepiride | 15.54 |
| Ertugliflozin 5 mg | 34.36 |
| Ertugliflozin 15 mg | 41.57 |
P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | Percent change (Mean) |
|---|---|
| Placebo/Glimepiride | 19.38 |
| Ertugliflozin 5 mg | 10.11 |
| Ertugliflozin 15 mg | 24.21 |
P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Mean) |
|---|---|
| Placebo/Glimepiride | 24.50 |
| Ertugliflozin 5 mg | 8.41 |
| Ertugliflozin 15 mg | 19.79 |
PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | Percent change (Mean) |
|---|---|
| Placebo/Glimepiride | -0.98 |
| Ertugliflozin 5 mg | 0.28 |
| Ertugliflozin 15 mg | 0.14 |
P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 26
| Intervention | Percent change (Mean) |
|---|---|
| Placebo/Glimepiride | 0.5 |
| Ertugliflozin 5 mg | 0.8 |
| Ertugliflozin 15 mg | 0.5 |
PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | Percent change (Mean) |
|---|---|
| Placebo/Glimepiride | 10.12 |
| Ertugliflozin 5 mg | 8.16 |
| Ertugliflozin 15 mg | 5.46 |
PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 52
| Intervention | Percent Change (Mean) |
|---|---|
| Placebo/Glimepiride | 8.11 |
| Ertugliflozin 5 mg | 11.09 |
| Ertugliflozin 15 mg | 2.48 |
BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications. (NCT02033889)
Timeframe: Baseline and Week 104
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Glimepiride | -0.58 |
| Ertugliflozin 5 mg | -0.40 |
| Ertugliflozin 15 mg | -0.64 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 104
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 2.4 |
| Ertugliflozin 5 mg | 3.4 |
| Ertugliflozin 15 mg | 3.9 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 106
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 77.5 |
| Ertugliflozin 5 mg | 70.5 |
| Ertugliflozin 15 mg | 75.6 |
Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 104
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo/Glimepiride | 24.4 |
| Ertugliflozin 5 mg | 11.1 |
| Ertugliflozin 15 mg | 10.7 |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 26
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 17.7 |
| Ertugliflozin 5 mg | 2.9 |
| Ertugliflozin 15 mg | 1.5 |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Up to Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 17.2 |
| Ertugliflozin 5 mg | 4.3 |
| Ertugliflozin 15 mg | 1.5 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 104
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 7.2 |
| Ertugliflozin 5 mg | 10.6 |
| Ertugliflozin 15 mg | 12.2 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 26
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 2.9 |
| Ertugliflozin 5 mg | 8.7 |
| Ertugliflozin 15 mg | 12.2 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 11.0 |
| Ertugliflozin 5 mg | 10.6 |
| Ertugliflozin 15 mg | 14.6 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 104
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 19.1 |
| Ertugliflozin 5 mg | 24.6 |
| Ertugliflozin 15 mg | 33.7 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 26
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 15.8 |
| Ertugliflozin 5 mg | 35.3 |
| Ertugliflozin 15 mg | 40.0 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Week 52
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo/Glimepiride | 30.6 |
| Ertugliflozin 5 mg | 34.8 |
| Ertugliflozin 15 mg | 36.6 |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. (NCT02033889)
Timeframe: Week 26
| Intervention | Days (Median) |
|---|---|
| Placebo/Glimepiride | 105 |
| Ertugliflozin 5 mg | 112 |
| Ertugliflozin 15 mg | 139 |
Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy. (NCT02033889)
Timeframe: Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 6:Pre-dose | Week 12:Pre-dose | Week 12:60 mins post-dose | Week 18:Pre-dose | Week 18:60 mins post-dose | Week 30:Pre-dose | |
| Ertugliflozin 15 mg | 38.38 | 29.23 | 228.13 | 24.46 | 214.96 | 30.55 |
| Ertugliflozin 5 mg | 14.89 | 12.34 | 74.84 | 9.91 | 74.39 | 12.66 |
| Placebo/Glimepiride | NA | NA | NA | 0.01 | 0.01 | 0.15 |
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required. (NCT00763815)
Timeframe: Baseline, Week 24
| Intervention | percentage of hemoglobin (Least Squares Mean) |
|---|---|
| Placebo | -0.34 |
| Lixisenatide | -0.90 |
Beta cell function was assessed by HOMA-beta. HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin [micro unit per milliliter]) divided by (fasting plasma glucose [mmol/L] minus 3.5). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required. (NCT00763815)
Timeframe: Baseline, Week 24
| Intervention | % of normal beta cells function (Least Squares Mean) |
|---|---|
| Placebo | 6.98 |
| Lixisenatide | 6.72 |
Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required. (NCT00763815)
Timeframe: Baseline, Week 24
| Intervention | kilogram (Least Squares Mean) |
|---|---|
| Placebo | 0.21 |
| Lixisenatide | -0.21 |
Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required. (NCT00763815)
Timeframe: Baseline, Week 24
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Placebo | -0.32 |
| Lixisenatide | -1.16 |
Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required. (NCT00763815)
Timeframe: Baseline, Week 24
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Placebo | -1.01 |
| Lixisenatide | -10.36 |
Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG >270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG >240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG >200 mg/dL (11.1 mmol/L) or HbA1c >8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required. (NCT00763815)
Timeframe: Baseline up to Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.3 |
| Lixisenatide | 3.8 |
The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required. (NCT00763815)
Timeframe: Baseline, Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 5.1 |
| Lixisenatide | 9.2 |
The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required. (NCT00763815)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 26.4 |
| Lixisenatide | 52.3 |
The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required. (NCT00763815)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 10.1 |
| Lixisenatide | 28.9 |
Symptomatic hypoglycemia was an event with clinical symptoms that were considered to result from a hypoglycemic episode with an accompanying plasma glucose less than 60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration if no plasma glucose measurement was available. Severe symptomatic hypoglycemia was symptomatic hypoglycemia event in which the patient required the assistance of another person and was associated with either a plasma glucose level below 36 mg/dL (2.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration, if no plasma glucose measurement was available. (NCT00763815)
Timeframe: First dose of study drug up to 3 days after the last dose administration, for up to 132 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Symptomatic Hypoglycemia | Severe Symptomatic Hypoglycemia | |
| Lixisenatide | 23 | 0 |
| Placebo | 7 | 0 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on total body fat mass measured by dual energy X-ray absorptiometry. (NCT00855166)
Timeframe: Baseline to Week 24
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | -0.74 |
| Dapagliflozin Plus Metformin | -2.22 |
To evaluate the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin on total body weight after 24 weeks of oral administration of double-blind treatment. (NCT00855166)
Timeframe: Baseline to Week 24
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | -0.88 |
| Dapagliflozin Plus Metformin | -2.96 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on waist circumference. (NCT00855166)
Timeframe: Baseline to Week 24
| Intervention | cm (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | -0.99 |
| Dapagliflozin Plus Metformin | -2.51 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at femoral neck as measured by Dual Energy X-ray Absorptiometry. (NCT00855166)
Timeframe: Baseline to Week 102
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | 0.09 |
| Dapagliflozin Plus Metformin | -0.85 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at lumbar spine (L1-4) as measured by Dual Energy X-ray Absorptiometry. (NCT00855166)
Timeframe: Baseline to Week 102
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | 0.47 |
| Dapagliflozin Plus Metformin | 0.69 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 102 weeks of double-blind treatment on Bone Mineral Density at total hip as measured by Dual Energy X-ray Absorptiometry. (NCT00855166)
Timeframe: Baseline to Week 102
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | -0.37 |
| Dapagliflozin Plus Metformin | -0.82 |
To assess the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin after 24 weeks of double-blind treatment on body weight decrease ≥5%. Least Squares Mean represents the percent of participants adjusted for body weight baseline value. (NCT00855166)
Timeframe: Baseline to Week 24
| Intervention | Percentage of participants (Least Squares Mean) |
|---|---|
| Placebo Plus Metformin | 4.3 |
| Dapagliflozin Plus Metformin | 30.6 |
The ALT hepatic transaminase levels are going to be measured at week 12 with standardized techniques. (NCT02113241)
Timeframe: Week 12.
| Intervention | U/L (Mean) |
|---|---|
| Dapagliflozin | 32.1 |
| Placebo | 38.1 |
The hepatic transaminase AST will be evaluated with standardized methods at week 12 (NCT02113241)
Timeframe: Week 12
| Intervention | U/L (Mean) |
|---|---|
| Dapagliflozin | 31.1 |
| Placebo | 29.5 |
The AUC of glucose will be calculated from the glucose values obtained from the minuted oral glucose tolerance curve at week 12 (NCT02113241)
Timeframe: Week 12
| Intervention | mmol*hr/L (Mean) |
|---|---|
| Dapagliflozin | 1153 |
| Placebo | 1129 |
The AUC will be calculated from the insulin values obtained from the minuted oral glucose tolerance curve at week 12 (NCT02113241)
Timeframe: Week 12
| Intervention | pmol*h/L (Mean) |
|---|---|
| Dapagliflozin | 45016 |
| Placebo | 119704 |
The Body Mass index it's going to be calculated at week 12 with the Quetelet index. (NCT02113241)
Timeframe: Week 12
| Intervention | kg/m^2 (Mean) |
|---|---|
| Dapagliflozin | 32.6 |
| Placebo | 32.1 |
The weight it's going to be measured at week 12 with a bioimpedance balance. (NCT02113241)
Timeframe: Week 12
| Intervention | kilograms (Mean) |
|---|---|
| Dapagliflozin | 81.2 |
| Placebo | 79.6 |
The creatinine levels are going to be measured at week 12 with standardized techniques. (NCT02113241)
Timeframe: Week 12.
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 0.07 |
| Placebo | 0.05 |
The diastolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer. (NCT02113241)
Timeframe: Week 12
| Intervention | mmHg (Mean) |
|---|---|
| Dapagliflozin | 76 |
| Placebo | 79 |
The fat mass is going to be evaluated at week 12 through bioimpedance. (NCT02113241)
Timeframe: Week 12
| Intervention | kilograms (Mean) |
|---|---|
| Dapagliflozin | 32.7 |
| Placebo | 34.4 |
The glucose at minute 120 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve (NCT02113241)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 8.5 |
| Placebo | 8.8 |
The glucose at minute 30 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve (NCT02113241)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 10.5 |
| Placebo | 10.0 |
The glucose at minute 60 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve (NCT02113241)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 11.1 |
| Placebo | 11.4 |
The glucose at minute 90 is going to be evaluated at week 12 during a minuted oral glucose tolerance curve (NCT02113241)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 9.8 |
| Placebo | 9.9 |
The fasting glucose (0') levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques. (NCT02113241)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 5.7 |
| Placebo | 5.8 |
The c-HDL levels are going to be evaluated at week 12 with enzymatic/colorimetric techniques. (NCT02113241)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 1.3 |
| Placebo | 1.3 |
"The insulinogenic index is a ratio that relates enhancement of circulating insulin to the magnitude of the corresponding glycemic stimulus.~Total insulin secretion was calculated with the insulinogenic index (ΔAUC insulin/ΔAUC glucose), the entered values reflect the total insulin secretion at week 12." (NCT02113241)
Timeframe: Week 12
| Intervention | index (Mean) |
|---|---|
| Dapagliflozin | 0.35 |
| Placebo | 0.99 |
The c-LDL levels are going to be measured at week 12 with standardized techniques. (NCT02113241)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 3.1 |
| Placebo | 2.8 |
Matsuda Index value is used to indicate insulin resistance on diabetes. Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]. The entered values reflect the insulin sensitivity at week 12. (NCT02113241)
Timeframe: Week 12
| Intervention | index (Mean) |
|---|---|
| Dapagliflozin | 2.7 |
| Placebo | 1.6 |
"Human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis.~First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), the entered values reflect the frst phase of insulin secretion at week 12." (NCT02113241)
Timeframe: Week 12
| Intervention | index (Mean) |
|---|---|
| Dapagliflozin | 1463 |
| Placebo | 2198 |
The systolic blood pressure is going to be evaluated at week 12 with a digital sphygmomanometer. (NCT02113241)
Timeframe: Week 12
| Intervention | mmHg (Mean) |
|---|---|
| Dapagliflozin | 117 |
| Placebo | 121 |
The total cholesterol will be estimated by standardized techniques at week 12. (NCT02113241)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 5.2 |
| Placebo | 4.9 |
The triglycerides levels are going to be evaluated at week 12 with enzymatic-colorimetric techniques. (NCT02113241)
Timeframe: Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Dapagliflozin | 1.7 |
| Placebo | 1.7 |
The uric acid levels are going to be measured at week 12 with standardized techniques. (NCT02113241)
Timeframe: Week 12.
| Intervention | umol/L (Mean) |
|---|---|
| Dapagliflozin | 243.9 |
| Placebo | 339.0 |
The waist circumference is going to be evaluated at week 12 with a flexible tape with standardized techniques. (NCT02113241)
Timeframe: Week 12
| Intervention | centimeters (Mean) |
|---|---|
| Dapagliflozin | 97.6 |
| Placebo | 97.2 |
To examine whether treatment with dapagliflozin in combination with insulin is superior in reducing body weight or causing less weight gain as compared to placebo added to insulin treatment after 24 weeks of treatment (LOCF), excluding data after insulin up-titration. (NCT00673231)
Timeframe: Baseline to Week 24
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo | 0.02 |
| Dapagliflozin 2.5mg | -0.98 |
| Dapagliflozin 5mg | -0.98 |
| Dapagliflozin 10mg | -1.67 |
To examine whether treatment with dapagliflozin in combination with insulin leads to a lower absolute calculated mean daily insulin dose as compared to placebo added to insulin treatment alone, from baseline to week 24, including data after insulin up-titration. (NCT00673231)
Timeframe: Baseline to Week 24
| Intervention | IU/day (Least Squares Mean) |
|---|---|
| Placebo | 5.08 |
| Dapagliflozin 2.5mg | -1.80 |
| Dapagliflozin 5mg | -0.61 |
| Dapagliflozin 10mg | -1.16 |
To examine whether treatment with dapagliflozin in combination with insulin is superior in reducing Fasting Plasma Glucose (FPG) as compared to placebo added to insulin treatment after 24 weeks of treatment, excluding data after insulin up-titration. (NCT00673231)
Timeframe: Baseline to Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 3.3 |
| Dapagliflozin 2.5mg | -12.5 |
| Dapagliflozin 5mg | -18.8 |
| Dapagliflozin 10mg | -21.7 |
To assess the efficacy of 2.5 mg, 5 mg and 10 mg dapagliflozin compared to placebo as add-on therapy to insulin in improving glycaemic control in participants with type 2 diabetes who have inadequate glycaemic control on ≥ 30 IU injectable insulin daily for at least 8 weeks prior to enrolment, as determined by the change in HbA1c levels from baseline to Week 24, excluding data after insulin up-titration. (NCT00673231)
Timeframe: Baseline to Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo | -0.30 |
| Dapagliflozin 2.5mg | -0.75 |
| Dapagliflozin 5mg | -0.82 |
| Dapagliflozin 10mg | -0.90 |
To examine whether treatment with dapagliflozin in combination with insulin leads to higher percentage of participants with calculated mean daily insulin dose reduction from baseline to week 24 (i.e. reduction >= 10%) as compared to placebo added to insulin treatment. (NCT00673231)
Timeframe: Baseline to Week 24
| Intervention | Percentage of participants (Least Squares Mean) |
|---|---|
| Placebo | 11.0 |
| Dapagliflozin 2.5mg | 18.1 |
| Dapagliflozin 5mg | 16.8 |
| Dapagliflozin 10mg | 19.7 |
Participants with lack of glycemic control or insulin up-titration for failing to achieve pre-specified glycemic targets (NCT00673231)
Timeframe: Baseline to Week 24
| Intervention | Participants (Number) |
|---|---|
| Placebo | 54 |
| Dapagliflozin 2.5mg | 22 |
| Dapagliflozin 5mg | 24 |
| Dapagliflozin 10mg | 19 |
To compare the change in 2-hour post liquid meal glucose rise achieved with dapagliflozin versus placebo from baseline to week 24. (NCT00984867)
Timeframe: Baseline to Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -6.84 |
| Dapagliflozin | -21.65 |
To compare the change in total body weight achieved with dapagliflozin versus placebo from baseline to week 24. (NCT00984867)
Timeframe: Baseline to Week 24
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo | -0.26 |
| Dapagliflozin | -2.14 |
To compare the change in FPG achieved with dapagliflozin versus placebo from baseline to week 24. (NCT00984867)
Timeframe: Baseline to Week 24
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 3.81 |
| Dapagliflozin | -24.11 |
To compare the change in HbA1c in participants with baseline HbA1c ≥8% achieved with dapagliflozin versus placebo from baseline to week 24. (NCT00984867)
Timeframe: Baseline to Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo | 0.03 |
| Dapagliflozin | -0.80 |
To compare the change from baseline in HbA1c after 24 weeks treatment (LOCF) between dapagliflozin and placebo in patients with type 2 diabetes who are inadequately controlled on sitagliptin alone or on sitagliptin plus metformin. (NCT00984867)
Timeframe: Baseline to Week 24
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo | 0.04 |
| Dapagliflozin | -0.45 |
To compare the change in seated systolic blood pressure (SBP) in participants with baseline seated SBP >=130 achieved with dapagliflozin versus placebo from baseline to week 8. (NCT00984867)
Timeframe: Baseline to Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | -5.12 |
| Dapagliflozin | -5.98 |
To compare the proportion of participants achieving a therapeutic glycaemic response, defined as a reduction in HbA1c of ≥0.7% compared to baseline, with dapagliflozin versus placebo at week 24. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value. (NCT00984867)
Timeframe: Baseline to Week 24
| Intervention | Percentage of participants (Least Squares Mean) |
|---|---|
| Placebo | 16.6 |
| Dapagliflozin | 35.3 |
Corresponds to the values of change in body weight in kilograms from baseline to week 26. (NCT01388361)
Timeframe: week 0, week 26
| Intervention | kg (Mean) |
|---|---|
| IDeg | 0.1 |
| IDeg + Liraglutide | -1.0 |
| IDeg + IAsp OD | 0.3 |
Values for change in FPG in mmol/L from baseline to week 26 of randomised period. (NCT01388361)
Timeframe: week 0, week 26
| Intervention | mmol/L (Mean) |
|---|---|
| IDeg | -1.23 |
| IDeg + Liraglutide | -0.14 |
| IDeg + IAsp OD | -0.04 |
Values for change in HbA1c from baseline to 26 weeks of treatment period. (NCT01388361)
Timeframe: week 0, week 26
| Intervention | percentage of glycosylated haemoglobin (Mean) |
|---|---|
| IDeg | 0.10 |
| IDeg + Liraglutide | -0.74 |
| IDeg + IAsp OD | -0.39 |
Corresponds to number of treatment emergent hypoglycaemic events from onset on or after the first day of exposure to investigational product and no later than 7 days after last exposure to investigational product. Confirmed hypoglycaemia was defined as the pool of severe hypoglycaemic episodes and minor episodes with a plasma glucose (PG) value < 3.1 mmol/L (56 mg/dL). (NCT01388361)
Timeframe: Onset on or after the first day of exposure to investigational product for 26 weeks of treatment period and no later than 7 days after last exposure to investigational product.
| Intervention | events (Number) | |
|---|---|---|
| Confirmed(severe+minor) | Severe | |
| IDeg | 313 | 1 |
| IDeg + IAsp OD | 330 | 0 |
| IDeg + Liraglutide | 40 | 0 |
The secondary endpoint was the change from baseline in body weight after 52 weeks of treatment (NCT01306214)
Timeframe: Baseline and 52 weeks
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo | 0.44 |
| Empagliflozin 10 mg | -1.95 |
| Empagliflozin 25 mg | -2.04 |
The primary endpoint was the change from baseline in HbA1c after 18 weeks of treatment. (NCT01306214)
Timeframe: Baseline and 18 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) |
|---|---|
| Placebo | -0.50 |
| Empagliflozin 10 mg | -0.94 |
| Empagliflozin 25 mg | -1.02 |
The secondary endpoint was the change from baseline in HbA1c after 52 weeks of treatment (NCT01306214)
Timeframe: Baseline and 52 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) |
|---|---|
| Placebo | -0.81 |
| Empagliflozin 10 mg | -1.18 |
| Empagliflozin 25 mg | -1.27 |
The secondary endpoint is change from baseline in insulin dose after 52 weeks of treatment (NCT01306214)
Timeframe: Baseline and 52 weeks
| Intervention | IU/day (Least Squares Mean) |
|---|---|
| Placebo | 10.16 |
| Empagliflozin 10 mg | 1.33 |
| Empagliflozin 25 mg | -1.06 |
Observed mean change from baseline in HbA1c after 26 Weeks of treatment. (NCT01392573)
Timeframe: Week 0, week 26
| Intervention | percentage of glycosylated haemoglobin (Mean) |
|---|---|
| IDegLira | -1.90 |
| IDeg | -0.89 |
Observed mean change from baseline in body weight after 26 Weeks of treatment. (NCT01392573)
Timeframe: Week 0, week 26
| Intervention | kg (Mean) |
|---|---|
| IDegLira | -2.7 |
| IDeg | 0.0 |
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Baseline, Week 104
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -0.65 |
| Canagliflozin 300 mg | -0.74 |
| Glimepiride | -0.55 |
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -0.82 |
| Canagliflozin 300 mg | -0.93 |
| Glimepiride | -0.81 |
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -4.2 |
| Canagliflozin 300 mg | -4.7 |
| Glimepiride | 1.0 |
The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percentage of patients (Number) |
|---|---|
| Canagliflozin 100 mg | 5.6 |
| Canagliflozin 300 mg | 4.9 |
| Glimepiride | 34.2 |
(NCT01376557)
Timeframe: 12 weeks
| Intervention | kg (Mean) |
|---|---|
| 75 mg LX4211 qd | -0.995 |
| 200 mg LX4211 qd | -1.956 |
| 400 mg LX4211 qd | -1.848 |
| 200 mg LX4211 Bid | -2.477 |
| Placebo qd | -0.395 |
(NCT01376557)
Timeframe: 12 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| 75 mg LX4211 qd | -9.5 |
| 200 mg LX4211 qd | -17.4 |
| 400 mg LX4211 qd | -27.1 |
| 200 mg LX4211 Bid | -26.9 |
| Placebo qd | 2.2 |
(NCT01376557)
Timeframe: 12 weeks
| Intervention | % change (Mean) |
|---|---|
| 75 mg LX4211 qd | -0.42 |
| 200 mg LX4211 qd | -0.52 |
| 400 mg LX4211 qd | -0.92 |
| 200 mg LX4211 Bid | -0.80 |
| Placebo qd | -0.09 |
(NCT01376557)
Timeframe: 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| 75 mg LX4211 qd | -0.123 |
| 200 mg LX4211 qd | -3.878 |
| 400 mg LX4211 qd | -5.746 |
| 200 mg LX4211 Bid | -4.452 |
| Placebo qd | -0.283 |
(NCT01376557)
Timeframe: 12 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| 75 mg LX4211 qd | -16.2 |
| 200 mg LX4211 qd | 6.6 |
| 400 mg LX4211 qd | -16.8 |
| 200 mg LX4211 Bid | -16.9 |
| Placebo qd | -30.5 |
(NCT01376557)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| 75 mg LX4211 qd | 16 |
| 200 mg LX4211 qd | 15 |
| 400 mg LX4211 qd | 22 |
| 200 mg LX4211 Bid | 17 |
| Placebo qd | 14 |
Change in BMI (body mass index) from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | Kg/m^2 (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.8 |
| DAPA (Dapagliflozin Plus Placebo) | -0.66 |
| PCB (Placebo Plus Placebo) | 0.16 |
Change in body weight from baseline to 16 weeks (NCT02613897)
Timeframe: Baseline to 16 weeks
| Intervention | Kg (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -2.28 |
| DAPA (Dapagliflozin Plus Placebo) | -1.76 |
| PCB (Placebo Plus Placebo) | 0.26 |
A measure of the change in fasting plasma glucagon from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -28.52 |
| DAPA (Dapagliflozin Plus Placebo) | 26.89 |
| PCB (Placebo Plus Placebo) | 6.88 |
Measure of change in Free Fatty Acids from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mEq/L (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.06 |
| DAPA (Dapagliflozin Plus Placebo) | -0.01 |
| PCB (Placebo Plus Placebo) | 0.00 |
Change in percentage of glucose oxidation from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -22.07 |
| DAPA (Dapagliflozin Plus Placebo) | -46.54 |
| PCB (Placebo Plus Placebo) | 4.65 |
Change in lipid oxidation percentage from baseline to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -11.87 |
| DAPA (Dapagliflozin Plus Placebo) | 22.02 |
| PCB (Placebo Plus Placebo) | -6.69 |
Change in blood glucose level measured over a 3 month period from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage change in blood glucose level (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -1.67 |
| DAPA (Dapagliflozin Plus Placebo) | -1.46 |
| PCB (Placebo Plus Placebo) | 0.44 |
Measure of change in OGTT from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -49.62 |
| DAPA (Dapagliflozin Plus Placebo) | -44.24 |
| PCB (Placebo Plus Placebo) | 20.26 |
All subjects received a Double-Tracer Oral Glucose Tolerance Test (OGTT) with 75g of glucose containing 14C-glucose together with intravenous primed-continuous infusion of 3(3H)-glucose for 240 minutes, at baseline (prior to) and after 16 weeks of therapy. Blood and urine samples were obtained during the OGTT to determine EGP. (NCT02613897)
Timeframe: Baseline and 16 weeks
| Intervention | mg/kg*min (Mean) | |
|---|---|---|
| Baseline Measurement | 16 weeks | |
| DAPA (Dapagliflozin Plus Placebo) | 2.56 | 2.8 |
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | 2.45 | 2.4 |
| PCB (Placebo Plus Placebo) | 1.95 | 2.15 |
Change in body fat mass measured by air displacement plethysmography (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -1.51 |
| Placebo Plus Weight Reduction Counseling | 1.81 |
Change in body fat mass by Dual Energy X-Ray Absorptiometry (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | 0.48 |
| Placebo Plus Weight Reduction Counseling | 1.88 |
Change in body weight (kg) (NCT00005669)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | 1.47 |
| Placebo Plus Weight Reduction Counseling | 4.85 |
Change in body weight as determined by body mass index (kg/m2) (NCT00005669)
Timeframe: 6 months
| Intervention | kg/m2 (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -0.78 |
| Placebo Plus Weight Reduction Counseling | 0.32 |
Change in Body Mass Index standard deviation score (BMI-SDS) determined using tables created by the CDC in 2000. BMI-SDS is a unitless transformation of the body mass index (measured in kg divided by the squared height in meters) using the L M S method. Possible values range from -3 to +3. See http://www.cdc.gov/growthcharts/percentile_data_files.htm for details. (NCT00005669)
Timeframe: 6 months
| Intervention | Units on a scale (Mean) |
|---|---|
| Metformin Plus Weight Reduction Counseling | -0.11 |
| Placebo Plus Weight Reduction Counseling | -0.07 |
Change from baseline in body weight for Metformin Background patients. (NCT01422876)
Timeframe: Baseline and 24 Weeks
| Intervention | kg change from baseline (Least Squares Mean) |
|---|---|
| Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg | -2.99 |
| Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg | -2.60 |
| Metformin Background: Empagliflozin 25 mg | -3.18 |
| Metformin Background: Empagliflozin 10 mg | -2.53 |
| Metformin Background: Linagliptin 5 mg | -0.69 |
Change from baseline in body weight for Treatment Naive patients. (NCT01422876)
Timeframe: Baseline and 24 Weeks
| Intervention | kg change from baseline (Least Squares Mean) |
|---|---|
| Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg | -2.00 |
| Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg | -2.74 |
| Treatment Naive: Empagliflozin 25 mg | -2.13 |
| Treatment Naive: Empagliflozin 10 mg | -2.27 |
| Treatment Naive: Linagliptin 5 mg | -0.78 |
Change from baseline in fasting plasma glucose at week 24 for Metformin Background patients. (NCT01422876)
Timeframe: Baseline and 24 Weeks
| Intervention | mg/dL change from baseline (Least Squares Mean) |
|---|---|
| Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg | -35.25 |
| Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg | -32.18 |
| Metformin Background: Empagliflozin 25 mg | -18.83 |
| Metformin Background: Empagliflozin 10 mg | -20.84 |
| Metformin Background: Linagliptin 5 mg | -13.05 |
Change from baseline in fasting plasma glucose at week 24 for Treatment Naive patients. (NCT01422876)
Timeframe: Baseline and 24 Weeks
| Intervention | mg/dL change from baseline (Least Squares Mean) |
|---|---|
| Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg | -29.55 |
| Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg | -28.21 |
| Treatment Naive: Empagliflozin 25 mg | -24.24 |
| Treatment Naive: Empagliflozin 10 mg | -22.39 |
| Treatment Naive: Linagliptin 5 mg | -5.92 |
Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage. (NCT01422876)
Timeframe: Baseline and 24 weeks
| Intervention | % change from baseline (Least Squares Mean) |
|---|---|
| Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg | -1.19 |
| Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg | -1.08 |
| Metformin Background: Empagliflozin 25 mg | -0.62 |
| Metformin Background: Empagliflozin 10 mg | -0.66 |
| Metformin Background: Linagliptin 5 mg | -0.70 |
Glycosylated hemoglobin (HbA1c) is a measurement of the percentage of hemoglobin that is glycated. The change from baseline in HbA1c is calculated as the week 24 HbA1c minus the baseline HbA1c. Since HbA1c is measured as a percentage the change from baseline is also a percentage. (NCT01422876)
Timeframe: Baseline and 24 weeks
| Intervention | % change from baseline (Least Squares Mean) |
|---|---|
| Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg | -1.08 |
| Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg | -1.24 |
| Treatment Naive: Empagliflozin 25 mg | -0.95 |
| Treatment Naive: Empagliflozin 10 mg | -0.83 |
| Treatment Naive: Linagliptin 5 mg | -0.67 |
Occurrence of the treat-to-target efficacy response for Metformin Background patients measured as HbA1c < 7.0% after 24 weeks of treatment for patients with HbA1c >=7.0% at baseline. (NCT01422876)
Timeframe: 24 Weeks
| Intervention | % of patients satisfying HbA1c <7.0% (Number) |
|---|---|
| Metformin Background: Empagliflozin 25 mg/Linagliptin 5 mg | 61.8 |
| Metformin Background: Empagliflozin 10 mg/Linagliptin 5 mg | 57.8 |
| Metformin Background: Empagliflozin 25 mg | 32.6 |
| Metformin Background: Empagliflozin 10 mg | 28.0 |
| Metformin Background: Linagliptin 5 mg | 36.1 |
Occurrence of the treat-to-target efficacy response for Treatment Naive patients measured as HbA1c < 7.0% after 24 weeks of treatment for patients with HbA1c >=7.0% at baseline. (NCT01422876)
Timeframe: 24 Weeks
| Intervention | % of patients satisfying HbA1c <7.0% (Number) |
|---|---|
| Treatment Naive: Empagliflozin 25 mg/Linagliptin 5 mg | 55.4 |
| Treament Naive: Empagliflozin 10 mg/Linagliptin 5 mg | 62.3 |
| Treatment Naive: Empagliflozin 25 mg | 41.5 |
| Treatment Naive: Empagliflozin 10 mg | 38.8 |
| Treatment Naive: Linagliptin 5 mg | 32.3 |
The number of participants with postbaseline detection of treatment-emergent antidrug LY2189265 antibodies (ADA) is summarized. (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) |
|---|---|
| LY2189265 | 9 |
Change from baseline in body weight was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks. (NCT00734474)
Timeframe: Baseline up to 27.4 weeks
| Intervention | kilograms (kg) (Mean) |
|---|---|
| 3.0 mg LY2189265 | -3.32 |
| 2.0 mg LY2189265 | -2.15 |
| 1.5 mg LY2189265 | -2.12 |
| 1.0 mg LY2189265 | -2.23 |
| 0.75 mg LY2189265 | -1.17 |
| 0.5 mg LY2189265 | -1.53 |
| 0.25 mg LY2189265 | -0.85 |
| Sitagliptin | -0.43 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.56 |
Change from baseline in HbA1c was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks. (NCT00734474)
Timeframe: Baseline up to 27.4 weeks
| Intervention | percentage of HbA1c (Mean) |
|---|---|
| 3.0 mg LY2189265 | -1.09 |
| 2.0 mg LY2189265 | -1.25 |
| 1.5 mg LY2189265 | -1.49 |
| 1.0 mg LY2189265 | -0.98 |
| 0.75 mg LY2189265 | -1.02 |
| 0.5 mg LY2189265 | -0.94 |
| 0.25 mg LY2189265 | -0.70 |
| Sitagliptin | -0.76 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.06 |
Sitting pulse rate was measured at the time that the dose decision was made (dose decision point). Change from baseline in pulse rate was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the decision point was 27.4 weeks. (NCT00734474)
Timeframe: Baseline up to 27.4 weeks
| Intervention | beats per minute (bpm) (Mean) |
|---|---|
| 3.0 mg LY2189265 | 6.63 |
| 2.0 mg LY2189265 | 3.43 |
| 1.5 mg LY2189265 | 2.39 |
| 1.0 mg LY2189265 | 3.34 |
| 0.75 mg LY2189265 | -1.63 |
| 0.5 mg LY2189265 | 1.91 |
| 0.25 mg LY2189265 | 1.05 |
| Sitagliptin | -0.16 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 1.81 |
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT00734474)
Timeframe: Baseline, 52 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) |
|---|---|
| 1.5 mg LY2189265 | -1.10 |
| 0.75 mg LY2189265 | -0.87 |
| Sitagliptin | -0.39 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) |
|---|---|
| 3.0 mg LY2189265 | 0 |
| 2.0 mg LY2189265 | 0 |
| 1.5 mg LY2189265 | 0 |
| 1.0 mg LY2189265 | 0 |
| 0.75 mg LY2189265 | 0 |
| 0.5 mg LY2189265 | 0 |
| 0.25 mg LY2189265 | 0 |
| Sitagliptin | 2 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0 |
| Placebo/Sitagliptin (26 Weeks Through 104 Weeks) | 1 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) |
|---|---|
| 1.5 mg LY2189265 | 259 |
| 0.75 mg LY2189265 | 255 |
| Sitagliptin | 242 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 26 weeks
| Intervention | participants (Number) |
|---|---|
| 1.5 mg LY2189265 | 208 |
| 0.75 mg LY2189265 | 204 |
| Sitagliptin | 185 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 111 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with 1 or more TEAEs is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 52 weeks
| Intervention | participants (Number) |
|---|---|
| 3.0 mg LY2189265 | 9 |
| 2.0 mg LY2189265 | 20 |
| 1.5 mg LY2189265 | 233 |
| 1.0 mg LY2189265 | 8 |
| 0.75 mg LY2189265 | 231 |
| 0.5 mg LY2189265 | 15 |
| 0.25 mg LY2189265 | 10 |
| Sitagliptin | 219 |
Pharmacokinetic (PK) parameter estimates from LY2189265 concentration data were obtained using a 2-compartment population PK model with first order absorption. Area under the plasma-concentration curve from 0 to 168 hours, steady state (AUC0-168h, ss) of LY2189265 is summarized. (NCT00734474)
Timeframe: Baseline through 52 weeks
| Intervention | nanograms times hours per milliliter (Mean) |
|---|---|
| 1.5 mg LY2189265 | 13378 |
| 0.75 mg LY2189265 | 7246 |
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-%B and HOMA2-%S were set at 100%. Least squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | HOMA2-% (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| HOMA2-%B, 26 Weeks (n=206, 226, 206, 84) | HOMA2-%B, 52 Weeks (n=188, 198, 180) | HOMA2-%B, 104 Weeks (n=148, 154, 134) | HOMA2-%S, 26 Weeks (n=206, 226, 206, 84) | HOMA2-%S, 52 Weeks (n=188, 198, 180) | HOMA2-%S, 104 Weeks (n=148, 154, 134) | |
| 0.75 mg LY2189265 | 26.98 | 22.30 | 19.11 | 0.78 | 2.28 | -0.12 |
| 1.5 mg LY2189265 | 32.28 | 33.57 | 30.89 | 5.75 | 4.69 | 3.82 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 1.60 | NA | NA | 9.82 | NA | NA |
| Sitagliptin | 10.81 | 6.66 | 1.47 | 2.29 | 4.25 | 5.61 |
Least squares (LS) means of change from baseline body weight were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | kilograms (kg) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks | 52 Weeks | 104 Weeks | |
| 0.75 mg LY2189265 | -2.63 | -2.60 | -2.39 |
| 1.5 mg LY2189265 | -3.18 | -3.03 | -2.88 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -1.47 | NA | NA |
| Sitagliptin | -1.46 | -1.53 | -1.75 |
Sitting and standing systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26 weeks, 104 weeks
| Intervention | millimeters of mercury (mmHg) (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Sitting SBP, 26 Weeks (n=271, 278, 283, 138) | Sitting SBP, 104 Weeks (n=197, 192, 191) | Sitting DBP, 26 Weeks (n=271, 278, 283, 138) | Sitting DBP, 104 Weeks (n=197, 192, 191) | Standing SBP, 26 Weeks (n=271, 277, 281, 138) | Standing SBP, 104 Weeks (n=197, 192, 191) | Standing DBP, 26 Weeks (n=271, 277, 281, 138) | Standing DBP, 104 Weeks (n=197, 192, 191) | |
| 0.75 mg LY2189265 | -1.40 | 1.28 | -0.20 | 1.40 | -1.72 | 0.17 | 0.03 | 0.36 |
| 1.5 mg LY2189265 | -1.73 | -0.07 | -0.43 | 0.38 | -1.53 | -1.30 | -0.11 | -0.23 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 1.12 | NA | 0.68 | NA | 0.26 | NA | -0.52 | NA |
| Sitagliptin | -1.94 | 0.02 | -1.06 | -0.36 | -2.54 | -1.20 | -1.36 | -0.67 |
Sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured at the dose decision point. Change from baseline in DBP was 1 of the 4 measures included in the clinical utility index (CUI) used to evaluate the dose decision. The maximum duration of exposure to LY2189265, Sitagliptin, or Placebo (across all treatment arms) at the time of the decision point was 27.4 weeks. (NCT00734474)
Timeframe: Baseline up to 27.4 weeks
| Intervention | millimeters of mercury (mmHg) (Mean) | |
|---|---|---|
| Sitting SBP | Sitting DBP | |
| 0.25 mg LY2189265 | 1.67 | 1.28 |
| 0.5 mg LY2189265 | 0.40 | -0.75 |
| 0.75 mg LY2189265 | -6.21 | -3.18 |
| 1.0 mg LY2189265 | -2.00 | -0.08 |
| 1.5 mg LY2189265 | -4.77 | -1.20 |
| 2.0 mg LY2189265 | -4.63 | -1.17 |
| 3.0 mg LY2189265 | -8.85 | -1.21 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.61 | -0.22 |
| Sitagliptin | -2.16 | -1.11 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26 weeks, 104 weeks
| Intervention | milliseconds (msec) (Least Squares Mean) | |||
|---|---|---|---|---|
| PR Interval, 26 Weeks (n=256, 261, 268, 132) | PR Interval, 104 Weeks (n=168, 170, 167) | QTcF Interval, 26 Weeks (n=258, 262, 268, 132) | QTcF Interval, 104 Weeks (n=169, 170, 168) | |
| 0.75 mg LY2189265 | 1.60 | 3.06 | -2.44 | -2.49 |
| 1.5 mg LY2189265 | 2.94 | 4.59 | -3.86 | -2.71 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 2.24 | NA | 1.76 | NA |
| Sitagliptin | 0.42 | 3.19 | -1.31 | -0.02 |
Sitting and standing pulse rate were measured. Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as covariate. (NCT00734474)
Timeframe: Baseline, 26 weeks, 104 weeks
| Intervention | beats per minute (bpm) (Least Squares Mean) | |||
|---|---|---|---|---|
| Sitting, 26 Weeks (n=271, 278, 283, 138) | Sitting, 104 Weeks (n=197, 192, 191) | Standing, 26 Weeks (n=271, 277, 281, 138) | Standing, 104 Weeks (n=197, 192, 191) | |
| 0.75 mg LY2189265 | 1.90 | 2.77 | 2.00 | 2.50 |
| 1.5 mg LY2189265 | 2.57 | 2.28 | 3.24 | 2.26 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.22 | NA | -0.17 | NA |
| Sitagliptin | -0.11 | -0.78 | -0.24 | -1.06 |
Durability of effect on body weight was assessed by comparing the differences in mean change from baseline in body weight at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline body weight data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 13, 26, 52, and 104 weeks
| Intervention | kilograms (kg) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks Versus 13 Weeks (n=271, 278, 282, 138) | 52 Weeks Versus 26 Weeks (n=246, 255, 253) | 104 Weeks Versus 26 Weeks (n=197, 192, 191) | |
| 0.75 mg LY2189265 | -0.57 | 0.06 | 0.32 |
| 1.5 mg LY2189265 | -0.53 | 0.17 | 0.42 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.37 | NA | NA |
| Sitagliptin | -0.42 | -0.04 | -0.39 |
Durability of effect on HbA1c was assessed by comparing the differences in mean change from baseline in HbA1c at 1 time point versus an earlier time point. Least squares (LS) means of change from baseline HbA1c data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 13, 26, 52, and 104 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks Versus 13 Weeks (n=269, 269, 276, 136) | 52 Weeks Versus 26 Weeks (n=245, 254, 250) | 104 Weeks Versus 52 Weeks (n=194, 191, 190) | |
| 0.75 mg LY2189265 | 0.02 | 0.16 | 0.16 |
| 1.5 mg LY2189265 | -0.03 | 0.14 | 0.13 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.14 | NA | NA |
| Sitagliptin | 0.00 | 0.24 | 0.09 |
Least squares (LS) means of change from baseline were calculated using mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | millimoles per liter (mmol/L) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks (n=265, 271, 276, 135) | 52 Weeks (n=239, 247, 244) | 104 Weeks (n=190, 187, 181) | |
| 0.75 mg LY2189265 | -1.97 | -1.63 | -1.39 |
| 1.5 mg LY2189265 | -2.38 | -2.38 | -1.99 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -0.49 | NA | NA |
| Sitagliptin | -0.97 | -0.90 | -0.47 |
Least squares (LS) means of change from baseline fasting insulin data were calculated using a mixed-effects model for repeated measures (MMRM) analysis with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | picomoles per liter (pmol/L) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks (n=238, 249, 230, 115) | 52 Weeks (n=207, 218, 200) | 104 Weeks (n=187, 200, 183) | |
| 0.75 mg LY2189265 | 10.15 | 12.95 | 21.56 |
| 1.5 mg LY2189265 | 11.59 | 10.57 | 11.36 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -6.92 | NA | NA |
| Sitagliptin | 8.48 | 4.18 | 0.29 |
Least squares (LS) means were calculated using analysis of covariance (ANCOVA) and last observation carried forward (LOCF) imputation with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT00734474)
Timeframe: Baseline, 26 weeks, 104 weeks
| Intervention | percentage of HbA1c (Least Squares Mean) | |
|---|---|---|
| 26 Weeks | 104 Weeks | |
| 0.75 mg LY2189265 | -1.01 | -0.71 |
| 1.5 mg LY2189265 | -1.22 | -0.99 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0.03 | NA |
| Sitagliptin | -0.61 | -0.32 |
Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of participants with self-reported hypoglycemic events is summarized cumulatively. (NCT00734474)
Timeframe: Baseline through 26 and 104 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Severe HE, 26 Weeks | Severe HE, 104 Weeks | Documented Symptomatic HE, 26 Weeks | Documented Symptomatic HE, 104 Weeks | Asymptomatic HE, 26 Weeks | Asymptomatic HE, 104 Weeks | Nocturnal HE, 26 Weeks | Nocturnal HE, 104 Weeks | Probable HE, 26 Weeks | Probable HE, 104 Weeks | |
| 0.75 mg LY2189265 | 0 | 0 | 8 | 19 | 5 | 9 | 5 | 13 | 0 | 2 |
| 1.5 mg LY2189265 | 0 | 0 | 17 | 33 | 5 | 9 | 7 | 14 | 5 | 6 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0 | NA | 2 | NA | 0 | NA | 0 | NA | 0 | NA |
| Sitagliptin | 0 | 0 | 10 | 18 | 0 | 3 | 2 | 10 | 2 | 6 |
Data on any new cardiovascular (CV) event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Participants With Any CV Event | Participants With a Fatal CV Event | Participants With a Non-fatal CV Event | |
| 0.25 mg LY2189265 | 0 | 0 | 0 |
| 0.5 mg LY2189265 | 0 | 0 | 0 |
| 0.75 mg LY2189265 | 4 | 0 | 4 |
| 1.0 mg LY2189265 | 0 | 0 | 0 |
| 1.5 mg LY2189265 | 6 | 1 | 6 |
| 2.0 mg LY2189265 | 0 | 0 | 0 |
| 3.0 mg LY2189265 | 0 | 0 | 0 |
| Placebo/Sitagliptin (26 Weeks Through 104 Weeks) | 3 | 1 | 2 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0 | 0 | 0 |
| Sitagliptin | 5 | 1 | 4 |
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR). (NCT00734474)
Timeframe: Baseline through 104 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphate, High (n=276, 258, 281) | ALT/SGPT, High (n=232, 237, 244) | Amylase Pancreatic, High (n=283, 277, 295) | Amylase Total, High (n=266, 265, 277) | AST/SGOT, High (n=273, 269, 284) | Basophils, High (n=276, 268, 288) | Basophils, Low (n=277, 268, 288) | Bilirubin Direct, High (n=295, 291, 307) | Bilirubin Total, High (n=295, 290, 305) | Calcitonin, High (n=233, 239, 235) | Chloride, High (n=299, 293, 310) | Chloride, Low (n=299, 293, 308) | CPK, High (n=273, 262, 276) | Creatinine, High (n=294, 285, 303) | Creatinine Clearance, High (n=164, 186, 180) | Creatinine Clearance, Low (n=292, 278, 303) | Eosinophils, High (n=265, 265, 284) | Eosinophils, Low (n=277, 268, 288) | Erythrocyte Count, High (n=283, 276, 292) | Erythrocyte Count, Low (n=278, 272, 285) | GGT, High (n=234, 240, 245) | Hematocrit, High (n=280, 274, 290) | Hematocrit, Low (n=262, 251, 269) | Hemoglobin, High (n=282, 275, 294) | Hemoglobin, Low (n=265, 253, 269) | Leukocyte Count, High (n=277, 270, 292) | Leukocyte Count, Low (n=277, 267, 284) | Lipase, High (n=255, 248, 269) | Lymphocytes, High (n=257, 262, 279) | Lymphocytes, Low (n=273, 266, 281) | MCHC, High (n=281, 274, 291) | MCHC, Low (n=280, 272, 290) | MCV, High (n=267, 256, 273) | MCV, Low (n=270, 261, 286) | Monocytes, High (n=274, 267, 284) | Monocytes, Low (n=271, 264, 283) | Neutrophils, High (n=272, 263, 286) | Neutrophils, Low (n=271, 260, 280) | Platelet Count, High (n=273, 268, 287) | Platelet Count, Low (n=270, 260, 275) | Potassium, High (n=297, 291, 307) | Potassium, Low (n=298, 293, 308) | Sodium, High (n=291, 291, 307) | Sodium, Low (n=298, 292, 305) | Urea Nitrogen, High (n=287, 282, 305) | UMCR, High (n=223, 212, 239) | |
| 0.75 mg LY2189265 | 11 | 37 | 78 | 55 | 27 | 0 | 0 | 1 | 8 | 3 | 2 | 2 | 41 | 16 | 32 | 25 | 22 | 0 | 2 | 14 | 24 | 6 | 24 | 3 | 28 | 9 | 7 | 132 | 20 | 9 | 0 | 4 | 25 | 3 | 1 | 14 | 12 | 6 | 3 | 7 | 9 | 8 | 10 | 1 | 29 | 27 |
| 1.5 mg LY2189265 | 13 | 29 | 81 | 44 | 21 | 1 | 0 | 2 | 3 | 5 | 0 | 3 | 52 | 11 | 26 | 24 | 12 | 0 | 3 | 18 | 16 | 3 | 30 | 4 | 30 | 13 | 9 | 142 | 19 | 5 | 0 | 5 | 39 | 9 | 3 | 10 | 15 | 10 | 2 | 8 | 14 | 8 | 10 | 5 | 17 | 38 |
| Sitagliptin | 20 | 39 | 61 | 43 | 36 | 1 | 0 | 3 | 6 | 4 | 1 | 3 | 54 | 9 | 34 | 20 | 14 | 0 | 1 | 19 | 45 | 3 | 29 | 2 | 25 | 8 | 14 | 126 | 21 | 12 | 0 | 5 | 25 | 4 | 11 | 17 | 13 | 10 | 3 | 8 | 8 | 5 | 6 | 5 | 29 | 30 |
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR). (NCT00734474)
Timeframe: Baseline through 26 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase (n=276, 258, 281, 162) | ALT/SGPT (n=232, 237, 244, 128) | Amylase Pancreatic, High (n=283, 277, 295, 160) | Amylase Total (n=266, 265, 277, 143) | AST/SGOT (n=273, 269, 284, 148) | Basophils, High (n=268, 259, 278, 163) | Basophils, Low (n=269, 259, 278, 163) | Bilirubin Direct, High (n=295, 291, 307, 171) | Bilirubin Total, High (n=295, 290, 305, 168) | Calcitonin, High (n=226, 233, 230, 113) | Chloride, High (n=299, 293, 310, 174) | Chloride, Low (n=299, 293, 308, 174) | CPK, High (n=273, 262, 276, 156 | Creatinine, High (n=294, 285, 303, 172) | Creatinine Clearance, High (n=164, 186, 180, 107) | Creatinine Clearance, Low (n=292, 278,303,168) | Eosinophils, High (n=258, 256, 275, 157) | Eosinophils, Low (n=269, 259, 278, 163) | Erythrocyte Count, High (n=279, 272, 287, 164) | Erythrocyte Count, Low (n=274, 268, 280, 161) | GGT, High (n=234, 240, 245, 144) | Hematocrit, High (n=273, 265, 279, 161) | Hematocrit, Low (n=256, 242, 259, 157) | Hemoglobin, High (n=278, 271, 289, 164) | Hemoglobin, Low (n=262, 249, 265, 162) | Leukocyte Count, High (n=272, 265, 286, 165) | Leukocyte Count, Low (n=272, 262, 280, 165) | Lipase, High (n=255, 248, 269, 147) | Lymphocytes, High (n=249, 253, 269, 161) | Lymphocytes, Low (n=265, 258, 273, 159) | MCHC, High (n=274, 265, 280, 163) | MCHC, Low (n=273, 263, 279, 163) | MCV, High (n=261, 248, 263, 156) | MCV, Low (n=264, 252, 275, 162) | Monocytes, High (n=266, 258, 274, 163) | Monocytes, Low (n=265, 255, 274, 158) | Neutrophils, High (n=264, 255, 276, 161) | Neutrophils, Low (n=263, 251, 271, 162) | Platelet Count, High (n=265, 260, 281, 160) | Platelet Count, Low (n=262, 252, 269, 154) | Potassium, High (n=297, 291, 307, 172) | Potassium, Low (n=298, 293, 308, 169) | Sodium, High (n=291, 291, 307, 170) | Sodium, Low (n=298, 292, 305, 174) | Urea Nitrogen, High (n=287, 282, 305, 169) | UMCR, High (n=217, 204, 232, 130) | |
| 0.75 mg LY2189265 | 3 | 24 | 55 | 33 | 12 | 0 | 0 | 1 | 4 | 2 | 1 | 2 | 20 | 10 | 28 | 17 | 11 | 0 | 1 | 7 | 11 | 1 | 10 | 1 | 16 | 6 | 3 | 92 | 9 | 3 | 0 | 2 | 12 | 2 | 0 | 5 | 5 | 1 | 0 | 3 | 2 | 6 | 4 | 1 | 17 | 9 |
| 1.5 mg LY2189265 | 9 | 18 | 54 | 33 | 14 | 1 | 0 | 1 | 2 | 1 | 0 | 1 | 29 | 7 | 17 | 11 | 4 | 0 | 1 | 12 | 9 | 1 | 13 | 1 | 13 | 3 | 2 | 109 | 5 | 3 | 0 | 0 | 19 | 3 | 1 | 6 | 4 | 2 | 0 | 2 | 7 | 4 | 3 | 2 | 11 | 18 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 3 | 8 | 18 | 13 | 7 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 7 | 5 | 25 | 6 | 2 | 0 | 0 | 3 | 10 | 2 | 5 | 2 | 3 | 0 | 1 | 37 | 3 | 2 | 0 | 0 | 5 | 0 | 1 | 10 | 1 | 1 | 0 | 3 | 4 | 1 | 4 | 1 | 5 | 5 |
| Sitagliptin | 12 | 25 | 42 | 27 | 18 | 1 | 0 | 1 | 4 | 2 | 0 | 1 | 30 | 5 | 26 | 12 | 6 | 0 | 0 | 7 | 23 | 1 | 6 | 1 | 5 | 1 | 4 | 97 | 6 | 4 | 0 | 0 | 14 | 2 | 3 | 8 | 3 | 2 | 1 | 6 | 5 | 3 | 4 | 4 | 13 | 13 |
The number of participants with treatment-emergent abnormal laboratory results (defined as abnormalities that first occur after baseline) was summarized cumulatively for alkaline phosphatase, alanine aminotransferase or serum glutamic pyruvic transaminase (ALT/SGPT), amylase (pancreatic and total), aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT), basophils, bilirubin (direct and total), calcitonin, chloride, creatine phosphokinase (CPK), creatinine, creatinine clearance, eosinophils, erythrocytes, gamma glutamyltransferase (GGT), hematocrit, hemoglobin, leukocytes, lipase, lymphocytes, mean cell hemoglobin concentration (MCHC), mean cell volume (MCV), monocytes, neutrophils, platelets, potassium, sodium, urea nitrogen, and urine microalbumin-to-creatinine ratio (UMCR) . (NCT00734474)
Timeframe: Baseline through 52 weeks
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkaline Phosphatase, High (n=276, 258, 281) | ALT/SGPT, High (n=232, 237, 244) | Amylase Pancreatic, High (n=283, 277, 295) | Amylase Total, High (n=266, 265, 277) | AST/SGOT, High (n=273, 269, 284) | Basophils, High (n=276, 268, 287) | Basophils, Low (n=277, 268, 287) | Bilirubin Direct, High (n=295, 291, 307) | Bilirubin Total, High (n=295, 290, 305) | Calcitonin, High (n=233, 239, 235) | Chloride, High (n=299, 293, 310) | Chloride, Low (n=299, 293, 308) | CPK, High (n=273, 262, 276) | Creatinine, High (n=294, 285, 303) | Creatinine Clearance, High (n=164, 186, 180) | Creatinine Clearance, Low (n=292, 278, 303) | Eosinophils, High (n=265, 265, 283) | Eosinophils, Low (n=277, 268, 287) | Erythrocyte Count, High (n=283, 276, 292) | Erythrocyte Count, Low (n=278, 272, 285) | GGT, High (n=234, 240, 245) | Hematocrit, High (n=280, 274, 290) | Hematocrit, Low (n=262, 251, 269) | Hemoglobin, High (n=282, 275, 294) | Hemoglobin, Low (n=265, 253, 269) | Leukocyte Count, High (n=277, 270, 292) | Leukocyte Count, Low (n=277, 267, 284) | Lipase, High (n=255, 248, 269) | Lymphocytes, High (n=257, 262, 278) | Lymphocytes, Low (n=273, 266, 280) | MCHC, High (n=281, 274, 291) | MCHC, Low (n=280, 272, 290) | MCV, High (n=267, 256, 273) | MCV, Low (n=270, 261, 286) | Monocytes, High (n=274, 267, 283) | Monocytes, Low (n=271, 264, 282) | Neutrophils, High (n=272, 263, 285) | Neutrophils, Low (n=271, 260, 279) | Platelet Count, High (n=272, 267, 287) | Platelet Count, Low (n=269, 259, 275) | Potassium, High (n=297, 291, 307) | Potassium, Low (n=298, 293, 308) | Sodium, High (n=291, 291, 307) | Sodium, Low (n=298, 292, 305) | Urea Nitrogen, High (n=287, 282, 305) | UMCR, High (n=223, 212, 238) | |
| 0.75 mg LY2189265 | 6 | 27 | 70 | 42 | 19 | 0 | 0 | 1 | 6 | 2 | 1 | 2 | 28 | 10 | 30 | 20 | 14 | 0 | 1 | 9 | 14 | 2 | 13 | 1 | 19 | 6 | 3 | 111 | 15 | 4 | 0 | 3 | 18 | 2 | 0 | 9 | 7 | 2 | 2 | 5 | 5 | 7 | 8 | 1 | 19 | 21 |
| 1.5 mg LY2189265 | 10 | 25 | 67 | 38 | 15 | 1 | 0 | 1 | 2 | 4 | 0 | 1 | 38 | 9 | 23 | 18 | 11 | 0 | 3 | 15 | 10 | 3 | 21 | 3 | 21 | 7 | 5 | 124 | 12 | 4 | 0 | 2 | 25 | 3 | 1 | 8 | 8 | 6 | 0 | 4 | 10 | 6 | 5 | 3 | 14 | 33 |
| Sitagliptin | 16 | 28 | 55 | 36 | 25 | 1 | 0 | 2 | 5 | 2 | 0 | 2 | 43 | 6 | 29 | 15 | 10 | 0 | 1 | 11 | 34 | 2 | 11 | 1 | 11 | 3 | 9 | 110 | 11 | 11 | 0 | 3 | 19 | 4 | 5 | 15 | 7 | 6 | 2 | 8 | 5 | 5 | 4 | 4 | 21 | 18 |
The number of participants with treatment-emergent abnormal lipid test (cholesterol, high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C], and triglycerides [TG]) results (defined as lipid test abnormalities that first occurred after baseline) is summarized cumulatively. (NCT00734474)
Timeframe: Baseline through 26 and 104 weeks
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cholesterol, High, 26 Weeks (n=144, 158, 139, 58) | Cholesterol, High, 104 Weeks (n=151, 164, 146) | HDL-C, High, 26 Weeks (n=197, 201, 189, 78) | HDL-C, Low, 26 Weeks (n=127, 137, 129, 52) | HDL-C, High, 104 Weeks (n=206, 212, 199) | HDL-C, Low, 104 Weeks (n=134, 143, 138) | LDL-C, High, 26 Weeks (n=155, 163, 150, 61) | LDL-C, High, 104 Weeks (n=163, 170, 157) | TG, High, 26 Weeks (n=163, 174, 156, 64) | TG, High, 104 Weeks (n=170, 183, 166) | |
| 0.75 mg LY2189265 | 21 | 29 | 0 | 13 | 1 | 20 | 11 | 23 | 13 | 22 |
| 1.5 mg LY2189265 | 16 | 34 | 1 | 9 | 2 | 13 | 15 | 31 | 6 | 13 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 8 | NA | 0 | 1 | NA | NA | 7 | NA | 2 | NA |
| Sitagliptin | 20 | 34 | 0 | 8 | 2 | 13 | 19 | 29 | 10 | 15 |
The EQ-5D questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts. The first part allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a three level scale of 1-3 (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). The second part of the questionnaire consists of a 100-millimeter visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT00734474)
Timeframe: Baseline, 52 weeks, and 104 weeks
| Intervention | units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| EQ-5D, UK, Baseline (n=285, 281, 300) | EQ-5D, UK, 52 Weeks (n=237, 250, 244) | EQ-5D, UK, 104 Weeks (n=189, 190, 185) | VAS, Baseline (n=285, 284, 301) | VAS, 52 Weeks (n=238, 251, 245) | VAS, 104 Weeks (n=189, 190, 185) | |
| 0.75 mg LY2189265 | 0.82 | 0.84 | 0.86 | 75.35 | 78.22 | 78.52 |
| 1.5 mg LY2189265 | 0.80 | 0.83 | 0.84 | 75.57 | 78.93 | 79.66 |
| Sitagliptin | 0.84 | 0.85 | 0.86 | 76.85 | 78.79 | 81.34 |
"The Impact of Weight on Quality of Life-Lite (IWQoL-Lite questionnaire) is an obesity-specific, 31-item questionnaire designed to measure the impact of weight on participants' quality of life. Items are scored on a 5-point numeric rating scale where 5 = always true and 1 = never true. Items are summed into 6 scales (physical function [11 items], self-esteem [7 items], sexual life [4 items], public distress [5 items], work [4 items], and total score [31 items]) based on the average for the valid responses on that scale multiplied by the number of items on that scale (rounded to the nearest whole integer). Higher scores indicate lower levels of functioning (negative effects). Scores are linearly transformed to a 0 to 100 scale." (NCT00734474)
Timeframe: Baseline, 52 weeks, and 104 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Total Score, Baseline (n=285, 284, 300) | Total Score, 52 Weeks (n=237, 252, 247) | Total Score, 104 Weeks (n=190, 190, 185) | |
| 0.75 mg LY2189265 | 82.55 | 86.31 | 87.47 |
| 1.5 mg LY2189265 | 83.41 | 86.92 | 88.08 |
| Sitagliptin | 83.97 | 86.25 | 86.93 |
The percentage of participants achieving HbA1c levels <7.0% and ≤6.5% was analyzed using a logistic regression model and last observation carried forward (LOCF) imputation with baseline, country, and treatment as factors included in the model. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| <7.0% at 26 Weeks | <7.0% at 52 Weeks | <7.0% at 104 Weeks | ≤6.5% at 26 Weeks | ≤6.5% at 52 Weeks | ≤6.5% at 104 Weeks | |
| 0.75 mg LY2189265 | 55.2 | 48.8 | 44.8 | 31.0 | 29.0 | 24.2 |
| 1.5 mg LY2189265 | 60.9 | 57.6 | 54.3 | 46.7 | 41.7 | 39.1 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 21.0 | NA | NA | 12.5 | NA | NA |
| Sitagliptin | 37.8 | 33.0 | 31.1 | 21.8 | 19.2 | 14.1 |
Hypoglycemic episodes (HE) were classified as severe (defined as episodes requiring assistance from another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia and has a plasma glucose level of ≤3.9 millimoles per liter [mmol/L]), asymptomatic (defined as episodes not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of ≤3.9 mmol/L), nocturnal (defined as any episode that occurred between bedtime and waking), or probable symptomatic (defined as episodes during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of HE is summarized cumulatively. (NCT00734474)
Timeframe: Baseline through 26 and 104 weeks
| Intervention | episodes per participant per year (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Severe HE, 26 Weeks | Severe HE, 104 Weeks | Documented Symptomatic HE, 26 Weeks | Documented Symptomatic HE, 104 Weeks | Asymptomatic HE, 26 Weeks | Asymptomatic HE, 104 Weeks | Nocturnal HE, 26 Weeks | Nocturnal HE, 104 Weeks | Probable Symptomatic HE, 26 Weeks | Probable Symptomatic HE, 104 Weeks | |
| 0.75 mg LY2189265 | 0.0 | 0.0 | 0.1 | 0.2 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
| 1.5 mg LY2189265 | 0.0 | 0.0 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | 0.0 | NA | 0.1 | NA | 0.0 | NA | 0.0 | NA | 0.0 | NA |
| Sitagliptin | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 |
The number of visits to the emergency room (ER) is summarized cumulatively. (NCT00734474)
Timeframe: Baseline through 52 and 104 weeks
| Intervention | events (Number) | |
|---|---|---|
| 52 Weeks | 104 Weeks | |
| 0.75 mg LY2189265 | NA | NA |
| 1.5 mg LY2189265 | NA | NA |
| Sitagliptin | NA | NA |
Least squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT00734474)
Timeframe: Baseline, 26, 52, and 104 weeks
| Intervention | centimeters (cm) (Least Squares Mean) | ||
|---|---|---|---|
| 26 Weeks (n=266, 273, 277, 138) | 52 Weeks (n=238, 250, 247) | 104 Weeks (n=192, 189, 188) | |
| 0.75 mg LY2189265 | -1.78 | -2.05 | -1.75 |
| 1.5 mg LY2189265 | -2.89 | -2.91 | -2.57 |
| Placebo/Sitagliptin (Baseline Through 26 Weeks) | -1.20 | NA | NA |
| Sitagliptin | -1.45 | -1.45 | -1.20 |
Values of mean change in normalised iAUC0-4h values based on LOCF data derived from the glucose concentration profiles during a meal test. The meal test was performed at selected sites at baseline and after 26 weeks of treatment in the main trial period. The incremental AUC was calculated using the trapezoidal method and the resulting area was divided length of the observation period to yield the (normalised) prandial increment in mmol/L using the available valid glucose observations and the associated actual elapsed time point. (NCT01336023)
Timeframe: Week 0, Week 26
| Intervention | mmol/L (Mean) |
|---|---|
| IDeg | -0.17 |
| IDegLira | -0.87 |
| Liraglutide | -0.78 |
Mean of the actual doses recorded at visit 28 (Week 26). (NCT01336023)
Timeframe: Week 26
| Intervention | units (Mean) |
|---|---|
| IDeg | 53 |
| IDegLira | 38 |
Values of mean change in body weight. (NCT01336023)
Timeframe: Week 0, Week 26
| Intervention | kg (Mean) |
|---|---|
| IDeg | 1.6 |
| IDegLira | -0.5 |
| Liraglutide | -3.0 |
Values of mean change in HbA1c. (NCT01336023)
Timeframe: Week 0, week 26
| Intervention | Percentage of glycosylated haemoglobin (Mean) |
|---|---|
| IDeg | -1.44 |
| IDegLira | -1.91 |
| Liraglutide | -1.28 |
Reported hypoglycemaic episodes are number of hypoglycemic events per 100 patient years of exposure. (NCT01336023)
Timeframe: Weeks 0-26
| Intervention | Events per 100 patient years of exposure (Number) |
|---|---|
| IDeg | 256.7 |
| IDegLira | 180.2 |
| Liraglutide | 22.0 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT01075282)
Timeframe: Baseline, 52 weeks
| Intervention | percentage of glycosylated hemoglobin (Least Squares Mean) |
|---|---|
| LY2189265 1.5 mg | -1.08 |
| LY2189265 0.75 mg | -0.76 |
| Insulin Glargine | -0.63 |
Least Squares (LS) means were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline HbA1c as a covariate. (NCT01075282)
Timeframe: Baseline, 26 weeks, and 78 weeks
| Intervention | percent (Least Squares Mean) | |
|---|---|---|
| 26 weeks (n=263, 266, 258) | 78 weeks (n=263, 267, 259) | |
| Insulin Glargine | -0.65 | -0.59 |
| LY2189265 0.75 mg | -0.89 | -0.62 |
| LY2189265 1.5 mg | -1.16 | -0.90 |
Body mass index (BMI) is an estimate of body fat based on body weight divided by height squared. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | kilograms per square meter (kg/m^2) (Least Squares Mean) | ||
|---|---|---|---|
| 26 weeks (n=257, 261, 245) | 52 weeks (n=250, 252, 238) | 78 weeks (n=246, 244, 238) | |
| Insulin Glargine | 0.44 | 0.62 | 0.59 |
| LY2189265 0.75 mg | -0.50 | -0.39 | -0.39 |
| LY2189265 1.5 mg | -0.64 | -0.64 | -0.64 |
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | kilogram (kg) (Least Squares Mean) | ||
|---|---|---|---|
| 26 weeks | 52 weeks | 78 weeks | |
| Insulin Glargine | 1.01 | 1.44 | 1.28 |
| LY2189265 0.75 mg | -1.47 | -1.33 | -1.54 |
| LY2189265 1.5 mg | -1.82 | -1.87 | -1.96 |
The self-monitored blood glucose (SMBG) data were collected at the following 8 time points: pre-morning meal; 2 hours post-morning meal; pre-midday meal; 2 hours post-midday meal; pre-evening meal; 2 hours post-evening meal; bedtime; and 3 AM or 5 hours after bedtime. Least Squares (LS) means of the mean of the 8 time points (Daily Mean) were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | millimoles per liter (mmol/L) (Least Squares Mean) | ||
|---|---|---|---|
| 26 weeks (n=199, 204, 190) | 52 weeks (n=180, 185, 176) | 78 weeks (n=172, 164, 168) | |
| Insulin Glargine | -1.58 | -1.44 | -1.47 |
| LY2189265 0.75 mg | -1.46 | -1.32 | -1.15 |
| LY2189265 1.5 mg | -1.79 | -1.69 | -1.55 |
The European Quality of Life - 5 dimensions (EQ-5D) questionnaire is a generic, multidimensional, health-related, quality-of-life instrument. It consists of 2 parts: the first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 3 possible levels of response (no problem, some problem, or extreme problem). These dimensions are converted into a weighted health-state Index Score. The EQ-5D United Kingdom (UK) score ranges from -0.59 to 1.0, where a score of 1.0 indicates perfect health and negative values are valued as worse than dead. The second part of the questionnaire consists of a 100-mm visual analog scale (VAS) on which the participants rated their perceived health state on that day from 0 (worst imaginable health state) to 100 (best imaginable health). Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) and adjusted by treatment, country, and baseline. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | units on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| EQ-5D UK, 26 weeks (n=257, 254, 249) | EQ-5D UK, 52 weeks (n=259, 260, 253) | EQ-5D UK, 78 weeks (n=259, 260, 253) | VAS, 26 weeks (n=253, 252, 243) | VAS, 52 weeks (n=260, 258, 252) | VAS, 78 weeks (n=260, 258, 252) | |
| Insulin Glargine | -0.01 | -0.04 | 0.00 | 0.8 | 1.1 | 2.2 |
| LY2189265 0.75 mg | 0.00 | 0.00 | 0.00 | 3.4 | 2.3 | 3.2 |
| LY2189265 1.5 mg | 0.01 | 0.01 | 0.01 | 3.3 | 3.2 | 3.8 |
"The Impact of Weight on Activities of Daily Living questionnaire (renamed the Ability to Perform Physical Activities of Daily Living Questionnaire [APPADL]) contains 7 items that assess how difficult it is for participants to engage in certain activities considered to be integral to normal daily life, such as walking, standing and climbing stairs. Items are scored on a 5-point numeric rating scale where 5 = not at all difficult and 1 = unable to do. The individual scores from all 7 items are summed and a single total score is calculated and may range between 7 and 35. A higher score indicates better ability to perform activities of daily living. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate." (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| 26 weeks (n=256, 256, 248) | 52 weeks (n=260, 261, 249) | 78 weeks (n=260, 261, 249) | |
| Insulin Glargine | -0.3 | -0.6 | -0.3 |
| LY2189265 0.75 mg | 0.1 | 0.4 | 0.3 |
| LY2189265 1.5 mg | 0.7 | 0.9 | 1.0 |
The Impact of Weight on Self-Perception (IW-SP) questionnaire contains 3 items that assess how often the participants' body weight affects how happy they are with their appearance and how often they feel self-conscious when out in public. Items are scored on a 5-point numeric rating scale where 5 = never and 1 = always. A single total score is calculated by summing the scores for all 3 items. Total score ranges between 3 and 15, where a higher score is indicative of better self-perception. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| 26 weeks (n=258, 258, 251) | 52 weeks (n=260, 261, 252) | 78 weeks (n=260, 261, 252) | |
| Insulin Glargine | -0.1 | 0.1 | 0.1 |
| LY2189265 0.75 mg | 0.2 | 0.2 | 0.3 |
| LY2189265 1.5 mg | 0.1 | 0.5 | 0.5 |
The Low Blood Sugar Survey (LBSS) contains 33 items comprised of 2 subscales (behavior and worry), each of which is rated on a 5-point numeric rating scale from 0 (never) to 4 (almost always). It captures behavioral changes associated with the concerns and experiences of hypoglycemia and the degree to which participants are worried about certain aspects associated with hypoglycemia during the previous 4 weeks. The behavior (or avoidance) subscale has 15 items, and the worry (or affect) subscale has 18 items. Subscale scores are calculated by summing participant responses to items (behavior range 0-60; worry range 0-72). A total score is calculated as the sum of both subscales (range 0-132). Higher scores indicate greater negative impact on subscales and total score. Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| 26 weeks (n=255, 255, 244) | 52 weeks (n=258, 259, 245) | 78 weeks (n=258, 259, 245) | |
| Insulin Glargine | 0.3 | -1.0 | -2.0 |
| LY2189265 0.75 mg | -2.4 | -4.1 | -4.7 |
| LY2189265 1.5 mg | -2.8 | -4.2 | -4.6 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | milliseconds (msec) (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| QTcF interval, 26 weeks (n=240, 245, 229) | QTcF interval, 52 weeks (n=231, 240, 228) | QTcF interval, 78 weeks (n=221, 220, 222) | PR interval, 26 weeks (n=240, 245, 229) | PR interval, 52 weeks (n=230, 240, 227) | PR interval, 78 weeks (n=221, 220, 222) | |
| Insulin Glargine | 1.24 | 3.70 | 4.44 | 1.24 | 1.50 | 1.21 |
| LY2189265 0.75 mg | -0.10 | 1.34 | 3.44 | 2.33 | 1.88 | 3.27 |
| LY2189265 1.5 mg | -1.71 | 1.55 | 1.66 | 2.78 | 2.61 | 2.62 |
Electrocardiogram (ECG) heart rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | beats per minute (bpm) (Least Squares Mean) | ||
|---|---|---|---|
| 26 weeks (n=241, 247, 231) | 52 weeks (n=232, 242, 231) | 78 weeks (n=223, 222, 225) | |
| Insulin Glargine | -1.24 | -1.01 | -0.26 |
| LY2189265 0.75 mg | 0.90 | 0.38 | 0.47 |
| LY2189265 1.5 mg | 2.64 | 2.41 | 2.49 |
Amylase (total and pancreas-derived) and lipase concentrations were measured. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | units/liter (Median) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Amylase (total), 26 weeks | Amylase (total), 52 weeks | Amylase (total), 78 weeks | Amylase (pancreas-derived), 26 weeks | Amylase (pancreas-derived), 52 weeks | Amylase (pancreas-derived), 78 weeks | Lipase, 26 weeks | Lipase, 52 weeks | Lipase, 78 weeks | |
| Insulin Glargine | 2.000 | 3.000 | 1.000 | 1.000 | 1.000 | 0.000 | -1.000 | -1.000 | -2.000 |
| LY2189265 0.75 mg | 4.000 | 5.000 | 4.000 | 3.000 | 3.000 | 2.000 | 5.000 | 4.000 | 4.000 |
| LY2189265 1.5 mg | 4.000 | 4.000 | 4.000 | 3.000 | 3.000 | 2.000 | 5.000 | 4.000 | 4.000 |
(NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | picogram/milliliter (Mean) | ||
|---|---|---|---|
| 26 weeks (n=266, 267, 258) | 52 weeks (n=266, 269, 259) | 78 weeks (n=267, 269, 259) | |
| Insulin Glargine | 0.149 | 0.176 | 0.151 |
| LY2189265 0.75 mg | 0.097 | 0.132 | 0.035 |
| LY2189265 1.5 mg | 0.163 | 0.128 | 0.086 |
Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | milliliter of mercury (mmHG) (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| SBP, 26 weeks (n=257, 261, 245) | SBP, 52 weeks (n=250, 252, 240) | SBP, 78 weeks (n=246, 244, 238) | DBP, 26 weeks (n=257, 261, 245) | DBP, 52 weeks (n=250, 252, 240) | DBP, 78 weeks (n=246, 244, 238) | |
| Insulin Glargine | -0.03 | 0.51 | 0.51 | -0.29 | -0.93 | -1.04 |
| LY2189265 0.75 mg | -1.60 | 0.09 | -0.59 | -0.17 | -0.19 | -0.36 |
| LY2189265 1.5 mg | -1.28 | 0.17 | -0.70 | -0.16 | -0.26 | -0.44 |
Least Squares (LS) means of change from baseline were calculated using analysis of covariance (ANCOVA) with country and treatment as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 52, and 78 weeks
| Intervention | picomoles per liter (pmol/L) (Least Squares Mean) | |
|---|---|---|
| 52 weeks (n=232, 231, 228) | 78 weeks (n=235, 235, 232) | |
| Insulin Glargine | -3.85 | -3.65 |
| LY2189265 0.75 mg | -3.31 | -3.37 |
| LY2189265 1.5 mg | -3.91 | -3.57 |
The homeostatic model assessment (HOMA) is a method used to quantify insulin resistance and beta (β)-cell function. HOMA2-B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state beta cell function (%B) as a percentage of a normal reference population (normal young adults). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S), as percentages of a normal reference population (normal young adults). The normal reference population for both HOMA2-B and HOMA-2S were set at 100%. Least Squares (LS) means of change from baseline of C-peptide based HOMA2-%B and HOMA2-%S were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 52, and 78 weeks
| Intervention | percentage of HOMA2 (Least Squares Mean) | |||
|---|---|---|---|---|
| HOMA2-%B, 52 weeks (n=175, 181) | HOMA2-%B, 78 weeks (n=167, 165) | HOMA2-%S, 52 weeks (n=175,181) | HOMA2-%S, 78 weeks (n=167, 165) | |
| LY2189265 0.75 mg | 24.60 | 15.66 | -2.66 | -3.62 |
| LY2189265 1.5 mg | 29.95 | 28.54 | -2.89 | -2.64 |
Sitting pulse rate was measured. Least Squares (LS) means of change from baseline were calculated using a mixed-effects model for repeated measures (MMRM) with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate. (NCT01075282)
Timeframe: Baseline, 26, 52, and 78 weeks
| Intervention | beats per minute (bpm) (Least Squares Mean) | ||
|---|---|---|---|
| 26 weeks (n=257, 260, 245) | 52 weeks (n=250, 252, 240) | 78 weeks (n=246, 244, 238) | |
| Insulin Glargine | -1.21 | -0.52 | -0.91 |
| LY2189265 0.75 mg | 0.74 | 0.51 | 0.61 |
| LY2189265 1.5 mg | 1.56 | 1.29 | 1.31 |
Number of participants achieving HbA1c levels less than 7.0% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model. (NCT01075282)
Timeframe: 26, 52, and 78 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| 26 weeks (n=263, 266, 258) | 52 weeks (n=263, 267, 259) | 78 weeks (n=263, 267, 259) | |
| Insulin Glargine | 84 | 80 | 79 |
| LY2189265 0.75 mg | 122 | 99 | 91 |
| LY2189265 1.5 mg | 153 | 140 | 129 |
Number of participants achieving HbA1c levels less than or equal to 6.5% was analyzed with a logistic regression model with baseline, country, and treatment as factors included in the model. (NCT01075282)
Timeframe: 26, 52, and 78 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| 26 weeks (n=263, 266, 258) | 52 weeks (n=263, 267, 259) | 78 weeks (n=263, 267, 259) | |
| Insulin Glargine | 40 | 35 | 43 |
| LY2189265 0.75 mg | 74 | 60 | 59 |
| LY2189265 1.5 mg | 97 | 71 | 74 |
Additional intervention was defined as any additional therapeutic intervention in participants who developed persistent, severe hyperglycemia despite full compliance with the assigned therapeutic regimen, or initiation of an alternative antihyperglycemic medication following study drug discontinuation. The number of participants requiring additional intervention due to hyperglycemia is summarized cumulatively at 26, 52, and 78 weeks. (NCT01075282)
Timeframe: 26, 52, and 78 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| 26 weeks | 52 weeks | 78 weeks | |
| Insulin Glargine | 0 | 8 | 16 |
| LY2189265 0.75 mg | 4 | 20 | 34 |
| LY2189265 1.5 mg | 2 | 11 | 24 |
Information on cardiovascular (CV) risk factors was collected at baseline. Data on any new CV event was prospectively collected using a CV event electronic case report form. At prespecified visits, participants were asked about any new CV event. Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. The number of participants with adjudicated CV events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any CV event, 26 weeks | Any fatal CV event, 26 weeks | Any non-fatal CV event, 26 weeks | Any CV event, 52 weeks | Any fatal CV event, 52 weeks | Any non-fatal CV event, 52 weeks | Any CV event, 78 week | Any fatal CV event, 78 week | Any non-fatal CV event, 78 week | |
| Insulin Glargine | 3 | 0 | 3 | 6 | 1 | 5 | 9 | 1 | 8 |
| LY2189265 0.75 mg | 1 | 0 | 1 | 4 | 0 | 4 | 6 | 1 | 6 |
| LY2189265 1.5 mg | 2 | 0 | 2 | 3 | 0 | 3 | 3 | 0 | 3 |
The number of participants with pancreatitis confirmed by adjudication is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| 26 weeks | 52 weeks | 78 weeks | |
| Insulin Glargine | 0 | 0 | 0 |
| LY2189265 0.75 mg | 1 | 1 | 1 |
| LY2189265 1.5 mg | 1 | 2 | 2 |
LY2189265 (Dulaglutide) anti-drug antibodies (ADA) were assessed at baseline, 26, 52, and 78 weeks, and at the safety follow-up visit 30 days after study drug discontinuation (83 weeks). The number of participants with initial postbaseline detection of treatment emergent (defined as a 4-fold increase in the ADA titer from baseline) LY2189265 ADA at each time point were summarized. (NCT01075282)
Timeframe: Baseline, 26, 52, 78, and 83 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| 26 weeks | 52 weeks | 78 weeks | 83 weeks | |
| LY2189265 1.5 mg and 0.75 mg | 11 | 3 | 1 | 0 |
A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: 26, 52, and 78 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| 26 weeks | 52 weeks | 78 weeks | |
| Insulin Glargine | 137 | 175 | 192 |
| LY2189265 0.75 mg | 146 | 175 | 188 |
| LY2189265 1.5 mg | 160 | 189 | 201 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks
| Intervention | events (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severe HE, 26 weeks | Severe HE, 52 weeks | Severe HE, 78 weeks | Documented symptomatic HE, 26 weeks | Documented symptomatic HE, 52 weeks | Documented symptomatic HE, 78 weeks | Asymptomatic HE, 26 weeks | Asymptomatic HE, 52 weeks | Asymptomatic HE, 78 weeks | Nocturnal HE, 26 weeks | Nocturnal HE, 52 weeks | Nocturnal HE, 78 weeks | Probable symptomatic HE, 26 weeks | Probable symptomatic HE, 52 weeks | Probable symptomatic HE, 78 weeks | |
| Insulin Glargine | 1 | 2 | 2 | 447 | 789 | 1033 | 609 | 1093 | 1358 | 240 | 519 | 635 | 20 | 22 | 26 |
| LY2189265 0.75 mg | 0 | 0 | 0 | 315 | 444 | 515 | 484 | 709 | 911 | 117 | 147 | 184 | 19 | 24 | 28 |
| LY2189265 1.5 mg | 1 | 1 | 2 | 311 | 515 | 607 | 500 | 757 | 884 | 145 | 185 | 215 | 11 | 17 | 20 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of =<3.9 mmol/L), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of =<3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The 1-year adjusted rate of hypoglycemic events is summarized cumulatively at 26, 52, and 78 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module. (NCT01075282)
Timeframe: Baseline through 26, 52, and 78 weeks
| Intervention | events per participant per year (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severe HE, 26 weeks | Severe HE, 52 weeks | Severe HE, 78 weeks | Documented symptomatic HE, 26 weeks | Documented symptomatic HE, 52 weeks | Documented symptomatic HE, 78 weeks | Asymptomatic HE, 26 weeks | Asymptomatic HE, 52 weeks | Asymptomatic HE, 78 weeks | Nocturnal HE, 26 weeks | Nocturnal HE, 52 weeks | Nocturnal HE, 78 weeks | Probable symptomatic HE, 26 weeks | Probable symptomatic HE, 52 weeks | Probable symptomatic HE, 78 weeks | |
| Insulin Glargine | 0.01 | 0.01 | 0.01 | 3.64 | 3.34 | 3.03 | 4.82 | 4.41 | 3.80 | 1.86 | 2.07 | 1.81 | 0.15 | 0.08 | 0.07 |
| LY2189265 0.75 mg | 0.00 | 0.00 | 0.00 | 2.52 | 1.97 | 1.66 | 3.58 | 2.68 | 2.38 | 0.96 | 0.65 | 0.59 | 0.14 | 0.09 | 0.07 |
| LY2189265 1.5 mg | 0.01 | 0.00 | 0.01 | 2.35 | 2.03 | 1.67 | 3.79 | 3.08 | 2.56 | 1.23 | 0.90 | 0.77 | 0.08 | 0.07 | 0.05 |
Total adiponectin was measured with a commercial ELISA kit (Millipore/Linco Research, St. Charles, MO) in the laboratory of Dr. Philipp Scherer. (NCT00618072)
Timeframe: 6 months
| Intervention | ug/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 10.6 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 10.9 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 18.5 |
Body weight measurement was performed three times and averaged by a single study coordinator. (NCT00618072)
Timeframe: 6 months
| Intervention | kg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 80.0 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 80.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 77.5 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 71.7 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 72.7 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 74.3 |
Insulin was determined with a Siemens Immulite assay with respective intra-and inter-CV's 5.7 and 5.9%, and no cross reactivity to pro-insulin. (NCT00618072)
Timeframe: 6 months
| Intervention | uIU/mL (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 8.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 8.0 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 6.3 |
HDL was measured using two reagents homogeneous systems with selective detergents to homogenize the lipoprotein of interest. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 56.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 70.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 68.3 |
HOMA-IR was calculated by the formula: fasting insulin (uU/mL) times fasting glucose (mg/L) divided by 22.5. (NCT00618072)
Timeframe: 6 months
| Intervention | HOMA-IR score (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 1.5 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 1.6 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 1.3 |
Blood pressure was assessed using NCEP guidelines. (NCT00618072)
Timeframe: 6 months
| Intervention | mmHg (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 113.8 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 107.2 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 114.2 |
Triglycerides were measured by enzymatic immunoassay on an AU400 chemistry auto-analyzer with commercially available enzymatic reagents. (NCT00618072)
Timeframe: 6 months
| Intervention | mg/dl (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 95.2 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 103.1 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 109.2 |
(NCT00618072)
Timeframe: 6 months
| Intervention | cm (Mean) |
|---|---|
| A: EMPOWIR Diet and Placebo | 93.1 |
| B: EMPOWIR Diet Plus Metformin and Placebo Avandia | 90.4 |
| C: EMPOWIR Diet Plus Metformin and Avandia | 87.5 |
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 7.39 |
| Canagliflozin 100 mg | -18.1 |
| Canagliflozin 300 mg | -20.3 |
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo | -0.03 |
| Canagliflozin 100 mg | -0.60 |
| Canagliflozin 300 mg | -0.73 |
Region percent total fat = body fat as a percentage of (body fat + lean body mass + bone mass content). The table below shows the least-squares (LS) mean change in region percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific dual-energy X-ray absorptiometry (DXA) analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo | 0.00 |
| Canagliflozin 100 mg | -1.03 |
| Canagliflozin 300 mg | -1.18 |
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo | 1.10 |
| Canagliflozin 100 mg | -3.52 |
| Canagliflozin 300 mg | -6.79 |
Tissue percent total fat = body fat as a percentage of body fat + lean body mass. The table below shows the least-squares (LS) mean change in tissue percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo | 0.02 |
| Canagliflozin 100 mg | -1.04 |
| Canagliflozin 300 mg | -1.18 |
The table below shows the least-squares (LS) mean change in total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | kg (Least Squares Mean) |
|---|---|
| Placebo | -0.28 |
| Canagliflozin 100 mg | -1.87 |
| Canagliflozin 300 mg | -2.38 |
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.1 |
| Canagliflozin 100 mg | -2.4 |
| Canagliflozin 300 mg | -3.1 |
The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in distal forearm BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.5 |
| Canagliflozin 100 mg | -0.7 |
| Canagliflozin 300 mg | -0.8 |
The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in femoral neck BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -1.0 |
| Canagliflozin 100 mg | -0.7 |
| Canagliflozin 300 mg | -0.6 |
The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 or each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | 1.5 |
| Canagliflozin 100 mg | 6.8 |
| Canagliflozin 300 mg | 6.2 |
The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in lumbar spine BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | 0.5 |
| Canagliflozin 100 mg | 0.7 |
| Canagliflozin 300 mg | 0.2 |
The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in total hip BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | -0.5 |
| Canagliflozin 100 mg | -0.9 |
| Canagliflozin 300 mg | -1.0 |
The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change. (NCT01106651)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo | 7.7 |
| Canagliflozin 100 mg | 2.8 |
| Canagliflozin 300 mg | 8.4 |
The table below shows the percentage of patients with HbA1c <7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage. (NCT01106651)
Timeframe: Week 26
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 28.0 |
| Canagliflozin 100 mg | 47.7 |
| Canagliflozin 300 mg | 58.5 |
The assessments were done pre-dose at Day -1 and Day 42. Baseline value was defined as the assessment done Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 42) value. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) and Day 42
| Intervention | Ratio (Mean) |
|---|---|
| Part B-Placebo+Liraglutide | -0.018 |
| Part B-GSK2890457+Liraglutide | -0.009 |
| Part C-Placebo+Metformin | 0.002 |
| Part C-GSK2890457+Metformin | -0.001 |
Baseline was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline (Day -1) values from the post-Baseline value (Day 42). Adjusted mean is reported as LS mean. (NCT01725126)
Timeframe: Baseline (Day -1) and Day 42 of Part B and C
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Part B-Placebo+Liraglutide | -0.384 |
| Part B-GSK2890457+Liraglutide | -0.230 |
| Part C-Placebo+Metformin | 0.136 |
| Part C-GSK2890457+Metformin | -0.387 |
Baseline was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline (Day -1) values from the post-Baseline value (Day 42). Adjusted mean is reported as LS mean. (NCT01725126)
Timeframe: Baseline (Day -1) and Day 42
| Intervention | Percent of TL hemoglobin (Least Squares Mean) |
|---|---|
| Part B-Placebo+Liraglutide | -0.214 |
| Part B-GSK2890457+Liraglutide | -0.278 |
| Part C-Placebo+Metformin | 0.018 |
| Part C-GSK2890457+Metformin | -0.201 |
HOMA-IR was calculated from the Day -1 and Day 42 fasting glucose and insulin values using dataset generated from the HOMA-2 model. It contained the estimates for HOMA-% insulin sensitivity (S) for pairs of fasting glucose and fasting insulin values. Study data was merged with the HOMA dataset by glucose and insulin. HOMA-IR was calculated as 100/HOMA-%S. HOMA-IR was not determined for any values outside the ranges of plasma glucose 3.5 to 25.0 mmol/L (63 - 450 mg/dL) and plasma insulin 20 to 400 pmol/L. Baseline was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline (Day -1) values from the post-Baseline value (Day 42). Data for Part C of the study was not collected because fasting glucose and insulin were not available at the specified time points. (NCT01725126)
Timeframe: Baseline (Day -1) and Day 42
| Intervention | mU*mmol/L^2 (Mean) |
|---|---|
| Part B-Placebo+Liraglutide | -0.150 |
| Part B-GSK2890457+Liraglutide | 0.017 |
The matsuda index was calculated from the Day -1 and Day 42 glucose and insulin results as 10,000 divided by (fasting plasma glucose x fasting plasma insulin x mean glucose at 0-2 hour post-dose x mean insulin at 0-2 hour post dose)^1/2, where glucose was measured in mmol/L and insulin in pmol/L. Baseline was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline (Day -1) values from the post-Baseline value (Day 42). Data for Part C of the study was not collected because fasting glucose and insulin were not available at the specified time points. (NCT01725126)
Timeframe: Baseline (Day -1) and Day 42
| Intervention | Deciliter*mL/mg*mU (Mean) |
|---|---|
| Part B-Placebo+Liraglutide | -0.991 |
| Part B-GSK2890457+Liraglutide | -0.602 |
Hypoglycemia is defined as symptoms consistent with hypoglycemia (e.g. dizziness, light-headedness, shakiness) which are confirmed by glucometer measurement of complete blood count (CBG) or plasma glucose value of <50 milligram per deciliter (mg/dL) for Part A or <70 mg/dL for Parts B and C (when possible, CBG values were confirmed with a laboratory measurement). In situations when no glucose sample could be measured at the time of the event, the investigator, at his or her discretion, characterized an event as 'hypoglycemia' based on reported signs and symptoms alone. Healthy participant also had asymptomatic blood glucose values <70 mg/dL as a physiological response to altered food intake (e.g., fasting). (NCT01725126)
Timeframe: Up to Follow-up (8 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Part A-Placebo | 0 |
| Part A-GSK2890457 | 0 |
Hypoglycemia is defined as symptoms consistent with hypoglycemia (e.g. dizziness, light-headedness, shakiness) which are confirmed by glucometer measurement of CBG or plasma glucose value of <50 mg/dL for Part A or <70 mg/dL for Parts B and C (when possible, CBG values were confirmed with a laboratory measurement). In situations when no glucose sample could be measured at the time of the event, the investigator, at his or her discretion, characterized an event as 'hypoglycemia' based on reported signs and symptoms alone. Healthy participant also had asymptomatic blood glucose values <70 mg/dL as a physiological response to altered food intake (e.g., fasting). (NCT01725126)
Timeframe: Up to Follow-up (8 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Part B-Placebo+Liraglutide | 0 |
| Part B-GSK2890457+Liraglutide | 0 |
| Part C-Placebo+Metformin | 0 |
| Part C-GSK2890457+Metformin | 0 |
Blood samples were collected on Day -1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4 (pre-lunch), 5.5, 6, 8, 10 (pre-dinner), 11.5, 12, 14 and 24 hours post dose. The AUC (0-t) was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. The analysis population included Liraglutide Pharmacokinetic (PK) Population in Part B comprising of all participants in All Subjects Population for whom a PK sample was obtained and analyzed for Liraglutide. (NCT01725126)
Timeframe: Day -1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4, 5.5, 6, 8, 10, 11.5, 12, 14 and 24 hours post-dose
| Intervention | Hour*nanograms/mL (Geometric Mean) | |
|---|---|---|
| Day -1 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 1268.65 | 1265.92 |
| Part B-Placebo+Liraglutide | 2210.15 | 2505.23 |
Blood samples were collected on Day 1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4 (pre-lunch), 5.5, 6, 8 and 10 (pre-dinner) hours post-dose. The AUC (0-10 hour) was determined using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. The analysis population included Metformin PK Population in Part A comprising of all participants in All Subjects Population for whom a PK sample was obtained and analyzed for metformin. (NCT01725126)
Timeframe: Day 1 and Day 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4, 5.5, 6, 8 and 10 hours post-dose
| Intervention | Hour*nanograms/mL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 42 | |
| Part A-GSK2890457 | 3402.6 | 2231.7 |
| Part A-Placebo | 4346.8 | 5081.9 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | g/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Albumin, Day 7 | Albumin, Day 14 | Albumin, Day 28 | Albumin, Day 42 | Total protein, Day 7 | Total protein, Day 14 | Total protein, Day 28 | Total protein, Day 42 | |
| Part A-GSK2890457 | -0.3 | 0.4 | 0.4 | 0.0 | -2.1 | -1.2 | -2.2 | -3.1 |
| Part A-Placebo | 0.0 | 2.0 | 2.5 | 2.5 | -0.8 | -0.3 | 1.0 | 0.8 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | g/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Albumin, Day 7 | Albumin, Day 14 | Albumin, Day 28 | Albumin, Day 42 | Total protein, Day 7 | Total protein, Day 14 | Total protein, Day 28 | Total protein, Day 42 | |
| Part B-GSK2890457+Liraglutide | 3.1 | 2.6 | 2.8 | 0.4 | 2.9 | 2.7 | 3.2 | -0.6 |
| Part B-Placebo+Liraglutide | 2.0 | 2.7 | 1.8 | 0.0 | 3.0 | 4.0 | 3.2 | 0.5 |
| Part C-GSK2890457+Metformin | 0.5 | 1.6 | 1.9 | -1.3 | 1.1 | 2.2 | 3.1 | -1.5 |
| Part C-Placebo+Metformin | 1.3 | 0.8 | 2.3 | -0.8 | 1.0 | 1.7 | 2.8 | -0.7 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | International unit per liter (IU/L) (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALP, Day 7 | ALP, Day 14 | ALP, Day 28 | ALP, Day 42 | ALT, Day 7 | ALT, Day 14 | ALT, Day 28 | ALT, Day 42 | AST, Day 7 | AST, Day 14 | AST, Day 28 | AST, Day 42 | GGT, Day 7 | GGT, Day 14 | GGT, Day 28 | GGT, Day 42 | |
| Part A-GSK2890457 | -3.8 | -1.4 | -1.8 | -1.8 | -4.1 | -4.4 | -8.2 | -7.7 | -0.4 | 1.4 | -3.1 | -0.3 | -0.1 | -0.1 | -2.9 | -0.5 |
| Part A-Placebo | -6.0 | -1.3 | 0.0 | -1.0 | 5.5 | 1.3 | 2.0 | 5.3 | 2.3 | -2.3 | -0.8 | 2.3 | 1.5 | 1.0 | 0.8 | 2.5 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | IU/L (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALP, Day 7 | ALP, Day 14 | ALP, Day 28 | ALP, Day 42 | ALT, Day 7 | ALT, Day 14 | ALT, Day 28 | ALT, Day 42 | AST, Day 7 | AST, Day 14 | AST, Day 28 | AST, Day 42 | GGT, Day 7 | GGT, Day 14 | GGT, Day 28 | GGT, Day 42 | |
| Part B-GSK2890457+Liraglutide | 5.5 | 1.8 | 2.8 | 2.2 | -0.1 | 0.6 | 0.9 | 1.0 | 1.1 | 1.9 | 2.2 | 3.8 | -1.2 | -1.4 | 0.8 | 0.2 |
| Part B-Placebo+Liraglutide | 5.3 | 5.2 | -0.3 | 4.3 | -1.3 | -2.3 | -2.5 | -4.3 | -1.2 | -1.3 | -2.0 | -3.8 | 0.7 | 0.8 | 0.0 | -0.7 |
| Part C-GSK2890457+Metformin | -2.2 | -3.7 | -2.5 | -2.8 | -1.0 | -6.3 | -3.8 | -4.2 | 0.2 | -0.3 | 1.4 | 1.9 | 1.3 | 2.3 | 0.5 | -0.9 |
| Part C-Placebo+Metformin | 1.8 | 6.7 | 6.3 | 0.5 | 1.5 | 3.0 | 0.7 | -0.5 | -0.5 | -1.0 | 0.7 | 1.0 | 0.3 | 5.3 | 2.3 | -0.7 |
The assessments were done pre-dose at Day -1 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 42) value. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) and Day 42
| Intervention | Units (U)/L (Mean) | |
|---|---|---|
| Amylase, Day 42 | Lipase, Day 42 | |
| Part B-GSK2890457+Liraglutide | 9.2 | 18.8 |
| Part B-Placebo+Liraglutide | 6.0 | 7.5 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Micromoles (umol)/L (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Direct bilirubin, Day 7 | Direct bilirubin, Day 14 | Direct bilirubin, Day 28 | Direct bilirubin, Day 42 | Total bilirubin, Day 7 | Total bilirubin, Day 14 | Total bilirubin, Day 28 | Total bilirubin, Day 42 | Creatinine, Day 7 | Creatinine, Day 14 | Creatinine, Day 28 | Creatinine, Day 42 | Uric acid, Day 7 | Uric acid, Day 14 | Uric acid, Day 28 | Uric acid, Day 42 | |
| Part A-GSK2890457 | -0.311 | -0.466 | -0.855 | -0.171 | -0.777 | -0.933 | -2.565 | 0.513 | -6.4 | -4.8 | -7.1 | -8.8 | -10.3 | -17.8 | 4.2 | -26.2 |
| Part A-Placebo | 0.000 | 0.428 | -0.428 | -0.855 | 0.000 | 0.428 | 1.283 | 0.855 | 2.2 | -4.4 | 0.0 | -2.2 | -7.4 | -14.9 | -1.5 | -7.4 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | umol/L (Mean) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Direct bilirubin, Day 7 | Direct bilirubin, Day 14 | Direct bilirubin, Day 28 | Direct bilirubin, Day 42 | Total bilirubin, Day 7 | Total bilirubin, Day 14 | Total bilirubin, Day 28 | Total bilirubin, Day 42 | Creatinine, Day 7 | Creatinine, Day 14 | Creatinine, Day 28 | Creatinine, Day 42 | Uric acid, Day 7 | Uric acid, Day 14 | Uric acid, Day 28 | Uric acid, Day 42 | |
| Part B-GSK2890457+Liraglutide | -0.208 | -0.305 | -0.197 | -0.197 | -0.855 | -0.611 | 0.132 | 0.263 | 3.0 | 4.2 | 2.0 | -2.4 | 25.1 | 15.3 | 16.9 | 7.8 |
| Part B-Placebo+Liraglutide | 0.542 | 0.314 | 0.513 | 0.599 | 0.570 | -0.570 | -0.000 | -1.425 | 4.6 | -0.1 | 1.9 | -1.0 | 15.9 | -11.9 | 2.0 | -5.0 |
| Part C-GSK2890457+Metformin | -0.200 | -0.185 | -0.014 | -0.328 | 0.000 | 0.285 | 0.998 | -0.428 | 3.4 | 4.6 | 8.2 | -0.8 | 9.9 | 25.3 | 34.7 | 0.5 |
| Part C-Placebo+Metformin | -0.513 | -0.086 | -0.171 | -0.200 | -3.705 | -0.855 | -0.855 | -0.285 | 6.9 | 5.7 | 4.9 | 0.6 | 3.0 | -21.8 | -13.9 | 9.9 |
The electrolytes include calcium, chloride, carbon dioxide content/bicarbonate, potassium, magnesium and sodium. Assessments were done pre-dose at on Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Millimoles (mmol)/L (Mean) | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calcium, Day 7 | Calcium, Day 14 | Calcium, Day 28 | Calcium, Day 42 | Chloride, Day 7 | Chloride, Day 14 | Chloride, Day 28 | Chloride, Day 42 | Carbon dioxide/Bicarbonate, Day 7 | Carbon dioxide/Bicarbonate, Day 14 | Carbon dioxide/Bicarbonate, Day 28 | Carbon dioxide/Bicarbonate, Day 42 | Glucose, Day 7 | Glucose, Day 14 | Glucose, Day 28 | Glucose, Day 42 | Potassium, Day 7 | Potassium, Day 14 | Potassium, Day 28 | Potassium, Day 42 | Magnesium, Day 7 | Magnesium, Day 14 | Magnesium, Day 28 | Magnesium, Day 42 | Sodium, Day 7 | Sodium, Day 14 | Sodium, Day 28 | Sodium, Day 42 | Urea/BUN, Day 7 | Urea/BUN, Day 14 | Urea/BUN, Day 28 | Urea/BUN, Day 42 | Phosphorus inorganic, Day 7 | Phosphorus inorganic, Day 14 | Phosphorus inorganic, Day 28 | Phosphorus inorganic, Day 42 | |
| Part A-GSK2890457 | -0.023 | -0.023 | -0.010 | -0.022 | 1.2 | 0.4 | 0.5 | 0.4 | -1.2 | -1.9 | -1.2 | -2.8 | -0.1 | -0.3 | -0.2 | -0.3 | -0.15 | -0.15 | -0.13 | -0.16 | -0.0299 | -0.0486 | -0.0288 | -0.0247 | 0.8 | -0.2 | 1.9 | -0.6 | -0.325 | -0.746 | -0.643 | -0.678 | -0.04 | -0.05 | -0.09 | -0.03 |
| Part A-Placebo | -0.025 | 0.056 | 0.056 | 0.050 | 0.8 | 1.0 | -1.5 | -0.8 | 0.3 | -1.0 | -0.5 | -2.5 | -0.0 | -0.0 | -0.1 | -0.2 | 0.15 | 0.20 | -0.07 | 0.30 | -0.0206 | -0.0617 | -0.0411 | -0.0308 | 0.3 | -0.3 | 1.0 | -1.3 | -0.179 | -0.268 | -0.536 | -0.625 | -0.07 | -0.14 | -0.02 | 0.01 |
The electrolytes include calcium, chloride, carbon dioxide content/bicarbonate, potassium, magnesium and sodium. Assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | mmol/L (Mean) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calcium, Day 7 | Calcium, Day 14 | Calcium, Day 28 | Calcium, Day 42 | Chloride, Day 7 | Chloride, Day 14 | Chloride, Day 28 | Chloride, Day 42 | Carbon dioxide/Bicarbonate, Day 7 | Carbon dioxide/Bicarbonate, Day 14 | Carbon dioxide/Bicarbonate, Day 28 | Carbon dioxide/Bicarbonate, Day 42 | Glucose, Day 7 | Glucose, Day 14 | Glucose, Day 28 | Glucose, Day 42 | Potassium, Day 7 | Potassium, Day 14 | Potassium, Day 28 | Potassium, Day 42 | Magnesium, Day 7 | Magnesium, Day 14 | Magnesium, Day 28 | Magnesium, Day 42 | Sodium, Day 7 | Sodium, Day 14 | Sodium, Day 28 | Sodium, Day 42 | Urea/BUN, Day 7 | Urea/BUN, Day 14 | Urea/BUN, Day 28 | Urea/BUN, Day 42 | Cholesterol, Day 42 | Phosphorus inorganic, Day 7 | Phosphorus inorganic, Day 14 | Phosphorus inorganic, Day 28 | Phosphorus inorganic, Day 42 | |
| Part B-GSK2890457+Liraglutide | 0.053 | 0.041 | 0.046 | -0.040 | -1.2 | -0.1 | 0.2 | 0.2 | -2.0 | -1.9 | -0.4 | -1.8 | 0.3 | 0.2 | -0.2 | -0.1 | 0.09 | 0.20 | 0.08 | 0.01 | 0.0294 | 0.0176 | 0.0379 | 0.0063 | 0.2 | 1.4 | 1.7 | -0.4 | 0.383 | 0.128 | 0.302 | -0.412 | -0.103 | 0.01 | 0.05 | -0.01 | -0.04 |
| Part B-Placebo+Liraglutide | 0.083 | 0.050 | 0.021 | -0.025 | -1.5 | -0.8 | 0.8 | -1.0 | 0.0 | -1.8 | -1.0 | 0.5 | -0.3 | -0.1 | -0.1 | 0.2 | 0.33 | 0.17 | 0.28 | -0.05 | 0.0206 | -0.0206 | 0.0274 | -0.0137 | 1.2 | 1.3 | 1.8 | 0.5 | -0.000 | -0.297 | 0.119 | -0.595 | -0.853 | 0.10 | 0.01 | 0.06 | 0.01 |
| Part C-GSK2890457+Metformin | -0.004 | 0.017 | 0.035 | -0.056 | 0.4 | 0.6 | 0.3 | 0.3 | -0.6 | -0.7 | -0.3 | -1.3 | -1.7 | -2.2 | -2.0 | 0.1 | 0.06 | 0.07 | -0.07 | 0.08 | -0.0206 | 0.0206 | 0.0240 | -0.0171 | 0.8 | 1.5 | 0.6 | -1.0 | -0.208 | -0.268 | 0.863 | -0.387 | -0.155 | 0.01 | 0.03 | 0.12 | -0.00 |
| Part C-Placebo+Metformin | 0.025 | 0.067 | 0.004 | -0.071 | 0.8 | 0.5 | 1.0 | 0.5 | -2.0 | -2.0 | -2.3 | -2.8 | 0.9 | 0.5 | 1.5 | 1.2 | 0.28 | 0.17 | 0.10 | -0.05 | 0.0206 | 0.0069 | 0.0411 | -0.0274 | 1.3 | 1.5 | 1.0 | -1.0 | 0.179 | 0.178 | 0.714 | -0.655 | -0.052 | -0.03 | -0.10 | -0.12 | -0.05 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Picomoles (pmol)/L (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part A-GSK2890457 | 12.516 | 1.973 | 8.969 | -13.735 |
| Part A-Placebo | -1.256 | 8.072 | -11.659 | -22.721 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | pmol/L (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part B-GSK2890457+Liraglutide | -20.05 | -9.62 | -35.18 | -8.12 |
| Part B-Placebo+Liraglutide | -20.21 | -21.65 | -53.41 | -12.99 |
| Part C-GSK2890457+Metformin | -29.59 | -41.14 | -7.22 | 35.28 |
| Part C-Placebo+Metformin | 45.11 | -79.39 | 34.28 | 34.28 |
The assessments were done pre-dose at Day -1, Day 7 and Day 42. Baseline value was defined as the assessment done Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | Milliunits (mu/L) (Mean) |
|---|---|
| Day 42 | |
| Part B-Placebo+Liraglutide | 0.137 |
| Part C-GSK2890457+Metformin | 0.149 |
| Part C-Placebo+Metformin | -0.187 |
The assessments were done pre-dose at Day -1, Day 7 and Day 42. Baseline value was defined as the assessment done Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | Milliunits (mu/L) (Mean) | |
|---|---|---|
| Day 7 | Day 42 | |
| Part B-GSK2890457+Liraglutide | -5.790 | -0.067 |
The assessments were done pre-dose at Day -1 and Day 42. Baseline value was defined as the assessment done Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 42) value. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) and Day 42
| Intervention | Nanomoles (nmol)/L (Mean) | |
|---|---|---|
| Total thyroxine | Total T3 | |
| Part B-GSK2890457+Liraglutide | 1.0891 | 0.1 |
| Part B-Placebo+Liraglutide | 0.8578 | -0.3 |
| Part C-GSK2890457+Metformin | -2.3597 | -0.2 |
| Part C-Placebo+Metformin | -5.1478 | -0.2 |
Single 12-lead ECGs was obtained after participants rested in a supine position for at least 10 minutes using an ECG machine that automatically calculated the HR and measured PR, QRS, QT, QTcB, QTcF and RR intervals. The assessments were done at Day -1 (pre-dose, triplicate), Day 42 (pre-dose) and Follow-up Visit. Baseline value was defined as the average of the triplicate pre-dose assessments done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 42 and Follow-up) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Follow-up (Day 56)
| Intervention | Milliseconds (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PR Interval, Day 42 | PR Interval, Follow-up | QRS Duration, Day 42 | QRS Duration, Follow-up | QT Interval, Day 42 | QT Interval, Follow-up | QTcB, Day 42 | QTcB, Follow-up | QTcF, Day 42 | QTcF, Follow-up | RR Interval, Day 42 | RR Interval, Follow-up | |
| Part B-GSK2890457+Liraglutide | 3.08 | -3.69 | -2.62 | -1.69 | -1.69 | -5.69 | -1.51 | -10.95 | -1.49 | -9.10 | -0.00 | 0.02 |
| Part B-Placebo+Liraglutide | 5.56 | -1.11 | 0.78 | 0.11 | 8.11 | 1.44 | -2.87 | -5.89 | 1.17 | -3.17 | 0.04 | 0.03 |
| Part C-GSK2890457+Metformin | -4.44 | -6.28 | -1.06 | 0.11 | 0.78 | -5.56 | -4.23 | -2.14 | -2.58 | -3.50 | 0.02 | -0.01 |
| Part C-Placebo+Metformin | -6.44 | -3.11 | 0.11 | 0.78 | 2.78 | 0.78 | 0.43 | -3.20 | 1.22 | -1.78 | 0.01 | 0.02 |
Single 12-lead ECGs was obtained after participants rested in a supine position for at least 10 minutes using an ECG machine that automatically calculated the HR and measured PR, QRS, QT, QT duration corrected for HR by Fridericia's formula (QTcF) and QT duration corrected for HR by Bazett's formula (QTcB intervals. The assessments were done at Day 1 (pre-dose, triplicate), Day 42 (pre-dose) and Follow-up Visit. Baseline value was defined as the average of the triplicate pre-dose assessments done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 42 and Follow-up) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Follow-up (Day 56)
| Intervention | Milliseconds (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PR Interval, Day 42 | PR Interval, Follow-up | QRS Duration, Day 42 | QRS Duration, Follow-up | QT Interval, Day 42 | QT Interval, Follow-up | QTcB, Day 42 | QTcB, Follow-up | QTcF, Day 42 | QTcF, Follow-up | |
| Part A-GSK2890457 | 1.1 | 1.5 | -2.1 | -0.7 | 16.4 | -10.2 | -3.3 | 6.3 | 3.2 | 0.7 |
| Part A-Placebo | 6.3 | 9.0 | 2.2 | 3.9 | 10.8 | 0.3 | 8.2 | 6.9 | 9.1 | 4.8 |
Two fasting samples 5 minutes apart were taken for insulin. Baseline insulin level was the average of the 2 fasting samples. For insulin weighted mean AUC (0-4 hour) and weighted mean AUC (0-24 hour) was calculated for Baseline (Day -1) and end of treatment (Day 42). AUC was calculated using the linear trapezoid method that is the sum of the areas between each chronological pair of assessments at the time points (at Day -1 and Day 42). The weighted mean was then calculated by dividing the AUC by the length of the time interval over which it was calculated. Baseline was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline (Day -1) values from the post-Baseline value (Day 42). Data is reported for weighted mean insulin AUC (0-4 hour) post-breakfast and AUC (0-24 hour) post-breakfast. (NCT01725126)
Timeframe: Baseline (Day -1) and Day 42
| Intervention | pmol/L (Mean) | ||
|---|---|---|---|
| Fasting Insulin | Insulin Weighted Mean AUC 0-4 hour | Insulin Weighted Mean AUC 0-24 hour | |
| Part B-GSK2890457+Liraglutide | 1.133 | 14.589 | -13.905 |
| Part B-Placebo+Liraglutide | -4.887 | 69.635 | 1.626 |
| Part C-GSK2890457+Metformin | 12.300 | 10.322 | 17.134 |
| Part C-Placebo+Metformin | -11.946 | 57.887 | 22.740 |
The assessments were done at Day -1, Day 7, Day 14, Day 28, Day 42 and Follow-up Visit. Baseline was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline (Day -1) values from the post-Baseline (Day 7, 14, 28, 42 and Follow-up visit) values. (NCT01725126)
Timeframe: Baseline (Day -1) up to Follow-up (Day 56)
| Intervention | mmol/L (Mean) | ||||
|---|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | Follow-up | |
| Part B-GSK2890457+Liraglutide | 0.285 | 0.210 | -0.201 | -0.098 | 0.444 |
| Part B-Placebo+Liraglutide | -0.278 | -0.093 | -0.111 | 0.194 | 0.962 |
| Part C-GSK2890457+Metformin | -1.665 | -2.216 | -1.989 | 0.074 | -1.226 |
| Part C-Placebo+Metformin | 0.879 | 0.518 | 1.536 | 1.184 | 1.249 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part A-GSK2890457 | -0.0128 | -0.0026 | -0.0066 | -0.0089 |
| Part A-Placebo | 0.0000 | 0.0128 | 0.0228 | 0.0060 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | Ratio (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 0.0019 | 0.0011 | -0.0003 | -0.0025 |
| Part B-Placebo+Liraglutide | 0.0032 | -0.0028 | -0.0003 | -0.0022 |
| Part C-GSK2890457+Metformin | -0.0072 | -0.0036 | 0.0003 | -0.0159 |
| Part C-Placebo+Metformin | -0.0082 | 0.0057 | -0.0010 | -0.0087 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | Picograms (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part B-GSK2890457+Liraglutide | -0.21 | -0.10 | 0.01 | 0.08 |
| Part B-Placebo+Liraglutide | -0.02 | 0.18 | 0.17 | -0.12 |
| Part C-GSK2890457+Metformin | -0.18 | 0.03 | -0.08 | 0.02 |
| Part C-Placebo+Metformin | -0.23 | -0.25 | -0.20 | -0.28 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | Femtoliters (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 0.39 | 0.54 | 0.55 | 0.07 |
| Part B-Placebo+Liraglutide | 0.35 | 0.02 | 0.05 | -0.90 |
| Part C-GSK2890457+Metformin | 0.25 | 0.76 | 0.17 | -0.27 |
| Part C-Placebo+Metformin | 0.40 | -0.47 | -0.18 | -0.78 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Picograms (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part A-GSK2890457 | 0.31 | 0.32 | 0.37 | 0.89 |
| Part A-Placebo | 0.25 | 0.27 | 0.70 | 1.40 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Femtoliters (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part A-GSK2890457 | -0.55 | 0.95 | -0.62 | 0.35 |
| Part A-Placebo | 0.15 | 0.85 | -0.30 | -0.90 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | GI/L (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils, Day 7 | Basophils, Day 14 | Basophils, Day 28 | Basophils, Day 42 | Eosinophils, Day 7 | Eosinophils, Day 14 | Eosinophils, Day 28 | Eosinophils, Day 42 | Lymphocytes, Day 7 | Lymphocytes, Day 14 | Lymphocytes, Day 28 | Lymphocytes, Day 42 | Monocytes, Day 7 | Monocytes, Day 14 | Monocytes, Day 28 | Monocytes, Day 42 | Total Neutrophils, Day 7 | Total Neutrophils, Day 14 | Total Neutrophils, Day 28 | Total Neutrophils, Day 42 | Platelet count, Day 7 | Platelet count, Day 14 | Platelet count, Day 28 | Platelet count, Day 42 | WBC count, Day 7 | WBC count, Day 14 | WBC count, Day 28 | WBC count, Day 42 | |
| Part B-GSK2890457+Liraglutide | 0.0047 | 0.0041 | 0.0050 | 0.0019 | 0.04 | 0.03 | 0.02 | 0.06 | 0.11 | 0.04 | 0.05 | -0.11 | -0.01 | -0.04 | -0.03 | -0.06 | -0.13 | -0.19 | -0.17 | -0.14 | 8.9 | 7.0 | 10.8 | -13.2 | -0.01 | -0.17 | -0.13 | -0.26 |
| Part B-Placebo+Liraglutide | 0.0270 | 0.0037 | -0.0002 | 0.0098 | 0.02 | 0.01 | 0.01 | 0.01 | 0.31 | 0.18 | 0.08 | 0.02 | 0.04 | -0.05 | 0.03 | 0.00 | 0.27 | 0.38 | -0.01 | -0.24 | 18.3 | 12.8 | 4.5 | -2.0 | 0.65 | 0.52 | 0.08 | -0.20 |
| Part C-GSK2890457+Metformin | -0.0078 | -0.0066 | -0.0068 | -0.0122 | -0.03 | -0.00 | -0.00 | -0.01 | 0.14 | 0.18 | 0.25 | -0.07 | 0.00 | 0.06 | 0.03 | -0.03 | 0.38 | 0.64 | 0.36 | -0.10 | 5.8 | 12.9 | 10.4 | -15.3 | 0.48 | 0.88 | 0.63 | -0.22 |
| Part C-Placebo+Metformin | 0.0047 | -0.0015 | -0.0065 | -0.0190 | -0.01 | -0.02 | 0.01 | -0.02 | 0.09 | 0.08 | 0.05 | -0.11 | 0.01 | 0.06 | 0.06 | -0.00 | -0.54 | -0.27 | -0.48 | -0.50 | 5.0 | 1.2 | 0.5 | -13.8 | -0.43 | -0.13 | -0.35 | -0.62 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Giga cells (GI)/L (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basophils, Day 7 | Basophils, Day 14 | Basophils, Day 28 | Basophils, Day 42 | Eosinophils, Day 7 | Eosinophils, Day 14 | Eosinophils, Day 28 | Eosinophils, Day 42 | Lymphocytes, Day 7 | Lymphocytes, Day 14 | Lymphocytes, Day 28 | Lymphocytes, Day 42 | Monocytes, Day 7 | Monocytes, Day 14 | Monocytes, Day 28 | Monocytes, Day 42 | Total Neutrophils, Day 7 | Total Neutrophils, Day 14 | Total Neutrophils, Day 28 | Total Neutrophils, Day 42 | Platelet count, Day 7 | Platelet count, Day 14 | Platelet count, Day 28 | Platelet count, Day 42 | WBC count, Day 7 | WBC count, Day 14 | WBC count, Day 28 | WBC count, Day 42 | |
| Part A-GSK2890457 | 0.00 | 0.01 | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 | 0.00 | -0.01 | -0.06 | -0.32 | 0.05 | -0.05 | -0.05 | 0.01 | -0.06 | 0.02 | -0.13 | 0.14 | -0.01 | -1.9 | 3.8 | 9.7 | 3.1 | -0.11 | -0.15 | -0.16 | -0.01 |
| Part A-Placebo | 0.00 | -0.03 | 0.00 | 0.00 | -0.03 | -0.03 | 0.10 | 0.03 | -0.22 | -0.22 | -0.23 | 0.15 | -0.08 | -0.10 | -0.05 | -0.05 | 0.15 | 0.50 | -0.32 | 0.48 | -4.8 | -14.0 | -11.5 | -8.8 | -0.15 | 0.18 | -0.50 | 0.65 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | g/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Hemoglobin, Day 7 | Hemoglobin, Day 14 | Hemoglobin, Day 28 | Hemoglobin, Day 42 | MCHC, Day 7 | MCHC, Day 14 | MCHC, Day 28 | MCHC, Day 42 | |
| Part B-GSK2890457+Liraglutide | -1.0 | -1.1 | -1.1 | -0.8 | -4.1 | -3.8 | -1.9 | 0.2 |
| Part B-Placebo+Liraglutide | 0.2 | 0.2 | 0.3 | 0.0 | -2.0 | 2.0 | 1.7 | 2.0 |
| Part C-GSK2890457+Metformin | -3.4 | -2.1 | -0.3 | -4.8 | -2.8 | -2.6 | -1.4 | 0.8 |
| Part C-Placebo+Metformin | -4.3 | 1.7 | -1.2 | -2.8 | -4.5 | -1.2 | -2.0 | -0.2 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | g/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Hemoglobin, Day 7 | Hemoglobin, Day 14 | Hemoglobin, Day 28 | Hemoglobin, Day 42 | MCHC, Day 7 | MCHC, Day 14 | MCHC, Day 28 | MCHC, Day 42 | |
| Part A-GSK2890457 | -2.0 | -0.9 | 0.5 | 0.9 | 5.4 | 0.0 | 6.3 | 9.0 |
| Part A-Placebo | 0.8 | 4.0 | 11.3 | 9.8 | 1.8 | -0.5 | 8.5 | 17.5 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | TI/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| RBC count, Day 7 | RBC count, Day 14 | RBC count, Day 28 | RBC count, Day 42 | Reticulocytes, Day 7 | Reticulocytes, Day 14 | Reticulocytes, Day 28 | Reticulocytes, Day 42 | |
| Part B-GSK2890457+Liraglutide | 0.004 | -0.011 | -0.023 | -0.031 | -0.0003 | 0.0095 | 0.0035 | 0.0096 |
| Part B-Placebo+Liraglutide | 0.018 | -0.030 | 0.002 | 0.032 | 0.0020 | -0.0019 | 0.0029 | 0.0062 |
| Part C-GSK2890457+Metformin | -0.085 | -0.072 | -0.003 | -0.168 | -0.0015 | 0.0147 | -0.0052 | -0.0042 |
| Part C-Placebo+Metformin | -0.107 | 0.093 | 0.020 | -0.053 | -0.0210 | -0.0286 | -0.0304 | -0.0200 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Trillion cells (TI)/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| RBC count, Day 7 | RBC count, Day 14 | RBC count, Day 28 | RBC count, Day 42 | Reticulocytes, Day 7 | Reticulocytes, Day 14 | Reticulocytes, Day 28 | Reticulocytes, Day 42 | |
| Part A-GSK2890457 | -0.116 | -0.084 | -0.045 | -0.115 | 0.0014 | -0.0017 | 0.0071 | 0.0044 |
| Part A-Placebo | -0.008 | 0.090 | 0.258 | 0.107 | 0.0115 | 0.0077 | 0.0073 | 0.0022 |
During the assessment of body weight in the unit, the participant wore lightweight indoor clothing and removed shoes. The assessments were done pre-dose at Day -1, Day 1, Day 7, Day 14, Day 28, Day 42 and Day 43. Baseline value was defined as the average of Day -1 and Day 1 values. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. Day 42 value was the average of Day 42 and Day 43 values. (NCT01725126)
Timeframe: Baseline (Day -1 and Day 1) up to Day 42
| Intervention | Kilograms (kg) (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 0.20 | 0.05 | 0.47 | -0.39 |
| Part B-Placebo+Liraglutide | -0.12 | 0.37 | 0.15 | -0.74 |
| Part C-GSK2890457+Metformin | 0.47 | 0.56 | 0.27 | 0.42 |
| Part C-Placebo+Metformin | 0.28 | 0.61 | 0.52 | -0.47 |
The impact of GI symptoms on health-related quality of life was assessed using the GSRS. The GSRS is a 15-item related to abdominal pain, reflux, indigestion, diarrhea and constipation syndromes, self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort). Overall GSRS was the mean of items 1 to 15. Possible overall scores range from 1 to 7, with lower scores indicating a better quality of life with respect to GI symptoms and higher scores indicating a lower quality of life with respect to GI symptoms. Baseline was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, 14 and 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Scores on scale (Mean) | ||
|---|---|---|---|
| Day 7 | Day 14 | Day 42 | |
| Part A-GSK2890457 | 0.08 | 0.04 | -0.02 |
| Part A-Placebo | 0.02 | 0.08 | 0.02 |
The impact of GI symptoms on health-related quality of life was assessed using the GSRS. The GSRS is a 15-item related to abdominal pain, reflux, indigestion, diarrhea and constipation syndromes, self-administered questionnaire that assesses the impact of gastrointestinal symptoms during the past week on a scale from 1 (no discomfort at all) to 7 (very severe discomfort). Overall GSRS was the mean of items 1 to 15. Possible overall scores range from 1 to 7, with lower scores indicating a better quality of life with respect to GI symptoms and higher scores indicating a lower quality of life with respect to GI symptoms. Baseline was defined as the assessment done on Day -2. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, 14, 28 and 41) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -2) up to Day 41
| Intervention | Scores on scale (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 41 | |
| Part B-GSK2890457+Liraglutide | -0.03 | 0.05 | 0.03 | -0.12 |
| Part B-Placebo+Liraglutide | 0.03 | -0.09 | -0.21 | -0.11 |
| Part C-GSK2890457+Metformin | 0.13 | 0.28 | 0.27 | 0.10 |
| Part C-Placebo+Metformin | 0.24 | 0.20 | 0.14 | 0.02 |
Vital sign assessments were performed after resting in a supine or semi-supine position for at least 10 minutes. The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Beats per minute (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part A-GSK2890457 | 4.6 | 0.6 | 3.3 | -4.4 |
| Part A-Placebo | 8.0 | 6.3 | 5.5 | -1.3 |
Vital sign assessments were performed after resting in a supine or semi-supine position for at least 10 minutes. The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | Beats per minute (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 0.3 | 0.4 | 3.7 | 1.6 |
| Part B-Placebo+Liraglutide | -3.6 | -3.3 | -7.8 | -4.8 |
| Part C-GSK2890457+Metformin | 1.6 | 3.6 | 1.5 | 0.5 |
| Part C-Placebo+Metformin | 0.1 | 0.8 | 1.8 | -3.2 |
Vital sign assessments were performed after resting in a supine or semi-supine position for at least 10 minutes. The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day -1) up to Day 42
| Intervention | mmHg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| SBP, Day 7 | SBP, Day 14 | SBP, Day 28 | SBP, Day 42 | DBP, Day 7 | DBP, Day 14 | DBP, Day 28 | DBP, Day 42 | |
| Part B-GSK2890457+Liraglutide | 2.0 | 3.6 | 0.2 | 0.1 | 0.4 | 0.8 | 0.4 | 0.8 |
| Part B-Placebo+Liraglutide | 1.6 | 5.6 | -0.6 | -2.6 | -2.4 | 2.1 | -3.3 | -1.5 |
| Part C-GSK2890457+Metformin | -3.7 | -2.8 | -7.4 | -3.0 | -0.8 | -2.5 | -3.4 | -3.2 |
| Part C-Placebo+Metformin | 3.2 | 3.2 | 4.5 | 0.0 | 0.9 | -0.8 | -0.4 | 1.1 |
Vital sign assessments were performed after resting in a supine or semi-supine position for at least 10 minutes. The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Baseline value was defined as the assessment done on Day 1. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. (NCT01725126)
Timeframe: Baseline (Day 1, Randomization) up to Day 42
| Intervention | Millimeters of mercury (mmHg) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| SBP, Day 7 | SBP, Day 14 | SBP, Day 28 | SBP, Day 42 | DBP, Day 7 | DBP, Day 14 | DBP, Day 28 | DBP, Day 42 | |
| Part A-GSK2890457 | -4.0 | -3.9 | -5.5 | -7.5 | -6.2 | -5.0 | -8.4 | -6.4 |
| Part A-Placebo | 0.8 | -0.5 | -3.3 | -1.0 | -5.3 | -1.8 | -1.3 | -0.8 |
AUC was calculated using the linear trapezoid method that is the sum of the areas between each chronological pair of assessments at the time points (at Day -1 and Day 42). The weighted mean was then calculated by dividing the AUC by the length of the time interval over which it was calculated. Baseline was defined as the assessment done on Day -1. Change from Baseline was calculated by subtracting the Baseline (Day -1) values from the post-Baseline value (Day 42). Data is reported for weighted mean glucose AUC (0-4 hour) post-breakfast and AUC (0-24 hour) post-breakfast. Adjusted mean is reported as least square (LS) mean. (NCT01725126)
Timeframe: Baseline (Day -1) and Day 42
| Intervention | mmol/L (Least Squares Mean) | |
|---|---|---|
| AUC (0-4 hour) | AUC (0-24 hour) | |
| Part B-GSK2890457+Liraglutide | -0.164 | -0.968 |
| Part B-Placebo+Liraglutide | 0.018 | -0.613 |
| Part C-GSK2890457+Metformin | 0.341 | 0.156 |
| Part C-Placebo+Metformin | 1.194 | 1.376 |
Blood samples were collected on Day 1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4 (pre-lunch), 5.5, 6, 8 and 10 (pre-dinner) hours post-dose. The first occurrence of the Cmax was determined directly from the raw concentration-time data. (NCT01725126)
Timeframe: Day 1 and Day 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4, 5.5, 6, 8 and 10 hours post-dose
| Intervention | Nanograms/mL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 42 | |
| Part A-GSK2890457 | 576.2 | 374.1 |
| Part A-Placebo | 681.8 | 860.1 |
Blood samples were collected on Day -1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4 (pre-lunch), 5.5, 6, 8, 10 (pre-dinner), 11.5, 12, 14 and 24 hours post-dose. The first occurrence of the Cmax was determined directly from the raw concentration-time data. (NCT01725126)
Timeframe: Day -1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4, 5.5, 6, 8, 10, 11.5, 12, 14 and 24 hours post-dose
| Intervention | Nanograms/mL (Geometric Mean) | |
|---|---|---|
| Day -1 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 72.24 | 70.86 |
| Part B-Placebo+Liraglutide | 120.00 | 128.57 |
Urinalysis parameter included urine pH. pH was calculated on a scale of 0 to 14, such that, the lower the number, more acidic the urine and higher the number, more alkaline the urine with 7 being neutral. The assessments were done pre-dose on Day 1, Day 7, Day 14, Day 28 and Day 42. (NCT01725126)
Timeframe: up to Day 42
| Intervention | pH (Mean) | ||||
|---|---|---|---|---|---|
| Day 1 | Day 7 | Day 14 | Day 28 | Day 42 | |
| Part A-GSK2890457 | 5.95 | 5.86 | 5.91 | 6.05 | 6.20 |
| Part A-Placebo | 5.25 | 5.88 | 5.50 | 6.13 | 5.63 |
Urinalysis parameter included urine pH. pH was calculated on a scale of 0 to 14, such that, the lower the number, more acidic the urine and higher the number, more alkaline the urine with 7 being neutral. The assessments were done pre-dose on Day -1, Day 7, Day 14, Day 28 and Day 42. (NCT01725126)
Timeframe: Up to Day 42
| Intervention | pH (Mean) | ||||
|---|---|---|---|---|---|
| Day -1 | Day 7 | Day 14 | Day 28 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 6.25 | 5.89 | 6.07 | 5.96 | 6.08 |
| Part B-Placebo+Liraglutide | 5.92 | 5.83 | 5.67 | 5.75 | 6.00 |
| Part C-GSK2890457+Metformin | 5.83 | 5.42 | 5.63 | 5.63 | 5.58 |
| Part C-Placebo+Metformin | 5.67 | 5.83 | 5.67 | 5.67 | 5.58 |
Urinary specific gravity is a measure of the concentration of solutes in urine. It measures the ratio of urine density compared with water density and provides information on the kidney's ability to concentrate urine. The assessments were done pre-dose at Da y 1, Day 7, Day 14, Day 28 and Day 42. (NCT01725126)
Timeframe: Up to Day 42
| Intervention | Ratio (Mean) | ||||
|---|---|---|---|---|---|
| Day 1 | Day 7 | Day 14 | Day 28 | Day 42 | |
| Part A-GSK2890457 | 1.0175 | 1.0165 | 1.0152 | 1.0122 | 1.0161 |
| Part A-Placebo | 1.0193 | 1.0133 | 1.0153 | 1.0125 | 1.0155 |
Urinary specific gravity is a measure of the concentration of solutes in urine. It measures the ratio of urine density compared with water density and provides information on the kidney's ability to concentrate urine. The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. (NCT01725126)
Timeframe: Up to Day 42
| Intervention | Ratio (Mean) | ||||
|---|---|---|---|---|---|
| Day -1 | Day 7 | Day 14 | Day 28 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 1.0174 | 1.0191 | 1.0196 | 1.0239 | 1.0188 |
| Part B-Placebo+Liraglutide | 1.0168 | 1.0208 | 1.0202 | 1.0232 | 1.0137 |
| Part C-GSK2890457+Metformin | 1.0187 | 1.0208 | 1.0201 | 1.0213 | 1.0172 |
| Part C-Placebo+Metformin | 1.0172 | 1.0197 | 1.0198 | 1.0213 | 1.0110 |
The assessments were done pre-dose at Day 1, Day 7, Day 14, Day 28 and Day 42. Only those parameters for which at least one value of abnormal urinalysis result was reported are summarized. The participants were categorized as rare, trace, +1, 2+, RBC's and WBC's as <1, 1, 2, 3 and 4. Protein concentration ranged from trace to 1+, where trace indicated lowest concentration and 1+ indicated highest concentration. Trace was the highest concentration for occult blood. Bacteria concentration ranged from rare to moderate, where rare indicated lowest concentration and moderate indicated highest concentration. Ketones ranged from trace to 1+, where trace indicated lowest concentration and 1+ indicated highest concentration. RBC and WBC ranged from <1 to 4, where <1 indicated lowest concentration and 4 indicated highest concentration. Highest concentration indicated worse outcome. (NCT01725126)
Timeframe: Up to Day 42
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein, Trace, Day 1 | Protein, Trace, Day 7 | Protein, 1+, Day 7 | Protein, Trace, Day 14 | Protein, Trace, Day 28 | Protein, Trace, Day 42 | Bacteria, Rare, Day 1 | Bacteria, Rare, Day 42 | Bacteria, Moderate, Day 42 | Occult blood, Trace, Day 1 | Occult blood, Trace, Day 14 | Occult blood, Trace, Day 28 | Ketones, 1+, Day 1 | Ketones, 1+, Day 7 | Ketones, Trace, Day 14 | Ketones, Trace, Day 28 | Ketones, Trace, Day 42 | RBC's, 1, Day 1 | RBC's, 3, Day 1 | RBC's, <1, Day 1 | RBC's, 1, Day 7 | RBC's, <1, Day 7 | RBC's, 2, Day 14 | RBC's, <1, Day 14 | RBC's, 1, Day 28 | RBC's, <1, Day 28 | RBC's, 1, Day 42 | RBC's, 2, Day 42 | RBC's, <1, Day 42 | WBC's, 1, Day 1 | WBC's, <1, Day 1 | WBC's, 1, Day 7 | WBC's, <1, Day 7 | WBC's, 2, Day 14 | WBC's, <1, Day 14 | WBC's, 1, Day 28 | WBC's, <1, Day 28 | WBC's, 1, Day 42 | WBC's, 2, Day 42 | WBC's, 4, Day 42 | |
| Part A-GSK2890457 | 3 | 2 | 1 | 1 | 4 | 2 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 2 | 2 | 1 | 0 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 |
| Part A-Placebo | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 1 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. Only those parameters for which at least one value of abnormal urinalysis result was reported are summarized. The participants were categorized as few, trace, +1, 2+, 3+, 0-3, 10-20, 0-5, 6-10, and 20-40. Few was the highest concentration of bacteria. Occult blood ranged from trace to 1+, trace indicated lowest and 1+ indicated highest concentration. Epithelial cell ranged from 0-5 to 10-20, 0-5 indicated lowest and 10-20 indicated highest concentration. Glucose ranged from trace to 3+, trace indicated lowest and 3+ indicated highest concentration. 0-5 was highest concentration for hyaline casts. Ketone ranged from trace to 1+, trace indicated lowest and 1+ indicated highest concentration. RBC and WBC ranged from 0-3 to 20-40, 0-3 indicated lowest and 20-40 indicated highest concentration. Highest concentration indicated worse outcome. (NCT01725126)
Timeframe: Up to Day 42
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bacteria, Few, Day -1 | Occult Blood, 1+, Day 14 | Occult Blood, Trace, Day 28 | Occult Blood, Trace, Day 42 | Epithelial Cells, 10-20, Day -1 | Epithelial Cells, 0-5, Day 7 | Epithelial Cells, 6-10, Day 7 | Epithelial Cells, 0-5, Day 14 | Epithelial Cells, 0-5, Day 42 | Glucose, 1+, Day -1 | Glucose, 3+, Day -1 | Glucose, Trace, Day -1 | Glucose, 1+, Day 7 | Glucose, 3+, Day 7 | Glucose, Trace, Day 7 | Glucose, 1+, Day 14 | Glucose, 2+, Day 14 | Glucose, 3+, Day 14 | Glucose, Trace, Day 14 | Glucose, 1+, Day 28 | Glucose, 2+, Day 28 | Glucose, 3+, Day 28 | Glucose, Trace, Day 28 | Glucose, 1+, Day 42 | Glucose, 2+, Day 42 | Glucose, 3+, Day 42 | Glucose, Trace, Day 42 | Hyaline Casts, 0-5, Day 14 | Ketones, 1+, Day 7 | Ketones, Trace, Day 14 | Ketones, Trace, Day 28 | RBC's, 0-3, Day-1 | RBC's, 0-3, Day 7 | RBC's, 0-3, Day 14 | RBC's, 0-3, Day 28 | RBC's, 0-3, Day 42 | WBC's, 20-40, Day -1 | WBC's, 0-5, Day 7 | WBC's, 6-10, Day 7 | WBC's, 0-5, Day 14 | WBC's, 0-5, Day 28 | WBC's, 0-5, Day 42 | |
| Part B-GSK2890457+Liraglutide | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 2 | 1 | 4 | 2 | 1 | 1 | 2 | 3 | 1 | 1 | 1 | 3 | 2 | 1 | 2 | 1 | 0 | 2 | 3 | 3 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 |
| Part B-Placebo+Liraglutide | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 |
The assessments were done pre-dose at Day -1, Day 7, Day 14, Day 28 and Day 42. The participants were categorized as few, many, moderate, trace, +1, 2+, 3+, 0-3, 10-20, 0-5, 6-10, 20-40, 40-60. Protein and ketone ranged from trace to 1+, trace indicated lowest and 1+ indicated highest concentration. Bacteria and uric acid crystals ranged from few to moderate, few indicated lowest and moderate indicated highest concentration. Trace was the highest concentration of occult blood. Epithelial cells ranged from 0-5 to >10, 0-5 indicated lowest and >10 indicated highest concentration. Glucose ranged from trace to 3+, trace indicated lowest and 3+ indicated highest concentration. 0-1 was highest concentration for hyaline casts. RBC and WBC ranged from 0-3 to 40-60, 0-3 indicated lowest and 20-40 indicated highest concentration. Highest concentration indicated worse outcome. (NCT01725126)
Timeframe: Up to Day 42
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protein, 1+, Day 7 | Protein, Trace, Day 7 | Protein, Trace, Day 14 | Protein, 1+, Day 28 | Bacteria, Few, Day -1 | Bacteria, Many, Day -1 | Bacteria, Few, Day 7 | Bacteria, Many, Day 7 | Bacteria, Many, Day 14 | Bacteria, Moderate, Day 14 | Bacteria, Few, Day 28 | Bacteria, Many, Day 28 | Bacteria, Many, Day 42 | Bacteria, Moderate, Day 42 | Occult Blood, Trace, Day 42 | Epithelial Cells, 0-10, Day -1 | Epithelial Cells, 0-10, Day 7 | Epithelial Cells, 0-5, Day 7 | Epithelial Cells, 6-10, Day 7 | Epithelial Cells, 0-5, Day 14 | Epithelial Cells, >10, Day 14 | Epithelial Cells, 0-10, Day 28 | Epithelial Cells, 0-10, Day 42 | Glucose, 1+, Day -1 | Glucose, 2+, Day -1 | Glucose, 3+, Day -1 | Glucose, 1+, Day 7 | Glucose, 2+, Day 7 | Glucose, 3+, Day 7 | Glucose, Trace, Day 7 | Glucose, 1+, Day 14 | Glucose, 3+, Day 14 | Glucose, Trace, Day 14 | Glucose, 2+, Day 28 | Glucose, 3+, Day 28 | Glucose, Trace, Day 28 | Glucose, 1+, Day 42 | Glucose, 2+, Day 42 | Glucose, 3+, Day 42 | Glucose, Trace, Day 42 | Hyaline Casts, 0-1, Day 7 | Ketones, 1+, Day 7 | Ketones, Trace, Day 7 | Ketones, Trace, Day 14 | Ketones, Trace, Day 28 | RBC's, 0-3, Day -1 | RBC's, 0-3, Day 7 | RBC's, 0-3, Day 14 | RBC's, 0-3, Day 28 | RBC's, 0-3, Day 42 | Uric acid crystals, Moderate, Day 7 | Uric acid crystals, Few, Day 14 | WBC's, 0-5, Day -1 | WBC's, 0-5, Day 7 | WBC's, 6-10, Day 7 | WBC's, 0-5, Day 14 | WBC's, 0-5, Day 28 | WBC's, 40-60, Day 28 | WBC's, 6-10, Day 42 | |
| Part C-GSK2890457+Metformin | 1 | 2 | 1 | 1 | 1 | 0 | 4 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 0 | 2 | 1 | 2 | 2 | 2 | 4 | 2 | 1 | 2 | 2 | 1 | 4 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 1 | 0 | 1 |
| Part C-Placebo+Metformin | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as alanine aminotransferase (ALT) >=3 x upper limit of normal (ULN), and total bilirubin >=2 x ULN or international normalized ratio >1.5. (NCT01725126)
Timeframe: Up to Follow-up (8 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Any AE | Any SAE | Any Death | |
| Part A-GSK2890457 | 10 | 0 | 0 |
| Part A-Placebo | 3 | 0 | 0 |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition, associated with liver injury and impaired liver function defined as ALT >=3 x ULN, and total bilirubin >=2 x ULN or international normalized ratio >1.5. (NCT01725126)
Timeframe: Up to Follow-up (8 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Any AE | Any SAE | Any Death | |
| Part B-GSK2890457+Liraglutide | 3 | 0 | 0 |
| Part B-Placebo+Liraglutide | 1 | 0 | 0 |
| Part C-GSK2890457+Metformin | 3 | 0 | 0 |
| Part C-Placebo+Metformin | 3 | 0 | 0 |
During the assessment of body weight in the unit, the participant wore lightweight indoor clothing and removed shoes. The assessments were done pre-dose at Day -1, Day 1, Day 7, Day 14, Day 28, Day 42 and Day 43. Baseline value was defined as the average of Day -1 and Day 1 values. Change from Baseline was calculated by subtracting the Baseline value from the individual post-Baseline (Day 7, Day 14, Day 28 and Day 42) values. Percent change was calculated by multiplying the change from Baseline value with 100. If either the Baseline or post-Baseline value was missing, the change from Baseline was set to be missing. Day 42 value was the average of Day 42 and Day 43 values. (NCT01725126)
Timeframe: Baseline (Day -1 and Day 1) up to Day 42
| Intervention | Percent change (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 28 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 0.18 | -0.04 | 0.39 | -0.51 |
| Part B-Placebo+Liraglutide | -0.16 | 0.47 | 0.25 | -0.80 |
| Part C-GSK2890457+Metformin | 0.59 | 0.60 | 0.30 | 0.50 |
| Part C-Placebo+Metformin | 0.36 | 0.79 | 0.66 | -0.53 |
Blood samples were collected on Day -1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4 (pre-lunch), 5.5, 6, 8, 10 (pre-dinner), 11.5, 12, 14 and 24 hours post-dose. The time at which Cmax was observed was determined directly from the raw concentration-time data. (NCT01725126)
Timeframe: Day -1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4, 5.5, 6, 8, 10, 11.5, 12, 14 and 24 hours post-dose
| Intervention | Hours (Median) | |
|---|---|---|
| Day -1 | Day 42 | |
| Part B-GSK2890457+Liraglutide | 8.00 | 9.98 |
| Part B-Placebo+Liraglutide | 9.74 | 9.92 |
Blood samples were collected on Day 1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4 (pre-lunch), 5.5, 6, 8 and 10 (pre-dinner) hours post-dose. The time at which Cmax was observed was determined directly from the raw concentration-time data. (NCT01725126)
Timeframe: Day 1 and 42 at pre-dose (0 hour), 15 minutes, 30 minutes, 1, 1.5, 2, 4, 5.5, 6, 8 and 10 hours post-dose
| Intervention | Hours (Median) | |
|---|---|---|
| Day 1 | Day 42 | |
| Part A-GSK2890457 | 2.000 | 2.000 |
| Part A-Placebo | 3.010 | 4.000 |
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Canagliflozin 300 mg | -29.9 |
| Sitagliptin 100 mg | -5.85 |
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Canagliflozin 300 mg | -1.03 |
| Sitagliptin 100 mg | -0.66 |
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Canagliflozin 300 mg | -5.06 |
| Sitagliptin 100 mg | 0.85 |
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean percent change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Canagliflozin 300 mg | -2.5 |
| Sitagliptin 100 mg | 0.3 |
The table below shows the mean percent change in HDL-C from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Canagliflozin 300 mg | 7.6 |
| Sitagliptin 100 mg | 0.6 |
The table below shows the mean percent change in triglycerides from Baseline to Week 52 for each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the LS mean change. (NCT01137812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Canagliflozin 300 mg | 9.6 |
| Sitagliptin 100 mg | 11.9 |
The table below shows the percentage of patients with HbA1c <7% at Week 52 in each treatment group. The statistical analysis shows the treatment difference (ie, between canagliflozin and sitagliptin) in the percentage. (NCT01137812)
Timeframe: Week 52
| Intervention | Percentage of patients (Number) |
|---|---|
| Canagliflozin 300 mg | 47.6 |
| Sitagliptin 100 mg | 35.3 |
The table below shows the least-squares (LS) mean change in 2-hour post-prandial glucose from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo/Sitagliptin | -9.79 |
| Canagliflozin 100 mg | -47.9 |
| Canagliflozin 300 mg | -57.1 |
| Sitagliptin 100 mg | -49.3 |
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo/Sitagliptin | 2.47 |
| Canagliflozin 100 mg | -27.3 |
| Canagliflozin 300 mg | -37.8 |
| Sitagliptin 100 mg | -20.2 |
The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -26.2 |
| Canagliflozin 300 mg | -35.2 |
| Sitagliptin 100 mg | -17.7 |
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Placebo/Sitagliptin | -0.17 |
| Canagliflozin 100 mg | -0.79 |
| Canagliflozin 300 mg | -0.94 |
| Sitagliptin 100 mg | -0.82 |
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -0.73 |
| Canagliflozin 300 mg | -0.88 |
| Sitagliptin 100 mg | -0.73 |
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Placebo/Sitagliptin | 1.52 |
| Canagliflozin 100 mg | -3.84 |
| Canagliflozin 300 mg | -5.06 |
| Sitagliptin 100 mg | -1.83 |
The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -3.53 |
| Canagliflozin 300 mg | -4.65 |
| Sitagliptin 100 mg | -0.66 |
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Sitagliptin | -1.2 |
| Canagliflozin 100 mg | -3.7 |
| Canagliflozin 300 mg | -4.2 |
| Sitagliptin 100 mg | -1.2 |
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -3.8 |
| Canagliflozin 300 mg | -4.2 |
| Sitagliptin 100 mg | -1.3 |
The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Sitagliptin | 3.7 |
| Canagliflozin 100 mg | 10.4 |
| Canagliflozin 300 mg | 12.1 |
| Sitagliptin 100 mg | 5.0 |
The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | 11.2 |
| Canagliflozin 300 mg | 13.3 |
| Sitagliptin 100 mg | 6.0 |
The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 26
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Placebo/Sitagliptin | 3.2 |
| Canagliflozin 100 mg | 1.6 |
| Canagliflozin 300 mg | -1.4 |
| Sitagliptin 100 mg | 1.0 |
The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 52 for each active treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus sitagliptin) in the LS mean percent change. (NCT01106677)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | 1.9 |
| Canagliflozin 300 mg | 2.7 |
| Sitagliptin 100 mg | -0.4 |
The table below shows the percentage of patients with HbA1c <7% at Week 26 in each treatment group. The statistical analyses show the treatment differences between each canagliflozin or sitagliptin group and placebo. (NCT01106677)
Timeframe: Week 26
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo/Sitagliptin | 29.8 |
| Canagliflozin 100 mg | 45.5 |
| Canagliflozin 300 mg | 57.8 |
| Sitagliptin 100 mg | 54.5 |
(NCT01722266)
Timeframe: 12 weeks
| Intervention | grams (Mean) |
|---|---|
| Placebo | -13.4 |
| Liraglutide 1.8mg | -46.4 |
| Liraglutide 1.2mg | -47.6 |
| Liraglutide 0.6 mg | -23.7 |
(NCT01722266)
Timeframe: Baseline and 12 weeks
| Intervention | Kg (Mean) |
|---|---|
| Placebo | -0.3 |
| Liraglutide 1.8mg | -4.8 |
| Liraglutide 1.2mg | -5.0 |
| Liraglutide 0.6 mg | -2.7 |
(NCT01722266)
Timeframe: Baseline and 12 Weeks
| Intervention | Percent (Mean) |
|---|---|
| Placebo | -0.30 |
| Liraglutide 1.8mg | -0.42 |
| Liraglutide 1.2mg | -0.78 |
| Liraglutide 0.6 mg | -0.26 |
The primary endpoint of the study is to detect a difference from baseline in mean weekly blood glucose concentrations before and after 12 weeks of treatment in each of the Liraglutide groups. (NCT01722266)
Timeframe: 12 Weeks
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | 1 |
| Liraglutide 1.8mg | -10 |
| Liraglutide 1.2mg | -10 |
| Liraglutide 0.6 mg | -0.3 |
Total insulin dose = Basal insulin dose plus bolus insulin dose. (NCT01722266)
Timeframe: Baseline and 12 weeks
| Intervention | Units (Mean) |
|---|---|
| Placebo | -3.4 |
| Liraglutide 1.8mg | -10 |
| Liraglutide 1.2mg | -12.1 |
| Liraglutide 0.6 mg | -2.8 |
fasting blood glucose (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -1.6 |
| Metformin | -2.3 |
Fasting insulin (NCT00816907)
Timeframe: 16 weeks
| Intervention | mU/L (Mean) |
|---|---|
| Placebo | 5.5 |
| Metformin | 1.6 |
high-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -0.4 |
| Metformin | -0.6 |
glycosylated hemoglobin (NCT00816907)
Timeframe: 16 weeks
| Intervention | percent (Least Squares Mean) |
|---|---|
| Placebo | 0.01 |
| Metformin | -0.06 |
low-density lipoprotein (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | -2.0 |
| Metformin | -7.1 |
Total cholesterol (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 0.2 |
| Metformin | -8.9 |
serum triglycerides (NCT00816907)
Timeframe: 16 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Placebo | 13.2 |
| Metformin | -7.0 |
Mean difference in body weight change between participants assigned to metformin and participants assigned to placebo from baseline to last study visit (up to 16 weeks) (NCT00816907)
Timeframe: Measured at the last study visit
| Intervention | kilograms (Mean) |
|---|---|
| Placebo | -1.0 |
| Metformin | -3.0 |
"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00614120)
Timeframe: week 0, week 16
| Intervention | percentage point (%point) (Mean) |
|---|---|
| Lira 0.6 + Met | 15.3 |
| Lira 1.2 + Met | 17.8 |
| Lira 1.8 + Met | 21.7 |
| Glim + Met | 21.8 |
Change in body weight from baseline (week 0) to 16 weeks (end of treatment) (NCT00614120)
Timeframe: week 0, week 16
| Intervention | kg (Mean) |
|---|---|
| Lira 0.6 + Met | -1.8 |
| Lira 1.2 + Met | -2.3 |
| Lira 1.8 + Met | -2.4 |
| Glim + Met | 0.1 |
Change in fasting lipid profiles based on apolipoprotein B (Apo-B) from baseline (week 0) to 16 weeks (end of treatment). (NCT00614120)
Timeframe: week 0, week 16
| Intervention | g/L (Median) |
|---|---|
| Lira 0.6 + Met | 0.02 |
| Lira 1.2 + Met | 0.00 |
| Lira 1.8 + Met | -0.00 |
| Glim + Met | 0.01 |
Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 16 weeks (end of treatment). (NCT00614120)
Timeframe: week 0, week 16
| Intervention | percentage point of total HbA1c (Mean) |
|---|---|
| Lira 0.6 + Met | -1.0 |
| Lira 1.2 + Met | -1.3 |
| Lira 1.8 + Met | -1.4 |
| Glim + Met | -1.3 |
Change in self-measured fasting plasma glucose from baseline (week 0) to 16 weeks (end of treatment). Self-measurement of plasma glucose was performed using a glucose meter and subjects were instructed to record self-measured plasma glucose values into a diary. (NCT00614120)
Timeframe: week 0, week 16
| Intervention | mg/dL (Mean) |
|---|---|
| Lira 0.6 + Met | -1.83 |
| Lira 1.2 + Met | -1.96 |
| Lira 1.8 + Met | -2.28 |
| Glim + Met | -2.13 |
Summary of 7-Point Profiles of Self-Measured Plasma Glucose by Treatment, Week and Time. The 7 time points for self-measurements for all treatment groups were: Before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime, measured over 16 weeks of treatment (at week 0, 8, 12 and 16). (NCT00614120)
Timeframe: week 0, 8, 12 and 16
| Intervention | mg/dl (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 0 - Before breakfast | Week 0 - 90 minutes after breakfast | Week 0 - Before lunch | Week 0 - 90 minutes after lunch | Week 0 - Before dinner | Week 0 - 90 minutes after dinner | Week 0 - Bedtime | Week 8 - Before breakfast | Week 8 - 90 minutes after breakfast | Week 8 - Before lunch | Week 8 - 90 minutes after lunch | Week 8 - Before dinner | Week 8 - 90 minutes after dinner | Week 8 - Bedtime | Week 12 - Before breakfast | Week 12 - 90 minutes after breakfast | Week 12 - Before lunch | Week 12 - 90 minutes after lunch | Week 12 - Before dinner | Week 12 - 90 minutes after dinner | Week 12 - Bedtime | Week 16 - Before breakfast | Week 16 - 90 minutes after breakfast | Week 16 - Before lunch | Week 16 - 90 minutes after lunch | Week 16 - Before dinner | Week 16 - 90 minutes after dinner | Week 16 - Bedtime | |
| Glim + Met | 163.8 | 238.5 | 175.8 | 227.6 | 180.2 | 231.6 | 202.7 | 130.1 | 201.2 | 132.6 | 184.3 | 143.3 | 190.2 | 163.6 | 128.5 | 200.8 | 129.3 | 185.3 | 144.2 | 188.5 | 159.9 | 131.0 | 195.1 | 128.8 | 182.2 | 144.9 | 192.6 | 157.7 |
| Lira 0.6 + Met | 168.2 | 245.9 | 178.5 | 234.2 | 194.8 | 239.6 | 205.7 | 137.0 | 198.5 | 144.8 | 187.2 | 159.1 | 193.7 | 169.1 | 137.8 | 197.5 | 141.8 | 183.7 | 156.4 | 197.2 | 168.2 | 137.3 | 195.6 | 140.5 | 185.8 | 151.5 | 195.0 | 166.4 |
| Lira 1.2 + Met | 167.5 | 248.0 | 180.5 | 232.3 | 184.8 | 239.6 | 208.1 | 130.4 | 190.1 | 136.5 | 176.9 | 147.8 | 187.1 | 161.6 | 130.2 | 185.7 | 135.6 | 174.7 | 143.4 | 185.7 | 158.9 | 132.9 | 188.7 | 137.0 | 181.4 | 148.4 | 183.3 | 159.8 |
| Lira 1.8 + Met | 168.8 | 245.4 | 176.9 | 234.4 | 190.9 | 244.0 | 219.3 | 133.7 | 178.5 | 138.0 | 177.9 | 144.2 | 183.3 | 155.8 | 130.2 | 178.6 | 134.1 | 173.7 | 144.5 | 183.5 | 158.9 | 128.6 | 177.6 | 137.8 | 173.2 | 140.9 | 173.2 | 151.6 |
"Change in fasting lipid profiles from baseline (week 0) to 16 weeks (end of treatment). Fasting lipid profiles is based on:~Total Cholesterol (TC)~Low-density Lipoprotein-cholesterol (LDL-C)~Very Low-density Lipoprotein-cholesterol (VLDL-C)~High-density Lipoprotein-cholesterol (HDL-C)~Triglyceride (TG)~Free Fatty Acid (FFA)" (NCT00614120)
Timeframe: week 0, week 16
| Intervention | mmol/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Change in TC (Absolute), N=221, 216, 216, 228 | Change in LDL-C (Absolute), N=221, 216, 216, 228 | Change in VLDL-C (Absolute), N=213, 210, 207, 220 | Change in HDL-C (Absolute), N=217, 212, 212, 220 | Change in TG (Absolute), N=220, 212, 213, 226 | Change in FFA (Absolute), N=218, 214, 216, 227 | |
| Glim + Met | 0.02 | 0.04 | 0.05 | -0.01 | -0.07 | -0.02 |
| Lira 0.6 + Met | 0.06 | 0.06 | 0.03 | -0.02 | -0.08 | -0.03 |
| Lira 1.2 + Met | -0.01 | -0.03 | 0.05 | -0.05 | -0.06 | -0.04 |
| Lira 1.8 + Met | -0.03 | 0.00 | 0.01 | -0.05 | -0.22 | -0.10 |
Total number of hypoglycaemic episodes over 16 weeks of treatment occurring from baseline (week 0) to end of treatment (week 16). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00614120)
Timeframe: weeks 0-16
| Intervention | episodes (Number) | ||
|---|---|---|---|
| Major | Minor | Symptoms only | |
| Glim + Met | 2 | 80 | 86 |
| Lira 0.6 + Met | 0 | 6 | 12 |
| Lira 1.2 + Met | 0 | 0 | 11 |
| Lira 1.8 + Met | 0 | 5 | 9 |
(NCT00789191)
Timeframe: Week 0, Week 26
| Intervention | kg/m^2 (Mean) |
|---|---|
| Comb | -0.30 |
| Sita | -0.58 |
(NCT00789191)
Timeframe: Week 0, Week 26
| Intervention | kg (Mean) |
|---|---|
| Comb | -0.81 |
| Sita | -1.66 |
(NCT00789191)
Timeframe: Week 26
| Intervention | mmol/L (Mean) |
|---|---|
| Comb | 6.08 |
| Sita | 8.52 |
(NCT00789191)
Timeframe: Week 26
| Intervention | Percent (%) glycosylated haemoglobin (Mean) |
|---|---|
| Comb | 7.08 |
| Sita | 7.64 |
Overall: All episodes. Minor: Symptomatic, with PG < 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L (NCT00789191)
Timeframe: Weeks 0-26
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Overall | Minor | Symptoms Only | Unclassified | |
| Comb | 1 | 0 | 0 | 0 |
| Sita | 1 | 0 | 0 | 0 |
Day time: Episodes between 6 pm and 11 am. Overall: All episodes. Minor: Symptomatic, with PG < 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L (NCT00789191)
Timeframe: Weeks 0-26
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Overall | Minor | Symptoms Only | Unclassified | |
| Comb | 1 | 0 | 0 | 0 |
| Sita | 1 | 0 | 0 | 0 |
Night time: Episodes between 11 am and 6 pm. Overall: All episodes. Minor: Symptomatic, with PG < 3.1 mmol/L. Symptoms only: Symptomatic with PG ≥ 3.1 mmol/L (NCT00789191)
Timeframe: Weeks 0-26
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Overall | Minor | Symptoms Only | Unclassified | |
| Comb | 0 | 0 | 0 | 0 |
| Sita | 0 | 0 | 0 | 0 |
(NCT00789191)
Timeframe: Week 26
| Intervention | Subjects (Number) | |
|---|---|---|
| Target achieved | Target not achieved | |
| Comb | 20 | 83 |
| Sita | 11 | 95 |
Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia (NCT00789191)
Timeframe: Week 26
| Intervention | Subjects (Number) | |
|---|---|---|
| Target achieved | Target not achieved | |
| Comb | 15 | 88 |
| Sita | 8 | 98 |
(NCT00789191)
Timeframe: Week 26
| Intervention | Subjects (Number) | |
|---|---|---|
| Target achieved | Target not achieved | |
| Comb | 46 | 57 |
| Sita | 25 | 81 |
Symptomatic hypoglycaemia is biochemically confirmed hypoglycaemia or major hypoglycaemia (NCT00789191)
Timeframe: Week 26
| Intervention | Subjects (Number) | |
|---|---|---|
| Target achieved | Target not achieved | |
| Comb | 37 | 66 |
| Sita | 21 | 85 |
(NCT00789191)
Timeframe: Week 26
| Intervention | mmol/L (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Before breakfast | 120 minutes after start of breakfast | Before Lunch | 120 minutes after start of lunch | Before dinner | 120 minutes after start of dinner | Bedtime | At 03:00 A.M. | Before breakfast the following day | |
| Comb | 6.16 | 8.82 | 6.99 | 8.69 | 7.85 | 9.30 | 8.38 | 6.85 | 6.07 |
| Sita | 8.17 | 10.50 | 8.01 | 9.99 | 8.61 | 10.20 | 9.42 | 8.02 | 7.87 |
Calculated as an estimate of the mean change from baseline in Adiponectin at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mcg/mL (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 1.69 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 1.51 |
| Sita -> Sita | 1.35 |
Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | g/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.06 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.07 |
| Sita -> Sita | -0.05 |
Calculated as an estimate of the change from baseline in apolipoprotein B (ApoB) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | g/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.03 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.03 |
| Sita -> Sita | -0.03 |
"Calculated as an estimate of the mean change from baseline in beta-cell function at Week 26.~Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B)." (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | percentage point (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 27.23 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 28.70 |
| Sita -> Sita | 4.18 |
"Calculated as an estimate of the mean change from baseline in beta-cell function at Week 52.~Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B)." (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | percentage point (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 22.58 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 25.76 |
| Sita -> Sita | 3.98 |
Calculated as an estimate of the mean change from baseline in body weight at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -2.86 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -3.38 |
| Sita -> Sita | -0.96 |
Calculated as an estimate of the mean change from baseline in body weight at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -2.78 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -3.68 |
| Sita -> Sita | -1.16 |
Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.71 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0.07 |
| Sita -> Sita | -1.78 |
Calculated as an estimate of the mean change from baseline in diastolic blood pressure (DBP) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.53 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.87 |
| Sita -> Sita | -1.47 |
Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -1.87 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -2.14 |
| Sita -> Sita | -0.83 |
Calculated as an estimate of the mean change from baseline in fasting plasma glucose (FPG) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -1.71 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -2.04 |
| Sita -> Sita | -0.59 |
Calculated as an estimate of the mean change in fasting plasma glucose (FPG) from baseline to Week 78. (NCT00700817)
Timeframe: Week 0, Week 78
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -1.30 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -1.65 |
Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.03 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.07 |
| Sita -> Sita | -0.05 |
Calculated as an estimate of the change from baseline in free fatty acids (FFA) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.07 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.10 |
| Sita -> Sita | -0.06 |
Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | Percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -1.24 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -1.5 |
| Sita -> Sita | -0.9 |
Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | Percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -1.29 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -1.51 |
| Sita -> Sita | -0.88 |
Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 78. (NCT00700817)
Timeframe: Week 0, Week 78
| Intervention | Percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.94 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -1.28 |
Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 0.00 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0.00 |
| Sita -> Sita | 0.00 |
Calculated as an estimate of the mean change from baseline in high-density lipoprotein-cholesterol (HDL-C) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 0.01 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0.02 |
| Sita -> Sita | 0.01 |
Calculated as an estimate of the mean change from baseline in highly sensitive C-reactive protein (hsCRP) at week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mg/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -1.02 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.99 |
| Sita -> Sita | -0.66 |
Calculated as an estimate of the mean change from baseline in interleukin-6 (IL-6) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -1.70 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 1.71 |
| Sita -> Sita | 0.91 |
Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 0.08 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0.05 |
| Sita -> Sita | 0.13 |
Calculated as an estimate of the mean change in low-density lipoprotein-cholesterol (LDL-C) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 0.09 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0.09 |
| Sita -> Sita | 0.17 |
Calculated as an estimate of the mean change from baseline in N-terminal pro B-type Natriuretic Peptide (NT-proBNP) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | pmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 5.19 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 3.74 |
| Sita -> Sita | 3.71 |
The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 3.51 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 4.35 |
| Sita -> Sita | 2.96 |
The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 3.32 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 4.31 |
| Sita -> Sita | 2.96 |
Calculated as an estimate of the mean change from baseline in plasminogen activator inhibitor-1 (PAI-1) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | U/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -833 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -561 |
| Sita -> Sita | 586 |
Calculated as an estimate of the mean change from baseline in pulse at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | beats/minute (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 2.32 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 3.94 |
| Sita -> Sita | -0.64 |
Calculated as an estimate of the mean change from baseline in pulse at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 1.72 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 3.09 |
| Sita -> Sita | 0.09 |
Calculated as an estimate of the mean change from baseline in Systolic Blood Pressure (SBP) at Week 26 (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.55 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.72 |
| Sita -> Sita | -0.94 |
Calculated as an estimate of the mean change from baseline in systolic blood pressure (SBP) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.37 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -2.55 |
| Sita -> Sita | -1.03 |
Calculated as an estimate of the mean change from baseline in total cholesterol at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.03 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.17 |
| Sita -> Sita | -0.02 |
Calculated as an estimate of the mean change from baseline in total cholesterol at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.01 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.09 |
| Sita -> Sita | 0.03 |
Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.19 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.43 |
| Sita -> Sita | -0.40 |
Calculated as an estimate of the change from baseline in triglycerides (TG) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.10 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.32 |
| Sita -> Sita | -0.23 |
Calculated as an estimate of the mean change from baseline in Tumour Necrosis Factor Alpha (TNF-alpha) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | pg/mL (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.55 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.74 |
| Sita -> Sita | -0.53 |
Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 26. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.11 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.20 |
| Sita -> Sita | -0.15 |
Calculated as an estimate of the change from baseline in very low-density lipoprotein-cholesterol (VLDL-C) at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.11 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.19 |
| Sita -> Sita | -0.15 |
Calculated as an estimate of the mean change from baseline in von Willebrand Factor (vWf) at Week 26. vWf is a blood glycoprotein involved in haemostasis. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | percentage point (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -1.73 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -4.34 |
| Sita -> Sita | -1.8 |
Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 26 (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | cm (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -2.69 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -2.63 |
| Sita -> Sita | -1.12 |
Calculated as an estimate of the mean change from baseline in Waist Circumference at Week 52. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | participants (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -2.36 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -3.02 |
| Sita -> Sita | -1.23 |
Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 26. The measure is assessed as the circumference of the waist divided by the circumference of the hip. (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | cm/cm (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.01 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.01 |
| Sita -> Sita | -0.00 |
Calculated as an estimate of the mean change from baseline in Waist to Hip Ratio at Week 52. The measure is assessed as the circumference of the waist divided by the circumference of the hip. (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | cm/cm (Least Squares Mean) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | -0.00 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | -0.01 |
| Sita -> Sita | -0.00 |
Mean change in apolipoprotein B (ApoB) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmol/L (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | 0.23 |
| Sita -> Sita -> Lira 1.8 mg | 0.17 |
Mean change in beta-cell function from Week 52 to Week 78. Derived from fasting plasma glucose (FPG) and fasting insulin using the homeostatic model assessment (HOMA) method with the assumption that normal-weight subjects aged under 35 years have a 100% beta-cell function (HOMA-B). (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | percentage point (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | 13.31 |
| Sita -> Sita -> Lira 1.8 mg | 23.09 |
Mean change in body weight from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | kg (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -1.64 |
| Sita -> Sita -> Lira 1.8 mg | -2.48 |
Mean change in diastolic blood pressure (DBP) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmHg (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -0.60 |
| Sita -> Sita -> Lira 1.8 mg | 0.03 |
Mean change in fasting plasma glucose (FPG) Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmol/L (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -0.84 |
| Sita -> Sita -> Lira 1.8 mg | -1.42 |
Mean change in free fatty acids (FFA) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmol/L (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | 0.02 |
| Sita -> Sita -> Lira 1.8 mg | -0.01 |
Mean Change in Glycosylated Haemoglobin A1c (HbA1c) from Week 52 to Week 78 (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | Percentage point of total HbA1c (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -0.24 |
| Sita -> Sita -> Lira 1.8 mg | -0.45 |
Mean change in high-density lipoprotein-cholesterol (HDL-C) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmol/L (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | 0.02 |
| Sita -> Sita -> Lira 1.8 mg | -0.01 |
Mean change in low-density lipoprotein-cholesterol (LDL-C) from week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmol/L (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -0.22 |
| Sita -> Sita -> Lira 1.8 mg | -0.25 |
The Overall Treatment Satisfaction is a sum of 6 items from the Diabetes Treatment Satisfaction Questionnaire, which is a self-assessment of treatment satisfaction. The scale of each sub-item goes from 0 (lowest satisfaction) to 6 (highest satisfaction) and the overall scale of OTS therefore goes from 0 to 36. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | scores on a scale (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | 1.48 |
| Sita -> Sita -> Lira 1.8 mg | 0.98 |
Mean change in pulse from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | beats/minute (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | 0.90 |
| Sita -> Sita -> Lira 1.8 mg | 2.19 |
Mean change in systolic blood pressure (SBP) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmHg (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -2.12 |
| Sita -> Sita -> Lira 1.8 mg | 0.35 |
Mean change in total cholesterol from Week 52 to Week 78 (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmol/L (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -0.16 |
| Sita -> Sita -> Lira 1.8 mg | -0.24 |
Mean change in triglycerides (TG) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmol/L (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -0.20 |
| Sita -> Sita -> Lira 1.8 mg | -0.26 |
Mean change in very low-density lipoprotein-cholesterol (VLDL-C) from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | mmol/L (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | 0.03 |
| Sita -> Sita -> Lira 1.8 mg | 0.02 |
Mean change in Waist Circumference from Week 52 to Week 78. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | kg (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -1.33 |
| Sita -> Sita -> Lira 1.8 mg | -2.05 |
Mean change in Waist to Hip Ratio from Week 52 to Week 78. The measure is assessed as the circumference of the waist divided by the circumference of the hip. (NCT00700817)
Timeframe: Week 52, Week 78
| Intervention | cm/cm (Mean) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | -0.01 |
| Sita -> Sita -> Lira 1.8 mg | -0.00 |
Calculated as the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 26 (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | percentage of subjects (Number) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 43 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 55 |
| Sita -> Sita | 22 |
Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 52 (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | percentage of subjects (Number) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 50 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 63 |
| Sita -> Sita | 27 |
Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 78. Based on the extension 2 FAS. (NCT00700817)
Timeframe: Week 0, Week 78
| Intervention | percentage of subjects (Number) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | 49 |
| Sita -> Sita -> Lira 1.8 mg | 50 |
Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c < 7.0% at Week 78. Based on the FAS. (NCT00700817)
Timeframe: Week 0, Week 78
| Intervention | percentage of subjects (Number) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 35 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 51 |
Calculated as the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 26 (NCT00700817)
Timeframe: Week 0, Week 26
| Intervention | percentage of subjects (Number) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 23 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 36 |
| Sita -> Sita | 12 |
Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 52 (NCT00700817)
Timeframe: Week 0, Week 52
| Intervention | percentage of subjects (Number) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 24 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 40 |
| Sita -> Sita | 17 |
Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 78. Based on the extension 2 FAS. (NCT00700817)
Timeframe: Week 0, Week 78
| Intervention | percentage of subjects (Number) |
|---|---|
| Sita -> Sita -> Lira 1.2 mg | 29 |
| Sita -> Sita -> Lira 1.8 mg | 25 |
Calculated as an estimate of the percentage of subjects achieving treatment target of HbA1c =< 6.5% at Week 78. Based on the FAS. (NCT00700817)
Timeframe: Week 0, Week 78
| Intervention | percentage of subjects (Number) |
|---|---|
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 12 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 27 |
Number of hypoglycaemic episodes from Week 52 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Week 52-78
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Major | Minor | Symptoms only | Unclassified | |
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 1 | 12 | 3 | 0 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0 | 5 | 11 | 0 |
| Sita -> Sita -> Lira 1.2 mg | 0 | 3 | 1 | 0 |
| Sita -> Sita -> Lira 1.8 mg | 0 | 6 | 0 | 0 |
Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-26
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Major | Minor | Symptoms only | Unclassified | |
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 1 | 17 | 12 | 0 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0 | 16 | 15 | 1 |
| Sita -> Sita | 0 | 11 | 10 | 0 |
Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-52
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Major | Minor | Symptoms only | Unclassified | |
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 1 | 24 | 14 | 0 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0 | 28 | 29 | 1 |
| Sita -> Sita | 0 | 25 | 12 | 0 |
Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-78
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Major | Minor | Symptoms only | Unclassified | |
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 2 | 36 | 18 | 0 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0 | 33 | 40 | 1 |
| Sita -> Sita | 0 | 34 | 13 | 0 |
Number of hypoglycaemic episodes from Week 0 to Week 26, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-26
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Major | Minor | Symptoms only | Unclassified | |
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 1 | 17 | 12 | 0 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0 | 37 | 15 | 1 |
| Sita -> Sita | 0 | 11 | 10 | 0 |
Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-52
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Major | Minor | Symptoms only | Unclassified | |
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 1 | 24 | 14 | 0 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0 | 51 | 29 | 1 |
| Sita -> Sita | 0 | 25 | 12 | 0 |
Number of hypoglycaemic episodes from Week 0 to Week 78, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00700817)
Timeframe: Weeks 0-78
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| Major | Minor | Symptoms only | Unclassified | |
| Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg | 2 | 36 | 18 | 0 |
| Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg | 0 | 56 | 40 | 1 |
| Sita -> Sita | 0 | 34 | 13 | 0 |
Value at 6 months minus value at baseline. Fibrinogen is a hepatic-derived factor directly involved in clotting and in the viscosity characteristics of blood flow. It binds to platelets and contributes to their aggregation, promotes fibrin formation and is also an acute phase reactant that is increased in inflammatory states. Fibrinogen concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA). (NCT00139477)
Timeframe: Baseline and 6 months
| Intervention | mg/dL (Median) |
|---|---|
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal) | 58.5 |
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal) | -105 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal) | 0.00 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal) | -33 |
Value at 6 months minus value at baseline. HsCRP is an acute phase protein which is a sensitive marker for systemic inflammation. HsCRP concentrations were measured in our laboratory by immuno-nephelometry (Siemens Healthcare Diagnostics, Deerfield IL, USA), with an hsCRP lower sensitivity of 0.156 mg/L. (NCT00139477)
Timeframe: Baseline and 6 months
| Intervention | mg/dL (Median) |
|---|---|
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal) | -0.37 |
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal) | -1.78 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal) | -0.29 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal) | 0.00 |
Value at 6 months minus value at baseline. IL-6 is a pro-inflammatory cytokine thought to produce a state of low-grade inflammation in obese individuals. IL-6 stimulates hepatic production of C-reactive protein (CRP), an acute phase protein which is a sensitive marker for systemic inflammation. IL-6 was measured by enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN, USA). (NCT00139477)
Timeframe: Baseline and 6 months
| Intervention | pg/mL (Median) |
|---|---|
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal) | -0.66 |
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal) | -0.99 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal) | 0.2 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal) | -0.35 |
Value at 6 months minus value at baseline. PAI-1 is the primary physiological inhibitor of fibrinolysis and proteolysis. High PAI-1 levels have been linked to thrombosis and fibrosis, insulin resistance and obesity. PAI-1 was measured by ELISA (American Diagnostica, Stamford, CT, USA). (NCT00139477)
Timeframe: Baseline and 6 months
| Intervention | ng/ML (Median) |
|---|---|
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Prepubertal) | 6.98 |
| Diet/Exercise, Then Diet/Exercise Plus Metformin (Pubertal) | -46.84 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Prepubertal) | 0.55 |
| Diet/Exercise Plus Metformin, Then Diet/Exercise (Pubertal) | -34.42 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
The table below shows the mean absolute change in body weight from Baseline to Week 12 for each treatment group. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
| Intervention | kg (Mean) |
|---|---|
| Placebo | -0.78 |
| Canagliflozin 50 mg Daily | -1.96 |
| Canagliflozin 100 mg Daily | -2.25 |
| Canagliflozin 200 mg Daily | -2.32 |
| Canagliflozin 300 mg Daily | -2.88 |
| Canagliflozin 300 mg Twice Daily | -2.87 |
| Sitagliptin 100 mg Daily | -0.43 |
The table below shows the mean change in FPG from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
| Intervention | mmol/L (Mean) |
|---|---|
| Placebo | 0.2 |
| Canagliflozin 50 mg Daily | -0.9 |
| Canagliflozin 100 mg Daily | -1.4 |
| Canagliflozin 200 mg Daily | -1.5 |
| Canagliflozin 300 mg Daily | -1.4 |
| Canagliflozin 300 mg Twice Daily | -1.3 |
| Sitagliptin 100 mg Daily | -0.7 |
The table below shows the mean change in HbA1c from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
| Intervention | Percent (Mean) |
|---|---|
| Placebo | -0.22 |
| Canagliflozin 50 mg Daily | -0.79 |
| Canagliflozin 100 mg Daily | -0.76 |
| Canagliflozin 200 mg Daily | -0.70 |
| Canagliflozin 300 mg Daily | -0.92 |
| Canagliflozin 300 mg Twice Daily | -0.95 |
| Sitagliptin 100 mg Daily | -0.74 |
The table below shows the mean change in overnight urine glucose/creatinine ratio from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
| Intervention | mg/mg (Mean) |
|---|---|
| Placebo | 1.9 |
| Canagliflozin 50 mg Daily | 35.4 |
| Canagliflozin 100 mg Daily | 51.5 |
| Canagliflozin 200 mg Daily | 50.5 |
| Canagliflozin 300 mg Daily | 49.4 |
| Canagliflozin 300 mg Twice Daily | 61.6 |
| Sitagliptin 100 mg Daily | -1.9 |
The table below shows the mean percent change in body weight from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12
| Intervention | Percent change (Mean) |
|---|---|
| Placebo | -1.1 |
| Canagliflozin 50 mg Daily | -2.3 |
| Canagliflozin 100 mg Daily | -2.6 |
| Canagliflozin 200 mg Daily | -2.7 |
| Canagliflozin 300 mg Daily | -3.4 |
| Canagliflozin 300 mg Twice Daily | -3.4 |
| Sitagliptin 100 mg Daily | -0.6 |
The table below shows the percentage of patients who experienced symptomatic hypoglycemic events between Baseline and Week 12. (NCT00642278)
Timeframe: Up to Week 12
| Intervention | Percentage of patients (Number) |
|---|---|
| Placebo | 2 |
| Canagliflozin 50 mg Daily | 0 |
| Canagliflozin 100 mg Daily | 2 |
| Canagliflozin 200 mg Daily | 6 |
| Canagliflozin 300 mg Daily | 0 |
| Canagliflozin 300 mg Twice Daily | 3 |
| Sitagliptin 100 mg Daily | 5 |
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 104
| Intervention | percentage point (%point) (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | 64.48 |
| Lira 1.2 + Met | 27.30 |
| Lira 1.8 + Met | 17.81 |
| Met Mono | -7.89 |
| Met + Glim | 11.25 |
"Change in beta cell function from baseline (week 0) to 16 weeks (end of treatment). Beta-cell function was derived from fasting plasma glucose (FPG) and fasting insulin concentrations using the homeostasic model assessment (HOMA) method which uses the assumption that normal-weight normal subjects aged under 35 years have a 100% beta-cell function (HOMA-B).~Beta-cell function: HOMA-B (%) = 20∙fasting insulin[uU/mL] divided by (FPG mmol/L]-3.5)." (NCT00318461)
Timeframe: week 0, week 26
| Intervention | percentage point (%point) (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | 20.45 |
| Lira 1.2 + Met | 20.33 |
| Lira 1.8 + Met | 26.12 |
| Met Mono | -1.63 |
| Met + Glim | 24.68 |
Change in body weight from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -2.07 |
| Lira 1.2 + Met | -3.03 |
| Lira 1.8 + Met | -2.91 |
| Met Mono | -1.80 |
| Met + Glim | 0.70 |
Change in body weight from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26
| Intervention | kg (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.78 |
| Lira 1.2 + Met | -2.58 |
| Lira 1.8 + Met | -2.79 |
| Met Mono | -1.51 |
| Met + Glim | 0.95 |
Change in Fasting plasma glucose (FPG) from baseline (week 0) to 104 weeks (end of treatment) (NCT00318461)
Timeframe: week 0, week 104
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.80 |
| Lira 1.2 + Met | -1.20 |
| Lira 1.8 + Met | -1.18 |
| Met Mono | 0.75 |
| Met + Glim | -0.64 |
Change in fasting plasma glucose (FPG) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.13 |
| Lira 1.2 + Met | -1.63 |
| Lira 1.8 + Met | -1.68 |
| Met Mono | 0.40 |
| Met + Glim | -1.31 |
Change in glycosylated A1c (HbA1c) baseline (week 0) to 104 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 104
| Intervention | percentage of total haemoglobin (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.36 |
| Lira 1.2 + Met | -0.56 |
| Lira 1.8 + Met | -0.58 |
| Met Mono | 0.25 |
| Met + Glim | -0.50 |
Percentage point change in Glycosylated A1c (HbA1c) from baseline (week 0) to 26 weeks (end of randomisation) (NCT00318461)
Timeframe: week 0, week 26
| Intervention | Percentage point of total HbA1c (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.69 |
| Lira 1.2 + Met | -0.97 |
| Lira 1.8 + Met | -1.00 |
| Met Mono | 0.09 |
| Met + Glim | -0.98 |
Change in mean post prandial plasma glucose from baseline (Week 0) to 104 weeks (end of treatment) The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 104
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.59 |
| Lira 1.2 + Met | -2.22 |
| Lira 1.8 + Met | -2.10 |
| Met Mono | -0.43 |
| Met + Glim | -1.80 |
Change in mean post prandial plasma glucose from baseline (Week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime. Mean post prandial plasma glucose were calculated as the sum of the post pradial plasma glucose values divided by three. (NCT00318461)
Timeframe: week 0, week 26
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -1.68 |
| Lira 1.2 + Met | -2.33 |
| Lira 1.8 + Met | -2.57 |
| Met Mono | -0.62 |
| Met + Glim | -2.46 |
"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 104 weeks (end of treatment). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 104
| Intervention | mmol/L (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.27 |
| Lira 1.2 + Met | -0.56 |
| Lira 1.8 + Met | -0.44 |
| Met Mono | -0.20 |
| Met + Glim | -0.29 |
"Change in mean prandial increments of plasma glucose based on self-measured 7-point plasma glucose profiles from baseline (week 0) to 26 weeks (end of randomisation). The 7 time points for self-measurements were: before each meal (breakfast, lunch and dinner), at 90 min after start of each meal (breakfast, lunch and dinner) and at bedtime.~Mean prandial increments of plasma glucose were calculated as the sum of the plasma glucose differences between values measured before and after a meal (breakfast, lunch and dinner) divided by three." (NCT00318461)
Timeframe: week 0, week 26
| Intervention | mmol/l (Least Squares Mean) |
|---|---|
| Lira 0.6 + Met | -0.23 |
| Lira 1.2 + Met | -0.40 |
| Lira 1.8 + Met | -0.56 |
| Met Mono | -0.44 |
| Met + Glim | -0.44 |
Total number of hypoglycaemic episodes occuring after baseline (week 0) until 104 weeks (end of treatment). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-104
| Intervention | episodes (Number) | |||
|---|---|---|---|---|
| All | Major | Minor | Symptoms only | |
| Lira 0.6 + Met | 52 | 0 | 23 | 29 |
| Lira 1.2 + Met | 51 | 1 | 26 | 24 |
| Lira 1.8 + Met | 49 | 0 | 22 | 27 |
| Met + Glim | 524 | 0 | 284 | 240 |
| Met Mono | 18 | 0 | 6 | 12 |
Total number of hypoglycaemic episodes occuring after baseline (week 0) until week 26 (end of randomisation). Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00318461)
Timeframe: weeks 0-26
| Intervention | episodes (Number) | ||
|---|---|---|---|
| Major | Minor | Symptoms only | |
| Lira 0.6 + Met | 0 | 15 | 17 |
| Lira 1.2 + Met | 0 | 3 | 7 |
| Lira 1.8 + Met | 0 | 9 | 22 |
| Met + Glim | 0 | 136 | 175 |
| Met Mono | 0 | 6 | 10 |
Mean decrease between pre- and post-randomization in 5 Weeks between the exenatide and placebo groups. (NCT00856609)
Timeframe: 5 weeks
| Intervention | kg (Mean) |
|---|---|
| Exenatide | 1.6 |
| Placebo | 0.27 |
Mean of 3-day food intake change between 3 days (Day 6-7-8) at baseline assessment and 3 days (Day 12-13-14) during the intervention period between the exenatide and placebo groups (NCT00856609)
Timeframe: Day 6-7-8 (at baseline) and Day 12-13-14 (3 days after starting study intervention)
| Intervention | kcal/day (Mean) |
|---|---|
| Exenatide | 1016.1 |
| Placebo | 245.1 |
Change of twenty-four-hour energy expenditure between at Day 5 at baseline assessment and at Day 11 two days after starting study medication between the exenatide and placebo groups (NCT00856609)
Timeframe: Day 5 and Day 11
| Intervention | kcal/day (Mean) |
|---|---|
| Exenatide | 51.6 |
| Placebo | 28.9 |
(NCT00529204)
Timeframe: 24 weeks
| Intervention | IU (Number) |
|---|---|
| Exenatide | 61 |
(NCT00529204)
Timeframe: 24 weeks
| Intervention | adverse events (Number) |
|---|---|
| Exenatide | 0 |
"Steatosis was grades on a scale of 0 (< 5%); 1 (5%- 33%); 2 (> 33% - 66%); and 3 (> 66%).~Inflammation was graded on a scale of 0 (No foci); 1 (< 2 foci per 200 X field); 2 (2-4 foci per 200 X field); and 3 (>4 foci per 200 X field) Fibrosis was graded on a scale of 0 (None); 1 (Mild periportal or perisinusoidal); 2 (Moderate periportal or perisinusoidal); 3 (Bridging fibrosis); and 4 (cirrhosis)" (NCT00529204)
Timeframe: 24 weeks
| Intervention | units on a scale (Number) | ||
|---|---|---|---|
| steatosis | inflammation | fibrosis | |
| Exenatide | -1 | -1 | 0 |
Change from baseline in Adiponectin after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | µg/mL (Mean) |
|---|---|
| Metformin | -0.71 |
| Placebo | -7.52 |
Change from baseline in Body Mass Index after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | kg/m^2 (Mean) |
|---|---|
| Metformin | -0.74 |
| Placebo | -0.71 |
Change from baseline in Fasting insulin after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | µU/mL (Mean) |
|---|---|
| Metformin | -3.97 |
| Placebo | 11.03 |
Change from baseline in Fasting plasma glucose after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin | -1.08 |
| Placebo | 1.71 |
Change from baseline in High-sensitivity C-reactive protein after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Metformin | -1.26 |
| Placebo | -1.35 |
Change from baseline in Interleukin 6 after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Metformin | -34.09 |
| Placebo | 16.42 |
Change from baseline in Tumour necrosis factor alpha after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | pg/mL (Mean) |
|---|---|
| Metformin | -34.08 |
| Placebo | -4.01 |
Change from baseline in Waist circumference after 3 months of treatment. (NCT01410604)
Timeframe: baseline and 3 months
| Intervention | cm (Mean) |
|---|---|
| Metformin | -0.57 |
| Placebo | -3.29 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | mmHg (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -0.47 |
| Delayed Intervention | -1.07 |
Change in sugar level as measured from fingerstick, at 6 Months as compared to Baseline (NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | mg/dL (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -1.79 |
| Delayed Intervention | -0.47 |
Change in sugar level as measured from fingerstick after a meal, at 6 Months as compared to Baseline (NCT01004848)
Timeframe: Change in 6 Months from Baseline
| Intervention | mg/dL (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | 1.41 |
| Delayed Intervention | 3.85 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | mmHg (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -1.39 |
| Delayed Intervention | -1.45 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | pounds (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -2.85 |
| Delayed Intervention | -1.13 |
percent energy expenditure (NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | percent expenditure/day (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -58.08 |
| Delayed Intervention | -12.54 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | grams per day (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -0.19 |
| Delayed Intervention | 0.013 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | percent change (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | 0.03 |
| Delayed Intervention | 1.20 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | mg/dl (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | 0.68 |
| Delayed Intervention | .029 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | mg/dl (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -2.93 |
| Delayed Intervention | -1.18 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | mg/dl (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -2.78 |
| Delayed Intervention | -0.66 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | mg/dl (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -0.1 |
| Delayed Intervention | 2.92 |
(NCT01004848)
Timeframe: Change from Baseline to 6 Months
| Intervention | inches (Mean) |
|---|---|
| Peer-Led Lifestyle Education on Weight Loss | -0.5 |
| Delayed Intervention | -0.29 |
(NCT00409786)
Timeframe: Baseline and 1 year
| Intervention | kg (Mean) |
|---|---|
| Group 1 | -4.79 |
A secondary outcome for this study will be change in diastolic blood pressure, measured pre and post intervention. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | mmHg (Mean) |
|---|---|
| GLB Group | -3.6 |
| GLB DVD | -1.43 |
A secondary outcome for this study will be change in fasting glucose, measured pre and post intervention. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | mg/dl (Mean) |
|---|---|
| GLB Group | 1.15 |
| GLB DVD | -4.71 |
A secondary outcome for this study will be change in HDL cholesterol, measured pre and post intervention. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | mg/dl (Mean) |
|---|---|
| GLB Group | -2.08 |
| GLB DVD | -0.72 |
A secondary outcome for this study will be change in HbA1c, measured pre and post intervention. The hemoglobin HbA1c test provides information regarding how well blood glucose (sugar) has been controlled for the previous 8-12 weeks.. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| GLB Group | -0.31 |
| GLB DVD | -0.16 |
A secondary outcome for this study will be change in LDL cholesterol, measured pre and post intervention. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | mg/dl (Mean) |
|---|---|
| GLB Group | 0.33 |
| GLB DVD | -2.67 |
A secondary outcome for this study will be change in systolic blood pressure, measured pre and post intervention. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | mmHg (Mean) |
|---|---|
| GLB Group | -6.55 |
| GLB DVD | -4.95 |
A secondary outcome for this study will be change in total cholesterol, measured pre and post intervention. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | mg/dl (Mean) |
|---|---|
| GLB Group | -8.29 |
| GLB DVD | -9.94 |
A secondary outcome for this study will be change in Triglyceride level, measured pre and post intervention. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | mg/dl (Median) |
|---|---|
| GLB Group | -2.0 |
| GLB DVD | 0 |
A secondary outcome for this study will be change in waist circumference, measured pre and post intervention. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | inches (Mean) |
|---|---|
| GLB Group | -2.49 |
| GLB DVD | -1.87 |
The primary outcome for this study will be change in weight measured pre and post intervention. (NCT00480779)
Timeframe: Baseline and 3 months
| Intervention | pounds (Mean) |
|---|---|
| GLB Group | -13.9 |
| GLB DVD | -11.8 |
(NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | meters / second (Mean) |
|---|---|
| Placebo | -7.2 |
| Metformin | -7.3 |
to evaluate improvement in endothelial function (NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | percentage change in diameter (Mean) |
|---|---|
| Placebo | 8.8 |
| Metformin | 10.5 |
Homeostatic Model Assessment of insulin sensitivity (NCT00105066)
Timeframe: 4.5 months
| Intervention | HOMA Score (Mean) |
|---|---|
| Placebo | 57.4 |
| Metformin | 64.5 |
(NCT03042936)
Timeframe: 16 weeks
| Intervention | A1c percentage points (Median) |
|---|---|
| Insulin Superheroes Club Curriculum | -0.5 |
Estimated maximal oxygen consumption (VO2 max) standardized to age and sex (NCT01616563)
Timeframe: Change at 12 months compared to baseline
| Intervention | percentile (Mean) |
|---|---|
| Diet and Exercise Intervention | 15.6 |
Canadian Health Eating Index (HEI-C) is reported on a 100 point score with a higher score indicating a better outcome. A higher score means a better outcome. HEI-C is on a 100 point score. (NCT01616563)
Timeframe: Change at 12 months compared to baseline
| Intervention | score on a scale out of 100 (Mean) |
|---|---|
| Diet and Exercise Intervention | 9.6 |
Mediterranean Diet Score (MDS) is reported on a 0-14 point score with a higher score indicating a better outcome. (NCT01616563)
Timeframe: Change at 12 months compared to baseline
| Intervention | score on a scale out of 14 (Mean) |
|---|---|
| Diet and Exercise Intervention | 1.4 |
Metabolic syndrome risk score is a composite continuous score that measures the severity of metabolic syndrome as a continuous variable rather than dichotomized with arbitrary cut-points . The score is the principal component of waist circumference, glucose, systolic blood pressure, triglycerides. It has a mean of 0 and a standard deviation of 1 with higher score meaning greater risk. Reference Hillier TA, et al., Practical way to assess metabolic syndrome using a continuous score obtained from principal components analysis. Diabetologia (2006) 49:1528-1535 (NCT01616563)
Timeframe: Change at 12 months compared to baseline
| Intervention | z-score (Mean) |
|---|---|
| Diet and Exercise Intervention | 0.4 |
Changes in PROCAM score, which estimates the risk of a myocardial infarction or dying from an acute coronary event within the next 10 years. Similar to Framingham risk score but for metabolic syndrome. A lower score means a better outcome. PROCAM score varies from 0-87,0 means there are no risk factors (pt is younger than 39), while 87 means the patient is a smoker and older than 60 years and presents all risk factors (NCT01616563)
Timeframe: Change at 12 months compared to baseline
| Intervention | percentage (Mean) |
|---|---|
| Diet and Exercise Intervention | 1.4 |
Percentage of the prescribed diet visits visits attended over 12 months. Each participant was to attend a total of 21 prescribed diet visits over 12 months. (NCT01616563)
Timeframe: At 12 months
| Intervention | prescribed diet visits (Count of Units) |
|---|---|
| Diet and Exercise Intervention | 4782 |
Percentage of the prescribed exercise visits attended over 12 months. Each participant was to attend a total of 21 prescribed exercise visits over 12 months. (NCT01616563)
Timeframe: At 12 months
| Intervention | prescribed exercise visits (Count of Units) |
|---|---|
| Diet and Exercise Intervention | 4038 |
Metabolic syndrome is defined as having 3/5 of the following: elevated blood pressure (or on medication), elevated blood sugars (or on medication), elevated triglycerides (or on medication), low HDL-C and a large waist circumference. Reversal of metabolic syndrome is defined as having less than 3/5 criteria (NCT01616563)
Timeframe: At 12 months compared to baseline measures
| Intervention | Participants (Count of Participants) |
|---|---|
| Diet and Exercise Intervention | 48 |
Improvements in blood pressure (or elimination of medication), blood sugars (or elimination of medication), triglycerides (or elimination of medication), HDL-C and waist circumference (NCT01616563)
Timeframe: At 12 months compared to baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Diet and Exercise Intervention | 106 |
108 reviews available for metformin and Weight Loss
| Article | Year |
|---|---|
Postpartum Use of Weight Loss and Metformin for the Prevention of Type 2 Diabetes Mellitus: a Review of the Evidence.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Metformin; Postpartum Period; Preg | 2021 |
Obesity and Diabetes.
Topics: Behavior Therapy; Body Mass Index; Diabetes Mellitus, Type 2; Exercise; Gastric Bypass; Humans; Hypo | 2021 |
Integrated or Independent Actions of Metformin in Target Tissues Underlying Its Current Use and New Possible Applications in the Endocrine and Metabolic Disorder Area.
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Female; Gluconeogenesis; Humans; Hypoglyc | 2021 |
Pharmacology: Non-Insulin Agents.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Metformin; | 2022 |
Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Child; Exenatide; Humans; Liraglutide; Metformin; Obesity; Orlistat | 2022 |
Neglecting regression to the mean continues to lead to unwarranted conclusions: Letter regarding "The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic | 2019 |
Management of obesity in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Female; Humans; Hyperandrogenism; Insulin Resistance; Life Style; Metformin; Pediatric O | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
Topics: Adult; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; | 2020 |
Pharmacotherapeutic options for prediabetes.
Topics: Diabetes Mellitus, Type 2; Glucose Intolerance; Humans; Hypoglycemic Agents; Life Style; Metformin; | 2021 |
GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin.
Topics: Case-Control Studies; Diabetes Mellitus; Gene Expression Regulation; Growth Differentiation Factor 1 | 2020 |
Pharmacological and non-pharmacological strategies for obese women with subfertility.
Topics: Abortion, Spontaneous; Appetite Depressants; Bias; Carnitine; Clomiphene; Dexfenfluramine; Drug Ther | 2021 |
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
Topics: Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Heart Disease Risk Factors; Humans; Hypoglycemi | 2021 |
Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycem | 2021 |
Treatment of type 2 diabetes in children: what are the specific considerations?
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liraglutide; Metformin; W | 2021 |
Insulin sensitizers in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Age Factors; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Pr | 2017 |
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; | 2018 |
Optimizing diabetes treatment in the presence of obesity.
Topics: Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Receptor; Gly | 2017 |
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins | 2018 |
Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.
Topics: Bariatric Surgery; Diet Therapy; Diuretics; Exercise Therapy; Female; Gout; Humans; Hypoglycemic Age | 2017 |
Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Pep | 2017 |
Prediabetes in Colombia: Expert Consensus.
Topics: Cardiovascular Diseases; Colombia; Consensus; Diabetes Mellitus, Type 2; Disease Progression; Humans | 2017 |
Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Comb | 2018 |
The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Cell Line, Tumor; Clinical Trials as Topic; Cogniti | 2019 |
Body Weight Considerations in the Management of Type 2 Diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2019 |
Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review.
Topics: Adult; Body Mass Index; Body Weight; Child; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2018 |
Metformin: Mechanisms in Human Obesity and Weight Loss.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gastrointestinal Microbiome; Huma | 2019 |
Once weekly exenatide: efficacy, tolerability and place in therapy.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Drug Administration | 2013 |
Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss.
Topics: Body Mass Index; Caloric Restriction; Evidence-Based Medicine; Exercise; Female; Humans; Hypoglycemi | 2013 |
The effect of antiobesity drugs on waist circumference: a mixed treatment comparison.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Combined Modality Therapy; Drug Administration S | 2014 |
Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients.
Topics: Abscess; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bandages; Biofilms; Combined Modality Ther | 2013 |
[SGLT-2 inhibitors: diabetes treatment by glycosuria; literature review on the effect of dapagliflozin].
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated He | 2013 |
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
Topics: Bariatric Surgery; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Me | 2014 |
Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome.
Topics: Androgen Antagonists; Androgens; Bariatric Surgery; Female; Hair Removal; Hirsutism; Humans; Metform | 2014 |
Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger.
Topics: Adolescent; Body Mass Index; Child; Humans; Hypoglycemic Agents; Metformin; Pediatric Obesity; Rando | 2014 |
Endocrine basis for recurrent pregnancy loss.
Topics: Abortion, Habitual; Female; Humans; Hyperinsulinism; Hyperprolactinemia; Hypoglycemic Agents; Lutein | 2014 |
Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-analysis.
Topics: Acarbose; Asian People; Diabetes Mellitus, Type 2; Female; Humans; Hyperglycemia; Hypoglycemic Agent | 2014 |
Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Topics: Adiposity; Animals; Caloric Restriction; Comorbidity; Exercise; Female; Humans; Hypoglycemic Agents; | 2014 |
Effects of metformin on weight loss: potential mechanisms.
Topics: Appetite Depressants; Diabetes Mellitus, Type 2; Eating; Humans; Hypoglycemic Agents; Hypothalamus; | 2014 |
What are the pharmacotherapy options for treating prediabetes?
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance | 2014 |
Obesity and polycystic ovary syndrome.
Topics: Adipokines; Bariatric Surgery; Combined Modality Therapy; Comorbidity; Diet, Reducing; Exercise Ther | 2015 |
[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Adm | 2014 |
Sex-specific differences in diabetes prevention: a systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Hypoglycemic Agents; Male; Metformin | 2015 |
Metformin: the past, presence, and future.
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; | 2015 |
Novel strategies in the management of polycystic ovary syndrome.
Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Female; Fertility Agents, Female; Fertilization i | 2015 |
User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combination; En | 2015 |
Obesity and cancer: mechanistic insights from transdisciplinary studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Caloric R | 2015 |
Mechanisms of obesity in the development of breast cancer.
Topics: Adipocytes; Adipose Tissue; Animals; Anti-Inflammatory Agents; Breast Neoplasms; Disease Progression | 2015 |
Metformin: an Old Therapy that Deserves a New Indication for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metformin; Neoplasms; Obesi | 2016 |
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug | 2016 |
Hepatic manifestations of women with polycystic ovary syndrome.
Topics: Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Contraceptives, Oral, Hormo | 2016 |
Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.
Topics: Anti-Obesity Agents; Body Mass Index; Child; Directive Counseling; Exenatide; Humans; Hypoglycemic A | 2016 |
EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Topics: Animals; Bariatric Surgery; Bile Acids and Salts; Cholecystokinin; Diabetes Mellitus, Type 2; Gastri | 2016 |
Current and emerging therapies in nonalcoholic fatty liver disease.
Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type | 2009 |
PCOS and infertility.
Topics: Clomiphene; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic A | 2008 |
PCOS.
Topics: Diabetes Mellitus, Type 2; Flutamide; Hair Removal; Hirsutism; Humans; Metformin; Polycystic Ovary S | 2009 |
Diabetes medications and body weight.
Topics: Abdominal Fat; Benzamides; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipepti | 2009 |
Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insuli | 2009 |
Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis.
Topics: Adult; Antipsychotic Agents; Child; Humans; Hypoglycemic Agents; Metformin; Racial Groups; Weight Ga | 2011 |
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
Topics: Amyloid; Bariatric Surgery; Diabetes Mellitus; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; E | 2010 |
[GLP-1: a new therapeutic principle for the treatment of type 2 diabetes mellitus].
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptid | 2010 |
Adjunct therapy for type 1 diabetes mellitus.
Topics: Amyloid; Carbohydrate Metabolism; Diabetes Mellitus, Type 1; Digestion; Drug Therapy, Combination; E | 2010 |
Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Toleranc | 2010 |
The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review.
Topics: Antipsychotic Agents; Blood Glucose; Body Weight; Humans; Hypoglycemic Agents; Metformin; Obesity; O | 2010 |
Liraglutide for the treatment of type 2 diabetes.
Topics: Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, | 2011 |
Weight beneficial treatments for type 2 diabetes.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insuli | 2011 |
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Topics: Biopsy; Databases, Bibliographic; Diagnosis, Differential; Fatty Liver; Humans; Hypoglycemic Agents; | 2011 |
The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?
Topics: Animals; Continuous Positive Airway Pressure; Electroacupuncture; Female; Heart Rate; Humans; Insuli | 2012 |
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type | 2013 |
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type | 2013 |
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type | 2013 |
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type | 2013 |
Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Ther | 2013 |
Polycystic ovarian syndrome management options.
Topics: Clomiphene; Contraceptives, Oral, Hormonal; Estrogen Antagonists; Exercise; Female; Humans; Infertil | 2012 |
Evaluation and treatment of anovulatory and unexplained infertility.
Topics: Anovulation; Clomiphene; Diet; Evidence-Based Medicine; Exercise; Female; Fertility Agents, Female; | 2012 |
Evolution of exenatide as a diabetes therapeutic.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D | 2013 |
Can reducing peaks prevent type 2 diabetes: implication from recent diabetes prevention trials.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diet; Exercise; Humans | 2002 |
[When and how should polycystic ovary syndrome be treated?].
Topics: Androgen Antagonists; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; Infertili | 2001 |
A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia.
Topics: Angiotensin-Converting Enzyme Inhibitors; Female; Humans; Hyperinsulinism; Hypertension; Hypertrigly | 2002 |
[Treatment of PCOS without IVF: weight loss, insulin-sensitizing agents].
Topics: Acarbose; Chromans; Enzyme Inhibitors; Female; Glucose Intolerance; Glucosidases; Humans; Hypoglycem | 2003 |
[Is it possible to prevent type 2 diabetes?].
Topics: Acarbose; Adult; Aged; Diabetes Mellitus, Type 2; Diet; Exercise; Female; Glucose Intolerance; Human | 2003 |
Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes?
Topics: Acarbose; Diabetes Complications; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Loss | 2003 |
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
Topics: Abdomen; Adipose Tissue; Arteriosclerosis; Blood Glucose; Body Constitution; Cardiovascular Diseases | 2003 |
[Optimized diabetes therapy in type 2 diabetics].
Topics: Adolescent; Adult; Benzamides; Blood Glucose; Body Mass Index; Child; Cholesterol, LDL; Diabetes Mel | 2003 |
Insulin-lowering agents in the management of polycystic ovary syndrome.
Topics: Female; Humans; Insulin; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Pregnanc | 2003 |
[Progress in the prevention of type 2 diabetes].
Topics: Acarbose; Adult; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Chromans | 2003 |
Metformin for the treatment of the polycystic ovary syndrome.
Topics: Adolescent; Adult; Amenorrhea; Clinical Trials as Topic; Clomiphene; Diabetes Mellitus, Type 2; Diab | 2004 |
Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Drug Resistance; Electrocoagulation; Female; Fertility Agents, Femal | 2004 |
Nonalcoholic fatty liver disease in the pediatric population.
Topics: Adolescent; Alanine Transaminase; Child; Fatty Liver; Female; Histocytochemistry; Humans; Hypoglycem | 2004 |
[Pathophysiological conditions progressing from impaired glucose tolerance: type 2 diabetes mellitus].
Topics: Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Disease Progression; Exercise Therapy; Glucose Into | 2005 |
The patient with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prognosis; Weight Loss | 2005 |
Review article: the treatment of fatty liver disease associated with the metabolic syndrome.
Topics: Adult; Fatty Liver; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metabolic Syndrome; | 2005 |
Ovulation induction in infertile patients with polycystic ovary syndrome.
Topics: Aromatase Inhibitors; Clomiphene; Decision Trees; Diet; Drug Therapy, Combination; Female; Gonadotro | 2006 |
Treatment of nonalcoholic fatty liver disease.
Topics: Alanine Transaminase; Animals; Antioxidants; Body Mass Index; Fatty Liver; Humans; Hypolipidemic Age | 2006 |
Insulin resistance and improvements in signal transduction.
Topics: Adiponectin; AMP-Activated Protein Kinases; Appetite Regulation; Diabetes Mellitus, Type 2; Enzyme A | 2006 |
The treatment of type 2 diabetes mellitus in youth : which therapies?
Topics: Adipose Tissue; Adolescent; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic | 2006 |
[The metabolic syndrome and sports].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Clinical Trials as Topic; Diabetes Mellitus; Ener | 2006 |
Treatment of fibrosis in nonalcoholic fatty liver disease.
Topics: Adiponectin; Adipose Tissue; Animals; Antioxidants; Cytokines; Fatty Liver; Humans; Hypoglycemic Age | 2007 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fem | 2008 |
Unmet needs in controlling metabolic disease.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Exercise; Humans; Hyp | 2007 |
Adipose tissue and diabetes therapy: do we hit the target?
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Drug Delivery Systems; Humans; Hypoglycemic Agen | 2007 |
Effects of insulin resistance on endothelial function: possible mechanisms and clinical implications.
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Endothelium, Vascular; Exercise | 2008 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exerci | 2007 |
Metabolic syndrome: are we at risk?
Topics: Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2007 |
Metformin.
Topics: Animals; Cardiovascular System; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinatio | 2007 |
Role of metformin for weight management in patients without type 2 diabetes.
Topics: Adolescent; Adult; Anti-Obesity Agents; Body Weight; Clinical Trials as Topic; Humans; Hypoglycemic | 2008 |
Implications of the United Kingdom prospective diabetes study for patients with obesity and type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; | 2000 |
Obesity medications and the treatment of type 2 diabetes.
Topics: Acarbose; Anti-Obesity Agents; Appetite Depressants; Diabetes Mellitus; Diabetes Mellitus, Type 2; D | 1999 |
In support of metformin use in adolescent polycystic ovary syndrome.
Topics: Adolescent; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Treatment Out | 2002 |
180 trials available for metformin and Weight Loss
| Article | Year |
|---|---|
A behavioral weight-loss intervention, but not metformin, decreases a marker of gut barrier permeability: results from the SPIRIT randomized trial.
Topics: Adult; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Lipopolysaccharides; Male; Metformin; | 2022 |
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Dru | 2022 |
Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Bariatric Surgery; Female; Humans; Metformin; Obesity; Polycystic Ovary Syndrome; | 2022 |
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglyc | 2022 |
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
Topics: Exenatide; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; O | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Gastroplasty; Glucose Intolerance; Humans; Hypoglyc | 2022 |
Weight Loss, Lifestyle Intervention, and Metformin Affect Longitudinal Relationship of Insulin Secretion and Sensitivity.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Secre | 2022 |
Effect of a Personalized Diet to Reduce Postprandial Glycemic Response vs a Low-fat Diet on Weight Loss in Adults With Abnormal Glucose Metabolism and Obesity: A Randomized Clinical Trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Female; Glucose; Glycated Hem | 2022 |
An Examination of Whether Diabetes Control and Treatments Are Associated With Change in Frailty Index Across 8 Years: An Ancillary Exploratory Study From the Action for Health in Diabetes (Look AHEAD) Trial.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Frailty; Glycated Hemoglobin; Humans; Metformin; | 2023 |
Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial.
Topics: Body Weight; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; | 2023 |
Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.
Topics: Female; Humans; Insulin Resistance; Metformin; Obesity; Pilot Projects; Polycystic Ovary Syndrome; W | 2023 |
Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.
Topics: Adult; Blood Glucose; Body Weight; Cardiometabolic Risk Factors; Cholesterol; Diabetes Mellitus, Typ | 2023 |
Effectiveness of Shared Decision-making for Diabetes Prevention: 12-Month Results from the Prediabetes Informed Decision and Education (PRIDE) Trial.
Topics: Adult; Aged; Decision Making, Shared; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents | 2019 |
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Femal | 2019 |
GDF15 mediates the effects of metformin on body weight and energy balance.
Topics: Administration, Oral; Adult; Aged; Animals; Blood Glucose; Body Weight; Diet, High-Fat; Double-Blind | 2020 |
Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Liraglutide; Longitudina | 2020 |
Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight/obese women with recent gestational diabetes: A double-blind, randomized, placebo-controlled
Topics: Adolescent; Adult; Diabetes, Gestational; Double-Blind Method; Drug Therapy, Combination; Energy Met | 2020 |
Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dose-Res | 2020 |
Diet-induced weight loss alters hepatic glucocorticoid metabolism in type 2 diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diet, Paleolithic; Diet, Reducing; Exercise; Exercise Therap | 2020 |
Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Anthropometry; Blood Pressure; Body Mass Index; Caloric Restriction; Energy | 2020 |
Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Topics: Adult; Blood Glucose; Body Weight; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2020 |
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.
Topics: Endometrial Neoplasms; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Metformin; M | 2021 |
Effects of Behavioral Weight Loss and Metformin on IGFs in Cancer Survivors: A Randomized Trial.
Topics: Body Mass Index; Cancer Survivors; Female; Health Behavior; Humans; Insulin-Like Growth Factor Bindi | 2021 |
Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial.
Topics: Adult; Fatty Acids, Volatile; Feces; Female; Gastrointestinal Microbiome; Humans; Metformin; Middle | 2021 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female | 2021 |
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Sche | 2021 |
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Combinations; D | 2018 |
The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from data of a phase IV open-labeled trial.
Topics: Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic A | 2017 |
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-C | 2017 |
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.
Topics: Adiposity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans | 2018 |
The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial.
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Blood Glucose; Contraceptives, Oral, Horm | 2018 |
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Bone Density; Bridged Bicyclo Compounds, Heterocyclic; D | 2018 |
Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
Topics: Adipocytes; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide | 2017 |
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine.
Topics: Antipsychotic Agents; Body Mass Index; Body Weight; Clozapine; Diabetes Mellitus, Type 2; Double-Bli | 2018 |
Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer.
Topics: Adiposity; Biomarkers; Body Composition; Body Mass Index; Endometrial Neoplasms; Endometrium; Female | 2018 |
High-Dose, Diazoxide-Mediated Insulin Suppression Boosts Weight Loss Induced by Lifestyle Intervention.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Diazoxide; Dose-Response Relationship, Drug; Dou | 2018 |
Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study.
Topics: Adult; Aged; Algorithms; Diabetes Mellitus, Type 2; Early Intervention, Educational; Humans; Hypogly | 2019 |
Does metformin therapy influence the effects of intensive lifestyle intervention? Exploring the interaction between first line therapies in the Look AHEAD trial.
Topics: Blood Glucose; Body Mass Index; Cardiorespiratory Fitness; Diabetes Mellitus, Type 2; Glycated Hemog | 2019 |
Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Combined Modality Therapy; Exercise Therapy; Female; Glucose Tolerance Test; | 2019 |
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Middle | 2019 |
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Middle | 2019 |
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Middle | 2019 |
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Life Style; Male; Metformin; Middle | 2019 |
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combinatio | 2019 |
The effects of weight loss and metformin on cognition among breast cancer survivors: Evidence from the Reach for Health study.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Cancer Survivors; Cognitive Dysfunction; Combined Modalit | 2019 |
Regression to Normal Glucose Regulation in American Indians and Alaska Natives of a Diabetes Prevention Program.
Topics: Adult; Aged; Alaskan Natives; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Female; Follow-Up | 2019 |
Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus, Typ | 2013 |
Metformin modifies the exercise training effects on risk factors for cardiovascular disease in impaired glucose tolerant adults.
Topics: Adiposity; Adult; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Dou | 2013 |
Variation at the melanocortin 4 receptor gene and response to weight-loss interventions in the diabetes prevention program.
Topics: Adult; Alleles; Body Mass Index; Diabetes Mellitus, Type 2; Diet; Exercise; Female; Genotype; Humans | 2013 |
Optimal macronutrient content of the diet for adolescents with prediabetes; RESIST a randomised control trial.
Topics: Adolescent; Adolescent Behavior; Body Mass Index; Child; Child Behavior; Combined Modality Therapy; | 2013 |
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; | 2013 |
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; | 2013 |
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; | 2013 |
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; | 2013 |
Gestational diabetes mellitus among Norwegian women with polycystic ovary syndrome: prevalence and risk factors according to the WHO and the modified IADPSG criteria.
Topics: Adult; Analysis of Variance; Diabetes, Gestational; Double-Blind Method; Female; Humans; Hypoglycemi | 2013 |
Sex steroid levels and response to weight loss interventions among postmenopausal women in the diabetes prevention program.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Female; Follow-Up Studies; Gonadal Steroid Hormones; Hu | 2014 |
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Meth | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes | 2014 |
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Topics: Absorptiometry, Photon; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Bone Density; Diabetes | 2014 |
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, | 2014 |
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, | 2014 |
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, | 2014 |
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, | 2014 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes M | 2013 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Topics: Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double- | 2014 |
Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program.
Topics: Adult; Blood Glucose; Body Composition; Body Mass Index; Carrier Proteins; Diabetes Mellitus, Type 2 | 2014 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2013 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2013 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2013 |
Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2013 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Topics: Adult; Body Weight; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Lirag | 2014 |
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combin | 2014 |
Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, C | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osm | 2014 |
Dietary glycemic load, insulin load, and weight loss in obese, insulin resistant adolescents: RESIST study.
Topics: Adolescent; Body Composition; Body Mass Index; Child; Diet; Energy Intake; Glucose Tolerance Test; G | 2015 |
Comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in China.
Topics: Body Mass Index; Carbamates; China; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diab | 2014 |
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Dr | 2014 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Dia | 2014 |
Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial.
Topics: Adenocarcinoma; Biomarkers, Tumor; Diet; Endometrial Neoplasms; Exercise; Female; Humans; Intrauteri | 2014 |
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy | 2014 |
Efficacy and safety of oral methazolamide in patients with type 2 diabetes: a 24-week, placebo-controlled, double-blind study.
Topics: Aged; Carbonic Anhydrase Inhibitors; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycate | 2014 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther | 2015 |
Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Adm | 2015 |
Weight loss increases follicle stimulating hormone in overweight postmenopausal women [corrected].
Topics: Aged; Behavior Therapy; Body Weight; Diabetes Mellitus, Type 2; Estradiol; Female; Follicle Stimulat | 2015 |
Metformin for overweight women at midlife: a double-blind, randomized, controlled trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Double-Blind Method; Fasting; Female; Humans; Hypoglyce | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans | 2015 |
Effects of metformin on energy intake and satiety in obese children.
Topics: Appetite Depressants; Body Mass Index; Child; Child Behavior; Child Nutritional Physiological Phenom | 2015 |
The effects of metformin on weight loss in women with gestational diabetes: a pilot randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Diabetes, Gestational; Drug Administration Schedule; Female; Follow-Up Studies; H | 2015 |
Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study.
Topics: Adolescent; Adult; Biomarkers; Cardiac Output; Coronary Artery Disease; Delayed-Action Preparations; | 2015 |
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; | 2015 |
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellit | 2015 |
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Th | 2015 |
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Comb | 2015 |
The comparative efficacy of lifestyle intervention and metformin by educational attainment in the Diabetes Prevention Program.
Topics: Adult; Diabetes Mellitus, Type 2; Educational Status; Exercise; Female; Health Promotion; Humans; Hy | 2015 |
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Topics: Adult; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Fema | 2015 |
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseas | 2015 |
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseas | 2015 |
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseas | 2015 |
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseas | 2015 |
METFORMIN-SUSTAINED WEIGHT LOSS AND REDUCED ANDROID FAT TISSUE AT 12 MONTHS IN EMPOWIR (ENHANCE THE METABOLIC PROFILE OF WOMEN WITH INSULIN RESISTANCE): A DOUBLE BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF NORMOGLYCEMIC WOMEN WITH MIDLIFE WEIGHT GAIN.
Topics: Adipose Tissue; Adult; Aging; Body Fat Distribution; Climacteric; Double-Blind Method; Drug Combinat | 2016 |
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.
Topics: Adiposity; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Diabetes Mellitus, Typ | 2016 |
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.
Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; I | 2016 |
Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Down-Regulation; Drug Therapy | 2016 |
Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.
Topics: Adiponectin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cohort Studies; Combined Modalit | 2016 |
Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Animals; Biological Factors; Blood Glucose; Body Weight; Diabetes Mellitus, | 2016 |
Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients.
Topics: Acupuncture Therapy; Adiponectin; Adult; Biomarkers; Body Mass Index; Body Weight; Cholesterol, HDL; | 2016 |
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type | 2016 |
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type | 2016 |
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type | 2016 |
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type | 2016 |
Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.
Topics: Adiposity; Body Weight; Child; Double-Blind Method; Female; Genotype; Glomerular Filtration Rate; Hu | 2017 |
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammat | 2017 |
Improvement of serum adiponectin and leptin concentrations: effects of a low-calorie or isocaloric diet combined with metformin or orlistat - a prospective randomized open-label trial.
Topics: Adiponectin; Aged; Caloric Restriction; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Lactone | 2016 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Beneficial effects of sitagliptin and metformin in non-diabetic hypertensive and dyslipidemic patients.
Topics: Adult; Antihypertensive Agents; Biomarkers; Blood Pressure; Dipeptidyl-Peptidase IV Inhibitors; Dysl | 2016 |
PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin.
Topics: Female; Glycated Hemoglobin; Hispanic or Latino; Humans; Hypoglycemic Agents; Life Style; Metformin; | 2017 |
First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes.
Topics: Behavior Therapy; Caloric Restriction; Chromans; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Fe | 2008 |
An RCT of metformin versus orlistat for the management of obese anovulatory women.
Topics: Adolescent; Adult; Androgens; Anovulation; Anti-Obesity Agents; Female; Humans; Hypoglycemic Agents; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics; | 2009 |
Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).
Topics: Adult; Androgens; Female; Humans; Insulin Resistance; Metformin; Piperidines; Polycystic Ovary Syndr | 2009 |
Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
Topics: Adult; Blood Coagulation; Cyproterone Acetate; Estrogens; Ethinyl Estradiol; Female; Fibrin Fibrinog | 2010 |
Changes in health state utilities with changes in body mass in the Diabetes Prevention Program.
Topics: Activities of Daily Living; Adult; Cost-Benefit Analysis; Diabetes Mellitus; Diet, Reducing; Exercis | 2009 |
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Mass Index; Caloric Restriction; Diabetes Mel | 2009 |
Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).
Topics: Adolescent; Adult; Aged; Benzoxazines; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; | 2010 |
Metformin for weight control in pediatric patients on atypical antipsychotic medication.
Topics: Adolescent; Antipsychotic Agents; Blood Glucose; Body Mass Index; Child; Female; Humans; Hypoglycemi | 2009 |
Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Insul | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
Topics: Aged; Analysis of Variance; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestationa | 2009 |
Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women.
Topics: Adult; Appetite Depressants; C-Reactive Protein; Cyclobutanes; Drug Therapy, Combination; Female; Hu | 2010 |
Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.
Topics: Adult; Alanine Transaminase; Biomarkers; Diabetes Mellitus; Fatty Liver; Female; Glucose Intolerance | 2010 |
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Blood Pressure; China; Diabetes Mellitus, | 2011 |
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated | 2011 |
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated | 2011 |
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated | 2011 |
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated | 2011 |
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucagon | 2011 |
Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program.
Topics: Diabetes Mellitus, Type 2; Exercise Therapy; Genotype; Glucose Tolerance Test; Humans; Hypoglycemic | 2011 |
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality | 2012 |
Lifestyle intervention improves fitness independent of metformin in obese adolescents.
Topics: Absorptiometry, Photon; Adiponectin; Adolescent; Analysis of Variance; Biomarkers; Body Composition; | 2012 |
Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Body Weight; Brain-Derived Neurotrophic Factor; Cell | 2012 |
[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Topics: Adult; Aged; Anti-Obesity Agents; Antihypertensive Agents; Blood Glucose; Combined Modality Therapy; | 2012 |
Weight loss/maintenance as an effective tool for controlling type 2 diabetes: novel methodology to sustain weight reduction.
Topics: Behavior Therapy; Cardiovascular Diseases; Computers; Diabetes Mellitus, Type 2; Feedback; Humans; L | 2012 |
Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemog | 2012 |
Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial.
Topics: Adiponectin; Adolescent; Biomarkers; C-Reactive Protein; Child; Child, Preschool; Drug Administratio | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up St | 2012 |
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Rela | 2012 |
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Rela | 2012 |
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Rela | 2012 |
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Rela | 2012 |
Therapeutic effects of calcium & vitamin D supplementation in women with PCOS.
Topics: Adult; Calcium; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; | 2012 |
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Comb | 2012 |
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Th | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
A clinical trial to maintain glycemic control in youth with type 2 diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2012 |
Metformin use in children with obesity and normal glucose tolerance--effects on cardiovascular markers and intrahepatic fat.
Topics: Abdominal Fat; Adolescent; Biomarkers; C-Reactive Protein; Child; Female; Fibrinogen; Glucose Tolera | 2012 |
Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Topics: Adult; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypo | 2012 |
Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Antioxidants; Aspartate Aminotransferases; | 2012 |
Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; C-Reactive Protein; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Ins | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabete | 2013 |
Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Topics: Adipose Tissue; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fluorodeoxygluc | 2003 |
Metabolic and psychosocial effects of minimal invasive gastric banding for morbid obesity.
Topics: Activities of Daily Living; Adult; Anthropometry; Body Composition; Cholesterol; Digestive System Su | 2003 |
Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.
Topics: Aged; Amyloid; Body Mass Index; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Bl | 2004 |
Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Female; Fertilization; Fertilization in Vi | 2004 |
The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial.
Topics: Adult; Biomarkers; Blood Glucose; Cell Adhesion Molecules; Double-Blind Method; Endothelium, Vascula | 2004 |
A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; Body Mass Index; Double-Blind Method; Electr | 2004 |
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu | 2004 |
Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.
Topics: Adult; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Enzyme Inhibitors; Female; Humans; | 2005 |
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
Topics: Adult; Aged; Anthropometry; Anti-Obesity Agents; Blood Glucose; Cholesterol; Diabetes Mellitus, Type | 2005 |
Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.
Topics: Administration, Oral; Androstenedione; Blood Glucose; Dehydroepiandrosterone Sulfate; Female; Humans | 2005 |
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
Topics: Adult; Anthropometry; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2006 |
Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Child; Contraceptives, Oral; Female; Humans; Hyperinsulinism; Hypoglyc | 2005 |
Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diet; Exercise; Female; Humans; Hypoglyce | 2006 |
Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type | 2007 |
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue.
Topics: Adult; Aged; Biopsy; Blood Glucose; Caloric Restriction; Chromans; Diabetes Mellitus, Type 2; Female | 2006 |
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabet | 2006 |
Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Cholesterol; Coronary Disease; Diet; Female; Humans; Insulin; Insulin Resistance; | 2006 |
Effects of metformin on microvascular function and exercise tolerance in women with angina and normal coronary arteries: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Angina Pectoris; Double-Blind Method; Electrocardiography; Exercise Tolerance; Female; Humans | 2006 |
An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Drug Therapy, Combination; Female; | 2007 |
[Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome].
Topics: Adolescent; Adult; Caloric Restriction; Exercise; Female; Hormones; Humans; Hypoglycemic Agents; Ins | 2006 |
Body size and shape changes and the risk of diabetes in the diabetes prevention program.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Size; Cohort Studies; Diabetes Mellitus; Diabetes Mellitu | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellit | 2007 |
Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.
Topics: Adipose Tissue; Adolescent; Adult; Aged; B-Lymphocytes; Blood Glucose; Body Composition; Female; Hum | 2008 |
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind M | 2007 |
Weight changes in type 2 diabetes and the impact of gender.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycat | 2008 |
Lowering the threshold for defining microalbuminuria: effects of a lifestyle-metformin intervention in obese "normoalbuminuric" non-diabetic subjects.
Topics: Adult; Albuminuria; Blood Pressure; Caloric Restriction; Cardiovascular Diseases; Creatinine; Exerci | 2008 |
Increased hematocrit and reduced blood pressure following control of glycemia in diabetes.
Topics: Blood Glucose; Blood Pressure; Creatinine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hy | 2008 |
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglyce | 2008 |
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Appetite Depressants; Benzodiazepines; Body Mass Index; Chronic Disease | 2008 |
A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.
Topics: Adult; Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Piperidines; Polycystic Ovar | 2008 |
Weight loss of black, white, and Hispanic men and women in the Diabetes Prevention Program.
Topics: Adult; Aged; Black or African American; Diabetes Mellitus, Type 2; Female; Hispanic or Latino; Human | 2008 |
Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS).
Topics: Adult; Fasting; Female; Humans; Metformin; Peptide YY; Polycystic Ovary Syndrome; Waist Circumferenc | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Addition of metformin to a lifestyle modification program in adolescents with insulin resistance.
Topics: Adolescent; Child; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lif | 2008 |
Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes.
Topics: Acarbose; Cohort Studies; Diabetes Mellitus, Type 2; Diet; Diet Records; Double-Blind Method; Drug T | 1997 |
Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Eating; Ene | 1998 |
Evidence for dissociation of insulin- and weight-reducing effects of metformin in non-diabetic male patients with coronary heart disease.
Topics: Adult; Blood Glucose; Coronary Disease; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin | 1998 |
Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.
Topics: Adult; Aged; Female; Fibrinolysis; Hemostasis; Humans; Hypoglycemic Agents; Insulin; Male; Metformin | 1998 |
Metformin added to insulin therapy in poorly controlled type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Huma | 1999 |
Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study.
Topics: Acarbose; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Food; Glycated Hemogl | 1999 |
Metabolic effects of metformin in patients with impaired glucose tolerance.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Energy Metabolism; Fatty Acid | 2001 |
Metformin in obesity associated with antipsychotic drug administration: a pilot study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Area Under Curve; Blood Glucose; Body Mass Index; Brie | 2001 |
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus; Double-Blind Meth | 2001 |
Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
Topics: Adipose Tissue; Adolescent; Blood Glucose; Body Composition; Body Mass Index; Cholesterol; Diet, Red | 2001 |
Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
Topics: Adipose Tissue; Adolescent; Blood Glucose; Body Composition; Body Mass Index; Cholesterol; Diet, Red | 2001 |
Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
Topics: Adipose Tissue; Adolescent; Blood Glucose; Body Composition; Body Mass Index; Cholesterol; Diet, Red | 2001 |
Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
Topics: Adipose Tissue; Adolescent; Blood Glucose; Body Composition; Body Mass Index; Cholesterol; Diet, Red | 2001 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Intake | 2002 |
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; Cyclo | 2002 |
131 other studies available for metformin and Weight Loss
| Article | Year |
|---|---|
Synthesis of propiophenone derivatives as new class of antidiabetic agents reducing body weight in db/db mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Eating; Hypoglycemic Agents; Hypolipidemic | 2012 |
Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients.
Topics: Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metfor | 2022 |
Weight gain in pregnancy: can metformin steady the scales?
Topics: Birth Weight; Diabetes Mellitus, Type 2; Female; Humans; Infant, Newborn; Metformin; Pregnancy; Preg | 2022 |
Association of gene polymorphisms with body weight changes in prediabetic patients.
Topics: Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Genotype; Humans; Metformin; M | 2022 |
Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Male; Metf | 2022 |
The GDF15-GFRAL pathway is dispensable for the effects of metformin on energy balance.
Topics: Animals; Glial Cell Line-Derived Neurotrophic Factor Receptors; Growth Differentiation Factor 15; Hu | 2022 |
Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus.
Topics: Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemo | 2022 |
A Health Care Professional Delivered Low Carbohydrate Diet Program Reduces Body Weight, Haemoglobin A1c, Diabetes Medication Use and Cardiovascular Risk Markers-A Single-Arm Intervention Analysis.
Topics: Adult; Body Weight; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Car | 2022 |
Combining Dietary Intervention with Metformin Treatment Enhances Non-Alcoholic Steatohepatitis Remission in Mice Fed a High-Fat High-Sucrose Diet.
Topics: Animals; Body Weight; Diet, High-Fat; Insulin Resistance; Liver; Male; Metformin; Mice; Mice, Inbred | 2022 |
Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight.
Topics: Animals; Area Postrema; Body Weight; Diabetes Mellitus, Type 2; Eating; Growth Differentiation Facto | 2023 |
Anti-Diabetic Drugs Inhibit Bulimia Induced Obesity.
Topics: Animals; Bulimia; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hypoglycemic Agents; Male; M | 2023 |
Management of Type 2 Diabetes in Frail Older Adults.
Topics: Aged; Diabetes Mellitus, Type 2; Frail Elderly; Frailty; Humans; Hypoglycemic Agents; Metformin; Obe | 2023 |
Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups.
Topics: Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Female; Humans; Lactones; Male; Metformin; Mi | 2023 |
The Effectiveness of Shared Decision-making for Diabetes Prevention: 24- and 36-Month Results From the Prediabetes Informed Decision and Education (PRIDE) Trial.
Topics: Adult; Decision Making; Decision Making, Shared; Humans; Life Style; Metformin; Patient Participatio | 2023 |
Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome.
Topics: Acanthosis Nigricans; Child; Contraceptives, Oral, Hormonal; Female; Humans; Hyperandrogenism; Insul | 2020 |
Metformin inhibits the activation of melanocortin receptors 2 and 3 in vitro: A possible mechanism for its anti-androgenic and weight balancing effects in vivo?
Topics: Adrenocorticotropic Hormone; Androgen Antagonists; Animals; Cell Line; Cell Survival; Hypoglycemic A | 2020 |
JPEN Journal Club 54. Correlation Coefficients.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Humans; Metformin; Parenteral Nutrition; Weight Loss | 2020 |
Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss.
Topics: Animals; Appetite Depressants; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Eating; Gluco | 2019 |
Glycemic control in youth-onset type 2 diabetes correlates with weight loss.
Topics: Adolescent; Body Mass Index; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Glycemic | 2020 |
[Starting insulin or not? And if so, which basal insulin?]
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic C | 2020 |
Exploration of SQC Formula Effect on Type 2 Diabetes Mellitus by Whole Transcriptome Profile in Rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drugs, Chinese H | 2021 |
Genetically proxied growth-differentiation factor 15 levels and body mass index.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Humans; Metformin; Obesity; Weight Loss | 2021 |
Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m
Topics: Adult; Anti-Obesity Agents; Bariatric Surgery; Body Mass Index; Combined Modality Therapy; Drug Ther | 2021 |
The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
Topics: Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Meta-Anal | 2021 |
Management of type 2 diabetes mellitus in older adults: eight case studies with focus SGLT-2 inhibitors and metformin.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Frailty; Humans; Hypoglycemic Age | 2022 |
Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
Topics: Adolescent; Advisory Committees; Behavior Therapy; Black or African American; Body Mass Index; Child | 2017 |
Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
Topics: Adolescent; Advisory Committees; Behavior Therapy; Black or African American; Body Mass Index; Child | 2017 |
Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
Topics: Adolescent; Advisory Committees; Behavior Therapy; Black or African American; Body Mass Index; Child | 2017 |
Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement.
Topics: Adolescent; Advisory Committees; Behavior Therapy; Black or African American; Body Mass Index; Child | 2017 |
Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptides; Glycated Hemoglobin; H | 2017 |
Update on off label use of metformin for obesity.
Topics: Administration, Oral; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agent | 2018 |
Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer.
Topics: Biomarkers; Breast Neoplasms; Humans; Life Style; Metformin; Obesity; Weight Loss | 2018 |
The Effects of Metformin and Weight Loss on Biomarkers Associated With Breast Cancer Outcomes.
Topics: Biomarkers; Breast Neoplasms; California; Female; Humans; Metformin; Patient Outcome Assessment; Pro | 2018 |
The protective effect of formononetin on cognitive impairment in streptozotocin (STZ)-induced diabetic mice.
Topics: Animals; Behavior, Animal; Blood Glucose; Cell Line, Tumor; Cognition; Cognition Disorders; Diabetes | 2018 |
Use of Metformin for Weight Management in Children and Adolescents With Obesity in the Clinical Setting.
Topics: Adolescent; Child; Female; Humans; Hypoglycemic Agents; Linear Models; Male; Metformin; Pediatric Ob | 2018 |
Could weight loss contribute to the improved mobility with metformin in patients with myotonic dystrophy type 1?
Topics: Humans; Metformin; Myotonic Dystrophy; Weight Loss | 2019 |
Reply: Could weight loss contribute to the improved mobility with metformin in patients with myotonic dystrophy type 1?
Topics: Humans; Metformin; Myotonic Dystrophy; Weight Loss | 2019 |
Long-term diabetes outcomes after bariatric surgery-managing medication withdrawl.
Topics: Adult; Bariatric Surgery; Body Weight; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Human | 2019 |
Metformin Triggers PYY Secretion in Human Gut Mucosa.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Colon; Diabetes Mellitus, Type 2; Enteroendocrine Cells; | 2019 |
Long-Term Weight Loss With Metformin or Lifestyle Intervention.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life Style; Metformin; Weight Loss | 2019 |
Advising Patients on How to Achieve Long-Term Weight Loss.
Topics: Diabetes Mellitus, Type 2; Humans; Life Style; Metformin; Obesity; Weight Loss | 2019 |
[Early insulin treatment in type 2 diabetes--yes].
Topics: Administration, Oral; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Dia | 2013 |
Infertility treatment in polycystic ovary syndrome: lifestyle interventions, medications and surgery.
Topics: Clomiphene; Exercise; Female; Fertilization in Vitro; Humans; Infertility, Female; Life Style; Metfo | 2013 |
[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].
Topics: Adiposity; Antineoplastic Agents; Breast Neoplasms; Energy Metabolism; Exercise; Female; Humans; Hyp | 2013 |
Clinical decisions. Management of type 2 diabetes--polling results.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exercise; | 2014 |
[Liraglutide in polycystic ovary syndrome].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucagon-Like Peptide 1; Hirsutism; Humans | 2014 |
[Aims of the diabetes passport].
Topics: Aged; Diabetes Mellitus, Type 2; Documentation; Drug Therapy, Combination; Glycated Hemoglobin; Heal | 2013 |
Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.
Topics: Adult; Bariatric Surgery; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exenatide; Female; G | 2014 |
Economic implications of weight change in patients with type 2 diabetes mellitus.
Topics: Body Weight; Cost Savings; Diabetes Mellitus, Type 2; Female; Health Care Costs; Humans; Hypoglycemi | 2014 |
Metformin for weight loss and control in patients with mood disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Hypoglycemic | 2014 |
The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study.
Topics: Adult; Biopsy; Body Mass Index; Cohort Studies; Cyclin D2; Endometrial Neoplasms; Endometrium; Femal | 2015 |
Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Blood Glucose; Cardiovascular A | 2014 |
Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats.
Topics: Age Factors; Animals; Behavior, Animal; Biomarkers; Blood Glucose; Caloric Restriction; Combined Mod | 2015 |
[Improvement of clinical parameters in a patient with metabolic syndrome through intervention in nutrition education and improvement of lifestyle].
Topics: Aged, 80 and over; Anthropometry; Blood Glucose; Diet Records; Diet, Diabetic; Diet, Fat-Restricted; | 2014 |
Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
Topics: Animals; Body Weight; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Synergism; Eating; Gast | 2015 |
Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Ma | 2015 |
Elevated plasma concentrations of pigment epithelium-derived factor in type 2 diabetic patients is reduced by metformin treatment in association with weight loss 2.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Eye Proteins; Female; Humans; Hypoglycemic Agents; Male; Met | 2015 |
Spontaneous Regression of Lumbar Disc Herniation After Weight Loss: Case Report.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Intervertebral Disc Displacem | 2015 |
Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erectile Dysfunctio | 2015 |
Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in people with Type 2 diabetes.
Topics: Aged; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fem | 2016 |
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Pha | 2016 |
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Pha | 2016 |
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Pha | 2016 |
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Pha | 2016 |
Involuntary Weight Loss Secondary to Metformin Use in Elderly Adults.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Ma | 2016 |
Diagnosis and Treatment of Polycystic Ovary Syndrome.
Topics: Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Hypogl | 2016 |
Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
Topics: Acarbose; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Pep | 2017 |
A Prospective Analysis of the Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors: Real World Evidence from Clinical Practice in India.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gl | 2016 |
C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug | 2016 |
Duodenal endoluminal barrier sleeve alters gut microbiota of ZDF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Duodenum; Dysbiosis; Gastric Bypass; Gas | 2017 |
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.
Topics: Administration, Oral; Adult; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug | 2017 |
Metformin and lifestyle changes help people taking antipsychotics lose weight.
Topics: Antipsychotic Agents; Humans; Hypoglycemic Agents; Metformin; Risk Reduction Behavior; Weight Loss | 2008 |
Considerations regarding the use of metformin with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Drug Administration Schedule; Huma | 2008 |
Management and 1 year outcome for UK children with type 2 diabetes.
Topics: Adolescent; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Epidemiolo | 2009 |
[Initial therapy of diabetes mellitus in the family practice. Give yourself time!].
Topics: Diabetes Mellitus, Type 2; Exercise; Family Practice; Glycated Hemoglobin; Humans; Hypoglycemic Agen | 2008 |
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exena | 2009 |
Conjugated linoleic acid activates AMP-activated protein kinase and reduces adiposity more effectively when used with metformin in mice.
Topics: 3T3 Cells; Adipocytes; AMP-Activated Protein Kinases; Animals; Body Weight; Cell Culture Techniques; | 2009 |
Treating type 2 diabetes. A specialist's approach.
Topics: Algorithms; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Human | 2009 |
Metformin provides weight reduction for hospitalized patients receiving polypharmacy.
Topics: Adult; Antipsychotic Agents; Female; Hospitalization; Humans; Male; Metformin; Middle Aged; Overweig | 2010 |
Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Composition; Body Mass Index; Cardiovascular Diseases; Diet; | 2010 |
Incorporating practical lifestyle management for obesity.
Topics: Appetite Depressants; Attitude to Health; Bariatric Surgery; Diabetes Mellitus, Type 2; Diet; Exerci | 2010 |
National survey on management of weight reduction in PCOS women in the United Kingdom.
Topics: Anti-Obesity Agents; Body Mass Index; Diet, Reducing; Exercise; Female; Guideline Adherence; Health | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhi | 2010 |
Ovulation induction in polycystic ovary syndrome: No. 242, May 2010.
Topics: Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotr | 2010 |
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Rem | 2010 |
Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant.
Topics: Humans; Hypoglycemic Agents; Metformin; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2011 |
The effect of a one-year weight reduction program on serum uric acid in overweight/obese children and adolescents.
Topics: Adolescent; Age Factors; Child; Diet; Exercise; Female; Humans; Male; Metformin; Obesity; Sex Factor | 2011 |
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Metformi | 2011 |
Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Carbamates; Diabetes Mellitus, Type 2; Drug T | 2011 |
Weight-reducing effects of metformin are sustained over 40 weeks for psychiatric inpatients receiving polypharmacy.
Topics: Exercise; Hospitalization; Hospitals, Psychiatric; Humans; Metformin; Obesity; Polypharmacy; Schizop | 2011 |
Obesity and type 2 diabetes mellitus in South Dakota: focused insight into prevalence, physiology and treatment.
Topics: Adipocytes; Adrenergic Agents; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Ob | 2011 |
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp | 2012 |
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp | 2012 |
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp | 2012 |
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp | 2012 |
Summaries for patients: Oral drug treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp | 2012 |
Steps toward the meaningful translation of prevention strategies for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Intention to Treat Analysis; Male; Metformin; Prediabetic | 2012 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
Non-alcoholic fatty liver disease in children.
Topics: Biopsy; Child; Fatty Liver; Humans; Hypoglycemic Agents; Life Style; Liver; Metformin; Obesity; Piog | 2012 |
The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Aorta; Body Mass Index; Drug Therapy, Combination; Ethinyl Estradiol | 2012 |
Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.
Topics: Adult; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dysli | 2012 |
Response letter. Effects of linagliptin.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Humans; Hypoglycemic Agents; Linagliptin | 2012 |
Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells.
Topics: AMP-Activated Protein Kinases; Animals; Animals, Newborn; Chief Cells, Gastric; Female; Gastric Muco | 2013 |
Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Behavior Therapy; Body Mass Index; Child; Dietetics; Endocrinology; Feeding Behav | 2012 |
Effectiveness of metformin on weight loss in non-diabetic individuals with obesity.
Topics: Adult; Age Factors; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; | 2013 |
Metformin induced anorexia and weight loss.
Topics: Aged; Aged, 80 and over; Anorexia; Female; Humans; Hypoglycemic Agents; Metformin; Weight Loss | 2003 |
Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
Topics: Adolescent; Adult; Diet, Reducing; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; M | 2003 |
THE EFFECT OF METFORMIN ON WEIGHT LOSS IN OBESITY.
Topics: Diabetes Mellitus; Diet; Diet, Reducing; Drug Therapy; Humans; Metformin; Obesity; Weight Loss | 1965 |
Acarbose for the prevention of diabetes.
Topics: Acarbose; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Loss | 2003 |
Acarbose for the prevention of diabetes.
Topics: Acarbose; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Loss | 2003 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations.
Topics: Adiponectin; Aged; Blood Glucose; Cytokines; Diabetes Mellitus, Lipoatrophic; Diabetes Mellitus, Typ | 2004 |
[Therapy objectives and daily practice--to which extent are blood sugar target values accessible in daily practice?].
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dru | 2004 |
Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change.
Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Guideline Adherence; Humans; Hydroxymethylgl | 2005 |
The management of type II diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Th | 2005 |
[Type 2 diabetic patient with reduced beta-cell function. New substance class: incretin-mimetics].
Topics: Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide | 2005 |
Metformin in the treatment of clomiphene citrate-resistant women with high BMI and primary infertility: clinical results and reproductive outcome.
Topics: Adult; Body Mass Index; Clomiphene; Drug Resistance; Female; Humans; Hypoglycemic Agents; Infertilit | 2005 |
Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus.
Topics: Age Factors; Aged; Body Mass Index; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Femal | 2006 |
[Improved blood sugar control plus weight loss].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exena | 2006 |
Effect of Sclerocarya birrea (Anacardiaceae) stem bark methylene chloride/methanol extract on streptozotocin-diabetic rats.
Topics: Anacardiaceae; Animals; Blood Glucose; Cameroon; Cholesterol; Diabetes Mellitus, Experimental; Gluco | 2007 |
Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Energy Intake; Female; Humans; | 2006 |
Metformin: now or later?
Topics: Diabetes Mellitus; Drug Administration Schedule; Exercise; Humans; Hyperglycemia; Hypoglycemic Agent | 2006 |
Ovulation induction management of PCOS.
Topics: Aromatase Inhibitors; Clomiphene; Endometrial Neoplasms; Female; Fertility Agents, Female; Glucocort | 2007 |
Summaries for patients. Exenatide therapy for type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; F | 2007 |
The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypoglycemic Agents; Metformin; Pioglita | 2007 |
Preventing diabetes, Part II: an action plan.
Topics: Diabetes Mellitus; Diet; Exercise; Humans; Hypoglycemic Agents; Life Style; Metformin; Obesity; Rosi | 2007 |
[New data on hypoglycemia risk and beta cell function].
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Gluc | 2007 |
Exenatide: new drug. Type 2 diabetes for some overweight patients.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptid | 2007 |
[Insulin-using woman with type 2 diabetes and weight problems].
Topics: C-Peptide; Caloric Restriction; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Exercise T | 2008 |
Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus; Exercise; Female; Glycated H | 2008 |
Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics.
Topics: Adipose Tissue; Body Composition; Carnitine; Citrates; Diabetes Mellitus; Humans; Hypoglycemic Agent | 1998 |
Clinical problem-solving. The importance of a name.
Topics: Acanthosis Nigricans; Adolescent; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 1999 |
Metformin therapy for diabetes in Prader-Willi syndrome.
Topics: Adolescent; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Metformin; Obesity; Prader | 1998 |
Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combinati | 2000 |
Obesity and Type 2 diabetes mellitus.
Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; G | 2000 |
Metformin for weight loss in pediatric patients taking psychotropic drugs.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Mass Index; Child; Dose-R | 2002 |
Preventing type 2 diabetes: lifestyle changes work better than drugs.
Topics: Diabetes Mellitus, Type 2; Diet; Exercise; Humans; Hypoglycemic Agents; Metformin; Placebo Effect; R | 2002 |
Diet and exercise. Preventing diabetes.
Topics: Diabetes Mellitus; Exercise; Food Preferences; Humans; Hyperglycemia; Hypoglycemic Agents; Life Styl | 2002 |
Study makes strong case for early diabetes intervention.
Topics: Adult; Aged; Aged, 80 and over; Child; Diabetes Mellitus; Diet; Disease Management; Exercise; Humans | 2002 |
Diabetes prevention.
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 1; Humans; Hypoglycemic Agents; Insulin Resistance; Metfo | 2002 |